Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,12186384,detection limit,The detection limit of levofloxacin was 50 ng/ml.,Pharmacokinetic study of levofloxacin in rat blood and bile by microdialysis and high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12186384/),[ng] / [ml],50,899,DB01137,Levofloxacin
,11296178,steady-state concentrations,"For once-daily dosing of levofloxacin, 500 mg, the mean (+/- SD) steady-state concentrations at 4 h, 12 h, and 24 h in ELF were 9.9 +/- 2.7 microg/mL, 6.5 +/- 2.5 microg/mL, and 0.7 +/- 0.4 microg/mL, respectively; AM concentrations were 97.9 +/- 80.0 microg/mL, 36.7 +/- 23.4 microg/mL, and 13.8 +/- 16.0 microg/mL, respectively.",Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11296178/),[μg] / [ml],9.9,1668,DB01137,Levofloxacin
,11296178,steady-state concentrations,"For once-daily dosing of levofloxacin, 500 mg, the mean (+/- SD) steady-state concentrations at 4 h, 12 h, and 24 h in ELF were 9.9 +/- 2.7 microg/mL, 6.5 +/- 2.5 microg/mL, and 0.7 +/- 0.4 microg/mL, respectively; AM concentrations were 97.9 +/- 80.0 microg/mL, 36.7 +/- 23.4 microg/mL, and 13.8 +/- 16.0 microg/mL, respectively.",Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11296178/),[μg] / [ml],6.5,1669,DB01137,Levofloxacin
,11296178,steady-state concentrations,"For once-daily dosing of levofloxacin, 500 mg, the mean (+/- SD) steady-state concentrations at 4 h, 12 h, and 24 h in ELF were 9.9 +/- 2.7 microg/mL, 6.5 +/- 2.5 microg/mL, and 0.7 +/- 0.4 microg/mL, respectively; AM concentrations were 97.9 +/- 80.0 microg/mL, 36.7 +/- 23.4 microg/mL, and 13.8 +/- 16.0 microg/mL, respectively.",Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11296178/),[μg] / [ml],0.7,1670,DB01137,Levofloxacin
,11296178,steady-state concentrations,"For once-daily dosing of levofloxacin, 500 mg, the mean (+/- SD) steady-state concentrations at 4 h, 12 h, and 24 h in ELF were 9.9 +/- 2.7 microg/mL, 6.5 +/- 2.5 microg/mL, and 0.7 +/- 0.4 microg/mL, respectively; AM concentrations were 97.9 +/- 80.0 microg/mL, 36.7 +/- 23.4 microg/mL, and 13.8 +/- 16.0 microg/mL, respectively.",Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11296178/),[μg] / [ml],97.9,1671,DB01137,Levofloxacin
,11296178,steady-state concentrations,"For once-daily dosing of levofloxacin, 500 mg, the mean (+/- SD) steady-state concentrations at 4 h, 12 h, and 24 h in ELF were 9.9 +/- 2.7 microg/mL, 6.5 +/- 2.5 microg/mL, and 0.7 +/- 0.4 microg/mL, respectively; AM concentrations were 97.9 +/- 80.0 microg/mL, 36.7 +/- 23.4 microg/mL, and 13.8 +/- 16.0 microg/mL, respectively.",Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11296178/),[μg] / [ml],36.7,1672,DB01137,Levofloxacin
,11296178,steady-state concentrations,"For once-daily dosing of levofloxacin, 500 mg, the mean (+/- SD) steady-state concentrations at 4 h, 12 h, and 24 h in ELF were 9.9 +/- 2.7 microg/mL, 6.5 +/- 2.5 microg/mL, and 0.7 +/- 0.4 microg/mL, respectively; AM concentrations were 97.9 +/- 80.0 microg/mL, 36.7 +/- 23.4 microg/mL, and 13.8 +/- 16.0 microg/mL, respectively.",Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11296178/),[μg] / [ml],13.8,1673,DB01137,Levofloxacin
,11296178,concentrations,"For once-daily dosing of levofloxacin, 500 mg, the mean (+/- SD) steady-state concentrations at 4 h, 12 h, and 24 h in ELF were 9.9 +/- 2.7 microg/mL, 6.5 +/- 2.5 microg/mL, and 0.7 +/- 0.4 microg/mL, respectively; AM concentrations were 97.9 +/- 80.0 microg/mL, 36.7 +/- 23.4 microg/mL, and 13.8 +/- 16.0 microg/mL, respectively.",Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11296178/),[μg] / [ml],97.9,1674,DB01137,Levofloxacin
,11296178,concentrations,"For once-daily dosing of levofloxacin, 500 mg, the mean (+/- SD) steady-state concentrations at 4 h, 12 h, and 24 h in ELF were 9.9 +/- 2.7 microg/mL, 6.5 +/- 2.5 microg/mL, and 0.7 +/- 0.4 microg/mL, respectively; AM concentrations were 97.9 +/- 80.0 microg/mL, 36.7 +/- 23.4 microg/mL, and 13.8 +/- 16.0 microg/mL, respectively.",Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11296178/),[μg] / [ml],36.7,1675,DB01137,Levofloxacin
,11296178,concentrations,"For once-daily dosing of levofloxacin, 500 mg, the mean (+/- SD) steady-state concentrations at 4 h, 12 h, and 24 h in ELF were 9.9 +/- 2.7 microg/mL, 6.5 +/- 2.5 microg/mL, and 0.7 +/- 0.4 microg/mL, respectively; AM concentrations were 97.9 +/- 80.0 microg/mL, 36.7 +/- 23.4 microg/mL, and 13.8 +/- 16.0 microg/mL, respectively.",Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11296178/),[μg] / [ml],13.8,1676,DB01137,Levofloxacin
,11296178,steady-state concentrations,"For levofloxacin, 750 mg, the mean steady-state concentrations in ELF were 22.1 +/- 14.9 microg/mL, 9.2 +/- 5.3 microg/mL, and 1.5 +/- 0.8 microg/mL, respectively; AM concentrations were 105.1 +/- 65.5 microg/mL, 36.2 +/- 26.1 microg/mL, and 15.1 +/- 2.0 microg/mL, respectively.",Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11296178/),[μg] / [ml],22.1,1677,DB01137,Levofloxacin
,11296178,steady-state concentrations,"For levofloxacin, 750 mg, the mean steady-state concentrations in ELF were 22.1 +/- 14.9 microg/mL, 9.2 +/- 5.3 microg/mL, and 1.5 +/- 0.8 microg/mL, respectively; AM concentrations were 105.1 +/- 65.5 microg/mL, 36.2 +/- 26.1 microg/mL, and 15.1 +/- 2.0 microg/mL, respectively.",Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11296178/),[μg] / [ml],9.2,1678,DB01137,Levofloxacin
,11296178,steady-state concentrations,"For levofloxacin, 750 mg, the mean steady-state concentrations in ELF were 22.1 +/- 14.9 microg/mL, 9.2 +/- 5.3 microg/mL, and 1.5 +/- 0.8 microg/mL, respectively; AM concentrations were 105.1 +/- 65.5 microg/mL, 36.2 +/- 26.1 microg/mL, and 15.1 +/- 2.0 microg/mL, respectively.",Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11296178/),[μg] / [ml],1.5,1679,DB01137,Levofloxacin
,11296178,steady-state concentrations,"For levofloxacin, 750 mg, the mean steady-state concentrations in ELF were 22.1 +/- 14.9 microg/mL, 9.2 +/- 5.3 microg/mL, and 1.5 +/- 0.8 microg/mL, respectively; AM concentrations were 105.1 +/- 65.5 microg/mL, 36.2 +/- 26.1 microg/mL, and 15.1 +/- 2.0 microg/mL, respectively.",Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11296178/),[μg] / [ml],105.1,1680,DB01137,Levofloxacin
,11296178,steady-state concentrations,"For levofloxacin, 750 mg, the mean steady-state concentrations in ELF were 22.1 +/- 14.9 microg/mL, 9.2 +/- 5.3 microg/mL, and 1.5 +/- 0.8 microg/mL, respectively; AM concentrations were 105.1 +/- 65.5 microg/mL, 36.2 +/- 26.1 microg/mL, and 15.1 +/- 2.0 microg/mL, respectively.",Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11296178/),[μg] / [ml],36.2,1681,DB01137,Levofloxacin
,11296178,steady-state concentrations,"For levofloxacin, 750 mg, the mean steady-state concentrations in ELF were 22.1 +/- 14.9 microg/mL, 9.2 +/- 5.3 microg/mL, and 1.5 +/- 0.8 microg/mL, respectively; AM concentrations were 105.1 +/- 65.5 microg/mL, 36.2 +/- 26.1 microg/mL, and 15.1 +/- 2.0 microg/mL, respectively.",Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11296178/),[μg] / [ml],15.1,1682,DB01137,Levofloxacin
,16050816,t(1/2(d)),"After intravenous administration, distribution was rapid (t(1/2(d)) 0.26 +/- 0.18 h) and wide as reflected by the steady-state volume of distribution of 1.75 +/- 0.42 L/kg.",Pharmacokinetics of levofloxacin after single intravenous and repeat oral administration to cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16050816/),h,0.26,1994,DB01137,Levofloxacin
,16050816,steady-state volume of distribution,"After intravenous administration, distribution was rapid (t(1/2(d)) 0.26 +/- 0.18 h) and wide as reflected by the steady-state volume of distribution of 1.75 +/- 0.42 L/kg.",Pharmacokinetics of levofloxacin after single intravenous and repeat oral administration to cats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16050816/),[l] / [kg],1.75,1995,DB01137,Levofloxacin
,16050816,total body clearance,Drug elimination was slow with a total body clearance of 0.14 +/- 0.04 L/h.kg and a t(1/2) for this process of 9.31 +/- 1.63 h.,Pharmacokinetics of levofloxacin after single intravenous and repeat oral administration to cats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16050816/),[l] / [h·kg],0.14,1996,DB01137,Levofloxacin
,16050816,t(1/2),Drug elimination was slow with a total body clearance of 0.14 +/- 0.04 L/h.kg and a t(1/2) for this process of 9.31 +/- 1.63 h.,Pharmacokinetics of levofloxacin after single intravenous and repeat oral administration to cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16050816/),h,9.31,1997,DB01137,Levofloxacin
,16050816,mean residence time,The mean residence time was of 12.99 +/- 2.12 h.,Pharmacokinetics of levofloxacin after single intravenous and repeat oral administration to cats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16050816/),h,12.99,1998,DB01137,Levofloxacin
,16050816,absorption half-life,"After repeat oral administration, absorption half-life was of 0.18 +/- 0.12 h and Tmax of 1.62 +/- 0.84 h.",Pharmacokinetics of levofloxacin after single intravenous and repeat oral administration to cats. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16050816/),h,0.18,1999,DB01137,Levofloxacin
,16050816,Tmax,"After repeat oral administration, absorption half-life was of 0.18 +/- 0.12 h and Tmax of 1.62 +/- 0.84 h.",Pharmacokinetics of levofloxacin after single intravenous and repeat oral administration to cats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16050816/),h,1.62,2000,DB01137,Levofloxacin
,16050816,bioavailability,The bioavailability was high (86.27 +/- 43.73%) with a peak plasma concentration at the steady state of 4.70 +/- 0.91 microg/mL.,Pharmacokinetics of levofloxacin after single intravenous and repeat oral administration to cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16050816/),%,86.27,2001,DB01137,Levofloxacin
,16050816,peak plasma concentration at the steady state,The bioavailability was high (86.27 +/- 43.73%) with a peak plasma concentration at the steady state of 4.70 +/- 0.91 microg/mL.,Pharmacokinetics of levofloxacin after single intravenous and repeat oral administration to cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16050816/),[μg] / [ml],4.70,2002,DB01137,Levofloxacin
below,16050816,MIC,Estimated efficacy predictors for levofloxacin after either intravenous or oral administration indicate a good profile against bacteria with a MIC value below of 0.5 microg/mL.,Pharmacokinetics of levofloxacin after single intravenous and repeat oral administration to cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16050816/),[μg] / [ml],0.5,2003,DB01137,Levofloxacin
,16050816,MIC,"However, for microorganisms with MIC values of 1 microg/mL it would be efficacious only when administered intravenously.",Pharmacokinetics of levofloxacin after single intravenous and repeat oral administration to cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16050816/),[μg] / [ml],1,2004,DB01137,Levofloxacin
<,12493793,clearance,"A lower clearance of levofloxacin (<2 mL/min/kg), conditioning both a longer elimination half-life (approximately 9 h) and a larger AUC(0-tau) (approximately 80 mg/L x h), was observed for both routes in our patients than in healthy volunteers.",Pharmacokinetic aspects of levofloxacin 500 mg once daily during sequential intravenous/oral therapy in patients with lower respiratory tract infections. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12493793/),[ml] / [kg·min],2,2292,DB01137,Levofloxacin
,12493793,elimination half-life,"A lower clearance of levofloxacin (<2 mL/min/kg), conditioning both a longer elimination half-life (approximately 9 h) and a larger AUC(0-tau) (approximately 80 mg/L x h), was observed for both routes in our patients than in healthy volunteers.",Pharmacokinetic aspects of levofloxacin 500 mg once daily during sequential intravenous/oral therapy in patients with lower respiratory tract infections. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12493793/),h,9,2293,DB01137,Levofloxacin
,12493793,AUC(0-tau),"A lower clearance of levofloxacin (<2 mL/min/kg), conditioning both a longer elimination half-life (approximately 9 h) and a larger AUC(0-tau) (approximately 80 mg/L x h), was observed for both routes in our patients than in healthy volunteers.",Pharmacokinetic aspects of levofloxacin 500 mg once daily during sequential intravenous/oral therapy in patients with lower respiratory tract infections. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12493793/),[mg] / [h·l],80,2294,DB01137,Levofloxacin
>,12493793,absolute oral bioavailability,The almost complete (> or =99%) absolute oral bioavailability suggests that a comparable exposure to the iv regimen may be achieved after oral administration.,Pharmacokinetic aspects of levofloxacin 500 mg once daily during sequential intravenous/oral therapy in patients with lower respiratory tract infections. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12493793/),%,99,2295,DB01137,Levofloxacin
,12493793,overall clinical success rate,The overall clinical success rate was 94.1%.,Pharmacokinetic aspects of levofloxacin 500 mg once daily during sequential intravenous/oral therapy in patients with lower respiratory tract infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12493793/),%,94.1,2296,DB01137,Levofloxacin
,26621623,bioavailability (F),The NCA showed significant differences in bioavailability (F) for the control group (0.4) and the TAR group (0.86) after i.t. administration.,"Simultaneous Semimechanistic Population Analyses of Levofloxacin in Plasma, Lung, and Prostate To Describe the Influence of Efflux Transporters on Drug Distribution following Intravenous and Intratracheal Administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26621623/),,0.4,4271,DB01137,Levofloxacin
,26621623,bioavailability (F),The NCA showed significant differences in bioavailability (F) for the control group (0.4) and the TAR group (0.86) after i.t. administration.,"Simultaneous Semimechanistic Population Analyses of Levofloxacin in Plasma, Lung, and Prostate To Describe the Influence of Efflux Transporters on Drug Distribution following Intravenous and Intratracheal Administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26621623/),,0.86,4272,DB01137,Levofloxacin
,26621623,volume of the central compartment (V1),"The estimated population means were as follows: volume of the central compartment (V1), 0.321 liters; total plasma clearance (CL), 0.220 liters/h; TAR plasma clearance (CLTAR), 0.180 liters/h.","Simultaneous Semimechanistic Population Analyses of Levofloxacin in Plasma, Lung, and Prostate To Describe the Influence of Efflux Transporters on Drug Distribution following Intravenous and Intratracheal Administration. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26621623/),l,0.321,4273,DB01137,Levofloxacin
,26621623,total plasma clearance (CL),"The estimated population means were as follows: volume of the central compartment (V1), 0.321 liters; total plasma clearance (CL), 0.220 liters/h; TAR plasma clearance (CLTAR), 0.180 liters/h.","Simultaneous Semimechanistic Population Analyses of Levofloxacin in Plasma, Lung, and Prostate To Describe the Influence of Efflux Transporters on Drug Distribution following Intravenous and Intratracheal Administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26621623/),[l] / [h],0.220,4274,DB01137,Levofloxacin
,26621623,plasma clearance (CLTAR),"The estimated population means were as follows: volume of the central compartment (V1), 0.321 liters; total plasma clearance (CL), 0.220 liters/h; TAR plasma clearance (CLTAR), 0.180 liters/h.","Simultaneous Semimechanistic Population Analyses of Levofloxacin in Plasma, Lung, and Prostate To Describe the Influence of Efflux Transporters on Drug Distribution following Intravenous and Intratracheal Administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26621623/),[l] / [h],0.180,4275,DB01137,Levofloxacin
,26621623,intercompartmental distribution rate constants,"The intercompartmental distribution rate constants (K values) were as follows: K12, 8.826 h(-1); K21, 7.271 h(-1); K13, 0.047 h(-1); K31, 7.738 h(-1); K14, 0.908 h(-1); K41, 0.409 h(-1); K21 lung TAR (K21LTAR), 8.883 h(-1); K31 prostate TAR (K31PTAR), 4.377 h(-1).","Simultaneous Semimechanistic Population Analyses of Levofloxacin in Plasma, Lung, and Prostate To Describe the Influence of Efflux Transporters on Drug Distribution following Intravenous and Intratracheal Administration. ","K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26621623/),1/[h],8.826,4276,DB01137,Levofloxacin
,26621623,K12,"The intercompartmental distribution rate constants (K values) were as follows: K12, 8.826 h(-1); K21, 7.271 h(-1); K13, 0.047 h(-1); K31, 7.738 h(-1); K14, 0.908 h(-1); K41, 0.409 h(-1); K21 lung TAR (K21LTAR), 8.883 h(-1); K31 prostate TAR (K31PTAR), 4.377 h(-1).","Simultaneous Semimechanistic Population Analyses of Levofloxacin in Plasma, Lung, and Prostate To Describe the Influence of Efflux Transporters on Drug Distribution following Intravenous and Intratracheal Administration. ","K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26621623/),1/[h],8.826,4277,DB01137,Levofloxacin
,26621623,K21,"The intercompartmental distribution rate constants (K values) were as follows: K12, 8.826 h(-1); K21, 7.271 h(-1); K13, 0.047 h(-1); K31, 7.738 h(-1); K14, 0.908 h(-1); K41, 0.409 h(-1); K21 lung TAR (K21LTAR), 8.883 h(-1); K31 prostate TAR (K31PTAR), 4.377 h(-1).","Simultaneous Semimechanistic Population Analyses of Levofloxacin in Plasma, Lung, and Prostate To Describe the Influence of Efflux Transporters on Drug Distribution following Intravenous and Intratracheal Administration. ","K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26621623/),1/[h],7.271,4278,DB01137,Levofloxacin
,26621623,K13,"The intercompartmental distribution rate constants (K values) were as follows: K12, 8.826 h(-1); K21, 7.271 h(-1); K13, 0.047 h(-1); K31, 7.738 h(-1); K14, 0.908 h(-1); K41, 0.409 h(-1); K21 lung TAR (K21LTAR), 8.883 h(-1); K31 prostate TAR (K31PTAR), 4.377 h(-1).","Simultaneous Semimechanistic Population Analyses of Levofloxacin in Plasma, Lung, and Prostate To Describe the Influence of Efflux Transporters on Drug Distribution following Intravenous and Intratracheal Administration. ","K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26621623/),1/[h],0.047,4279,DB01137,Levofloxacin
,26621623,K31,"The intercompartmental distribution rate constants (K values) were as follows: K12, 8.826 h(-1); K21, 7.271 h(-1); K13, 0.047 h(-1); K31, 7.738 h(-1); K14, 0.908 h(-1); K41, 0.409 h(-1); K21 lung TAR (K21LTAR), 8.883 h(-1); K31 prostate TAR (K31PTAR), 4.377 h(-1).","Simultaneous Semimechanistic Population Analyses of Levofloxacin in Plasma, Lung, and Prostate To Describe the Influence of Efflux Transporters on Drug Distribution following Intravenous and Intratracheal Administration. ","K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26621623/),1/[h],7.738,4280,DB01137,Levofloxacin
,26621623,K14,"The intercompartmental distribution rate constants (K values) were as follows: K12, 8.826 h(-1); K21, 7.271 h(-1); K13, 0.047 h(-1); K31, 7.738 h(-1); K14, 0.908 h(-1); K41, 0.409 h(-1); K21 lung TAR (K21LTAR), 8.883 h(-1); K31 prostate TAR (K31PTAR), 4.377 h(-1).","Simultaneous Semimechanistic Population Analyses of Levofloxacin in Plasma, Lung, and Prostate To Describe the Influence of Efflux Transporters on Drug Distribution following Intravenous and Intratracheal Administration. ","K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26621623/),1/[h],0.908,4281,DB01137,Levofloxacin
,26621623,K41,"The intercompartmental distribution rate constants (K values) were as follows: K12, 8.826 h(-1); K21, 7.271 h(-1); K13, 0.047 h(-1); K31, 7.738 h(-1); K14, 0.908 h(-1); K41, 0.409 h(-1); K21 lung TAR (K21LTAR), 8.883 h(-1); K31 prostate TAR (K31PTAR), 4.377 h(-1).","Simultaneous Semimechanistic Population Analyses of Levofloxacin in Plasma, Lung, and Prostate To Describe the Influence of Efflux Transporters on Drug Distribution following Intravenous and Intratracheal Administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26621623/),1/[h],0.409,4282,DB01137,Levofloxacin
,26621623,K,"The intercompartmental distribution rate constants (K values) were as follows: K12, 8.826 h(-1); K21, 7.271 h(-1); K13, 0.047 h(-1); K31, 7.738 h(-1); K14, 0.908 h(-1); K41, 0.409 h(-1); K21 lung TAR (K21LTAR), 8.883 h(-1); K31 prostate TAR (K31PTAR), 4.377 h(-1).","Simultaneous Semimechanistic Population Analyses of Levofloxacin in Plasma, Lung, and Prostate To Describe the Influence of Efflux Transporters on Drug Distribution following Intravenous and Intratracheal Administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26621623/),1/[h],8.883,4283,DB01137,Levofloxacin
,32233138,AUC0-last,"Mean AUC0-last values of 9.03 ± 2.66, 9.07 ± 1.80, and 9.28 ± 1.56 mg/h*L were obtained via I/V, I/M, and S/C, respectively.","Pharmacokinetic profiles of levofloxacin after intravenous, intramuscular and subcutaneous administration to rabbits (Oryctolagus cuniculus). ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32233138/),[mg] / [h·l],9.03,4848,DB01137,Levofloxacin
,32233138,AUC0-last,"Mean AUC0-last values of 9.03 ± 2.66, 9.07 ± 1.80, and 9.28 ± 1.56 mg/h*L were obtained via I/V, I/M, and S/C, respectively.","Pharmacokinetic profiles of levofloxacin after intravenous, intramuscular and subcutaneous administration to rabbits (Oryctolagus cuniculus). ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32233138/),[mg] / [h·l],9.07,4849,DB01137,Levofloxacin
,32233138,AUC0-last,"Mean AUC0-last values of 9.03 ± 2.66, 9.07 ± 1.80, and 9.28 ± 1.56 mg/h*L were obtained via I/V, I/M, and S/C, respectively.","Pharmacokinetic profiles of levofloxacin after intravenous, intramuscular and subcutaneous administration to rabbits (Oryctolagus cuniculus). ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32233138/),[mg] / [h·l],9.28,4850,DB01137,Levofloxacin
,32233138,Plasma clearance,Plasma clearance was 0.6 mL/g*h after I/V administration.,"Pharmacokinetic profiles of levofloxacin after intravenous, intramuscular and subcutaneous administration to rabbits (Oryctolagus cuniculus). ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32233138/),[ml] / [g·h],0.6,4851,DB01137,Levofloxacin
,32233138,Peak plasma concentrations,Peak plasma concentrations using the I/M and S/C routes were 3.33 ± 0.39 and 2.91 ± 0.56 μg/mL.,"Pharmacokinetic profiles of levofloxacin after intravenous, intramuscular and subcutaneous administration to rabbits (Oryctolagus cuniculus). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32233138/),[μg] / [ml],3.33,4852,DB01137,Levofloxacin
,32233138,Peak plasma concentrations,Peak plasma concentrations using the I/M and S/C routes were 3.33 ± 0.39 and 2.91 ± 0.56 μg/mL.,"Pharmacokinetic profiles of levofloxacin after intravenous, intramuscular and subcutaneous administration to rabbits (Oryctolagus cuniculus). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32233138/),[μg] / [ml],2.91,4853,DB01137,Levofloxacin
,32233138,Bioavailability,"Bioavailability values, after extravascular administration were complete, - 105% ± 27% (I/M) and 118% ± 40% (S/C).","Pharmacokinetic profiles of levofloxacin after intravenous, intramuscular and subcutaneous administration to rabbits (Oryctolagus cuniculus). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32233138/),%,105,4854,DB01137,Levofloxacin
,32233138,Bioavailability,"Bioavailability values, after extravascular administration were complete, - 105% ± 27% (I/M) and 118% ± 40% (S/C).","Pharmacokinetic profiles of levofloxacin after intravenous, intramuscular and subcutaneous administration to rabbits (Oryctolagus cuniculus). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32233138/),%,118,4855,DB01137,Levofloxacin
,32233138,extraction ratio,Average extraction ratio of levofloxacin after I/V administration was 7%.,"Pharmacokinetic profiles of levofloxacin after intravenous, intramuscular and subcutaneous administration to rabbits (Oryctolagus cuniculus). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32233138/),%,7,4856,DB01137,Levofloxacin
<,32233138,MIC,"The studied dose is unlikely to be effective in rabbits; however, it was calculated that a daily dose of 29 mg/kg appears effective for I/V administration for pathogens with MIC < 0.5 μg/mL.","Pharmacokinetic profiles of levofloxacin after intravenous, intramuscular and subcutaneous administration to rabbits (Oryctolagus cuniculus). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32233138/),[μg] / [ml],0.5,4857,DB01137,Levofloxacin
,20226636,area under the concentration-time curve (AUC)/MIC,"For all the isolates, Gram-negative bacilli, Gram-positive cocci, Escherichia coli and Enterococcus faecalis, the target values of the area under the concentration-time curve (AUC)/MIC were 14.65, 31.46, 4.85, 43.00 and 3.06, respectively, and the targets of the maximum plasma concentration (C(max))/MIC were 1.22, 2.74, 0.39, 3.61 and 0.25, respectively.",Microbiological outcome of complicated urinary tract infections treated with levofloxacin: a pharmacokinetic/pharmacodynamic analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20226636/),,14.65,4937,DB01137,Levofloxacin
,20226636,area under the concentration-time curve (AUC)/MIC,"For all the isolates, Gram-negative bacilli, Gram-positive cocci, Escherichia coli and Enterococcus faecalis, the target values of the area under the concentration-time curve (AUC)/MIC were 14.65, 31.46, 4.85, 43.00 and 3.06, respectively, and the targets of the maximum plasma concentration (C(max))/MIC were 1.22, 2.74, 0.39, 3.61 and 0.25, respectively.",Microbiological outcome of complicated urinary tract infections treated with levofloxacin: a pharmacokinetic/pharmacodynamic analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20226636/),,31.46,4938,DB01137,Levofloxacin
,20226636,area under the concentration-time curve (AUC)/MIC,"For all the isolates, Gram-negative bacilli, Gram-positive cocci, Escherichia coli and Enterococcus faecalis, the target values of the area under the concentration-time curve (AUC)/MIC were 14.65, 31.46, 4.85, 43.00 and 3.06, respectively, and the targets of the maximum plasma concentration (C(max))/MIC were 1.22, 2.74, 0.39, 3.61 and 0.25, respectively.",Microbiological outcome of complicated urinary tract infections treated with levofloxacin: a pharmacokinetic/pharmacodynamic analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20226636/),,4.85,4939,DB01137,Levofloxacin
,20226636,area under the concentration-time curve (AUC)/MIC,"For all the isolates, Gram-negative bacilli, Gram-positive cocci, Escherichia coli and Enterococcus faecalis, the target values of the area under the concentration-time curve (AUC)/MIC were 14.65, 31.46, 4.85, 43.00 and 3.06, respectively, and the targets of the maximum plasma concentration (C(max))/MIC were 1.22, 2.74, 0.39, 3.61 and 0.25, respectively.",Microbiological outcome of complicated urinary tract infections treated with levofloxacin: a pharmacokinetic/pharmacodynamic analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20226636/),,43.00,4940,DB01137,Levofloxacin
,20226636,area under the concentration-time curve (AUC)/MIC,"For all the isolates, Gram-negative bacilli, Gram-positive cocci, Escherichia coli and Enterococcus faecalis, the target values of the area under the concentration-time curve (AUC)/MIC were 14.65, 31.46, 4.85, 43.00 and 3.06, respectively, and the targets of the maximum plasma concentration (C(max))/MIC were 1.22, 2.74, 0.39, 3.61 and 0.25, respectively.",Microbiological outcome of complicated urinary tract infections treated with levofloxacin: a pharmacokinetic/pharmacodynamic analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20226636/),,3.06,4941,DB01137,Levofloxacin
,20226636,maximum plasma concentration (C(max))/MIC,"For all the isolates, Gram-negative bacilli, Gram-positive cocci, Escherichia coli and Enterococcus faecalis, the target values of the area under the concentration-time curve (AUC)/MIC were 14.65, 31.46, 4.85, 43.00 and 3.06, respectively, and the targets of the maximum plasma concentration (C(max))/MIC were 1.22, 2.74, 0.39, 3.61 and 0.25, respectively.",Microbiological outcome of complicated urinary tract infections treated with levofloxacin: a pharmacokinetic/pharmacodynamic analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20226636/),,1.22,4942,DB01137,Levofloxacin
,20226636,maximum plasma concentration (C(max))/MIC,"For all the isolates, Gram-negative bacilli, Gram-positive cocci, Escherichia coli and Enterococcus faecalis, the target values of the area under the concentration-time curve (AUC)/MIC were 14.65, 31.46, 4.85, 43.00 and 3.06, respectively, and the targets of the maximum plasma concentration (C(max))/MIC were 1.22, 2.74, 0.39, 3.61 and 0.25, respectively.",Microbiological outcome of complicated urinary tract infections treated with levofloxacin: a pharmacokinetic/pharmacodynamic analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20226636/),,2.74,4943,DB01137,Levofloxacin
,20226636,maximum plasma concentration (C(max))/MIC,"For all the isolates, Gram-negative bacilli, Gram-positive cocci, Escherichia coli and Enterococcus faecalis, the target values of the area under the concentration-time curve (AUC)/MIC were 14.65, 31.46, 4.85, 43.00 and 3.06, respectively, and the targets of the maximum plasma concentration (C(max))/MIC were 1.22, 2.74, 0.39, 3.61 and 0.25, respectively.",Microbiological outcome of complicated urinary tract infections treated with levofloxacin: a pharmacokinetic/pharmacodynamic analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20226636/),,0.39,4944,DB01137,Levofloxacin
,20226636,maximum plasma concentration (C(max))/MIC,"For all the isolates, Gram-negative bacilli, Gram-positive cocci, Escherichia coli and Enterococcus faecalis, the target values of the area under the concentration-time curve (AUC)/MIC were 14.65, 31.46, 4.85, 43.00 and 3.06, respectively, and the targets of the maximum plasma concentration (C(max))/MIC were 1.22, 2.74, 0.39, 3.61 and 0.25, respectively.",Microbiological outcome of complicated urinary tract infections treated with levofloxacin: a pharmacokinetic/pharmacodynamic analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20226636/),,3.61,4945,DB01137,Levofloxacin
,20226636,maximum plasma concentration (C(max))/MIC,"For all the isolates, Gram-negative bacilli, Gram-positive cocci, Escherichia coli and Enterococcus faecalis, the target values of the area under the concentration-time curve (AUC)/MIC were 14.65, 31.46, 4.85, 43.00 and 3.06, respectively, and the targets of the maximum plasma concentration (C(max))/MIC were 1.22, 2.74, 0.39, 3.61 and 0.25, respectively.",Microbiological outcome of complicated urinary tract infections treated with levofloxacin: a pharmacokinetic/pharmacodynamic analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20226636/),,0.25,4946,DB01137,Levofloxacin
<,20226636,C(max)/MIC,"In particular, the C(max)/MIC thresholds for Gram-positive cocci and E. faecalis were <1.",Microbiological outcome of complicated urinary tract infections treated with levofloxacin: a pharmacokinetic/pharmacodynamic analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20226636/),,1,4947,DB01137,Levofloxacin
,17570646,"maximum free plasma levofloxacin concentration (fC(max,ss))","The maximum free plasma levofloxacin concentration (fC(max,ss)) and the area under the free concentration-time curve (fAUC) were 8.13+/-1.64 mg/L and 49.63+/-15.60 mgh/L, respectively.",Pharmacokinetics and pharmacodynamics of levofloxacin in critically ill patients with ventilator-associated pneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17570646/),[mg] / [l],8.13,6111,DB01137,Levofloxacin
,17570646,area under the free concentration-time curve (fAUC),"The maximum free plasma levofloxacin concentration (fC(max,ss)) and the area under the free concentration-time curve (fAUC) were 8.13+/-1.64 mg/L and 49.63+/-15.60 mgh/L, respectively.",Pharmacokinetics and pharmacodynamics of levofloxacin in critically ill patients with ventilator-associated pneumonia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17570646/),[mgh] / [l],49.63,6112,DB01137,Levofloxacin
,17532709,maximum concentrations (C(max)),Both antibacterials showed a high level of intracellular penetration exhibiting PMNs/plasma ratios of 17.34 +/- 8.29 for moxifloxacin versus 8.15 +/- 5.23 for levofloxacin for maximum concentrations (C(max)) and 14.72 +/- 8.29 for moxifloxacin versus 8.15 +/- 5.23 for levofloxacin for the area under the plasma concentration-time curve.,In vivo comparative pharmacokinetics and pharmacodynamics of moxifloxacin and levofloxacin in human neutrophils. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17532709/),,8.15,6636,DB01137,Levofloxacin
,17532709,area under the plasma concentration-time curve,Both antibacterials showed a high level of intracellular penetration exhibiting PMNs/plasma ratios of 17.34 +/- 8.29 for moxifloxacin versus 8.15 +/- 5.23 for levofloxacin for maximum concentrations (C(max)) and 14.72 +/- 8.29 for moxifloxacin versus 8.15 +/- 5.23 for levofloxacin for the area under the plasma concentration-time curve.,In vivo comparative pharmacokinetics and pharmacodynamics of moxifloxacin and levofloxacin in human neutrophils. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17532709/),,14.72,6637,DB01137,Levofloxacin
,17532709,area under the plasma concentration-time curve,Both antibacterials showed a high level of intracellular penetration exhibiting PMNs/plasma ratios of 17.34 +/- 8.29 for moxifloxacin versus 8.15 +/- 5.23 for levofloxacin for maximum concentrations (C(max)) and 14.72 +/- 8.29 for moxifloxacin versus 8.15 +/- 5.23 for levofloxacin for the area under the plasma concentration-time curve.,In vivo comparative pharmacokinetics and pharmacodynamics of moxifloxacin and levofloxacin in human neutrophils. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17532709/),,8.15,6638,DB01137,Levofloxacin
,17532709,C(max)/MIC ratios,"Indeed, C(max)/MIC ratios calculated in PMNs for moxifloxacin were 287.3 and 718.2 for S. pneumoniae and S. aureus, respectively, and for levofloxacin were 25.6 and 205.1, respectively.",In vivo comparative pharmacokinetics and pharmacodynamics of moxifloxacin and levofloxacin in human neutrophils. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17532709/),,287.3,6639,DB01137,Levofloxacin
,17532709,C(max)/MIC ratios,"Indeed, C(max)/MIC ratios calculated in PMNs for moxifloxacin were 287.3 and 718.2 for S. pneumoniae and S. aureus, respectively, and for levofloxacin were 25.6 and 205.1, respectively.",In vivo comparative pharmacokinetics and pharmacodynamics of moxifloxacin and levofloxacin in human neutrophils. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17532709/),,718.2,6640,DB01137,Levofloxacin
,17532709,C(max)/MIC ratios,"Indeed, C(max)/MIC ratios calculated in PMNs for moxifloxacin were 287.3 and 718.2 for S. pneumoniae and S. aureus, respectively, and for levofloxacin were 25.6 and 205.1, respectively.",In vivo comparative pharmacokinetics and pharmacodynamics of moxifloxacin and levofloxacin in human neutrophils. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17532709/),,25.6,6641,DB01137,Levofloxacin
,17532709,C(max)/MIC ratios,"Indeed, C(max)/MIC ratios calculated in PMNs for moxifloxacin were 287.3 and 718.2 for S. pneumoniae and S. aureus, respectively, and for levofloxacin were 25.6 and 205.1, respectively.",In vivo comparative pharmacokinetics and pharmacodynamics of moxifloxacin and levofloxacin in human neutrophils. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17532709/),,205.1,6642,DB01137,Levofloxacin
,11913498,effects,"At 10-times the MIC, the post-antibiotic effects of BMS-284756, levofloxacin, and ciprofloxacin were 1.6-2.6 h for the methicillin-susceptible Staphylococcus aureus strain and 1.5-1.9 h for the methicillin-resistant Staphylococcus aureus strain.","Comparison of the bactericidal activities and post-antibiotic effects of the Des-F(6)-quinolone BMS-284756, levofloxacin, and ciprofloxacin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11913498/),h,1.6-2.6,8340,DB01137,Levofloxacin
,11913498,effects,"At 10-times the MIC, the post-antibiotic effects of BMS-284756, levofloxacin, and ciprofloxacin were 1.6-2.6 h for the methicillin-susceptible Staphylococcus aureus strain and 1.5-1.9 h for the methicillin-resistant Staphylococcus aureus strain.","Comparison of the bactericidal activities and post-antibiotic effects of the Des-F(6)-quinolone BMS-284756, levofloxacin, and ciprofloxacin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11913498/),h,1.5-1.9,8341,DB01137,Levofloxacin
,21444699,maximum plasma concentration (C(max)),"The mean maximum plasma concentration (C(max)) ranged between 2,563 and 2,932 mg/liter for 180-mg doses of the 50- and 100-mg/ml formulations, respectively.",Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21444699/),[mg] / [l],"2,563 and 2,932",8537,DB01137,Levofloxacin
,21444699,C(max),"After 7 days of dosing, the mean C(max) for the 240-mg dose was 4,691 mg/liter.",Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21444699/),[mg] / [l],"4,691",8538,DB01137,Levofloxacin
,21444699,C(max),The mean serum levofloxacin C(max) ranged between 0.95 and 1.28 for the 180-mg doses and was 1.71 for the 240-mg dose.,Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21444699/),,0.95 and 1.28,8539,DB01137,Levofloxacin
,21444699,C(max),The mean serum levofloxacin C(max) ranged between 0.95 and 1.28 for the 180-mg doses and was 1.71 for the 240-mg dose.,Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21444699/),,1.71,8540,DB01137,Levofloxacin
,8593013,peak concentrations,"Mean peak concentrations in plasma of 9.3 and 6.6 micrograms/ml were attained 1.1 and 1.2 h after the 12- and 24-h regimens, respectively.",Open-label crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593013/),[μg] / [ml],9.3,8864,DB01137,Levofloxacin
,8593013,peak concentrations,"Mean peak concentrations in plasma of 9.3 and 6.6 micrograms/ml were attained 1.1 and 1.2 h after the 12- and 24-h regimens, respectively.",Open-label crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593013/),[μg] / [ml],6.6,8865,DB01137,Levofloxacin
,8593013,peak concentrations is inflammatory fluid,"Mean peak concentrations is inflammatory fluid of 6.8 and 4.3 micrograms/ml were attained at 2.3 and 3.7 h, respectively.",Open-label crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593013/),[μg] / [ml],6.8,8866,DB01137,Levofloxacin
,8593013,peak concentrations is inflammatory fluid,"Mean peak concentrations is inflammatory fluid of 6.8 and 4.3 micrograms/ml were attained at 2.3 and 3.7 h, respectively.",Open-label crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593013/),[μg] / [ml],4.3,8867,DB01137,Levofloxacin
,8593013,steady-state concentrations,"The average steady-state concentrations were 5.0 and 2.2 micrograms/ml in plasma and 4.7 and 2.3 micrograms/ml in inflammatory fluid, respectively.",Open-label crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593013/),[μg] / [ml],5.0,8868,DB01137,Levofloxacin
,8593013,steady-state concentrations,"The average steady-state concentrations were 5.0 and 2.2 micrograms/ml in plasma and 4.7 and 2.3 micrograms/ml in inflammatory fluid, respectively.",Open-label crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593013/),[μg] / [ml],2.2,8869,DB01137,Levofloxacin
,8593013,steady-state concentrations,"The average steady-state concentrations were 5.0 and 2.2 micrograms/ml in plasma and 4.7 and 2.3 micrograms/ml in inflammatory fluid, respectively.",Open-label crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593013/),[μg] / [ml],4.7,8870,DB01137,Levofloxacin
,8593013,steady-state concentrations,"The average steady-state concentrations were 5.0 and 2.2 micrograms/ml in plasma and 4.7 and 2.3 micrograms/ml in inflammatory fluid, respectively.",Open-label crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593013/),[μg] / [ml],2.3,8871,DB01137,Levofloxacin
,8593013,terminal elimination half-lives,"The mean terminal elimination half-lives for plasma were 7.9 and 8.0 h for the two regimens, respectively, and the same values were noted for inflammatory fluid.",Open-label crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593013/),h,7.9,8872,DB01137,Levofloxacin
,8593013,terminal elimination half-lives,"The mean terminal elimination half-lives for plasma were 7.9 and 8.0 h for the two regimens, respectively, and the same values were noted for inflammatory fluid.",Open-label crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593013/),h,8.0,8873,DB01137,Levofloxacin
,8593013,overall penetration into inflammatory fluid,The overall penetration into inflammatory fluid ranged from 88 to 101% with the 12-h regimen and 83 to 112% with the 24-h regimen.,Open-label crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593013/),%,88 to 101,8874,DB01137,Levofloxacin
,8593013,overall penetration into inflammatory fluid,The overall penetration into inflammatory fluid ranged from 88 to 101% with the 12-h regimen and 83 to 112% with the 24-h regimen.,Open-label crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593013/),%,83 to 112,8875,DB01137,Levofloxacin
,8593013,urinary recoveries,"Mean urinary recoveries were 87 and 86% over the corresponding interval of the 12- and 24-h regimens, respectively.",Open-label crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593013/),%,87,8876,DB01137,Levofloxacin
,8593013,urinary recoveries,"Mean urinary recoveries were 87 and 86% over the corresponding interval of the 12- and 24-h regimens, respectively.",Open-label crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593013/),%,86,8877,DB01137,Levofloxacin
,18155885,maximum serum concentration (C(max)),"The mean pharmacokinetic parameters for the first dose were: maximum serum concentration (C(max)) 12.5+/-4.7 mg/L (range 5.6-16.0mg/L) (fC(max) 8.8+/-3.3, where f indicates the levofloxacin free or non-protein-bound fraction), area under the serum concentration-time curve (AUC) 85.4+/-14.1 mgh/L (range 66.2-96.8 mgh/L) (fAUC 59.8+/-9.9) and serum half-life (t(1/2)) 6.7+/-0.5h.",Pharmacokinetics/pharmacodynamics of levofloxacin 750 mg once daily in young women with acute uncomplicated pyelonephritis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18155885/),[mg] / [l],12.5,10018,DB01137,Levofloxacin
,18155885,fC(max),"The mean pharmacokinetic parameters for the first dose were: maximum serum concentration (C(max)) 12.5+/-4.7 mg/L (range 5.6-16.0mg/L) (fC(max) 8.8+/-3.3, where f indicates the levofloxacin free or non-protein-bound fraction), area under the serum concentration-time curve (AUC) 85.4+/-14.1 mgh/L (range 66.2-96.8 mgh/L) (fAUC 59.8+/-9.9) and serum half-life (t(1/2)) 6.7+/-0.5h.",Pharmacokinetics/pharmacodynamics of levofloxacin 750 mg once daily in young women with acute uncomplicated pyelonephritis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18155885/),,8.8,10019,DB01137,Levofloxacin
,18155885,area under the serum concentration-time curve (AUC),"The mean pharmacokinetic parameters for the first dose were: maximum serum concentration (C(max)) 12.5+/-4.7 mg/L (range 5.6-16.0mg/L) (fC(max) 8.8+/-3.3, where f indicates the levofloxacin free or non-protein-bound fraction), area under the serum concentration-time curve (AUC) 85.4+/-14.1 mgh/L (range 66.2-96.8 mgh/L) (fAUC 59.8+/-9.9) and serum half-life (t(1/2)) 6.7+/-0.5h.",Pharmacokinetics/pharmacodynamics of levofloxacin 750 mg once daily in young women with acute uncomplicated pyelonephritis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18155885/),[mgh] / [l],85.4,10020,DB01137,Levofloxacin
,18155885,fAUC,"The mean pharmacokinetic parameters for the first dose were: maximum serum concentration (C(max)) 12.5+/-4.7 mg/L (range 5.6-16.0mg/L) (fC(max) 8.8+/-3.3, where f indicates the levofloxacin free or non-protein-bound fraction), area under the serum concentration-time curve (AUC) 85.4+/-14.1 mgh/L (range 66.2-96.8 mgh/L) (fAUC 59.8+/-9.9) and serum half-life (t(1/2)) 6.7+/-0.5h.",Pharmacokinetics/pharmacodynamics of levofloxacin 750 mg once daily in young women with acute uncomplicated pyelonephritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18155885/),,59.8,10021,DB01137,Levofloxacin
,18155885,serum half-life (t(1/2)),"The mean pharmacokinetic parameters for the first dose were: maximum serum concentration (C(max)) 12.5+/-4.7 mg/L (range 5.6-16.0mg/L) (fC(max) 8.8+/-3.3, where f indicates the levofloxacin free or non-protein-bound fraction), area under the serum concentration-time curve (AUC) 85.4+/-14.1 mgh/L (range 66.2-96.8 mgh/L) (fAUC 59.8+/-9.9) and serum half-life (t(1/2)) 6.7+/-0.5h.",Pharmacokinetics/pharmacodynamics of levofloxacin 750 mg once daily in young women with acute uncomplicated pyelonephritis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18155885/),h,6.7,10022,DB01137,Levofloxacin
,18155885,urine concentrations,"Mean urine concentrations were 88.0+/-100mg/L at the 0-3 h collection, 307+/-143 mg/L at 3-6 h, 170+/-107 mg/L at 6-12 h and 85+/-8 mg/L at 12-24 h.",Pharmacokinetics/pharmacodynamics of levofloxacin 750 mg once daily in young women with acute uncomplicated pyelonephritis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18155885/),[mg] / [l],88.0,10023,DB01137,Levofloxacin
,18155885,urine concentrations,"Mean urine concentrations were 88.0+/-100mg/L at the 0-3 h collection, 307+/-143 mg/L at 3-6 h, 170+/-107 mg/L at 6-12 h and 85+/-8 mg/L at 12-24 h.",Pharmacokinetics/pharmacodynamics of levofloxacin 750 mg once daily in young women with acute uncomplicated pyelonephritis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18155885/),[mg] / [l],307,10024,DB01137,Levofloxacin
,18155885,urine concentrations,"Mean urine concentrations were 88.0+/-100mg/L at the 0-3 h collection, 307+/-143 mg/L at 3-6 h, 170+/-107 mg/L at 6-12 h and 85+/-8 mg/L at 12-24 h.",Pharmacokinetics/pharmacodynamics of levofloxacin 750 mg once daily in young women with acute uncomplicated pyelonephritis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18155885/),[mg] / [l],170,10025,DB01137,Levofloxacin
,18155885,urine concentrations,"Mean urine concentrations were 88.0+/-100mg/L at the 0-3 h collection, 307+/-143 mg/L at 3-6 h, 170+/-107 mg/L at 6-12 h and 85+/-8 mg/L at 12-24 h.",Pharmacokinetics/pharmacodynamics of levofloxacin 750 mg once daily in young women with acute uncomplicated pyelonephritis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18155885/),[mg] / [l],85,10026,DB01137,Levofloxacin
,18155885,C(max)/minimum inhibitory concentration (MIC),Mean levofloxacin serum pharmacodynamics for infecting Escherichia coli were: C(max)/minimum inhibitory concentration (MIC) 323+/-185(fC(max)/MIC 226+/-129); and AUC/MIC 2339+/-830(fAUC/MIC 1647+/-579).,Pharmacokinetics/pharmacodynamics of levofloxacin 750 mg once daily in young women with acute uncomplicated pyelonephritis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18155885/),,323,10027,DB01137,Levofloxacin
,18155885,fC(max)/MIC,Mean levofloxacin serum pharmacodynamics for infecting Escherichia coli were: C(max)/minimum inhibitory concentration (MIC) 323+/-185(fC(max)/MIC 226+/-129); and AUC/MIC 2339+/-830(fAUC/MIC 1647+/-579).,Pharmacokinetics/pharmacodynamics of levofloxacin 750 mg once daily in young women with acute uncomplicated pyelonephritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18155885/),,226,10028,DB01137,Levofloxacin
,18155885,AUC/MIC,Mean levofloxacin serum pharmacodynamics for infecting Escherichia coli were: C(max)/minimum inhibitory concentration (MIC) 323+/-185(fC(max)/MIC 226+/-129); and AUC/MIC 2339+/-830(fAUC/MIC 1647+/-579).,Pharmacokinetics/pharmacodynamics of levofloxacin 750 mg once daily in young women with acute uncomplicated pyelonephritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18155885/),,2339,10029,DB01137,Levofloxacin
,18155885,fAUC/MIC,Mean levofloxacin serum pharmacodynamics for infecting Escherichia coli were: C(max)/minimum inhibitory concentration (MIC) 323+/-185(fC(max)/MIC 226+/-129); and AUC/MIC 2339+/-830(fAUC/MIC 1647+/-579).,Pharmacokinetics/pharmacodynamics of levofloxacin 750 mg once daily in young women with acute uncomplicated pyelonephritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18155885/),,1647,10030,DB01137,Levofloxacin
,18155885,concentration/MIC ratios,"Mean urine levofloxacin concentration/MIC ratios were: 900+/-1389 for 0-3 h, 12100+/-4950 for 3-6 h, 5922+/-3912 for 6-12 h and 2233+/-1037 for 12-24 h.",Pharmacokinetics/pharmacodynamics of levofloxacin 750 mg once daily in young women with acute uncomplicated pyelonephritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18155885/),,900,10031,DB01137,Levofloxacin
,18155885,concentration/MIC ratios,"Mean urine levofloxacin concentration/MIC ratios were: 900+/-1389 for 0-3 h, 12100+/-4950 for 3-6 h, 5922+/-3912 for 6-12 h and 2233+/-1037 for 12-24 h.",Pharmacokinetics/pharmacodynamics of levofloxacin 750 mg once daily in young women with acute uncomplicated pyelonephritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18155885/),,12100,10032,DB01137,Levofloxacin
,18155885,concentration/MIC ratios,"Mean urine levofloxacin concentration/MIC ratios were: 900+/-1389 for 0-3 h, 12100+/-4950 for 3-6 h, 5922+/-3912 for 6-12 h and 2233+/-1037 for 12-24 h.",Pharmacokinetics/pharmacodynamics of levofloxacin 750 mg once daily in young women with acute uncomplicated pyelonephritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18155885/),,5922,10033,DB01137,Levofloxacin
,18155885,concentration/MIC ratios,"Mean urine levofloxacin concentration/MIC ratios were: 900+/-1389 for 0-3 h, 12100+/-4950 for 3-6 h, 5922+/-3912 for 6-12 h and 2233+/-1037 for 12-24 h.",Pharmacokinetics/pharmacodynamics of levofloxacin 750 mg once daily in young women with acute uncomplicated pyelonephritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18155885/),,2233,10034,DB01137,Levofloxacin
less,11120966,MICs,"The MICs at which 90% of the isolates were inhibited of L-036 against methicillin-susceptible staphylococci, Streptococcus pneumoniae including penicillin-resistant organisms, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae including ampicillin-resistant organisms, Legionella pneumophila, and Moraxella catarrhalis were equal to or less than 1 microg/ml.","In vitro and in vivo antibacterial activities of L-084, a novel oral carbapenem, against causative organisms of respiratory tract infections. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11120966/),[μg] / [ml],1,12036,DB01137,Levofloxacin
,11120966,maximum concentration in serum,"In pharmacokinetics studies of L-084 in lungs of mice, the maximum concentration in serum, half-life, and area under the concentration-time curve of this drug were 9.09 microg/g of tissue, 6.18 h, and 31.0 microg.","In vitro and in vivo antibacterial activities of L-084, a novel oral carbapenem, against causative organisms of respiratory tract infections. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11120966/),[μg] / [g],9.09,12037,DB01137,Levofloxacin
,11120966,half-life,"In pharmacokinetics studies of L-084 in lungs of mice, the maximum concentration in serum, half-life, and area under the concentration-time curve of this drug were 9.09 microg/g of tissue, 6.18 h, and 31.0 microg.","In vitro and in vivo antibacterial activities of L-084, a novel oral carbapenem, against causative organisms of respiratory tract infections. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11120966/),h,6.18,12038,DB01137,Levofloxacin
,11120966,area under the concentration-time curve,"In pharmacokinetics studies of L-084 in lungs of mice, the maximum concentration in serum, half-life, and area under the concentration-time curve of this drug were 9.09 microg/g of tissue, 6.18 h, and 31.0 microg.","In vitro and in vivo antibacterial activities of L-084, a novel oral carbapenem, against causative organisms of respiratory tract infections. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11120966/),μg,31.0,12039,DB01137,Levofloxacin
,25870068,MICs,Doses in the range of 17 to 20 mg/kg showed good target attainment for MICs from 0.25 to 0.50.,Limited sampling strategy and target attainment analysis for levofloxacin in patients with tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25870068/),,0,13072,DB01137,Levofloxacin
,25870068,MIC,"At an MIC of 2, poor target attainment was observed across all doses.",Limited sampling strategy and target attainment analysis for levofloxacin in patients with tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25870068/),,2,13073,DB01137,Levofloxacin
,32384070,distribution half-life,"Following the administration of levofloxacin alone, the mean distribution half-life, elimination half-life, total clearance, volume of distribution at steady state and area under the plasma concentration-time curve were 0.20 h, 1.82 h, 0.39 L/h/kg, 0.96 L/kg and 10.40 h × µg/mL, respectively.",Influences of tolfenamic acid and flunixin meglumine on the disposition kinetics of levofloxacin in sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32384070/),h,0.20,13080,DB01137,Levofloxacin
,32384070,elimination half-life,"Following the administration of levofloxacin alone, the mean distribution half-life, elimination half-life, total clearance, volume of distribution at steady state and area under the plasma concentration-time curve were 0.20 h, 1.82 h, 0.39 L/h/kg, 0.96 L/kg and 10.40 h × µg/mL, respectively.",Influences of tolfenamic acid and flunixin meglumine on the disposition kinetics of levofloxacin in sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32384070/),h,1.82,13081,DB01137,Levofloxacin
,32384070,area under the plasma concentration-time curve,"Following the administration of levofloxacin alone, the mean distribution half-life, elimination half-life, total clearance, volume of distribution at steady state and area under the plasma concentration-time curve were 0.20 h, 1.82 h, 0.39 L/h/kg, 0.96 L/kg and 10.40 h × µg/mL, respectively.",Influences of tolfenamic acid and flunixin meglumine on the disposition kinetics of levofloxacin in sheep. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32384070/),[h·μg] / [ml],10.40,13082,DB01137,Levofloxacin
,18968121,linear,"The linear dynamic ranges are 0.36-2.16 (R), 0.36-2.89 and 3.16-31.6 mug/ml (S), respectively, for determining OFLX in urine samples.",Recognition and simultaneous determination of ofloxacin enantiomers by synchronization-1st derivative fluorescence spectroscopy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18968121/),[μg] / [ml],0.36-2.16,14397,DB01137,Levofloxacin
,18968121,linear,"The linear dynamic ranges are 0.36-2.16 (R), 0.36-2.89 and 3.16-31.6 mug/ml (S), respectively, for determining OFLX in urine samples.",Recognition and simultaneous determination of ofloxacin enantiomers by synchronization-1st derivative fluorescence spectroscopy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18968121/),[μg] / [ml],0.36-2.89,14398,DB01137,Levofloxacin
,18968121,linear,"The linear dynamic ranges are 0.36-2.16 (R), 0.36-2.89 and 3.16-31.6 mug/ml (S), respectively, for determining OFLX in urine samples.",Recognition and simultaneous determination of ofloxacin enantiomers by synchronization-1st derivative fluorescence spectroscopy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18968121/),[μg] / [ml],3.16-31.6,14399,DB01137,Levofloxacin
,18968121,limits of detection,The limits of detection are 0.36 mug/ml (R) and the recoveries of R-(+)- and S-(-)-OFLX in urine samples are 97-104%.,Recognition and simultaneous determination of ofloxacin enantiomers by synchronization-1st derivative fluorescence spectroscopy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18968121/),[μg] / [ml],0.36,14400,DB01137,Levofloxacin
,18968121,recoveries,The limits of detection are 0.36 mug/ml (R) and the recoveries of R-(+)- and S-(-)-OFLX in urine samples are 97-104%.,Recognition and simultaneous determination of ofloxacin enantiomers by synchronization-1st derivative fluorescence spectroscopy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18968121/),%,97-104,14401,DB01137,Levofloxacin
,28109739,MICs,"The MICs of DS-8587 and LVFX were 0.015 and 1 mg/mL, respectively.","In vivo antianaerobe activity of DS-8587, a new fluoroquinolone, against Fusobacterium necrophorum in a mouse model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28109739/),[mg] / [ml],0.015,17822,DB01137,Levofloxacin
,28109739,MICs,"The MICs of DS-8587 and LVFX were 0.015 and 1 mg/mL, respectively.","In vivo antianaerobe activity of DS-8587, a new fluoroquinolone, against Fusobacterium necrophorum in a mouse model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28109739/),[mg] / [ml],1,17823,DB01137,Levofloxacin
,28109739,AUC/MIC ratios,"The pharmacokinetic parameter AUC/MIC ratios for DS-8587 (4 mg/kg) and LVFX (100 mg/kg) were 96.7 and 60.8 in plasma and 600 and 145.6 in the liver, respectively.","In vivo antianaerobe activity of DS-8587, a new fluoroquinolone, against Fusobacterium necrophorum in a mouse model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28109739/),,96.7,17824,DB01137,Levofloxacin
,28109739,AUC/MIC ratios,"The pharmacokinetic parameter AUC/MIC ratios for DS-8587 (4 mg/kg) and LVFX (100 mg/kg) were 96.7 and 60.8 in plasma and 600 and 145.6 in the liver, respectively.","In vivo antianaerobe activity of DS-8587, a new fluoroquinolone, against Fusobacterium necrophorum in a mouse model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28109739/),,60.8,17825,DB01137,Levofloxacin
,28109739,AUC/MIC ratios,"The pharmacokinetic parameter AUC/MIC ratios for DS-8587 (4 mg/kg) and LVFX (100 mg/kg) were 96.7 and 60.8 in plasma and 600 and 145.6 in the liver, respectively.","In vivo antianaerobe activity of DS-8587, a new fluoroquinolone, against Fusobacterium necrophorum in a mouse model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28109739/),,600,17826,DB01137,Levofloxacin
,28109739,AUC/MIC ratios,"The pharmacokinetic parameter AUC/MIC ratios for DS-8587 (4 mg/kg) and LVFX (100 mg/kg) were 96.7 and 60.8 in plasma and 600 and 145.6 in the liver, respectively.","In vivo antianaerobe activity of DS-8587, a new fluoroquinolone, against Fusobacterium necrophorum in a mouse model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28109739/),,145.6,17827,DB01137,Levofloxacin
,21730117,MIC(90),"Among these agents, sitafloxacin (a fluoroquinolone) showed the greatest activity (MIC(90), 0.06 μg/ml), with high bactericidal activity and synergy in sitafloxacin-lansoprazole (a proton pump inhibitor) combination.",Helicobacter pylori eradication by sitafloxacin-lansoprazole combination and sitafloxacin pharmacokinetics in Mongolian gerbils and its in vitro activity and resistance development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21730117/),[μg] / [ml],0.06,18754,DB01137,Levofloxacin
,21730117,MIC,"In a Mongolian gerbil model with a H. pylori ATCC 43504 challenge, marked eradication effects were observed at ≥1 mg/kg for sitafloxacin, ≥10 mg/kg for levofloxacin, and ≥10 mg/kg for lansoprazole, reflecting MIC levels for each agent (0.008, 0.25, and 2 μg/ml, respectively).",Helicobacter pylori eradication by sitafloxacin-lansoprazole combination and sitafloxacin pharmacokinetics in Mongolian gerbils and its in vitro activity and resistance development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21730117/),[μg] / [ml],0.008,18755,DB01137,Levofloxacin
,21730117,MIC,"In a Mongolian gerbil model with a H. pylori ATCC 43504 challenge, marked eradication effects were observed at ≥1 mg/kg for sitafloxacin, ≥10 mg/kg for levofloxacin, and ≥10 mg/kg for lansoprazole, reflecting MIC levels for each agent (0.008, 0.25, and 2 μg/ml, respectively).",Helicobacter pylori eradication by sitafloxacin-lansoprazole combination and sitafloxacin pharmacokinetics in Mongolian gerbils and its in vitro activity and resistance development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21730117/),[μg] / [ml],0.25,18756,DB01137,Levofloxacin
,21730117,MIC,"In a Mongolian gerbil model with a H. pylori ATCC 43504 challenge, marked eradication effects were observed at ≥1 mg/kg for sitafloxacin, ≥10 mg/kg for levofloxacin, and ≥10 mg/kg for lansoprazole, reflecting MIC levels for each agent (0.008, 0.25, and 2 μg/ml, respectively).",Helicobacter pylori eradication by sitafloxacin-lansoprazole combination and sitafloxacin pharmacokinetics in Mongolian gerbils and its in vitro activity and resistance development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21730117/),[μg] / [ml],2,18757,DB01137,Levofloxacin
,21730117,therapeutic rates,The therapeutic rates were 83.3% for the sitafloxacin (0.3 mg/kg)-lansoprazole (2.5 mg/kg) combination and 0% for either sitafloxacin or lansoprazole alone.,Helicobacter pylori eradication by sitafloxacin-lansoprazole combination and sitafloxacin pharmacokinetics in Mongolian gerbils and its in vitro activity and resistance development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21730117/),%,83,18758,DB01137,Levofloxacin
,21730117,therapeutic rates,The therapeutic rates were 83.3% for the sitafloxacin (0.3 mg/kg)-lansoprazole (2.5 mg/kg) combination and 0% for either sitafloxacin or lansoprazole alone.,Helicobacter pylori eradication by sitafloxacin-lansoprazole combination and sitafloxacin pharmacokinetics in Mongolian gerbils and its in vitro activity and resistance development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21730117/),%,0,18759,DB01137,Levofloxacin
,21730117,maximum serum concentration (C(max)),"The maximum serum concentration (C(max)) of sitafloxacin was 0.080 ± 0.054 μg/ml at 30 min, when orally administered at 1 mg/kg.",Helicobacter pylori eradication by sitafloxacin-lansoprazole combination and sitafloxacin pharmacokinetics in Mongolian gerbils and its in vitro activity and resistance development. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21730117/),[μg] / [ml],0.080,18760,DB01137,Levofloxacin
,24594453,MIC,The MIC range of DS-8587 against MDR A. baumannii was 0.25-2 mg/L.,Anti-multidrug-resistant Acinetobacter baumannii activity of DS-8587: In vitro activity and in vivo efficacy in a murine calf muscle infection model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24594453/),[mg] / [l],0.25-2,20401,DB01137,Levofloxacin
,24594453,AUC/MIC,"The total and free drug AUC/MIC value required for a static effect was 29.4 and 14.1, respectively.",Anti-multidrug-resistant Acinetobacter baumannii activity of DS-8587: In vitro activity and in vivo efficacy in a murine calf muscle infection model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24594453/),,29.4,20402,DB01137,Levofloxacin
,24594453,AUC/MIC,"The total and free drug AUC/MIC value required for a static effect was 29.4 and 14.1, respectively.",Anti-multidrug-resistant Acinetobacter baumannii activity of DS-8587: In vitro activity and in vivo efficacy in a murine calf muscle infection model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24594453/),,14.1,20403,DB01137,Levofloxacin
≤,30025351,MIC,The preliminary results indicated that all mono-isatin-ciprofloxacin hybrids exhibited excellent antibacterial activities with MIC ranging from ≤0.03 to 0.5 μg/mL against most of the tested strains.,"Design, synthesis and antimicrobial evaluation of propylene-tethered ciprofloxacin-isatin hybrids. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30025351/),[μg] / [ml],0,21477,DB01137,Levofloxacin
,30025351,MIC,"Whereas, conjugate 3b (MIC: 0.10 and 0.5 μg/mL) was 4- and 8-fold more active than ciprofloxacin (MIC: 0.78 μg/mL) and rifampicin (MIC: 0.39 μg/mL) against MTB H37Rv, and 4->256 times more potent than the three references ciprofloxacin (MIC: 2.0 μg/mL), rifampicin (MIC: 32 μg/mL) and isoniazid (>128 μg/mL) against MDR-TB.","Design, synthesis and antimicrobial evaluation of propylene-tethered ciprofloxacin-isatin hybrids. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30025351/),[μg] / [ml],0.10,21478,DB01137,Levofloxacin
,30025351,MIC,"Whereas, conjugate 3b (MIC: 0.10 and 0.5 μg/mL) was 4- and 8-fold more active than ciprofloxacin (MIC: 0.78 μg/mL) and rifampicin (MIC: 0.39 μg/mL) against MTB H37Rv, and 4->256 times more potent than the three references ciprofloxacin (MIC: 2.0 μg/mL), rifampicin (MIC: 32 μg/mL) and isoniazid (>128 μg/mL) against MDR-TB.","Design, synthesis and antimicrobial evaluation of propylene-tethered ciprofloxacin-isatin hybrids. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30025351/),[μg] / [ml],0.5,21479,DB01137,Levofloxacin
,30025351,MIC,"Whereas, conjugate 3b (MIC: 0.10 and 0.5 μg/mL) was 4- and 8-fold more active than ciprofloxacin (MIC: 0.78 μg/mL) and rifampicin (MIC: 0.39 μg/mL) against MTB H37Rv, and 4->256 times more potent than the three references ciprofloxacin (MIC: 2.0 μg/mL), rifampicin (MIC: 32 μg/mL) and isoniazid (>128 μg/mL) against MDR-TB.","Design, synthesis and antimicrobial evaluation of propylene-tethered ciprofloxacin-isatin hybrids. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30025351/),[μg] / [ml],0.78,21480,DB01137,Levofloxacin
,30025351,MIC,"Whereas, conjugate 3b (MIC: 0.10 and 0.5 μg/mL) was 4- and 8-fold more active than ciprofloxacin (MIC: 0.78 μg/mL) and rifampicin (MIC: 0.39 μg/mL) against MTB H37Rv, and 4->256 times more potent than the three references ciprofloxacin (MIC: 2.0 μg/mL), rifampicin (MIC: 32 μg/mL) and isoniazid (>128 μg/mL) against MDR-TB.","Design, synthesis and antimicrobial evaluation of propylene-tethered ciprofloxacin-isatin hybrids. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30025351/),[μg] / [ml],0.39,21481,DB01137,Levofloxacin
,30025351,MIC,"Whereas, conjugate 3b (MIC: 0.10 and 0.5 μg/mL) was 4- and 8-fold more active than ciprofloxacin (MIC: 0.78 μg/mL) and rifampicin (MIC: 0.39 μg/mL) against MTB H37Rv, and 4->256 times more potent than the three references ciprofloxacin (MIC: 2.0 μg/mL), rifampicin (MIC: 32 μg/mL) and isoniazid (>128 μg/mL) against MDR-TB.","Design, synthesis and antimicrobial evaluation of propylene-tethered ciprofloxacin-isatin hybrids. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30025351/),[μg] / [ml],2.0,21482,DB01137,Levofloxacin
,30025351,MIC,"Whereas, conjugate 3b (MIC: 0.10 and 0.5 μg/mL) was 4- and 8-fold more active than ciprofloxacin (MIC: 0.78 μg/mL) and rifampicin (MIC: 0.39 μg/mL) against MTB H37Rv, and 4->256 times more potent than the three references ciprofloxacin (MIC: 2.0 μg/mL), rifampicin (MIC: 32 μg/mL) and isoniazid (>128 μg/mL) against MDR-TB.","Design, synthesis and antimicrobial evaluation of propylene-tethered ciprofloxacin-isatin hybrids. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30025351/),[μg] / [ml],32,21483,DB01137,Levofloxacin
>,30025351,MIC,"Whereas, conjugate 3b (MIC: 0.10 and 0.5 μg/mL) was 4- and 8-fold more active than ciprofloxacin (MIC: 0.78 μg/mL) and rifampicin (MIC: 0.39 μg/mL) against MTB H37Rv, and 4->256 times more potent than the three references ciprofloxacin (MIC: 2.0 μg/mL), rifampicin (MIC: 32 μg/mL) and isoniazid (>128 μg/mL) against MDR-TB.","Design, synthesis and antimicrobial evaluation of propylene-tethered ciprofloxacin-isatin hybrids. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30025351/),[μg] / [ml],128,21484,DB01137,Levofloxacin
,30025351,CC50,"Both hybrid 3b and 3d with low cytotoxicity (CC50: 64 and 256 μg/mL) also showed acceptable metabolic stability and in vivo PK properties, could act as leads for further optimization.","Design, synthesis and antimicrobial evaluation of propylene-tethered ciprofloxacin-isatin hybrids. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30025351/),[μg] / [ml],64,21485,DB01137,Levofloxacin
,30025351,CC50,"Both hybrid 3b and 3d with low cytotoxicity (CC50: 64 and 256 μg/mL) also showed acceptable metabolic stability and in vivo PK properties, could act as leads for further optimization.","Design, synthesis and antimicrobial evaluation of propylene-tethered ciprofloxacin-isatin hybrids. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30025351/),[μg] / [ml],256,21486,DB01137,Levofloxacin
,33039880,terminal half-life,"Mean values of terminal half-life for IV and SC groups were 4.56 and 5.14 h, respectively.",Pharmacokinetics of levofloxacin in non-lactating goats and evaluation of drug effects on resistance in coliform rectal flora. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33039880/),h,4.56,24204,DB01137,Levofloxacin
,33039880,terminal half-life,"Mean values of terminal half-life for IV and SC groups were 4.56 and 5.14 h, respectively.",Pharmacokinetics of levofloxacin in non-lactating goats and evaluation of drug effects on resistance in coliform rectal flora. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33039880/),h,5.14,24205,DB01137,Levofloxacin
,33039880,Cmax,"After SC administration, the peak plasma concentration was achieved at 2 h, with a Cmax of 3681 ng/mL.",Pharmacokinetics of levofloxacin in non-lactating goats and evaluation of drug effects on resistance in coliform rectal flora. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33039880/),[ng] / [ml],3681,24206,DB01137,Levofloxacin
,33039880,bioavailability,Mean bioavailability was 92.12%.,Pharmacokinetics of levofloxacin in non-lactating goats and evaluation of drug effects on resistance in coliform rectal flora. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33039880/),%,92.12,24207,DB01137,Levofloxacin
,31061152,time to culture conversion,"New-generation fluoroquinolones showed a faster time to culture conversion (median 16 versus 40 weeks, P = 0.012).",Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31061152/),weeks,16,25010,DB01137,Levofloxacin
,31061152,time to culture conversion,"New-generation fluoroquinolones showed a faster time to culture conversion (median 16 versus 40 weeks, P = 0.012).",Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31061152/),weeks,40,25011,DB01137,Levofloxacin
,24961375,AUCpancreas /AUCblood,"Levofloxacin was equally distributed into ECF of rat pancreatic tissues with either intravenous route (AUCpancreas /AUCblood , 0.97 ± 0.02) or oral route (AUCpancreas /AUCblood , 0.96 ± 0.03).",Quantitative determination of unbound levofloxacin by simultaneous microdialysis in rat pancreas after intravenous and oral doses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24961375/),,0.97,25457,DB01137,Levofloxacin
,24961375,AUCpancreas /AUCblood,"Levofloxacin was equally distributed into ECF of rat pancreatic tissues with either intravenous route (AUCpancreas /AUCblood , 0.97 ± 0.02) or oral route (AUCpancreas /AUCblood , 0.96 ± 0.03).",Quantitative determination of unbound levofloxacin by simultaneous microdialysis in rat pancreas after intravenous and oral doses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24961375/),,0.96,25458,DB01137,Levofloxacin
,24961375,AUC/MIC ratios,"The intravenous antibiotic AUC/MIC ratios of common Gram-positive pancreatic bacteria ranged from 83.43 to 667.44; meanwhile, the ratio of common Gram-negative pancreatic bacteria ranged from 41.71 to 2669.74.",Quantitative determination of unbound levofloxacin by simultaneous microdialysis in rat pancreas after intravenous and oral doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24961375/),,83.43,25459,DB01137,Levofloxacin
,24961375,AUC/MIC ratios,"The intravenous antibiotic AUC/MIC ratios of common Gram-positive pancreatic bacteria ranged from 83.43 to 667.44; meanwhile, the ratio of common Gram-negative pancreatic bacteria ranged from 41.71 to 2669.74.",Quantitative determination of unbound levofloxacin by simultaneous microdialysis in rat pancreas after intravenous and oral doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24961375/),,41,25460,DB01137,Levofloxacin
,24961375,ratio,"The intravenous antibiotic AUC/MIC ratios of common Gram-positive pancreatic bacteria ranged from 83.43 to 667.44; meanwhile, the ratio of common Gram-negative pancreatic bacteria ranged from 41.71 to 2669.74.",Quantitative determination of unbound levofloxacin by simultaneous microdialysis in rat pancreas after intravenous and oral doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24961375/),,41,25461,DB01137,Levofloxacin
,24961375,AUC/MIC ratios,"The oral antibiotic AUC/MIC ratios for common gram-positive and Gram-negative pancreatic bacteria were from 78.54 to 628.31, and 39.27 to 2513.22, respectively (P > 0.05).",Quantitative determination of unbound levofloxacin by simultaneous microdialysis in rat pancreas after intravenous and oral doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24961375/),,78.54 to 628.31,25462,DB01137,Levofloxacin
,24961375,AUC/MIC ratios,"The oral antibiotic AUC/MIC ratios for common gram-positive and Gram-negative pancreatic bacteria were from 78.54 to 628.31, and 39.27 to 2513.22, respectively (P > 0.05).",Quantitative determination of unbound levofloxacin by simultaneous microdialysis in rat pancreas after intravenous and oral doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24961375/),,39.27 to 2513.22,25463,DB01137,Levofloxacin
,12793843,Area under the concentration-time curve (AUC(tau)),Area under the concentration-time curve (AUC(tau)) over the 12-hour dosage interval was about 30-40% lower than in healthy volunteers (33.90 vs 49.60 mg.,Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12793843/),mg,33.90,25881,DB01137,Levofloxacin
,12793843,Area under the concentration-time curve (AUC(tau)),Area under the concentration-time curve (AUC(tau)) over the 12-hour dosage interval was about 30-40% lower than in healthy volunteers (33.90 vs 49.60 mg.,Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12793843/),mg,49.60,25882,DB01137,Levofloxacin
,12793843,clearance,"The reduced exposure may be due to a greater clearance of levofloxacin (0.204 vs 0.145 L/h/kg [3.40 vs 2.42 mL/min/kg]), leading to a shorter elimination half-life (5.2 vs 7.6 hours).",Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12793843/),[l] / [h·kg],0.204,25883,DB01137,Levofloxacin
,12793843,clearance,"The reduced exposure may be due to a greater clearance of levofloxacin (0.204 vs 0.145 L/h/kg [3.40 vs 2.42 mL/min/kg]), leading to a shorter elimination half-life (5.2 vs 7.6 hours).",Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12793843/),[l] / [h·kg],0.145,25884,DB01137,Levofloxacin
,12793843,clearance,"The reduced exposure may be due to a greater clearance of levofloxacin (0.204 vs 0.145 L/h/kg [3.40 vs 2.42 mL/min/kg]), leading to a shorter elimination half-life (5.2 vs 7.6 hours).",Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12793843/),[ml] / [kg·min],3.40,25885,DB01137,Levofloxacin
,12793843,clearance,"The reduced exposure may be due to a greater clearance of levofloxacin (0.204 vs 0.145 L/h/kg [3.40 vs 2.42 mL/min/kg]), leading to a shorter elimination half-life (5.2 vs 7.6 hours).",Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12793843/),[ml] / [kg·min],2.42,25886,DB01137,Levofloxacin
,12793843,elimination half-life,"The reduced exposure may be due to a greater clearance of levofloxacin (0.204 vs 0.145 L/h/kg [3.40 vs 2.42 mL/min/kg]), leading to a shorter elimination half-life (5.2 vs 7.6 hours).",Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12793843/),h,5.2,25887,DB01137,Levofloxacin
,12793843,elimination half-life,"The reduced exposure may be due to a greater clearance of levofloxacin (0.204 vs 0.145 L/h/kg [3.40 vs 2.42 mL/min/kg]), leading to a shorter elimination half-life (5.2 vs 7.6 hours).",Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12793843/),h,7.6,25888,DB01137,Levofloxacin
,12793843,C(max)/MIC (maximum plasma concentration/minimum inhibitory concentration) ratio,Intravenous levofloxacin 500mg twice daily ensured a median C(max)/MIC (maximum plasma concentration/minimum inhibitory concentration) ratio of 102 and a median 24-hour AUC/MIC ratio of 930 SIT(-1).,Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12793843/),,102,25889,DB01137,Levofloxacin
,12793843,24-hour,Intravenous levofloxacin 500mg twice daily ensured a median C(max)/MIC (maximum plasma concentration/minimum inhibitory concentration) ratio of 102 and a median 24-hour AUC/MIC ratio of 930 SIT(-1).,Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12793843/),1/[sit],930,25890,DB01137,Levofloxacin
,12793843,AUC/MIC ratio,Intravenous levofloxacin 500mg twice daily ensured a median C(max)/MIC (maximum plasma concentration/minimum inhibitory concentration) ratio of 102 and a median 24-hour AUC/MIC ratio of 930 SIT(-1).,Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12793843/),1/[sit],930,25891,DB01137,Levofloxacin
,11778184,s,"The sputum conversion rates at the end of treatments of groups I, II, III and IV were 97%, 97%, 82% and 84% respectively.",[Antituberculosis effect of levofloxacin]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11778184/),%,97,25956,DB01137,Levofloxacin
,11778184,s,"The sputum conversion rates at the end of treatments of groups I, II, III and IV were 97%, 97%, 82% and 84% respectively.",[Antituberculosis effect of levofloxacin]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11778184/),%,82,25957,DB01137,Levofloxacin
,11778184,s,"The sputum conversion rates at the end of treatments of groups I, II, III and IV were 97%, 97%, 82% and 84% respectively.",[Antituberculosis effect of levofloxacin]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11778184/),%,84,25958,DB01137,Levofloxacin
,11778184,resolution rates,"X-ray resolution rates were 97%, 94%, 88% and 88% respectively.",[Antituberculosis effect of levofloxacin]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11778184/),%,97,25959,DB01137,Levofloxacin
,11778184,resolution rates,"X-ray resolution rates were 97%, 94%, 88% and 88% respectively.",[Antituberculosis effect of levofloxacin]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11778184/),%,94,25960,DB01137,Levofloxacin
,11778184,resolution rates,"X-ray resolution rates were 97%, 94%, 88% and 88% respectively.",[Antituberculosis effect of levofloxacin]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11778184/),%,88,25961,DB01137,Levofloxacin
,25987620,Cmax,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[mg] / [l],24.9,28221,DB01137,Levofloxacin
,25987620,Cmax,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[h·mg] / [l],242.3,28222,DB01137,Levofloxacin
,25987620,Cmax,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[mg] / [l],65.9,28223,DB01137,Levofloxacin
,25987620,Cmax,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[mg] / [l],5.3,28224,DB01137,Levofloxacin
,25987620,Cmax,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[mg] / [l],6.6,28225,DB01137,Levofloxacin
,25987620,Cmax,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[mg] / [l],4.7,28226,DB01137,Levofloxacin
,25987620,Cmax,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[mg] / [l],42.0,28227,DB01137,Levofloxacin
,25987620,Cmax,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[mg] / [l],34.5,28228,DB01137,Levofloxacin
,25987620,AUCτ,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[h·mg] / [l],242.3,28229,DB01137,Levofloxacin
,25987620,AUCτ,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[mg] / [l],6.6,28230,DB01137,Levofloxacin
,25987620,AUCτ,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[h·mg] / [l],64.4,28231,DB01137,Levofloxacin
,25987620,AUCτ,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[mg] / [l],4.7,28232,DB01137,Levofloxacin
,25987620,AUCτ,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[h·mg] / [l],54.2,28233,DB01137,Levofloxacin
,25987620,AUCτ,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[mg] / [l],42.0,28234,DB01137,Levofloxacin
,25987620,AUCτ,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[h·mg] / [l],196.7,28235,DB01137,Levofloxacin
,25987620,AUCτ,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[mg] / [l],34.5,28236,DB01137,Levofloxacin
,25987620,AUCτ,"The mean Cmax and AUCτ, respectively, for each drug were as follows: cycloserine, 24.9 mg/liter and 242.3 mg · h/liter; PAS, 65.9 mg/liter and 326.5 mg · h/liter; prothionamide, 5.3 mg/liter and 22.1 mg · h/liter; levofloxacin, 6.6 mg/liter and 64.4 mg · h/liter; moxifloxacin, 4.7 mg/liter and 54.2 mg · h/liter; streptomycin, 42.0 mg/liter and 196.7 mg · h/liter; kanamycin, 34.5 mg/liter and 153.5 mg · h/liter.",Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25987620/),[h·mg] / [l],153.5,28237,DB01137,Levofloxacin
,12016861,recoveries,"The mean recoveries were 74.76% in plasma and 82.43% in cerebrospinal fluid, with the lowest detectable limits of 10 micrograms.",[Determination of levofloxacin in plasma and cerebrospinal fluid with HPLC and its pharmacokinetics in patients undergoing neurosurgical operations]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016861/),%,74.76,31685,DB01137,Levofloxacin
,12016861,recoveries,"The mean recoveries were 74.76% in plasma and 82.43% in cerebrospinal fluid, with the lowest detectable limits of 10 micrograms.",[Determination of levofloxacin in plasma and cerebrospinal fluid with HPLC and its pharmacokinetics in patients undergoing neurosurgical operations]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016861/),%,82.43,31686,DB01137,Levofloxacin
,12016861,blood Ke,"The pharmacokinetic parameters were: blood Ke 0.12 +/- 0.04 h-1, T1/2 6.05 +/- 1.68 h, Tmax 1.05 +/- 0.29 h, Cmax 3.67 +/- 0.42 mg.L-1, AUC 33.43 +/- 7.32 mg.",[Determination of levofloxacin in plasma and cerebrospinal fluid with HPLC and its pharmacokinetics in patients undergoing neurosurgical operations]. ,Km-Q52,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016861/),1/[h],0.12,31687,DB01137,Levofloxacin
,12016861,T1/2,"The pharmacokinetic parameters were: blood Ke 0.12 +/- 0.04 h-1, T1/2 6.05 +/- 1.68 h, Tmax 1.05 +/- 0.29 h, Cmax 3.67 +/- 0.42 mg.L-1, AUC 33.43 +/- 7.32 mg.",[Determination of levofloxacin in plasma and cerebrospinal fluid with HPLC and its pharmacokinetics in patients undergoing neurosurgical operations]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016861/),h,6.05,31688,DB01137,Levofloxacin
,12016861,Tmax,"The pharmacokinetic parameters were: blood Ke 0.12 +/- 0.04 h-1, T1/2 6.05 +/- 1.68 h, Tmax 1.05 +/- 0.29 h, Cmax 3.67 +/- 0.42 mg.L-1, AUC 33.43 +/- 7.32 mg.",[Determination of levofloxacin in plasma and cerebrospinal fluid with HPLC and its pharmacokinetics in patients undergoing neurosurgical operations]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016861/),h,1.05,31689,DB01137,Levofloxacin
,12016861,Cmax,"The pharmacokinetic parameters were: blood Ke 0.12 +/- 0.04 h-1, T1/2 6.05 +/- 1.68 h, Tmax 1.05 +/- 0.29 h, Cmax 3.67 +/- 0.42 mg.L-1, AUC 33.43 +/- 7.32 mg.",[Determination of levofloxacin in plasma and cerebrospinal fluid with HPLC and its pharmacokinetics in patients undergoing neurosurgical operations]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016861/),[mg] / [l],3.67,31690,DB01137,Levofloxacin
,12016861,AUC,"The pharmacokinetic parameters were: blood Ke 0.12 +/- 0.04 h-1, T1/2 6.05 +/- 1.68 h, Tmax 1.05 +/- 0.29 h, Cmax 3.67 +/- 0.42 mg.L-1, AUC 33.43 +/- 7.32 mg.",[Determination of levofloxacin in plasma and cerebrospinal fluid with HPLC and its pharmacokinetics in patients undergoing neurosurgical operations]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016861/),mg,33.43,31691,DB01137,Levofloxacin
,12016861,CLs,"h.L-1, CLs 9.46 +/- 2.53 L.h-1, Vd 77.49 +/- 7.39 L; cerebrospinal fluid Ke 0.11 +/- 0.04 h-1, T1/2 6.95 +/- 1.88 h, Tmax 3.56 +/- 1.24 h, Cmax 1.68 +/- 0.25 mg.L-1, AUC 23.70 +/- 5.62 mg.h.L-1, CLs 13.70 +/- 5.11 L.h-1, Vd 126.61 +/- 13.20 L.",[Determination of levofloxacin in plasma and cerebrospinal fluid with HPLC and its pharmacokinetics in patients undergoing neurosurgical operations]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016861/),[l] / [h],9.46,31692,DB01137,Levofloxacin
,12016861,Vd,"h.L-1, CLs 9.46 +/- 2.53 L.h-1, Vd 77.49 +/- 7.39 L; cerebrospinal fluid Ke 0.11 +/- 0.04 h-1, T1/2 6.95 +/- 1.88 h, Tmax 3.56 +/- 1.24 h, Cmax 1.68 +/- 0.25 mg.L-1, AUC 23.70 +/- 5.62 mg.h.L-1, CLs 13.70 +/- 5.11 L.h-1, Vd 126.61 +/- 13.20 L.",[Determination of levofloxacin in plasma and cerebrospinal fluid with HPLC and its pharmacokinetics in patients undergoing neurosurgical operations]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016861/),l,77.49,31693,DB01137,Levofloxacin
,12016861,Ke,"h.L-1, CLs 9.46 +/- 2.53 L.h-1, Vd 77.49 +/- 7.39 L; cerebrospinal fluid Ke 0.11 +/- 0.04 h-1, T1/2 6.95 +/- 1.88 h, Tmax 3.56 +/- 1.24 h, Cmax 1.68 +/- 0.25 mg.L-1, AUC 23.70 +/- 5.62 mg.h.L-1, CLs 13.70 +/- 5.11 L.h-1, Vd 126.61 +/- 13.20 L.",[Determination of levofloxacin in plasma and cerebrospinal fluid with HPLC and its pharmacokinetics in patients undergoing neurosurgical operations]. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016861/),1/[h],0.11,31694,DB01137,Levofloxacin
,12016861,T1/2,"h.L-1, CLs 9.46 +/- 2.53 L.h-1, Vd 77.49 +/- 7.39 L; cerebrospinal fluid Ke 0.11 +/- 0.04 h-1, T1/2 6.95 +/- 1.88 h, Tmax 3.56 +/- 1.24 h, Cmax 1.68 +/- 0.25 mg.L-1, AUC 23.70 +/- 5.62 mg.h.L-1, CLs 13.70 +/- 5.11 L.h-1, Vd 126.61 +/- 13.20 L.",[Determination of levofloxacin in plasma and cerebrospinal fluid with HPLC and its pharmacokinetics in patients undergoing neurosurgical operations]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016861/),h,6.95,31695,DB01137,Levofloxacin
,12016861,Tmax,"h.L-1, CLs 9.46 +/- 2.53 L.h-1, Vd 77.49 +/- 7.39 L; cerebrospinal fluid Ke 0.11 +/- 0.04 h-1, T1/2 6.95 +/- 1.88 h, Tmax 3.56 +/- 1.24 h, Cmax 1.68 +/- 0.25 mg.L-1, AUC 23.70 +/- 5.62 mg.h.L-1, CLs 13.70 +/- 5.11 L.h-1, Vd 126.61 +/- 13.20 L.",[Determination of levofloxacin in plasma and cerebrospinal fluid with HPLC and its pharmacokinetics in patients undergoing neurosurgical operations]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016861/),h,3.56,31696,DB01137,Levofloxacin
,12016861,Cmax,"h.L-1, CLs 9.46 +/- 2.53 L.h-1, Vd 77.49 +/- 7.39 L; cerebrospinal fluid Ke 0.11 +/- 0.04 h-1, T1/2 6.95 +/- 1.88 h, Tmax 3.56 +/- 1.24 h, Cmax 1.68 +/- 0.25 mg.L-1, AUC 23.70 +/- 5.62 mg.h.L-1, CLs 13.70 +/- 5.11 L.h-1, Vd 126.61 +/- 13.20 L.",[Determination of levofloxacin in plasma and cerebrospinal fluid with HPLC and its pharmacokinetics in patients undergoing neurosurgical operations]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016861/),[mg] / [l],1.68,31697,DB01137,Levofloxacin
,12016861,AUC,"h.L-1, CLs 9.46 +/- 2.53 L.h-1, Vd 77.49 +/- 7.39 L; cerebrospinal fluid Ke 0.11 +/- 0.04 h-1, T1/2 6.95 +/- 1.88 h, Tmax 3.56 +/- 1.24 h, Cmax 1.68 +/- 0.25 mg.L-1, AUC 23.70 +/- 5.62 mg.h.L-1, CLs 13.70 +/- 5.11 L.h-1, Vd 126.61 +/- 13.20 L.",[Determination of levofloxacin in plasma and cerebrospinal fluid with HPLC and its pharmacokinetics in patients undergoing neurosurgical operations]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016861/),[h·mg] / [l],23.70,31698,DB01137,Levofloxacin
,12016861,CLs,"h.L-1, CLs 9.46 +/- 2.53 L.h-1, Vd 77.49 +/- 7.39 L; cerebrospinal fluid Ke 0.11 +/- 0.04 h-1, T1/2 6.95 +/- 1.88 h, Tmax 3.56 +/- 1.24 h, Cmax 1.68 +/- 0.25 mg.L-1, AUC 23.70 +/- 5.62 mg.h.L-1, CLs 13.70 +/- 5.11 L.h-1, Vd 126.61 +/- 13.20 L.",[Determination of levofloxacin in plasma and cerebrospinal fluid with HPLC and its pharmacokinetics in patients undergoing neurosurgical operations]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016861/),[l] / [h],13.70,31699,DB01137,Levofloxacin
,12016861,Vd,"h.L-1, CLs 9.46 +/- 2.53 L.h-1, Vd 77.49 +/- 7.39 L; cerebrospinal fluid Ke 0.11 +/- 0.04 h-1, T1/2 6.95 +/- 1.88 h, Tmax 3.56 +/- 1.24 h, Cmax 1.68 +/- 0.25 mg.L-1, AUC 23.70 +/- 5.62 mg.h.L-1, CLs 13.70 +/- 5.11 L.h-1, Vd 126.61 +/- 13.20 L.",[Determination of levofloxacin in plasma and cerebrospinal fluid with HPLC and its pharmacokinetics in patients undergoing neurosurgical operations]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016861/),l,126.61,31700,DB01137,Levofloxacin
,18725438,MIC,"P. aeruginosa ATCC 27853 was exposed to gentamicin (0 to 16x MIC; MIC = 2 mg/liter), and A. baumannii ATCC BAA 747 was exposed to amikacin (0 to 32x MIC; MIC = 4 mg/liter) for 24 h.",Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18725438/),,0 to 16x,33699,DB01137,Levofloxacin
,18725438,MIC,"P. aeruginosa ATCC 27853 was exposed to gentamicin (0 to 16x MIC; MIC = 2 mg/liter), and A. baumannii ATCC BAA 747 was exposed to amikacin (0 to 32x MIC; MIC = 4 mg/liter) for 24 h.",Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18725438/),[mg] / [l],2,33700,DB01137,Levofloxacin
,18725438,MIC,"P. aeruginosa ATCC 27853 was exposed to gentamicin (0 to 16x MIC; MIC = 2 mg/liter), and A. baumannii ATCC BAA 747 was exposed to amikacin (0 to 32x MIC; MIC = 4 mg/liter) for 24 h.",Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18725438/),,0 to 32,33701,DB01137,Levofloxacin
,18725438,MIC,"P. aeruginosa ATCC 27853 was exposed to gentamicin (0 to 16x MIC; MIC = 2 mg/liter), and A. baumannii ATCC BAA 747 was exposed to amikacin (0 to 32x MIC; MIC = 4 mg/liter) for 24 h.",Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18725438/),[mg] / [l],4,33702,DB01137,Levofloxacin
,18725438,half-life,"Using the estimates of the best-fit model parameters, bacterial responses to various fluctuating aminoglycoside exposures (half-life, 2.5 h) over 72 h were predicted via computer simulation.",Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18725438/),h,2.5,33703,DB01137,Levofloxacin
,18725438,maximum concentration of the drug (C(max))/MIC,"However, regrowth over time due to resistance emergence was predicted for regimens with a maximum concentration of the drug (C(max))/MIC (dosing frequency) of 4 (every 8 h [q8h]), 12 (q24h), and 36 (q24h).",Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18725438/),,4,33704,DB01137,Levofloxacin
,18725438,maximum concentration of the drug (C(max))/MIC,"However, regrowth over time due to resistance emergence was predicted for regimens with a maximum concentration of the drug (C(max))/MIC (dosing frequency) of 4 (every 8 h [q8h]), 12 (q24h), and 36 (q24h).",Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18725438/),,12,33705,DB01137,Levofloxacin
,18725438,maximum concentration of the drug (C(max))/MIC,"However, regrowth over time due to resistance emergence was predicted for regimens with a maximum concentration of the drug (C(max))/MIC (dosing frequency) of 4 (every 8 h [q8h]), 12 (q24h), and 36 (q24h).",Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18725438/),,36,33706,DB01137,Levofloxacin
,18725438,C(max)/MIC,Sustained suppression of bacterial populations was forecast with a C(max)/MIC of 30 (q12h).,Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18725438/),,30,33707,DB01137,Levofloxacin
,18310966,Clearance (CL),"Clearance (CL) is 5.8 L/hr, distribution volume (Vd) is 58.5 L, area under the blood concentration-time curve (AUC(0-24)) is 69.0 microg x hr/mL, t1/2 is 6.9 hr, Cmax is 3.4 microg/mL at administration of 200 mg b.i.d. Cmax (peak) of 500 mg, and q.d. is simulated as 8.54 microg/mL.",Population pharmacokinetics of levofloxacin as prophylaxis for febrile neutropenia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18310966/),[l] / [h],5.8,35911,DB01137,Levofloxacin
,18310966,distribution volume (Vd),"Clearance (CL) is 5.8 L/hr, distribution volume (Vd) is 58.5 L, area under the blood concentration-time curve (AUC(0-24)) is 69.0 microg x hr/mL, t1/2 is 6.9 hr, Cmax is 3.4 microg/mL at administration of 200 mg b.i.d. Cmax (peak) of 500 mg, and q.d. is simulated as 8.54 microg/mL.",Population pharmacokinetics of levofloxacin as prophylaxis for febrile neutropenia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18310966/),l,58.5,35912,DB01137,Levofloxacin
,18310966,area under the blood concentration-time curve (AUC(0-24)),"Clearance (CL) is 5.8 L/hr, distribution volume (Vd) is 58.5 L, area under the blood concentration-time curve (AUC(0-24)) is 69.0 microg x hr/mL, t1/2 is 6.9 hr, Cmax is 3.4 microg/mL at administration of 200 mg b.i.d. Cmax (peak) of 500 mg, and q.d. is simulated as 8.54 microg/mL.",Population pharmacokinetics of levofloxacin as prophylaxis for febrile neutropenia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18310966/),[h·μg] / [ml],69.0,35913,DB01137,Levofloxacin
,18310966,t1/2,"Clearance (CL) is 5.8 L/hr, distribution volume (Vd) is 58.5 L, area under the blood concentration-time curve (AUC(0-24)) is 69.0 microg x hr/mL, t1/2 is 6.9 hr, Cmax is 3.4 microg/mL at administration of 200 mg b.i.d. Cmax (peak) of 500 mg, and q.d. is simulated as 8.54 microg/mL.",Population pharmacokinetics of levofloxacin as prophylaxis for febrile neutropenia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18310966/),h,6.9,35914,DB01137,Levofloxacin
,18310966,Cmax,"Clearance (CL) is 5.8 L/hr, distribution volume (Vd) is 58.5 L, area under the blood concentration-time curve (AUC(0-24)) is 69.0 microg x hr/mL, t1/2 is 6.9 hr, Cmax is 3.4 microg/mL at administration of 200 mg b.i.d. Cmax (peak) of 500 mg, and q.d. is simulated as 8.54 microg/mL.",Population pharmacokinetics of levofloxacin as prophylaxis for febrile neutropenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18310966/),[μg] / [ml],3.4,35915,DB01137,Levofloxacin
,18310966,Cmax (peak),"Clearance (CL) is 5.8 L/hr, distribution volume (Vd) is 58.5 L, area under the blood concentration-time curve (AUC(0-24)) is 69.0 microg x hr/mL, t1/2 is 6.9 hr, Cmax is 3.4 microg/mL at administration of 200 mg b.i.d. Cmax (peak) of 500 mg, and q.d. is simulated as 8.54 microg/mL.",Population pharmacokinetics of levofloxacin as prophylaxis for febrile neutropenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18310966/),[μg] / [ml],8.54,35916,DB01137,Levofloxacin
,24735473,elimination half-life (t0.5(β)),"3. Following IV administration, the elimination half-life (t0.5(β)), volume of distribution at steady state (Vdss) and total body clearance (Cl) were 4.49 h, 1.31 l/kg and 0.23 l/h/kg, respectively.","Bioavailability and pharmacokinetic profile of levofloxacin following intravenous, intramuscular and oral administration in turkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24735473/),h,4.49,36080,DB01137,Levofloxacin
,24735473,volume of distribution at steady state (Vdss),"3. Following IV administration, the elimination half-life (t0.5(β)), volume of distribution at steady state (Vdss) and total body clearance (Cl) were 4.49 h, 1.31 l/kg and 0.23 l/h/kg, respectively.","Bioavailability and pharmacokinetic profile of levofloxacin following intravenous, intramuscular and oral administration in turkeys. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24735473/),[l] / [kg],1.31,36081,DB01137,Levofloxacin
,24735473,total body clearance (Cl),"3. Following IV administration, the elimination half-life (t0.5(β)), volume of distribution at steady state (Vdss) and total body clearance (Cl) were 4.49 h, 1.31 l/kg and 0.23 l/h/kg, respectively.","Bioavailability and pharmacokinetic profile of levofloxacin following intravenous, intramuscular and oral administration in turkeys. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24735473/),[l] / [h·kg],0.23,36082,DB01137,Levofloxacin
,24735473,absorption half-life (t0.5ab),"4. After single IM and PO administrations at the same dose, levofloxacin was rapidly absorbed as indicated by an absorption half-life (t0.5ab) of 1.02 and 0.76 h, respectively; maximum plasma concentrations (Cmax) of 5.59 and 5.15 μg/ml were obtained at a maximum time (Tmax) of 2 h for both routes and levofloxacin bioavailability (F) was 96.5 h and 79.9% respectively after IM and PO administration.","Bioavailability and pharmacokinetic profile of levofloxacin following intravenous, intramuscular and oral administration in turkeys. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24735473/),h,1.02,36083,DB01137,Levofloxacin
,24735473,absorption half-life (t0.5ab),"4. After single IM and PO administrations at the same dose, levofloxacin was rapidly absorbed as indicated by an absorption half-life (t0.5ab) of 1.02 and 0.76 h, respectively; maximum plasma concentrations (Cmax) of 5.59 and 5.15 μg/ml were obtained at a maximum time (Tmax) of 2 h for both routes and levofloxacin bioavailability (F) was 96.5 h and 79.9% respectively after IM and PO administration.","Bioavailability and pharmacokinetic profile of levofloxacin following intravenous, intramuscular and oral administration in turkeys. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24735473/),h,0.76,36084,DB01137,Levofloxacin
,24735473,maximum plasma concentrations (Cmax),"4. After single IM and PO administrations at the same dose, levofloxacin was rapidly absorbed as indicated by an absorption half-life (t0.5ab) of 1.02 and 0.76 h, respectively; maximum plasma concentrations (Cmax) of 5.59 and 5.15 μg/ml were obtained at a maximum time (Tmax) of 2 h for both routes and levofloxacin bioavailability (F) was 96.5 h and 79.9% respectively after IM and PO administration.","Bioavailability and pharmacokinetic profile of levofloxacin following intravenous, intramuscular and oral administration in turkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24735473/),[μg] / [ml],5.59,36085,DB01137,Levofloxacin
,24735473,maximum plasma concentrations (Cmax),"4. After single IM and PO administrations at the same dose, levofloxacin was rapidly absorbed as indicated by an absorption half-life (t0.5ab) of 1.02 and 0.76 h, respectively; maximum plasma concentrations (Cmax) of 5.59 and 5.15 μg/ml were obtained at a maximum time (Tmax) of 2 h for both routes and levofloxacin bioavailability (F) was 96.5 h and 79.9% respectively after IM and PO administration.","Bioavailability and pharmacokinetic profile of levofloxacin following intravenous, intramuscular and oral administration in turkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24735473/),[μg] / [ml],5.15,36086,DB01137,Levofloxacin
,24735473,maximum time (Tmax),"4. After single IM and PO administrations at the same dose, levofloxacin was rapidly absorbed as indicated by an absorption half-life (t0.5ab) of 1.02 and 0.76 h, respectively; maximum plasma concentrations (Cmax) of 5.59 and 5.15 μg/ml were obtained at a maximum time (Tmax) of 2 h for both routes and levofloxacin bioavailability (F) was 96.5 h and 79.9% respectively after IM and PO administration.","Bioavailability and pharmacokinetic profile of levofloxacin following intravenous, intramuscular and oral administration in turkeys. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24735473/),h,2,36087,DB01137,Levofloxacin
,24735473,bioavailability (F),"4. After single IM and PO administrations at the same dose, levofloxacin was rapidly absorbed as indicated by an absorption half-life (t0.5ab) of 1.02 and 0.76 h, respectively; maximum plasma concentrations (Cmax) of 5.59 and 5.15 μg/ml were obtained at a maximum time (Tmax) of 2 h for both routes and levofloxacin bioavailability (F) was 96.5 h and 79.9% respectively after IM and PO administration.","Bioavailability and pharmacokinetic profile of levofloxacin following intravenous, intramuscular and oral administration in turkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24735473/),h,96.5,36088,DB01137,Levofloxacin
,24735473,bioavailability (F),"4. After single IM and PO administrations at the same dose, levofloxacin was rapidly absorbed as indicated by an absorption half-life (t0.5ab) of 1.02 and 0.76 h, respectively; maximum plasma concentrations (Cmax) of 5.59 and 5.15 μg/ml were obtained at a maximum time (Tmax) of 2 h for both routes and levofloxacin bioavailability (F) was 96.5 h and 79.9% respectively after IM and PO administration.","Bioavailability and pharmacokinetic profile of levofloxacin following intravenous, intramuscular and oral administration in turkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24735473/),%,79.9,36089,DB01137,Levofloxacin
,24735473,plasma protein binding,In vitro plasma protein binding of levofloxacin was 24.3%.,"Bioavailability and pharmacokinetic profile of levofloxacin following intravenous, intramuscular and oral administration in turkeys. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24735473/),%,24.3,36090,DB01137,Levofloxacin
>,24735473,minimum inhibitory concentration) MIC90,"5. Based on these pharmacokinetic parameters, a dose of 10 mg/kg body weight given intramuscularly or orally every 24 h in turkeys can maintain effective plasma concentrations with bacterial infections with (minimum inhibitory concentration) MIC90 > 0.1 μg/ml.","Bioavailability and pharmacokinetic profile of levofloxacin following intravenous, intramuscular and oral administration in turkeys. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24735473/),[μg] / [ml],0.1,36091,DB01137,Levofloxacin
,11996208,half-life,"In critically ill patients with impaired renal function not on CVVH, mean half-life was prolonged by a factor of about 3 (20-25 hours).",Elimination of levofloxacin in critically ill patients with renal failure: influence of continuous veno-venous hemofiltration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11996208/),h,20-25,38457,DB01137,Levofloxacin
,11996208,half-life,The half-life was about 30 hours and the mean levofloxacin clearance was raised by a factor of 2.,Elimination of levofloxacin in critically ill patients with renal failure: influence of continuous veno-venous hemofiltration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11996208/),h,30,38458,DB01137,Levofloxacin
,14576116,MIC,No difference in bacterial killing of a select Staphylococcus aureus strain for which the MIC was 0.5 microg/ml was found between individuals after exposure to dynamically changing concentrations of levofloxacin in plasma and tissue in vitro.,Relevance of soft-tissue penetration by levofloxacin for target site bacterial killing in patients with sepsis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14576116/),[μg] / [ml],0.5,38588,DB01137,Levofloxacin
,14576116,MIC,"In contrast, the decrease in the bacterial counts of Pseudomonas aeruginosa (MIC = 2 microg/ml) varied extensively when the bacteria were exposed to levofloxacin at the concentrations determined from the individual concentration-versus-time profiles obtained in skeletal muscle.",Relevance of soft-tissue penetration by levofloxacin for target site bacterial killing in patients with sepsis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14576116/),[μg] / [ml],2,38589,DB01137,Levofloxacin
,14576116,MICs,We have therefore shown in the present study that individual differences in the tissue penetration of levofloxacin may markedly affect target site killing of bacteria for which MICs are close to 2 microg/ml.,Relevance of soft-tissue penetration by levofloxacin for target site bacterial killing in patients with sepsis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14576116/),[μg] / [ml],2,38590,DB01137,Levofloxacin
,16423485,recoveries,"The recoveries of levofloxacin and ciprofloxacin were 55.2% and 77.3%, respectively.",Hydrophilic interaction liquid chromatography-tandem mass spectrometry for the determination of levofloxacin in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16423485/),%,55.2,38834,DB01137,Levofloxacin
,16423485,recoveries,"The recoveries of levofloxacin and ciprofloxacin were 55.2% and 77.3%, respectively.",Hydrophilic interaction liquid chromatography-tandem mass spectrometry for the determination of levofloxacin in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16423485/),%,77.3,38835,DB01137,Levofloxacin
,11549786,C(max),"The C(max) achieved after an oral 250-mg dose ranged from a low of 1.2 microg/ml/70 kg for ciprofloxacin, to 1.71 for gatifloxacin and 2.17 for moxifloxacin, to a high of 2.48 for levofloxacin (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],1.2,39031,DB01137,Levofloxacin
,11549786,C(max),"The C(max) achieved after an oral 250-mg dose ranged from a low of 1.2 microg/ml/70 kg for ciprofloxacin, to 1.71 for gatifloxacin and 2.17 for moxifloxacin, to a high of 2.48 for levofloxacin (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],1.71,39032,DB01137,Levofloxacin
,11549786,C(max),"The C(max) achieved after an oral 250-mg dose ranged from a low of 1.2 microg/ml/70 kg for ciprofloxacin, to 1.71 for gatifloxacin and 2.17 for moxifloxacin, to a high of 2.48 for levofloxacin (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],2.17,39033,DB01137,Levofloxacin
,11549786,C(max),"The C(max) achieved after an oral 250-mg dose ranged from a low of 1.2 microg/ml/70 kg for ciprofloxacin, to 1.71 for gatifloxacin and 2.17 for moxifloxacin, to a high of 2.48 for levofloxacin (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],2.48,39034,DB01137,Levofloxacin
,11549786,AUC,"Ciprofloxacin had the lowest AUC of 4.6 microg/ml/70 kg, gatifloxacin 15, levofloxacin 17.9, and moxifloxacin 19.7 microg/ml/70 kg (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],4.6,39035,DB01137,Levofloxacin
,11549786,AUC,"Ciprofloxacin had the lowest AUC of 4.6 microg/ml/70 kg, gatifloxacin 15, levofloxacin 17.9, and moxifloxacin 19.7 microg/ml/70 kg (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],15,39036,DB01137,Levofloxacin
,11549786,AUC,"Ciprofloxacin had the lowest AUC of 4.6 microg/ml/70 kg, gatifloxacin 15, levofloxacin 17.9, and moxifloxacin 19.7 microg/ml/70 kg (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],17.9,39037,DB01137,Levofloxacin
,11549786,AUC,"Ciprofloxacin had the lowest AUC of 4.6 microg/ml/70 kg, gatifloxacin 15, levofloxacin 17.9, and moxifloxacin 19.7 microg/ml/70 kg (p < 0.01).",Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549786/),[μg] / [70·kg·ml],19.7,39038,DB01137,Levofloxacin
,17502404,MIC,"The MIC, logarithmic-growth-phase minimal bactericidal concentration, and stationary-growth-phase minimal bactericidal concentration of ABI-0043 were 0.001, 0.008, and 0.25 microg/ml, respectively; the corresponding concentrations of rifampin were 0.016, 0.8, and 3.6 microg/ml, respectively.","Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17502404/),[μg] / [ml],0.001,41685,DB01137,Levofloxacin
,17502404,log,"The MIC, logarithmic-growth-phase minimal bactericidal concentration, and stationary-growth-phase minimal bactericidal concentration of ABI-0043 were 0.001, 0.008, and 0.25 microg/ml, respectively; the corresponding concentrations of rifampin were 0.016, 0.8, and 3.6 microg/ml, respectively.","Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17502404/),[μg] / [ml],0.001,41686,DB01137,Levofloxacin
,17502404,log,"The MIC, logarithmic-growth-phase minimal bactericidal concentration, and stationary-growth-phase minimal bactericidal concentration of ABI-0043 were 0.001, 0.008, and 0.25 microg/ml, respectively; the corresponding concentrations of rifampin were 0.016, 0.8, and 3.6 microg/ml, respectively.","Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17502404/),[μg] / [ml],0.008,41687,DB01137,Levofloxacin
,17502404,log,"The MIC, logarithmic-growth-phase minimal bactericidal concentration, and stationary-growth-phase minimal bactericidal concentration of ABI-0043 were 0.001, 0.008, and 0.25 microg/ml, respectively; the corresponding concentrations of rifampin were 0.016, 0.8, and 3.6 microg/ml, respectively.","Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17502404/),[μg] / [ml],0.016,41688,DB01137,Levofloxacin
,17502404,stationary-growth-phase minimal bactericidal concentration,"The MIC, logarithmic-growth-phase minimal bactericidal concentration, and stationary-growth-phase minimal bactericidal concentration of ABI-0043 were 0.001, 0.008, and 0.25 microg/ml, respectively; the corresponding concentrations of rifampin were 0.016, 0.8, and 3.6 microg/ml, respectively.","Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17502404/),[μg] / [ml],0.25,41689,DB01137,Levofloxacin
,17502404,stationary-growth-phase minimal bactericidal concentration,"The MIC, logarithmic-growth-phase minimal bactericidal concentration, and stationary-growth-phase minimal bactericidal concentration of ABI-0043 were 0.001, 0.008, and 0.25 microg/ml, respectively; the corresponding concentrations of rifampin were 0.016, 0.8, and 3.6 microg/ml, respectively.","Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17502404/),[μg] / [ml],0.016,41690,DB01137,Levofloxacin
,17502404,stationary-growth-phase minimal bactericidal concentration,"The MIC, logarithmic-growth-phase minimal bactericidal concentration, and stationary-growth-phase minimal bactericidal concentration of ABI-0043 were 0.001, 0.008, and 0.25 microg/ml, respectively; the corresponding concentrations of rifampin were 0.016, 0.8, and 3.6 microg/ml, respectively.","Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17502404/),[μg] / [ml],0.8,41691,DB01137,Levofloxacin
,17502404,stationary-growth-phase minimal bactericidal concentration,"The MIC, logarithmic-growth-phase minimal bactericidal concentration, and stationary-growth-phase minimal bactericidal concentration of ABI-0043 were 0.001, 0.008, and 0.25 microg/ml, respectively; the corresponding concentrations of rifampin were 0.016, 0.8, and 3.6 microg/ml, respectively.","Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17502404/),[μg] / [ml],3.6,41692,DB01137,Levofloxacin
,17502404,peak concentration,"After a single intraperitoneal dose of 12.5 mg/kg of body weight, the peak concentration in cage fluid was 1.13 micarog/ml of ABI-0043 and 0.98 microg/ml of rifampin.","Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17502404/),[micarog] / [ml],1.13,41693,DB01137,Levofloxacin
,17502404,peak concentration,"After a single intraperitoneal dose of 12.5 mg/kg of body weight, the peak concentration in cage fluid was 1.13 micarog/ml of ABI-0043 and 0.98 microg/ml of rifampin.","Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17502404/),[μg] / [ml],0.98,41694,DB01137,Levofloxacin
,17502404,cure rates,"The cure rates of cage-associated infections with rifampin and ABI-0043 administered alone were 46% and 58%, respectively, and increased to 88% and 92% in combination with levofloxacin.","Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17502404/),%,46,41695,DB01137,Levofloxacin
,17502404,cure rates,"The cure rates of cage-associated infections with rifampin and ABI-0043 administered alone were 46% and 58%, respectively, and increased to 88% and 92% in combination with levofloxacin.","Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17502404/),%,58,41696,DB01137,Levofloxacin
,17502404,cure rates,"The cure rates of cage-associated infections with rifampin and ABI-0043 administered alone were 46% and 58%, respectively, and increased to 88% and 92% in combination with levofloxacin.","Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17502404/),%,88,41697,DB01137,Levofloxacin
,17502404,cure rates,"The cure rates of cage-associated infections with rifampin and ABI-0043 administered alone were 46% and 58%, respectively, and increased to 88% and 92% in combination with levofloxacin.","Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17502404/),,92,41698,DB01137,Levofloxacin
,10898674,penetration ratio,"When calculated from the mean population parameters, this penetration ratio was 2.96.",A population pharmacokinetic analysis of the penetration of the prostate by levofloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10898674/),,2.96,41939,DB01137,Levofloxacin
,10898674,penetration ratio,The mean penetration ratio here was 4.14 with a 95% confidence interval of 0.20 to 19.6.,A population pharmacokinetic analysis of the penetration of the prostate by levofloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10898674/),,4.14,41940,DB01137,Levofloxacin
excess of,10898674,penetration ratio,Over 70% of the population had a penetration ratio in excess of 1.0.,A population pharmacokinetic analysis of the penetration of the prostate by levofloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10898674/),,1.0,41941,DB01137,Levofloxacin
,11914204,peak concentration,A peak concentration of 1.6 microg/ml (or mg/l) was measured between 2.5 and 4 hours post-dose.,Vitreous penetration of levofloxacin in the uninflamed phakic human eye. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11914204/),[μg] / [ml],1.6,42472,DB01137,Levofloxacin
,11389113,Maximum kills,Maximum kills ranged from 5 to >6 logs.,"Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11389113/),logs,5 to >6,42722,DB01137,Levofloxacin
,26658531,Cmax,"With results from the Federated States of Micronesia, dosages were increased in RMI toward the target Cmax for Mycobacterium tuberculosis, 8-12 µg/mL.","Pharmacokinetics and Dosing of Levofloxacin in Children Treated for Active or Latent Multidrug-resistant Tuberculosis, Federated States of Micronesia and Republic of the Marshall Islands. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26658531/),[μg] / [ml],8-12,43128,DB01137,Levofloxacin
≥,26658531,Cmax,"At levofloxacin dosage of 15-20 mg/kg, Cmax ≥8 µg/mL was observed, and modeling corroborated a high target attainment across the ratio of the area under the free concentration versus time curve to minimum inhibitory concentration (fAUCss,0-24/MIC) values.","Pharmacokinetics and Dosing of Levofloxacin in Children Treated for Active or Latent Multidrug-resistant Tuberculosis, Federated States of Micronesia and Republic of the Marshall Islands. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26658531/),[μg] / [ml],8,43129,DB01137,Levofloxacin
≥,26658531,Cmax,"Levofloxacin dosage should be 15-20 mg/kg for Cmax ≥8 µg/mL and a high target attainment across fAUCss,0-24/MIC values in children ≥2 years of age.","Pharmacokinetics and Dosing of Levofloxacin in Children Treated for Active or Latent Multidrug-resistant Tuberculosis, Federated States of Micronesia and Republic of the Marshall Islands. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26658531/),[μg] / [ml],8,43130,DB01137,Levofloxacin
,8031039,MICs,"The MICs of sparfloxacin, erythromycin, levofloxacin, ofloxacin, and minocycline for 90% of the 43 M. pneumoniae strains tested were 0.063, 0.016, 0.5, 1, and 0.5 microgram/ml, respectively.",In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8031039/),[μg] / [ml],0.063,43941,DB01137,Levofloxacin
,8031039,MICs,"The MICs of sparfloxacin, erythromycin, levofloxacin, ofloxacin, and minocycline for 90% of the 43 M. pneumoniae strains tested were 0.063, 0.016, 0.5, 1, and 0.5 microgram/ml, respectively.",In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8031039/),[μg] / [ml],0.016,43942,DB01137,Levofloxacin
,8031039,MICs,"The MICs of sparfloxacin, erythromycin, levofloxacin, ofloxacin, and minocycline for 90% of the 43 M. pneumoniae strains tested were 0.063, 0.016, 0.5, 1, and 0.5 microgram/ml, respectively.",In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8031039/),[μg] / [ml],0.5,43943,DB01137,Levofloxacin
,8031039,MICs,"The MICs of sparfloxacin, erythromycin, levofloxacin, ofloxacin, and minocycline for 90% of the 43 M. pneumoniae strains tested were 0.063, 0.016, 0.5, 1, and 0.5 microgram/ml, respectively.",In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8031039/),[μg] / [ml],1,43944,DB01137,Levofloxacin
,30803965,plasma AUC/MIC ratio,"On the basis of these metrics, moxifloxacin emerged with a clear advantage, whereas plasma-based PK/PD favored levofloxacin (the ranges of the plasma AUC/MIC ratio [i.e., the area under the concentration-time curve over 24 h in the steady state divided by the MIC] are 46 to 86 for moxifloxacin and 74 to 258 for levofloxacin).",Fluoroquinolone Efficacy against Tuberculosis Is Driven by Penetration into Lesions and Activity against Resident Bacterial Populations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30803965/),,46 to 86,45480,DB01137,Levofloxacin
,30803965,plasma AUC/MIC ratio,"On the basis of these metrics, moxifloxacin emerged with a clear advantage, whereas plasma-based PK/PD favored levofloxacin (the ranges of the plasma AUC/MIC ratio [i.e., the area under the concentration-time curve over 24 h in the steady state divided by the MIC] are 46 to 86 for moxifloxacin and 74 to 258 for levofloxacin).",Fluoroquinolone Efficacy against Tuberculosis Is Driven by Penetration into Lesions and Activity against Resident Bacterial Populations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30803965/),,74 to 258,45481,DB01137,Levofloxacin
,30803965,area under the concentration-time curve over 24 h in the steady state divided by the MIC,"On the basis of these metrics, moxifloxacin emerged with a clear advantage, whereas plasma-based PK/PD favored levofloxacin (the ranges of the plasma AUC/MIC ratio [i.e., the area under the concentration-time curve over 24 h in the steady state divided by the MIC] are 46 to 86 for moxifloxacin and 74 to 258 for levofloxacin).",Fluoroquinolone Efficacy against Tuberculosis Is Driven by Penetration into Lesions and Activity against Resident Bacterial Populations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30803965/),,46 to 86,45482,DB01137,Levofloxacin
,30803965,area under the concentration-time curve over 24 h in the steady state divided by the MIC,"On the basis of these metrics, moxifloxacin emerged with a clear advantage, whereas plasma-based PK/PD favored levofloxacin (the ranges of the plasma AUC/MIC ratio [i.e., the area under the concentration-time curve over 24 h in the steady state divided by the MIC] are 46 to 86 for moxifloxacin and 74 to 258 for levofloxacin).",Fluoroquinolone Efficacy against Tuberculosis Is Driven by Penetration into Lesions and Activity against Resident Bacterial Populations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30803965/),,74 to 258,45483,DB01137,Levofloxacin
,12376030,MICs,Levofloxacin MICs ranged from 1.4 to 3.2 micro g/ml.,Pharmacodynamics of 750 mg and 500 mg doses of levofloxacin against ciprofloxacin-resistant strains of Streptococcus pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12376030/),[μg] / [ml],1.4 to 3.2,49205,DB01137,Levofloxacin
,12376030,MICs,"Against strains with levofloxacin MICs of 1.4 and 1.8 micro g/ml, the 500 mg dose exhibited pharmacodynamics similar to the 750 mg dose.",Pharmacodynamics of 750 mg and 500 mg doses of levofloxacin against ciprofloxacin-resistant strains of Streptococcus pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12376030/),[μg] / [ml],1.4,49206,DB01137,Levofloxacin
,12376030,MICs,"Against strains with levofloxacin MICs of 1.4 and 1.8 micro g/ml, the 500 mg dose exhibited pharmacodynamics similar to the 750 mg dose.",Pharmacodynamics of 750 mg and 500 mg doses of levofloxacin against ciprofloxacin-resistant strains of Streptococcus pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12376030/),[μg] / [ml],1.8,49207,DB01137,Levofloxacin
,12376030,MICs,"In contrast, against strains with levofloxacin MICs of 2.6 and 3.2 micro g/ml, viable counts never fell below 10(4) cfu/ml.",Pharmacodynamics of 750 mg and 500 mg doses of levofloxacin against ciprofloxacin-resistant strains of Streptococcus pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12376030/),[μg] / [ml],2.6,49208,DB01137,Levofloxacin
,12376030,MICs,"In contrast, against strains with levofloxacin MICs of 2.6 and 3.2 micro g/ml, viable counts never fell below 10(4) cfu/ml.",Pharmacodynamics of 750 mg and 500 mg doses of levofloxacin against ciprofloxacin-resistant strains of Streptococcus pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12376030/),[μg] / [ml],3.2,49209,DB01137,Levofloxacin
,16255991,C(max),"The results of clinical pharmacokinetic study showed that the C(max) of levofloxacin was 3.4 mg/L +/- 0.8 mg/L, 4.8 mg/L +/- 1.4 mg/L and 7.6 mg/L +/- 1.1 mg/L respectively, AUC(0-infinity) was 14.4 mg.h/L +/- 2.5 mg.h/L, 21.9 mg.h/L +/- 4.5 mg.h/L and 38.3 mg.h/L +/- 4.9 mg.h/L respectively, T(1)/2 beta was 6.2 h +/- 0.4 h, 6.4 h +/- 0.9 h and 6.5 h +/- 0.6 h respectively, and 69% +/- 5%, 69% +/- 6%, and 65% +/- 4% of the doses were excreted in urine within 24 h after intravenous infusion of a single dose of levofloxacin 200 mg, 300 mg and 500 mg.",[Study of pharmacokinetics/pharmacodynamics of levofloxacin]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16255991/),[mg] / [l],3.4,49734,DB01137,Levofloxacin
,16255991,C(max),"The results of clinical pharmacokinetic study showed that the C(max) of levofloxacin was 3.4 mg/L +/- 0.8 mg/L, 4.8 mg/L +/- 1.4 mg/L and 7.6 mg/L +/- 1.1 mg/L respectively, AUC(0-infinity) was 14.4 mg.h/L +/- 2.5 mg.h/L, 21.9 mg.h/L +/- 4.5 mg.h/L and 38.3 mg.h/L +/- 4.9 mg.h/L respectively, T(1)/2 beta was 6.2 h +/- 0.4 h, 6.4 h +/- 0.9 h and 6.5 h +/- 0.6 h respectively, and 69% +/- 5%, 69% +/- 6%, and 65% +/- 4% of the doses were excreted in urine within 24 h after intravenous infusion of a single dose of levofloxacin 200 mg, 300 mg and 500 mg.",[Study of pharmacokinetics/pharmacodynamics of levofloxacin]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16255991/),[mg] / [l],4.8,49735,DB01137,Levofloxacin
,16255991,C(max),"The results of clinical pharmacokinetic study showed that the C(max) of levofloxacin was 3.4 mg/L +/- 0.8 mg/L, 4.8 mg/L +/- 1.4 mg/L and 7.6 mg/L +/- 1.1 mg/L respectively, AUC(0-infinity) was 14.4 mg.h/L +/- 2.5 mg.h/L, 21.9 mg.h/L +/- 4.5 mg.h/L and 38.3 mg.h/L +/- 4.9 mg.h/L respectively, T(1)/2 beta was 6.2 h +/- 0.4 h, 6.4 h +/- 0.9 h and 6.5 h +/- 0.6 h respectively, and 69% +/- 5%, 69% +/- 6%, and 65% +/- 4% of the doses were excreted in urine within 24 h after intravenous infusion of a single dose of levofloxacin 200 mg, 300 mg and 500 mg.",[Study of pharmacokinetics/pharmacodynamics of levofloxacin]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16255991/),[mg] / [l],7.6,49736,DB01137,Levofloxacin
,16255991,AUC(0-infinity),"The results of clinical pharmacokinetic study showed that the C(max) of levofloxacin was 3.4 mg/L +/- 0.8 mg/L, 4.8 mg/L +/- 1.4 mg/L and 7.6 mg/L +/- 1.1 mg/L respectively, AUC(0-infinity) was 14.4 mg.h/L +/- 2.5 mg.h/L, 21.9 mg.h/L +/- 4.5 mg.h/L and 38.3 mg.h/L +/- 4.9 mg.h/L respectively, T(1)/2 beta was 6.2 h +/- 0.4 h, 6.4 h +/- 0.9 h and 6.5 h +/- 0.6 h respectively, and 69% +/- 5%, 69% +/- 6%, and 65% +/- 4% of the doses were excreted in urine within 24 h after intravenous infusion of a single dose of levofloxacin 200 mg, 300 mg and 500 mg.",[Study of pharmacokinetics/pharmacodynamics of levofloxacin]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16255991/),[h·mg] / [l],14.4,49737,DB01137,Levofloxacin
,16255991,AUC(0-infinity),"The results of clinical pharmacokinetic study showed that the C(max) of levofloxacin was 3.4 mg/L +/- 0.8 mg/L, 4.8 mg/L +/- 1.4 mg/L and 7.6 mg/L +/- 1.1 mg/L respectively, AUC(0-infinity) was 14.4 mg.h/L +/- 2.5 mg.h/L, 21.9 mg.h/L +/- 4.5 mg.h/L and 38.3 mg.h/L +/- 4.9 mg.h/L respectively, T(1)/2 beta was 6.2 h +/- 0.4 h, 6.4 h +/- 0.9 h and 6.5 h +/- 0.6 h respectively, and 69% +/- 5%, 69% +/- 6%, and 65% +/- 4% of the doses were excreted in urine within 24 h after intravenous infusion of a single dose of levofloxacin 200 mg, 300 mg and 500 mg.",[Study of pharmacokinetics/pharmacodynamics of levofloxacin]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16255991/),[h·mg] / [l],21.9,49738,DB01137,Levofloxacin
,16255991,AUC(0-infinity),"The results of clinical pharmacokinetic study showed that the C(max) of levofloxacin was 3.4 mg/L +/- 0.8 mg/L, 4.8 mg/L +/- 1.4 mg/L and 7.6 mg/L +/- 1.1 mg/L respectively, AUC(0-infinity) was 14.4 mg.h/L +/- 2.5 mg.h/L, 21.9 mg.h/L +/- 4.5 mg.h/L and 38.3 mg.h/L +/- 4.9 mg.h/L respectively, T(1)/2 beta was 6.2 h +/- 0.4 h, 6.4 h +/- 0.9 h and 6.5 h +/- 0.6 h respectively, and 69% +/- 5%, 69% +/- 6%, and 65% +/- 4% of the doses were excreted in urine within 24 h after intravenous infusion of a single dose of levofloxacin 200 mg, 300 mg and 500 mg.",[Study of pharmacokinetics/pharmacodynamics of levofloxacin]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16255991/),[h·mg] / [l],38.3,49739,DB01137,Levofloxacin
,16255991,T(1)/2 beta,"The results of clinical pharmacokinetic study showed that the C(max) of levofloxacin was 3.4 mg/L +/- 0.8 mg/L, 4.8 mg/L +/- 1.4 mg/L and 7.6 mg/L +/- 1.1 mg/L respectively, AUC(0-infinity) was 14.4 mg.h/L +/- 2.5 mg.h/L, 21.9 mg.h/L +/- 4.5 mg.h/L and 38.3 mg.h/L +/- 4.9 mg.h/L respectively, T(1)/2 beta was 6.2 h +/- 0.4 h, 6.4 h +/- 0.9 h and 6.5 h +/- 0.6 h respectively, and 69% +/- 5%, 69% +/- 6%, and 65% +/- 4% of the doses were excreted in urine within 24 h after intravenous infusion of a single dose of levofloxacin 200 mg, 300 mg and 500 mg.",[Study of pharmacokinetics/pharmacodynamics of levofloxacin]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16255991/),h,6.2,49740,DB01137,Levofloxacin
,16255991,T(1)/2 beta,"The results of clinical pharmacokinetic study showed that the C(max) of levofloxacin was 3.4 mg/L +/- 0.8 mg/L, 4.8 mg/L +/- 1.4 mg/L and 7.6 mg/L +/- 1.1 mg/L respectively, AUC(0-infinity) was 14.4 mg.h/L +/- 2.5 mg.h/L, 21.9 mg.h/L +/- 4.5 mg.h/L and 38.3 mg.h/L +/- 4.9 mg.h/L respectively, T(1)/2 beta was 6.2 h +/- 0.4 h, 6.4 h +/- 0.9 h and 6.5 h +/- 0.6 h respectively, and 69% +/- 5%, 69% +/- 6%, and 65% +/- 4% of the doses were excreted in urine within 24 h after intravenous infusion of a single dose of levofloxacin 200 mg, 300 mg and 500 mg.",[Study of pharmacokinetics/pharmacodynamics of levofloxacin]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16255991/),h,6.4,49741,DB01137,Levofloxacin
,16255991,T(1)/2 beta,"The results of clinical pharmacokinetic study showed that the C(max) of levofloxacin was 3.4 mg/L +/- 0.8 mg/L, 4.8 mg/L +/- 1.4 mg/L and 7.6 mg/L +/- 1.1 mg/L respectively, AUC(0-infinity) was 14.4 mg.h/L +/- 2.5 mg.h/L, 21.9 mg.h/L +/- 4.5 mg.h/L and 38.3 mg.h/L +/- 4.9 mg.h/L respectively, T(1)/2 beta was 6.2 h +/- 0.4 h, 6.4 h +/- 0.9 h and 6.5 h +/- 0.6 h respectively, and 69% +/- 5%, 69% +/- 6%, and 65% +/- 4% of the doses were excreted in urine within 24 h after intravenous infusion of a single dose of levofloxacin 200 mg, 300 mg and 500 mg.",[Study of pharmacokinetics/pharmacodynamics of levofloxacin]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16255991/),h,6.5,49742,DB01137,Levofloxacin
,16255991,T(1)/2 beta,"The results of clinical pharmacokinetic study showed that the C(max) of levofloxacin was 3.4 mg/L +/- 0.8 mg/L, 4.8 mg/L +/- 1.4 mg/L and 7.6 mg/L +/- 1.1 mg/L respectively, AUC(0-infinity) was 14.4 mg.h/L +/- 2.5 mg.h/L, 21.9 mg.h/L +/- 4.5 mg.h/L and 38.3 mg.h/L +/- 4.9 mg.h/L respectively, T(1)/2 beta was 6.2 h +/- 0.4 h, 6.4 h +/- 0.9 h and 6.5 h +/- 0.6 h respectively, and 69% +/- 5%, 69% +/- 6%, and 65% +/- 4% of the doses were excreted in urine within 24 h after intravenous infusion of a single dose of levofloxacin 200 mg, 300 mg and 500 mg.",[Study of pharmacokinetics/pharmacodynamics of levofloxacin]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16255991/),%,69,49743,DB01137,Levofloxacin
,16255991,T(1)/2 beta,"The results of clinical pharmacokinetic study showed that the C(max) of levofloxacin was 3.4 mg/L +/- 0.8 mg/L, 4.8 mg/L +/- 1.4 mg/L and 7.6 mg/L +/- 1.1 mg/L respectively, AUC(0-infinity) was 14.4 mg.h/L +/- 2.5 mg.h/L, 21.9 mg.h/L +/- 4.5 mg.h/L and 38.3 mg.h/L +/- 4.9 mg.h/L respectively, T(1)/2 beta was 6.2 h +/- 0.4 h, 6.4 h +/- 0.9 h and 6.5 h +/- 0.6 h respectively, and 69% +/- 5%, 69% +/- 6%, and 65% +/- 4% of the doses were excreted in urine within 24 h after intravenous infusion of a single dose of levofloxacin 200 mg, 300 mg and 500 mg.",[Study of pharmacokinetics/pharmacodynamics of levofloxacin]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16255991/),%,69,49744,DB01137,Levofloxacin
,16255991,T(1)/2 beta,"The results of clinical pharmacokinetic study showed that the C(max) of levofloxacin was 3.4 mg/L +/- 0.8 mg/L, 4.8 mg/L +/- 1.4 mg/L and 7.6 mg/L +/- 1.1 mg/L respectively, AUC(0-infinity) was 14.4 mg.h/L +/- 2.5 mg.h/L, 21.9 mg.h/L +/- 4.5 mg.h/L and 38.3 mg.h/L +/- 4.9 mg.h/L respectively, T(1)/2 beta was 6.2 h +/- 0.4 h, 6.4 h +/- 0.9 h and 6.5 h +/- 0.6 h respectively, and 69% +/- 5%, 69% +/- 6%, and 65% +/- 4% of the doses were excreted in urine within 24 h after intravenous infusion of a single dose of levofloxacin 200 mg, 300 mg and 500 mg.",[Study of pharmacokinetics/pharmacodynamics of levofloxacin]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16255991/),%,65,49745,DB01137,Levofloxacin
,11931699,Cmax,The main pharmacokinetic parameters af ter the first dosing were as follows: Cmax was (2.4+/-0.4) mg/L; AUC0- was (16.1 +/- 1.4) mg . h . L-1; T1/2beta was (6.3 +/- 0.3) h.,Pharmacokinetics of multiple intravenous instillation of levofloxacin in Chinese healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11931699/),[mg] / [l],2.4,49957,DB01137,Levofloxacin
,11931699,AUC0-,The main pharmacokinetic parameters af ter the first dosing were as follows: Cmax was (2.4+/-0.4) mg/L; AUC0- was (16.1 +/- 1.4) mg . h . L-1; T1/2beta was (6.3 +/- 0.3) h.,Pharmacokinetics of multiple intravenous instillation of levofloxacin in Chinese healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11931699/),[h·mg] / [l],16.1,49958,DB01137,Levofloxacin
,11931699,T1/2beta,The main pharmacokinetic parameters af ter the first dosing were as follows: Cmax was (2.4+/-0.4) mg/L; AUC0- was (16.1 +/- 1.4) mg . h . L-1; T1/2beta was (6.3 +/- 0.3) h.,Pharmacokinetics of multiple intravenous instillation of levofloxacin in Chinese healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11931699/),h,6.3,49959,DB01137,Levofloxacin
,11931699,Cssmax,The main parameters after the last dosing were as follows: Cssmax was (2.9 +/- 0.4) mg/L; Cssmin was (0.71 +/- 0.19) mg/L; Cav was (1.40 +/- 0.29) mg/L; AUCss0-12 was (17 +/- 3) mg . h . L-1; T1/2beta was (6.2 +/- 0.8) h.,Pharmacokinetics of multiple intravenous instillation of levofloxacin in Chinese healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11931699/),[mg] / [l],2.9,49960,DB01137,Levofloxacin
,11931699,Cssmin,The main parameters after the last dosing were as follows: Cssmax was (2.9 +/- 0.4) mg/L; Cssmin was (0.71 +/- 0.19) mg/L; Cav was (1.40 +/- 0.29) mg/L; AUCss0-12 was (17 +/- 3) mg . h . L-1; T1/2beta was (6.2 +/- 0.8) h.,Pharmacokinetics of multiple intravenous instillation of levofloxacin in Chinese healthy subjects. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11931699/),[mg] / [l],0.71,49961,DB01137,Levofloxacin
,11931699,Cav,The main parameters after the last dosing were as follows: Cssmax was (2.9 +/- 0.4) mg/L; Cssmin was (0.71 +/- 0.19) mg/L; Cav was (1.40 +/- 0.29) mg/L; AUCss0-12 was (17 +/- 3) mg . h . L-1; T1/2beta was (6.2 +/- 0.8) h.,Pharmacokinetics of multiple intravenous instillation of levofloxacin in Chinese healthy subjects. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11931699/),[mg] / [l],1.40,49962,DB01137,Levofloxacin
,11931699,AUCss0-12,The main parameters after the last dosing were as follows: Cssmax was (2.9 +/- 0.4) mg/L; Cssmin was (0.71 +/- 0.19) mg/L; Cav was (1.40 +/- 0.29) mg/L; AUCss0-12 was (17 +/- 3) mg . h . L-1; T1/2beta was (6.2 +/- 0.8) h.,Pharmacokinetics of multiple intravenous instillation of levofloxacin in Chinese healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11931699/),[h·mg] / [l],17,49963,DB01137,Levofloxacin
,11931699,T1/2beta,The main parameters after the last dosing were as follows: Cssmax was (2.9 +/- 0.4) mg/L; Cssmin was (0.71 +/- 0.19) mg/L; Cav was (1.40 +/- 0.29) mg/L; AUCss0-12 was (17 +/- 3) mg . h . L-1; T1/2beta was (6.2 +/- 0.8) h.,Pharmacokinetics of multiple intravenous instillation of levofloxacin in Chinese healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11931699/),h,6.2,49964,DB01137,Levofloxacin
,11931699,cumulative urinary excretion rate,The 24-h cumulative urinary excretion rate was (88 +/- 5) %.,Pharmacokinetics of multiple intravenous instillation of levofloxacin in Chinese healthy subjects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11931699/),%,88,49965,DB01137,Levofloxacin
,11181363,area under the concentration-time curve (AUC)/MIC ratios,Moxifloxacin regimens produced a range of area under the concentration-time curve (AUC)/MIC ratios ranging from 9.2 to 444 and peak/MIC ratios ranging from 1.3 to 102.,Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11181363/),,9.2 to 444,50392,DB01137,Levofloxacin
,11181363,peak/MIC ratios,Moxifloxacin regimens produced a range of area under the concentration-time curve (AUC)/MIC ratios ranging from 9.2 to 444 and peak/MIC ratios ranging from 1.3 to 102.,Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11181363/),,1.3 to 102,50393,DB01137,Levofloxacin
,11181363,AUC/MIC ratios,Levofloxacin doses produced AUC/MIC ratios of 5.1 to 85.5 and peak/MIC ratio of 0.9 to 14.8.,Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11181363/),,5.1 to 85.5,50394,DB01137,Levofloxacin
,11181363,peak/MIC ratio,Levofloxacin doses produced AUC/MIC ratios of 5.1 to 85.5 and peak/MIC ratio of 0.9 to 14.8.,Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11181363/),,0.9 to 14.8,50395,DB01137,Levofloxacin
,12709329,half-life,"A series of monoexponential pharmacokinetic profiles that mimic once-daily administration of MOX (half-life, 12 h), GAT (half-life, 7 h), and LEV (half-life, 6.8 h) and twice-daily administration of CIP (half-life, 4 h) provided peak concentrations (C(max)) that either equaled the MIC, fell between the MIC and the mutant prevention concentration (MPC) (i.e., within or ""inside"" the MSW), or exceeded the MPC.",In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709329/),h,12,50495,DB01137,Levofloxacin
,12709329,half-life,"A series of monoexponential pharmacokinetic profiles that mimic once-daily administration of MOX (half-life, 12 h), GAT (half-life, 7 h), and LEV (half-life, 6.8 h) and twice-daily administration of CIP (half-life, 4 h) provided peak concentrations (C(max)) that either equaled the MIC, fell between the MIC and the mutant prevention concentration (MPC) (i.e., within or ""inside"" the MSW), or exceeded the MPC.",In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709329/),h,7,50496,DB01137,Levofloxacin
,12709329,half-life,"A series of monoexponential pharmacokinetic profiles that mimic once-daily administration of MOX (half-life, 12 h), GAT (half-life, 7 h), and LEV (half-life, 6.8 h) and twice-daily administration of CIP (half-life, 4 h) provided peak concentrations (C(max)) that either equaled the MIC, fell between the MIC and the mutant prevention concentration (MPC) (i.e., within or ""inside"" the MSW), or exceeded the MPC.",In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709329/),h,6.8,50497,DB01137,Levofloxacin
,12709329,half-life,"A series of monoexponential pharmacokinetic profiles that mimic once-daily administration of MOX (half-life, 12 h), GAT (half-life, 7 h), and LEV (half-life, 6.8 h) and twice-daily administration of CIP (half-life, 4 h) provided peak concentrations (C(max)) that either equaled the MIC, fell between the MIC and the mutant prevention concentration (MPC) (i.e., within or ""inside"" the MSW), or exceeded the MPC.",In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709329/),h,4,50498,DB01137,Levofloxacin
,12709329,ratios of the area under the curve (AUC) over a 24-h dosing interval (AUC(24)) to the MIC,"The respective ratios of the area under the curve (AUC) over a 24-h dosing interval (AUC(24)) to the MIC varied from 13 to 244 h, and the starting inoculum was 10(8) CFU/ml (6 x 10(9) CFU per 60-ml central compartment).",In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709329/),h,13 to 244,50499,DB01137,Levofloxacin
,12709329,ratios of the area under the curve (AUC) over a 24-h dosing interval (AUC(24)) to the MIC,"The respective ratios of the area under the curve (AUC) over a 24-h dosing interval (AUC(24)) to the MIC varied from 13 to 244 h, and the starting inoculum was 10(8) CFU/ml (6 x 10(9) CFU per 60-ml central compartment).",In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709329/),,6,50500,DB01137,Levofloxacin
,12709329,AUC(24)/MIC,"With all four quinolones, the greatest increases in MIC were observed at those AUC(24)/MIC values (from 24 to 62 h) that corresponded to quinolone concentrations within the MSW over most of the dosing interval (>20%).",In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709329/),h,24,50501,DB01137,Levofloxacin
,12709329,AUC(24)/MIC,"With all four quinolones, the greatest increases in MIC were observed at those AUC(24)/MIC values (from 24 to 62 h) that corresponded to quinolone concentrations within the MSW over most of the dosing interval (>20%).",In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709329/),h,62,50502,DB01137,Levofloxacin
,12709329,AUC(24)/MIC,"Less-pronounced increases in MIC were associated with the smallest simulated AUC(24)/MIC values (15 to 16 h) of GAT and CIP, whose C(max) exceeded the MICs.",In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709329/),h,15 to 16,50503,DB01137,Levofloxacin
,12709329,AUC(24)/MIC,"No such increases were observed with the smallest AUC(24)/MIC values (13 to 17 h) of MOX and LEV, whose C(max) were close to the MICs.",In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709329/),h,13 to 17,50504,DB01137,Levofloxacin
,12709329,AUC(24)/MIC,"Also, less pronounced but significant increases in MIC occurred at AUC(24)/MIC values (107 to 123 h) that correspond to quinolone concentrations partly overlapping the MIC-to-MPC range.",In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709329/),h,107 to 123,50505,DB01137,Levofloxacin
,12709329,AUC(24)/MIC,"With all four drugs, no change in MIC was seen at the highest AUC(24)/MIC values (201 to 244 h), where quinolone concentrations exceeded the MPC over most of the dosing interval.",In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709329/),h,201 to 244,50506,DB01137,Levofloxacin
,18534825,maximum plasma concentration (C(max)),"Median (+/-standard error) pharmacokinetic parameters after single and multiple dosing, respectively, were: maximum plasma concentration (C(max)) 5.04+/-0.87 mg/L and 8.32+/-0.64 mg/L; area under the concentration-time curve with extrapolation to infinity (AUC(0-->Inf)) 190.24+/-29.23 mg h/L and 720.79+/-75.57 mg h/L; elimination half-time (t(1/2)) 22.84+/-5.56 h and 38.05+/-4.14 h; and clearance rate 2.67+/-0.39 L/h and 2.10+/-0.21 L/h.",Pharmacokinetics of levofloxacin after single and multiple oral doses in patients undergoing intermittent haemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18534825/),[mg] / [l],5.04,51835,DB01137,Levofloxacin
,18534825,maximum plasma concentration (C(max)),"Median (+/-standard error) pharmacokinetic parameters after single and multiple dosing, respectively, were: maximum plasma concentration (C(max)) 5.04+/-0.87 mg/L and 8.32+/-0.64 mg/L; area under the concentration-time curve with extrapolation to infinity (AUC(0-->Inf)) 190.24+/-29.23 mg h/L and 720.79+/-75.57 mg h/L; elimination half-time (t(1/2)) 22.84+/-5.56 h and 38.05+/-4.14 h; and clearance rate 2.67+/-0.39 L/h and 2.10+/-0.21 L/h.",Pharmacokinetics of levofloxacin after single and multiple oral doses in patients undergoing intermittent haemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18534825/),[mg] / [l],8.32,51836,DB01137,Levofloxacin
,18534825,area under the concentration-time curve with extrapolation to infinity (AUC(0-->Inf)),"Median (+/-standard error) pharmacokinetic parameters after single and multiple dosing, respectively, were: maximum plasma concentration (C(max)) 5.04+/-0.87 mg/L and 8.32+/-0.64 mg/L; area under the concentration-time curve with extrapolation to infinity (AUC(0-->Inf)) 190.24+/-29.23 mg h/L and 720.79+/-75.57 mg h/L; elimination half-time (t(1/2)) 22.84+/-5.56 h and 38.05+/-4.14 h; and clearance rate 2.67+/-0.39 L/h and 2.10+/-0.21 L/h.",Pharmacokinetics of levofloxacin after single and multiple oral doses in patients undergoing intermittent haemodialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18534825/),[h·mg] / [l],190.24,51837,DB01137,Levofloxacin
,18534825,area under the concentration-time curve with extrapolation to infinity (AUC(0-->Inf)),"Median (+/-standard error) pharmacokinetic parameters after single and multiple dosing, respectively, were: maximum plasma concentration (C(max)) 5.04+/-0.87 mg/L and 8.32+/-0.64 mg/L; area under the concentration-time curve with extrapolation to infinity (AUC(0-->Inf)) 190.24+/-29.23 mg h/L and 720.79+/-75.57 mg h/L; elimination half-time (t(1/2)) 22.84+/-5.56 h and 38.05+/-4.14 h; and clearance rate 2.67+/-0.39 L/h and 2.10+/-0.21 L/h.",Pharmacokinetics of levofloxacin after single and multiple oral doses in patients undergoing intermittent haemodialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18534825/),[h·mg] / [l],720.79,51838,DB01137,Levofloxacin
,18534825,elimination half-time (t(1/2)),"Median (+/-standard error) pharmacokinetic parameters after single and multiple dosing, respectively, were: maximum plasma concentration (C(max)) 5.04+/-0.87 mg/L and 8.32+/-0.64 mg/L; area under the concentration-time curve with extrapolation to infinity (AUC(0-->Inf)) 190.24+/-29.23 mg h/L and 720.79+/-75.57 mg h/L; elimination half-time (t(1/2)) 22.84+/-5.56 h and 38.05+/-4.14 h; and clearance rate 2.67+/-0.39 L/h and 2.10+/-0.21 L/h.",Pharmacokinetics of levofloxacin after single and multiple oral doses in patients undergoing intermittent haemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18534825/),h,22.84,51839,DB01137,Levofloxacin
,18534825,elimination half-time (t(1/2)),"Median (+/-standard error) pharmacokinetic parameters after single and multiple dosing, respectively, were: maximum plasma concentration (C(max)) 5.04+/-0.87 mg/L and 8.32+/-0.64 mg/L; area under the concentration-time curve with extrapolation to infinity (AUC(0-->Inf)) 190.24+/-29.23 mg h/L and 720.79+/-75.57 mg h/L; elimination half-time (t(1/2)) 22.84+/-5.56 h and 38.05+/-4.14 h; and clearance rate 2.67+/-0.39 L/h and 2.10+/-0.21 L/h.",Pharmacokinetics of levofloxacin after single and multiple oral doses in patients undergoing intermittent haemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18534825/),h,38.05,51840,DB01137,Levofloxacin
,18534825,clearance rate,"Median (+/-standard error) pharmacokinetic parameters after single and multiple dosing, respectively, were: maximum plasma concentration (C(max)) 5.04+/-0.87 mg/L and 8.32+/-0.64 mg/L; area under the concentration-time curve with extrapolation to infinity (AUC(0-->Inf)) 190.24+/-29.23 mg h/L and 720.79+/-75.57 mg h/L; elimination half-time (t(1/2)) 22.84+/-5.56 h and 38.05+/-4.14 h; and clearance rate 2.67+/-0.39 L/h and 2.10+/-0.21 L/h.",Pharmacokinetics of levofloxacin after single and multiple oral doses in patients undergoing intermittent haemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18534825/),[l] / [h],2.67,51841,DB01137,Levofloxacin
,18534825,clearance rate,"Median (+/-standard error) pharmacokinetic parameters after single and multiple dosing, respectively, were: maximum plasma concentration (C(max)) 5.04+/-0.87 mg/L and 8.32+/-0.64 mg/L; area under the concentration-time curve with extrapolation to infinity (AUC(0-->Inf)) 190.24+/-29.23 mg h/L and 720.79+/-75.57 mg h/L; elimination half-time (t(1/2)) 22.84+/-5.56 h and 38.05+/-4.14 h; and clearance rate 2.67+/-0.39 L/h and 2.10+/-0.21 L/h.",Pharmacokinetics of levofloxacin after single and multiple oral doses in patients undergoing intermittent haemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18534825/),[l] / [h],2.10,51842,DB01137,Levofloxacin
>,18534825,C(max)/MIC,"The C(max)/MIC and AUC(0-->24)/MIC ratios (where MIC is the minimum inhibitory concentration of the pathogen) remained above >100 and >10, respectively, rendering levofloxacin a candidate for infections in these patients.",Pharmacokinetics of levofloxacin after single and multiple oral doses in patients undergoing intermittent haemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18534825/),,100,51843,DB01137,Levofloxacin
>,18534825,AUC(0-->24)/MIC ratios,"The C(max)/MIC and AUC(0-->24)/MIC ratios (where MIC is the minimum inhibitory concentration of the pathogen) remained above >100 and >10, respectively, rendering levofloxacin a candidate for infections in these patients.",Pharmacokinetics of levofloxacin after single and multiple oral doses in patients undergoing intermittent haemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18534825/),,100,51844,DB01137,Levofloxacin
>,18534825,AUC(0-->24)/MIC ratios,"The C(max)/MIC and AUC(0-->24)/MIC ratios (where MIC is the minimum inhibitory concentration of the pathogen) remained above >100 and >10, respectively, rendering levofloxacin a candidate for infections in these patients.",Pharmacokinetics of levofloxacin after single and multiple oral doses in patients undergoing intermittent haemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18534825/),,10,51845,DB01137,Levofloxacin
,10224340,peak lung concentration,"A pharmacokinetic study in infected mice revealed good oral absorption and lung tissue penetration of levofloxacin (peak lung concentration: 5.95 microg/g of lung), low oral absorption of ciprofloxacin in spite of a good penetration into lung tissue (1.10 microg/g of lung), and low lung tissue penetration of ampicillin despite rather good oral absorption (1.71 microg/g of lung).","Therapeutic effect of oral levofloxacin, ciprofloxacin, and ampicillin on experimental murine pneumonia caused by penicillin intermediate Streptococcus pneumoniae for which the minimum inhibitory concentrations of the quinolones are similar. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10224340/),[μg] / [g],5.95,53608,DB01137,Levofloxacin
,10224340,penetration into lung,"A pharmacokinetic study in infected mice revealed good oral absorption and lung tissue penetration of levofloxacin (peak lung concentration: 5.95 microg/g of lung), low oral absorption of ciprofloxacin in spite of a good penetration into lung tissue (1.10 microg/g of lung), and low lung tissue penetration of ampicillin despite rather good oral absorption (1.71 microg/g of lung).","Therapeutic effect of oral levofloxacin, ciprofloxacin, and ampicillin on experimental murine pneumonia caused by penicillin intermediate Streptococcus pneumoniae for which the minimum inhibitory concentrations of the quinolones are similar. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10224340/),[μg] / [g],1.10,53609,DB01137,Levofloxacin
,10224340,oral absorption,"A pharmacokinetic study in infected mice revealed good oral absorption and lung tissue penetration of levofloxacin (peak lung concentration: 5.95 microg/g of lung), low oral absorption of ciprofloxacin in spite of a good penetration into lung tissue (1.10 microg/g of lung), and low lung tissue penetration of ampicillin despite rather good oral absorption (1.71 microg/g of lung).","Therapeutic effect of oral levofloxacin, ciprofloxacin, and ampicillin on experimental murine pneumonia caused by penicillin intermediate Streptococcus pneumoniae for which the minimum inhibitory concentrations of the quinolones are similar. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10224340/),[μg] / [g],1.71,53610,DB01137,Levofloxacin
less,31372767,in,"Topical dosage forms available in the market for the treatment of bacterial conjunctivitis such as simple drug solutions and suspensions are rapidly eliminated from the precorneal space upon instillation due to tear turn over and nasolacrimal drainage, limiting intraocular bioavailability of drug to less than 10% of the administered dose.",Levofloxacin Hemihydrate In Situ Gelling Ophthalmic Solution: Formulation Optimization and In Vitro and In Vivo Evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31372767/),%,10,56564,DB01137,Levofloxacin
less,31372767,bioavailability,"Topical dosage forms available in the market for the treatment of bacterial conjunctivitis such as simple drug solutions and suspensions are rapidly eliminated from the precorneal space upon instillation due to tear turn over and nasolacrimal drainage, limiting intraocular bioavailability of drug to less than 10% of the administered dose.",Levofloxacin Hemihydrate In Situ Gelling Ophthalmic Solution: Formulation Optimization and In Vitro and In Vivo Evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31372767/),%,10,56565,DB01137,Levofloxacin
,31372767,AUC0-24,"Tested formulations were found to be well-tolerated and showed significant increase in AUC0-24 (22,660.39 h ng/mL) and mean residence time (MRT 12 h) as compared with commercially available solution Levotop PF® (Ajanta Pharma Ltd., India)(AUC0-24 6414.63 h ng/mL and MRT 4 h).",Levofloxacin Hemihydrate In Situ Gelling Ophthalmic Solution: Formulation Optimization and In Vitro and In Vivo Evaluation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31372767/),[h·ng] / [ml],"22,660.39",56566,DB01137,Levofloxacin
,31372767,AUC0-24,"Tested formulations were found to be well-tolerated and showed significant increase in AUC0-24 (22,660.39 h ng/mL) and mean residence time (MRT 12 h) as compared with commercially available solution Levotop PF® (Ajanta Pharma Ltd., India)(AUC0-24 6414.63 h ng/mL and MRT 4 h).",Levofloxacin Hemihydrate In Situ Gelling Ophthalmic Solution: Formulation Optimization and In Vitro and In Vivo Evaluation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31372767/),[h·ng] / [ml],6414.63,56567,DB01137,Levofloxacin
,31372767,MRT,"Tested formulations were found to be well-tolerated and showed significant increase in AUC0-24 (22,660.39 h ng/mL) and mean residence time (MRT 12 h) as compared with commercially available solution Levotop PF® (Ajanta Pharma Ltd., India)(AUC0-24 6414.63 h ng/mL and MRT 4 h).",Levofloxacin Hemihydrate In Situ Gelling Ophthalmic Solution: Formulation Optimization and In Vitro and In Vivo Evaluation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31372767/),h,4,56568,DB01137,Levofloxacin
<,33675664,serum AUC0-24,Subtarget exposures of levofloxacin were defined by serum AUC0-24 <80 mg·h/L.,Levofloxacin pharmacokinetics in saliva as measured by a mobile microvolume UV spectrophotometer among people treated for rifampicin-resistant TB in Tanzania. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33675664/),[h·mg] / [l],80,59790,DB01137,Levofloxacin
,33675664,AUC0-24,Median AUC0-24 in serum was 140 (IQR = 102.4-179.09) mg·h/L and median AUC0-24 in saliva was 97.10 (IQR = 74.80-121.10) mg·h/L.,Levofloxacin pharmacokinetics in saliva as measured by a mobile microvolume UV spectrophotometer among people treated for rifampicin-resistant TB in Tanzania. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33675664/),[h·mg] / [l],140,59791,DB01137,Levofloxacin
,33675664,AUC0-24,Median AUC0-24 in serum was 140 (IQR = 102.4-179.09) mg·h/L and median AUC0-24 in saliva was 97.10 (IQR = 74.80-121.10) mg·h/L.,Levofloxacin pharmacokinetics in saliva as measured by a mobile microvolume UV spectrophotometer among people treated for rifampicin-resistant TB in Tanzania. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33675664/),[h·mg] / [l],97.10,59792,DB01137,Levofloxacin
,33675664,AUC0-24,"Utilizing a saliva AUC0-24 cut-off of 91.6 mg·h/L, the assay was 88.9% sensitive and 69.4% specific in detecting subtarget serum AUC0-24 values, including identifying eight of nine patients below target.",Levofloxacin pharmacokinetics in saliva as measured by a mobile microvolume UV spectrophotometer among people treated for rifampicin-resistant TB in Tanzania. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33675664/),[h·mg] / [l],91.6,59793,DB01137,Levofloxacin
,22210007,Mean plasma concentrations,"Mean plasma concentrations at 4, 12, and 24 h were 8.0 ± 2.5, 5.8 ± 1.2, and 2.2 ± 1.2 μg/mL.",Bronchopulmonary pharmacokinetic and pharmacodynamic profiles of levofloxacin 750 mg once daily in adults undergoing treatment for acute exacerbation of chronic bronchitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22210007/),[μg] / [ml],8.0,60174,DB01137,Levofloxacin
,22210007,Mean plasma concentrations,"Mean plasma concentrations at 4, 12, and 24 h were 8.0 ± 2.5, 5.8 ± 1.2, and 2.2 ± 1.2 μg/mL.",Bronchopulmonary pharmacokinetic and pharmacodynamic profiles of levofloxacin 750 mg once daily in adults undergoing treatment for acute exacerbation of chronic bronchitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22210007/),[μg] / [ml],5.8,60175,DB01137,Levofloxacin
,22210007,Mean plasma concentrations,"Mean plasma concentrations at 4, 12, and 24 h were 8.0 ± 2.5, 5.8 ± 1.2, and 2.2 ± 1.2 μg/mL.",Bronchopulmonary pharmacokinetic and pharmacodynamic profiles of levofloxacin 750 mg once daily in adults undergoing treatment for acute exacerbation of chronic bronchitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22210007/),[μg] / [ml],2.2,60176,DB01137,Levofloxacin
,22210007,ELF,"Mean ELF values at 4, 12, and 24 h were 7.5 ± 3.0, 8.3 ± 6.0, and 1.2 ± 0.9 μg/mL.",Bronchopulmonary pharmacokinetic and pharmacodynamic profiles of levofloxacin 750 mg once daily in adults undergoing treatment for acute exacerbation of chronic bronchitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22210007/),[μg] / [ml],7.5,60177,DB01137,Levofloxacin
,22210007,ELF,"Mean ELF values at 4, 12, and 24 h were 7.5 ± 3.0, 8.3 ± 6.0, and 1.2 ± 0.9 μg/mL.",Bronchopulmonary pharmacokinetic and pharmacodynamic profiles of levofloxacin 750 mg once daily in adults undergoing treatment for acute exacerbation of chronic bronchitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22210007/),[μg] / [ml],8.3,60178,DB01137,Levofloxacin
,22210007,ELF,"Mean ELF values at 4, 12, and 24 h were 7.5 ± 3.0, 8.3 ± 6.0, and 1.2 ± 0.9 μg/mL.",Bronchopulmonary pharmacokinetic and pharmacodynamic profiles of levofloxacin 750 mg once daily in adults undergoing treatment for acute exacerbation of chronic bronchitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22210007/),[μg] / [ml],1.2,60179,DB01137,Levofloxacin
,22210007,alveolar macrophage,"Mean alveolar macrophage (AM) concentrations at 4, 12, and 24 h were 38.5 ± 43.7, 13.4 ± 14.4, and 9.0 ± 7.5 μg/mL.",Bronchopulmonary pharmacokinetic and pharmacodynamic profiles of levofloxacin 750 mg once daily in adults undergoing treatment for acute exacerbation of chronic bronchitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22210007/),[μg] / [ml],38.5,60180,DB01137,Levofloxacin
,22210007,alveolar macrophage,"Mean alveolar macrophage (AM) concentrations at 4, 12, and 24 h were 38.5 ± 43.7, 13.4 ± 14.4, and 9.0 ± 7.5 μg/mL.",Bronchopulmonary pharmacokinetic and pharmacodynamic profiles of levofloxacin 750 mg once daily in adults undergoing treatment for acute exacerbation of chronic bronchitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22210007/),[μg] / [ml],13.4,60181,DB01137,Levofloxacin
,22210007,alveolar macrophage,"Mean alveolar macrophage (AM) concentrations at 4, 12, and 24 h were 38.5 ± 43.7, 13.4 ± 14.4, and 9.0 ± 7.5 μg/mL.",Bronchopulmonary pharmacokinetic and pharmacodynamic profiles of levofloxacin 750 mg once daily in adults undergoing treatment for acute exacerbation of chronic bronchitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22210007/),[μg] / [ml],9.0,60182,DB01137,Levofloxacin
,22210007,concentrations,"Mean alveolar macrophage (AM) concentrations at 4, 12, and 24 h were 38.5 ± 43.7, 13.4 ± 14.4, and 9.0 ± 7.5 μg/mL.",Bronchopulmonary pharmacokinetic and pharmacodynamic profiles of levofloxacin 750 mg once daily in adults undergoing treatment for acute exacerbation of chronic bronchitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22210007/),[μg] / [ml],38.5,60183,DB01137,Levofloxacin
,22210007,concentrations,"Mean alveolar macrophage (AM) concentrations at 4, 12, and 24 h were 38.5 ± 43.7, 13.4 ± 14.4, and 9.0 ± 7.5 μg/mL.",Bronchopulmonary pharmacokinetic and pharmacodynamic profiles of levofloxacin 750 mg once daily in adults undergoing treatment for acute exacerbation of chronic bronchitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22210007/),[μg] / [ml],13.4,60184,DB01137,Levofloxacin
,22210007,concentrations,"Mean alveolar macrophage (AM) concentrations at 4, 12, and 24 h were 38.5 ± 43.7, 13.4 ± 14.4, and 9.0 ± 7.5 μg/mL.",Bronchopulmonary pharmacokinetic and pharmacodynamic profiles of levofloxacin 750 mg once daily in adults undergoing treatment for acute exacerbation of chronic bronchitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22210007/),[μg] / [ml],9.0,60185,DB01137,Levofloxacin
,22210007,penetration (ELF/plasma ratio),The penetration (ELF/plasma ratio) into the infection site was 113%.,Bronchopulmonary pharmacokinetic and pharmacodynamic profiles of levofloxacin 750 mg once daily in adults undergoing treatment for acute exacerbation of chronic bronchitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22210007/),%,113,60186,DB01137,Levofloxacin
,11157914,concentration peak,The mean levofloxacin concentration peak was 1.9 +/- 1.0 mg/L.,Single-dose pharmacokinetics of levofloxacin during continuous veno-venous haemofiltration in critically ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11157914/),[mg] / [l],1.9,61231,DB01137,Levofloxacin
,11157914,elimination half-life,"The elimination half-life, haemofiltration clearance and total removal were 8.3 +/- 2.6 h, 27.6 +/- 8.4 mL/min and 56 +/- 19%, respectively.",Single-dose pharmacokinetics of levofloxacin during continuous veno-venous haemofiltration in critically ill patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11157914/),h,8.3,61232,DB01137,Levofloxacin
,11157914,haemofiltration clearance,"The elimination half-life, haemofiltration clearance and total removal were 8.3 +/- 2.6 h, 27.6 +/- 8.4 mL/min and 56 +/- 19%, respectively.",Single-dose pharmacokinetics of levofloxacin during continuous veno-venous haemofiltration in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11157914/),[ml] / [min],27.6,61233,DB01137,Levofloxacin
,11157914,total removal,"The elimination half-life, haemofiltration clearance and total removal were 8.3 +/- 2.6 h, 27.6 +/- 8.4 mL/min and 56 +/- 19%, respectively.",Single-dose pharmacokinetics of levofloxacin during continuous veno-venous haemofiltration in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11157914/),%,56,61234,DB01137,Levofloxacin
,15969945,flow rate,The lung was perfused with Krebs-Henseleit medium containing 3% bovine albumin at a flow rate of 5 mL min(-1).,"Comparative study of the disposition of levofloxacin, netilmicin and cefepime in the isolated rat lung. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15969945/),[ml] / [min],5,62006,DB01137,Levofloxacin
,15969945,distribution coefficient,"The results show pharmacokinetic differences among these antibiotics, which are in accordance with previously reported data, levofloxacin being the drug with the highest distribution coefficient in this tissue (1.25 +/- 0.14 vs 0.39 +/- 0.07 and 0.41 +/- 0.06 mL g(-1) for netilmicin and cefepime, respectively).","Comparative study of the disposition of levofloxacin, netilmicin and cefepime in the isolated rat lung. ",CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15969945/),[ml] / [g],1.25,62007,DB01137,Levofloxacin
,15969945,distribution coefficient,"The results show pharmacokinetic differences among these antibiotics, which are in accordance with previously reported data, levofloxacin being the drug with the highest distribution coefficient in this tissue (1.25 +/- 0.14 vs 0.39 +/- 0.07 and 0.41 +/- 0.06 mL g(-1) for netilmicin and cefepime, respectively).","Comparative study of the disposition of levofloxacin, netilmicin and cefepime in the isolated rat lung. ",CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15969945/),[ml] / [g],0.39,62008,DB01137,Levofloxacin
,15969945,distribution coefficient,"The results show pharmacokinetic differences among these antibiotics, which are in accordance with previously reported data, levofloxacin being the drug with the highest distribution coefficient in this tissue (1.25 +/- 0.14 vs 0.39 +/- 0.07 and 0.41 +/- 0.06 mL g(-1) for netilmicin and cefepime, respectively).","Comparative study of the disposition of levofloxacin, netilmicin and cefepime in the isolated rat lung. ",CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15969945/),[ml] / [g],0.41,62009,DB01137,Levofloxacin
,18070980,maximum plasma concentrations,"Levofloxacin produced the highest maximum plasma concentrations (median, 15.55 microg/ml; gatifloxacin, 4.75 microg/ml; moxifloxacin, 6.13 microg/ml), largest volume of distribution (median, 81 liters; gatifloxacin, 79 liters; moxifloxacin, 63 liters), and longest elimination half-life (median, 7.4 h; gatifloxacin, 5.0 h; moxifloxacin, 6.5 h).","Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18070980/),[μg] / [ml],15.55,62438,DB01137,Levofloxacin
,18070980,maximum plasma concentrations,"Levofloxacin produced the highest maximum plasma concentrations (median, 15.55 microg/ml; gatifloxacin, 4.75 microg/ml; moxifloxacin, 6.13 microg/ml), largest volume of distribution (median, 81 liters; gatifloxacin, 79 liters; moxifloxacin, 63 liters), and longest elimination half-life (median, 7.4 h; gatifloxacin, 5.0 h; moxifloxacin, 6.5 h).","Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18070980/),[μg] / [ml],4.75,62439,DB01137,Levofloxacin
,18070980,maximum plasma concentrations,"Levofloxacin produced the highest maximum plasma concentrations (median, 15.55 microg/ml; gatifloxacin, 4.75 microg/ml; moxifloxacin, 6.13 microg/ml), largest volume of distribution (median, 81 liters; gatifloxacin, 79 liters; moxifloxacin, 63 liters), and longest elimination half-life (median, 7.4 h; gatifloxacin, 5.0 h; moxifloxacin, 6.5 h).","Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18070980/),[μg] / [ml],6.13,62440,DB01137,Levofloxacin
,18070980,volume of distribution,"Levofloxacin produced the highest maximum plasma concentrations (median, 15.55 microg/ml; gatifloxacin, 4.75 microg/ml; moxifloxacin, 6.13 microg/ml), largest volume of distribution (median, 81 liters; gatifloxacin, 79 liters; moxifloxacin, 63 liters), and longest elimination half-life (median, 7.4 h; gatifloxacin, 5.0 h; moxifloxacin, 6.5 h).","Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18070980/),l,81,62441,DB01137,Levofloxacin
,18070980,volume of distribution,"Levofloxacin produced the highest maximum plasma concentrations (median, 15.55 microg/ml; gatifloxacin, 4.75 microg/ml; moxifloxacin, 6.13 microg/ml), largest volume of distribution (median, 81 liters; gatifloxacin, 79 liters; moxifloxacin, 63 liters), and longest elimination half-life (median, 7.4 h; gatifloxacin, 5.0 h; moxifloxacin, 6.5 h).","Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18070980/),l,79,62442,DB01137,Levofloxacin
,18070980,volume of distribution,"Levofloxacin produced the highest maximum plasma concentrations (median, 15.55 microg/ml; gatifloxacin, 4.75 microg/ml; moxifloxacin, 6.13 microg/ml), largest volume of distribution (median, 81 liters; gatifloxacin, 79 liters; moxifloxacin, 63 liters), and longest elimination half-life (median, 7.4 h; gatifloxacin, 5.0 h; moxifloxacin, 6.5 h).","Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18070980/),l,63,62443,DB01137,Levofloxacin
,18070980,elimination half-life,"Levofloxacin produced the highest maximum plasma concentrations (median, 15.55 microg/ml; gatifloxacin, 4.75 microg/ml; moxifloxacin, 6.13 microg/ml), largest volume of distribution (median, 81 liters; gatifloxacin, 79 liters; moxifloxacin, 63 liters), and longest elimination half-life (median, 7.4 h; gatifloxacin, 5.0 h; moxifloxacin, 6.5 h).","Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18070980/),h,7.4,62444,DB01137,Levofloxacin
,18070980,elimination half-life,"Levofloxacin produced the highest maximum plasma concentrations (median, 15.55 microg/ml; gatifloxacin, 4.75 microg/ml; moxifloxacin, 6.13 microg/ml), largest volume of distribution (median, 81 liters; gatifloxacin, 79 liters; moxifloxacin, 63 liters), and longest elimination half-life (median, 7.4 h; gatifloxacin, 5.0 h; moxifloxacin, 6.5 h).","Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18070980/),h,5.0,62445,DB01137,Levofloxacin
,18070980,elimination half-life,"Levofloxacin produced the highest maximum plasma concentrations (median, 15.55 microg/ml; gatifloxacin, 4.75 microg/ml; moxifloxacin, 6.13 microg/ml), largest volume of distribution (median, 81 liters; gatifloxacin, 79 liters; moxifloxacin, 63 liters), and longest elimination half-life (median, 7.4 h; gatifloxacin, 5.0 h; moxifloxacin, 6.5 h).","Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18070980/),h,6.5,62446,DB01137,Levofloxacin
,29251833,Clearance,"Clearance was 14.0 L/h, and distribution volume was 77 L.",Population Pharmacokinetics of Levofloxacin in Plasma and Bone of Patients Undergoing Hip or Knee Surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29251833/),[l] / [h],14.0,64630,DB01137,Levofloxacin
,29251833,distribution volume,"Clearance was 14.0 L/h, and distribution volume was 77 L.",Population Pharmacokinetics of Levofloxacin in Plasma and Bone of Patients Undergoing Hip or Knee Surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29251833/),l,77,64631,DB01137,Levofloxacin
,29251833,Bone uptake t½,"Bone uptake t½ was calculated as 4.2 and 5.4 hours for cortical bone and trabecular bone, respectively.",Population Pharmacokinetics of Levofloxacin in Plasma and Bone of Patients Undergoing Hip or Knee Surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29251833/),h,4.2,64632,DB01137,Levofloxacin
,29251833,Bone uptake t½,"Bone uptake t½ was calculated as 4.2 and 5.4 hours for cortical bone and trabecular bone, respectively.",Population Pharmacokinetics of Levofloxacin in Plasma and Bone of Patients Undergoing Hip or Knee Surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29251833/),h,5.4,64633,DB01137,Levofloxacin
,27531420,bioavailability,"The bioavailability for the intratracheal levofloxacin solution and intratracheal chitosan microspheres was estimated to be 98% and 71%, respectively, both with a direct release into the ELF compartment.",Pulmonary pharmacokinetics of levofloxacin in rats after aerosolization of immediate-release chitosan or sustained-release PLGA microspheres. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27531420/),%,98,65586,DB01137,Levofloxacin
,27531420,bioavailability,"The bioavailability for the intratracheal levofloxacin solution and intratracheal chitosan microspheres was estimated to be 98% and 71%, respectively, both with a direct release into the ELF compartment.",Pulmonary pharmacokinetics of levofloxacin in rats after aerosolization of immediate-release chitosan or sustained-release PLGA microspheres. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27531420/),%,71,65587,DB01137,Levofloxacin
above,27531420,-to-unbound plasma AUC ratios,The ELF-to-unbound plasma AUC ratios were slightly above 2 and may result from an efflux transport.,Pulmonary pharmacokinetics of levofloxacin in rats after aerosolization of immediate-release chitosan or sustained-release PLGA microspheres. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27531420/),,2,65588,DB01137,Levofloxacin
,27531420,-,"For the intratracheal PLGA microspheres, a high ELF-to-unbound plasma AUC concentration ratio (311) was observed and high levofloxacin concentrations were maintained in ELF for at least 72h in consistency with the in vitro release studies.",Pulmonary pharmacokinetics of levofloxacin in rats after aerosolization of immediate-release chitosan or sustained-release PLGA microspheres. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27531420/),,311,65589,DB01137,Levofloxacin
,27531420,to-unbound plasma AUC concentration ratio,"For the intratracheal PLGA microspheres, a high ELF-to-unbound plasma AUC concentration ratio (311) was observed and high levofloxacin concentrations were maintained in ELF for at least 72h in consistency with the in vitro release studies.",Pulmonary pharmacokinetics of levofloxacin in rats after aerosolization of immediate-release chitosan or sustained-release PLGA microspheres. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27531420/),,311,65590,DB01137,Levofloxacin
,27531420,bioavailability,"The bioavailability was 92%, with 19% of the dose released immediately (burst release) into the ELF and 73% released slowly into the ELF from a depot compartment, i.e. the PLGA microspheres, according to a Weibull model.",Pulmonary pharmacokinetics of levofloxacin in rats after aerosolization of immediate-release chitosan or sustained-release PLGA microspheres. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27531420/),%,92,65591,DB01137,Levofloxacin
,27531420,bioavailability,"The bioavailability was 92%, with 19% of the dose released immediately (burst release) into the ELF and 73% released slowly into the ELF from a depot compartment, i.e. the PLGA microspheres, according to a Weibull model.",Pulmonary pharmacokinetics of levofloxacin in rats after aerosolization of immediate-release chitosan or sustained-release PLGA microspheres. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27531420/),%,19,65592,DB01137,Levofloxacin
,27531420,bioavailability,"The bioavailability was 92%, with 19% of the dose released immediately (burst release) into the ELF and 73% released slowly into the ELF from a depot compartment, i.e. the PLGA microspheres, according to a Weibull model.",Pulmonary pharmacokinetics of levofloxacin in rats after aerosolization of immediate-release chitosan or sustained-release PLGA microspheres. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27531420/),%,73,65593,DB01137,Levofloxacin
,31372937,maximum concentrations,"The maximum concentrations of azithromycin, levofloxacin, and ofloxacin were 35.6, 34.1, and 55.1 µg/g in the eyelid, 44.2, 46.8, and 20.4 µg/g in the conjunctiva, and 79.9, 18.0, and 2.21 µg/g in the cornea, respectively.","Pharmacokinetics of Azithromycin, Levofloxacin, and Ofloxacin in Rabbit Extraocular Tissues After Ophthalmic Administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31372937/),[μg] / [g],35.6,65756,DB01137,Levofloxacin
,31372937,maximum concentrations,"The maximum concentrations of azithromycin, levofloxacin, and ofloxacin were 35.6, 34.1, and 55.1 µg/g in the eyelid, 44.2, 46.8, and 20.4 µg/g in the conjunctiva, and 79.9, 18.0, and 2.21 µg/g in the cornea, respectively.","Pharmacokinetics of Azithromycin, Levofloxacin, and Ofloxacin in Rabbit Extraocular Tissues After Ophthalmic Administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31372937/),[μg] / [g],34.1,65757,DB01137,Levofloxacin
,31372937,maximum concentrations,"The maximum concentrations of azithromycin, levofloxacin, and ofloxacin were 35.6, 34.1, and 55.1 µg/g in the eyelid, 44.2, 46.8, and 20.4 µg/g in the conjunctiva, and 79.9, 18.0, and 2.21 µg/g in the cornea, respectively.","Pharmacokinetics of Azithromycin, Levofloxacin, and Ofloxacin in Rabbit Extraocular Tissues After Ophthalmic Administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31372937/),[μg] / [g],55.1,65758,DB01137,Levofloxacin
,31372937,maximum concentrations,"The maximum concentrations of azithromycin, levofloxacin, and ofloxacin were 35.6, 34.1, and 55.1 µg/g in the eyelid, 44.2, 46.8, and 20.4 µg/g in the conjunctiva, and 79.9, 18.0, and 2.21 µg/g in the cornea, respectively.","Pharmacokinetics of Azithromycin, Levofloxacin, and Ofloxacin in Rabbit Extraocular Tissues After Ophthalmic Administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31372937/),[μg] / [g],44.2,65759,DB01137,Levofloxacin
,31372937,maximum concentrations,"The maximum concentrations of azithromycin, levofloxacin, and ofloxacin were 35.6, 34.1, and 55.1 µg/g in the eyelid, 44.2, 46.8, and 20.4 µg/g in the conjunctiva, and 79.9, 18.0, and 2.21 µg/g in the cornea, respectively.","Pharmacokinetics of Azithromycin, Levofloxacin, and Ofloxacin in Rabbit Extraocular Tissues After Ophthalmic Administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31372937/),[μg] / [g],46.8,65760,DB01137,Levofloxacin
,31372937,maximum concentrations,"The maximum concentrations of azithromycin, levofloxacin, and ofloxacin were 35.6, 34.1, and 55.1 µg/g in the eyelid, 44.2, 46.8, and 20.4 µg/g in the conjunctiva, and 79.9, 18.0, and 2.21 µg/g in the cornea, respectively.","Pharmacokinetics of Azithromycin, Levofloxacin, and Ofloxacin in Rabbit Extraocular Tissues After Ophthalmic Administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31372937/),[μg] / [g],20.4,65761,DB01137,Levofloxacin
,31372937,maximum concentrations,"The maximum concentrations of azithromycin, levofloxacin, and ofloxacin were 35.6, 34.1, and 55.1 µg/g in the eyelid, 44.2, 46.8, and 20.4 µg/g in the conjunctiva, and 79.9, 18.0, and 2.21 µg/g in the cornea, respectively.","Pharmacokinetics of Azithromycin, Levofloxacin, and Ofloxacin in Rabbit Extraocular Tissues After Ophthalmic Administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31372937/),[μg] / [g],79.9,65762,DB01137,Levofloxacin
,31372937,maximum concentrations,"The maximum concentrations of azithromycin, levofloxacin, and ofloxacin were 35.6, 34.1, and 55.1 µg/g in the eyelid, 44.2, 46.8, and 20.4 µg/g in the conjunctiva, and 79.9, 18.0, and 2.21 µg/g in the cornea, respectively.","Pharmacokinetics of Azithromycin, Levofloxacin, and Ofloxacin in Rabbit Extraocular Tissues After Ophthalmic Administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31372937/),[μg] / [g],18.0,65763,DB01137,Levofloxacin
,31372937,maximum concentrations,"The maximum concentrations of azithromycin, levofloxacin, and ofloxacin were 35.6, 34.1, and 55.1 µg/g in the eyelid, 44.2, 46.8, and 20.4 µg/g in the conjunctiva, and 79.9, 18.0, and 2.21 µg/g in the cornea, respectively.","Pharmacokinetics of Azithromycin, Levofloxacin, and Ofloxacin in Rabbit Extraocular Tissues After Ophthalmic Administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31372937/),[μg] / [g],2.21,65764,DB01137,Levofloxacin
,31372937,area under the curve from 0 to 24 h,"The values of the area under the curve from 0 to 24 h after administration of azithromycin, levofloxacin, and ofloxacin were 602, 58.5, and 267 µg·h/g in the eyelid, 837, 43.2, and 51.9 µg·h/g in the conjunctiva, and 1250, 26.4, and 5.46 µg h/g in the cornea, respectively.","Pharmacokinetics of Azithromycin, Levofloxacin, and Ofloxacin in Rabbit Extraocular Tissues After Ophthalmic Administration. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31372937/),[h·μg] / [g],602,65765,DB01137,Levofloxacin
,31372937,area under the curve from 0 to 24 h,"The values of the area under the curve from 0 to 24 h after administration of azithromycin, levofloxacin, and ofloxacin were 602, 58.5, and 267 µg·h/g in the eyelid, 837, 43.2, and 51.9 µg·h/g in the conjunctiva, and 1250, 26.4, and 5.46 µg h/g in the cornea, respectively.","Pharmacokinetics of Azithromycin, Levofloxacin, and Ofloxacin in Rabbit Extraocular Tissues After Ophthalmic Administration. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31372937/),[h·μg] / [g],58.5,65766,DB01137,Levofloxacin
,31372937,area under the curve from 0 to 24 h,"The values of the area under the curve from 0 to 24 h after administration of azithromycin, levofloxacin, and ofloxacin were 602, 58.5, and 267 µg·h/g in the eyelid, 837, 43.2, and 51.9 µg·h/g in the conjunctiva, and 1250, 26.4, and 5.46 µg h/g in the cornea, respectively.","Pharmacokinetics of Azithromycin, Levofloxacin, and Ofloxacin in Rabbit Extraocular Tissues After Ophthalmic Administration. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31372937/),[h·μg] / [g],267,65767,DB01137,Levofloxacin
,31372937,area under the curve from 0 to 24 h,"The values of the area under the curve from 0 to 24 h after administration of azithromycin, levofloxacin, and ofloxacin were 602, 58.5, and 267 µg·h/g in the eyelid, 837, 43.2, and 51.9 µg·h/g in the conjunctiva, and 1250, 26.4, and 5.46 µg h/g in the cornea, respectively.","Pharmacokinetics of Azithromycin, Levofloxacin, and Ofloxacin in Rabbit Extraocular Tissues After Ophthalmic Administration. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31372937/),[h·μg] / [g],837,65768,DB01137,Levofloxacin
,31372937,area under the curve from 0 to 24 h,"The values of the area under the curve from 0 to 24 h after administration of azithromycin, levofloxacin, and ofloxacin were 602, 58.5, and 267 µg·h/g in the eyelid, 837, 43.2, and 51.9 µg·h/g in the conjunctiva, and 1250, 26.4, and 5.46 µg h/g in the cornea, respectively.","Pharmacokinetics of Azithromycin, Levofloxacin, and Ofloxacin in Rabbit Extraocular Tissues After Ophthalmic Administration. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31372937/),[h·μg] / [g],43.2,65769,DB01137,Levofloxacin
,31372937,area under the curve from 0 to 24 h,"The values of the area under the curve from 0 to 24 h after administration of azithromycin, levofloxacin, and ofloxacin were 602, 58.5, and 267 µg·h/g in the eyelid, 837, 43.2, and 51.9 µg·h/g in the conjunctiva, and 1250, 26.4, and 5.46 µg h/g in the cornea, respectively.","Pharmacokinetics of Azithromycin, Levofloxacin, and Ofloxacin in Rabbit Extraocular Tissues After Ophthalmic Administration. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31372937/),[h·μg] / [g],51.9,65770,DB01137,Levofloxacin
,31372937,area under the curve from 0 to 24 h,"The values of the area under the curve from 0 to 24 h after administration of azithromycin, levofloxacin, and ofloxacin were 602, 58.5, and 267 µg·h/g in the eyelid, 837, 43.2, and 51.9 µg·h/g in the conjunctiva, and 1250, 26.4, and 5.46 µg h/g in the cornea, respectively.","Pharmacokinetics of Azithromycin, Levofloxacin, and Ofloxacin in Rabbit Extraocular Tissues After Ophthalmic Administration. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31372937/),[h·μg] / [g],1250,65771,DB01137,Levofloxacin
,31372937,area under the curve from 0 to 24 h,"The values of the area under the curve from 0 to 24 h after administration of azithromycin, levofloxacin, and ofloxacin were 602, 58.5, and 267 µg·h/g in the eyelid, 837, 43.2, and 51.9 µg·h/g in the conjunctiva, and 1250, 26.4, and 5.46 µg h/g in the cornea, respectively.","Pharmacokinetics of Azithromycin, Levofloxacin, and Ofloxacin in Rabbit Extraocular Tissues After Ophthalmic Administration. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31372937/),[h·μg] / [g],26.4,65772,DB01137,Levofloxacin
,31372937,area under the curve from 0 to 24 h,"The values of the area under the curve from 0 to 24 h after administration of azithromycin, levofloxacin, and ofloxacin were 602, 58.5, and 267 µg·h/g in the eyelid, 837, 43.2, and 51.9 µg·h/g in the conjunctiva, and 1250, 26.4, and 5.46 µg h/g in the cornea, respectively.","Pharmacokinetics of Azithromycin, Levofloxacin, and Ofloxacin in Rabbit Extraocular Tissues After Ophthalmic Administration. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31372937/),[h·μg] / [g],5.46,65773,DB01137,Levofloxacin
,26666946,Cockcroft-Gault crea,"The mean (standard deviation [SD]) age, weight, and Cockcroft-Gault creatinine clearance for the critically ill and for the non-critically ill patients were 60.3 (16.4) and 72.0 (11.6) years, 78.5 (14.8) and 70.9 (15.8) kg, and 71.9 (65.8) and 68.2 (30.1) ml/min, respectively.",Does Critical Illness Change Levofloxacin Pharmacokinetics? ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26666946/),,78.5,68200,DB01137,Levofloxacin
,26666946,Cockcroft-Gault crea,"The mean (standard deviation [SD]) age, weight, and Cockcroft-Gault creatinine clearance for the critically ill and for the non-critically ill patients were 60.3 (16.4) and 72.0 (11.6) years, 78.5 (14.8) and 70.9 (15.8) kg, and 71.9 (65.8) and 68.2 (30.1) ml/min, respectively.",Does Critical Illness Change Levofloxacin Pharmacokinetics? ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26666946/),[ml] / [min],71.9,68201,DB01137,Levofloxacin
,26666946,clearance,"The mean (SD) parameter estimates were as follows: clearance, 8.66 (3.85) liters/h; volume of the central compartment (Vc), 41.5 (24.5) liters; intercompartmental clearance constants from central to peripheral, 2.58 (3.51) liters/h; and peripheral to central compartments, 0.90 (0.58) liters/h.",Does Critical Illness Change Levofloxacin Pharmacokinetics? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26666946/),[l] / [h],8.66,68202,DB01137,Levofloxacin
,26666946,volume of the central compartment (Vc),"The mean (SD) parameter estimates were as follows: clearance, 8.66 (3.85) liters/h; volume of the central compartment (Vc), 41.5 (24.5) liters; intercompartmental clearance constants from central to peripheral, 2.58 (3.51) liters/h; and peripheral to central compartments, 0.90 (0.58) liters/h.",Does Critical Illness Change Levofloxacin Pharmacokinetics? ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26666946/),l,41.5,68203,DB01137,Levofloxacin
,26666946,intercompartmental clearance constants from central to peripheral,"The mean (SD) parameter estimates were as follows: clearance, 8.66 (3.85) liters/h; volume of the central compartment (Vc), 41.5 (24.5) liters; intercompartmental clearance constants from central to peripheral, 2.58 (3.51) liters/h; and peripheral to central compartments, 0.90 (0.58) liters/h.",Does Critical Illness Change Levofloxacin Pharmacokinetics? ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26666946/),[l] / [h],2.58,68204,DB01137,Levofloxacin
,26666946,peripheral to central compartments,"The mean (SD) parameter estimates were as follows: clearance, 8.66 (3.85) liters/h; volume of the central compartment (Vc), 41.5 (24.5) liters; intercompartmental clearance constants from central to peripheral, 2.58 (3.51) liters/h; and peripheral to central compartments, 0.90 (0.58) liters/h.",Does Critical Illness Change Levofloxacin Pharmacokinetics? ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26666946/),[l] / [h],0.90,68205,DB01137,Levofloxacin
,17092740,mucosal concentrations,"Median of mucosal concentrations were 0.96 mg l(-1) at 1 h, 2.50 mg l(-1) at 2 h, 5.84 mg l(-1) at 3 h.",Penetration of levofloxacin into paranasal sinuses mucosa of patients with chronic rhinosinusitis after a single 500 mg oral dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17092740/),[mg] / [l],0.96,69985,DB01137,Levofloxacin
,17092740,mucosal concentrations,"Median of mucosal concentrations were 0.96 mg l(-1) at 1 h, 2.50 mg l(-1) at 2 h, 5.84 mg l(-1) at 3 h.",Penetration of levofloxacin into paranasal sinuses mucosa of patients with chronic rhinosinusitis after a single 500 mg oral dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17092740/),[mg] / [l],2.50,69986,DB01137,Levofloxacin
,17092740,mucosal concentrations,"Median of mucosal concentrations were 0.96 mg l(-1) at 1 h, 2.50 mg l(-1) at 2 h, 5.84 mg l(-1) at 3 h.",Penetration of levofloxacin into paranasal sinuses mucosa of patients with chronic rhinosinusitis after a single 500 mg oral dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17092740/),[mg] / [l],5.84,69987,DB01137,Levofloxacin
,17092740,mucosa-to-plasma ratios,"Average paranasal sinuses mucosa-to-plasma ratios raised from 1.46 at 1 h, to 1.81 at 2 h and to 2.56 at 3 h.",Penetration of levofloxacin into paranasal sinuses mucosa of patients with chronic rhinosinusitis after a single 500 mg oral dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17092740/),,1.46,69988,DB01137,Levofloxacin
,17092740,mucosa-to-plasma ratios,"Average paranasal sinuses mucosa-to-plasma ratios raised from 1.46 at 1 h, to 1.81 at 2 h and to 2.56 at 3 h.",Penetration of levofloxacin into paranasal sinuses mucosa of patients with chronic rhinosinusitis after a single 500 mg oral dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17092740/),,1.81,69989,DB01137,Levofloxacin
,17092740,mucosa-to-plasma ratios,"Average paranasal sinuses mucosa-to-plasma ratios raised from 1.46 at 1 h, to 1.81 at 2 h and to 2.56 at 3 h.",Penetration of levofloxacin into paranasal sinuses mucosa of patients with chronic rhinosinusitis after a single 500 mg oral dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17092740/),,2.56,69990,DB01137,Levofloxacin
,21362374,maximum concentration of drug in serum (C(max)),"In single dose study, the maximum concentration of drug in serum (C(max)), the time to reach C(max) (T(max)), and the area under the serum concentration-time curve (AUC (0-∞)) of antofloxacin were (1.89 ± 0.65) mg/L, (1.29 ± 0.26) hours, and (25.24 ± 7.26) mg×h(-1)×L(-1), respectively.",Pharmacokinetic study of single and multiple oral dose administration of antofloxacin hydrochloride in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21362374/),[mg] / [l],1.89,72369,DB01137,Levofloxacin
,21362374,time to reach C(max) (T(max)),"In single dose study, the maximum concentration of drug in serum (C(max)), the time to reach C(max) (T(max)), and the area under the serum concentration-time curve (AUC (0-∞)) of antofloxacin were (1.89 ± 0.65) mg/L, (1.29 ± 0.26) hours, and (25.24 ± 7.26) mg×h(-1)×L(-1), respectively.",Pharmacokinetic study of single and multiple oral dose administration of antofloxacin hydrochloride in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21362374/),h,1.29,72370,DB01137,Levofloxacin
,21362374,area under the serum concentration-time curve (AUC (0-∞)),"In single dose study, the maximum concentration of drug in serum (C(max)), the time to reach C(max) (T(max)), and the area under the serum concentration-time curve (AUC (0-∞)) of antofloxacin were (1.89 ± 0.65) mg/L, (1.29 ± 0.26) hours, and (25.24 ± 7.26) mg×h(-1)×L(-1), respectively.",Pharmacokinetic study of single and multiple oral dose administration of antofloxacin hydrochloride in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21362374/),[mg] / [h·l],25.24,72371,DB01137,Levofloxacin
,21362374,Accumulating elimination rate,Accumulating elimination rate of antoflocaxin from urine within 120 hours was 39.1%.,Pharmacokinetic study of single and multiple oral dose administration of antofloxacin hydrochloride in healthy male volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21362374/),%,39.1,72372,DB01137,Levofloxacin
,21362374,minimum concentration drug in serum (C(min)),"The minimum concentration drug in serum (C(min)), AUCss, mean concentration of drug in serum (C(av)), and degree of fluctuation (DF) were (0.73 ± 0.18) mg/L, (47.59 ± 7.85) mg×h(-1)×L(-1), (1.98 ± 0.33) mg/L, and 1.74 ± 0.60, respectively.",Pharmacokinetic study of single and multiple oral dose administration of antofloxacin hydrochloride in healthy male volunteers. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21362374/),[mg] / [l],0.73,72373,DB01137,Levofloxacin
,21362374,AUCss,"The minimum concentration drug in serum (C(min)), AUCss, mean concentration of drug in serum (C(av)), and degree of fluctuation (DF) were (0.73 ± 0.18) mg/L, (47.59 ± 7.85) mg×h(-1)×L(-1), (1.98 ± 0.33) mg/L, and 1.74 ± 0.60, respectively.",Pharmacokinetic study of single and multiple oral dose administration of antofloxacin hydrochloride in healthy male volunteers. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21362374/),[mg] / [h·l],47.59,72374,DB01137,Levofloxacin
,21362374,T(max),"On day 7 after dosing, T(max), C(max), and AUC (0-∞) was (1.14 ± 0.50) hours, (2.52 ± 0.38) mg/L, and (48.77 ± 8.44) mg×h(-1)×L(-1), respectively.",Pharmacokinetic study of single and multiple oral dose administration of antofloxacin hydrochloride in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21362374/),h,1.14,72375,DB01137,Levofloxacin
,21362374,C(max),"On day 7 after dosing, T(max), C(max), and AUC (0-∞) was (1.14 ± 0.50) hours, (2.52 ± 0.38) mg/L, and (48.77 ± 8.44) mg×h(-1)×L(-1), respectively.",Pharmacokinetic study of single and multiple oral dose administration of antofloxacin hydrochloride in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21362374/),[mg] / [l],2.52,72376,DB01137,Levofloxacin
,21362374,AUC (0-∞),"On day 7 after dosing, T(max), C(max), and AUC (0-∞) was (1.14 ± 0.50) hours, (2.52 ± 0.38) mg/L, and (48.77 ± 8.44) mg×h(-1)×L(-1), respectively.",Pharmacokinetic study of single and multiple oral dose administration of antofloxacin hydrochloride in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21362374/),[mg] / [h·l],48.77,72377,DB01137,Levofloxacin
,21362374,Accumulating elimination rate,Accumulating elimination rate of antofloxaxin from urine within 120 hours after the last dosing was 60.06%.,Pharmacokinetic study of single and multiple oral dose administration of antofloxacin hydrochloride in healthy male volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21362374/),%,60.06,72378,DB01137,Levofloxacin
,29947489,volume of distribution (V),"The population PKs of levofloxacin were; the volume of distribution (V) = 101.71±1.41 L, total clearance (CL) = 8.51±1.43 L/hour and the area under the plasma time-concentration curve from 0 to 24 hours (AUC0-24 ) = 66.19±1.30 mg*hour/L.",Population Pharmacokinetics and Pharmacodynamics Modeling of Oral Levofloxacin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29947489/),l,101.71,73950,DB01137,Levofloxacin
,29947489,total clearance (CL),"The population PKs of levofloxacin were; the volume of distribution (V) = 101.71±1.41 L, total clearance (CL) = 8.51±1.43 L/hour and the area under the plasma time-concentration curve from 0 to 24 hours (AUC0-24 ) = 66.19±1.30 mg*hour/L.",Population Pharmacokinetics and Pharmacodynamics Modeling of Oral Levofloxacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29947489/),[l] / [h],8.51,73951,DB01137,Levofloxacin
,29947489,area under the plasma time-concentration curve from 0 to 24 hours (AUC0-24 ),"The population PKs of levofloxacin were; the volume of distribution (V) = 101.71±1.41 L, total clearance (CL) = 8.51±1.43 L/hour and the area under the plasma time-concentration curve from 0 to 24 hours (AUC0-24 ) = 66.19±1.30 mg*hour/L.",Population Pharmacokinetics and Pharmacodynamics Modeling of Oral Levofloxacin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29947489/),[h·mg] / [l],66.19,73952,DB01137,Levofloxacin
,29947489,AUC0-24 /MIC ratio,"The predicted CFRs for a target AUC0-24 /MIC ratio of 30 for S. aureus and S. pneumoniae were 83.12% and 92.63%, respectively for 500 mg levofloxacin, and 84.96% and 98.17%, respectively for 750 mg levofloxacin.",Population Pharmacokinetics and Pharmacodynamics Modeling of Oral Levofloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29947489/),,30,73953,DB01137,Levofloxacin
,29947489,AUC0-24 /MIC ratio,"The predicted CFRs for a target AUC0-24 /MIC ratio of 125 for E. coli and Klebsiella spp. were 84.25% and 88.81%, respectively for 500 mg levofloxacin and 86.00% and 91.34%, respectively for 750 mg levofloxacin.",Population Pharmacokinetics and Pharmacodynamics Modeling of Oral Levofloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29947489/),,125,73954,DB01137,Levofloxacin
,30396379,flow rate,"Chromatographic separation was achieved using a Shiseido C18 MGII (250×4.6mm i.d.; 5 μm) column under an isocratic mobile phase comprising of 50 mM potassium dihydrogen phosphate (pH 2.4) - acetonitrile (77:23, v/v) at a flow rate of 1.5 mL/min.",A simple and sensitive HPLC-fluorescence method for the determination of moxifloxacin in human plasma and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30396379/),[ml] / [min],1.5,74104,DB01137,Levofloxacin
,30396379,total chromatographic run time,"The total chromatographic run time was 8 min with the retention times of moxifloxacin and internal standard at 6.5 and 3.0 min, respectively.",A simple and sensitive HPLC-fluorescence method for the determination of moxifloxacin in human plasma and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30396379/),min,8,74105,DB01137,Levofloxacin
,30396379,retention times,"The total chromatographic run time was 8 min with the retention times of moxifloxacin and internal standard at 6.5 and 3.0 min, respectively.",A simple and sensitive HPLC-fluorescence method for the determination of moxifloxacin in human plasma and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30396379/),min,6.5,74106,DB01137,Levofloxacin
,30396379,retention times,"The total chromatographic run time was 8 min with the retention times of moxifloxacin and internal standard at 6.5 and 3.0 min, respectively.",A simple and sensitive HPLC-fluorescence method for the determination of moxifloxacin in human plasma and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30396379/),min,3.0,74107,DB01137,Levofloxacin
at,15728883,MICs,"A new pharmacokinetically enhanced formulation of amoxicillin-clavulanate (2,000 mg of amoxicillin/125 mg of clavulanate twice a day; ratio 16:1) has been designed, with sustained-release technology, to allow coverage of bacterial strains with amoxicillin-clavulanic acid MICs of at least 4/2 mug/ml.",Comparative bacteriological efficacy of pharmacokinetically enhanced amoxicillin-clavulanate against Streptococcus pneumoniae with elevated amoxicillin MICs and Haemophilus influenzae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15728883/),[μg] / [ml],4/2,74470,DB01137,Levofloxacin
,15728883,MICs,"Bacterial strains included Streptococcus pneumoniae, with amoxicillin-clavulanic acid MICs of 2/1 (one strain), 4/2, or 8/4 microg/ml (three strains each), and Haemophilus influenzae, one beta-lactamase-positive strain and one beta-lactamase-negative, ampicillin-resistant strain.",Comparative bacteriological efficacy of pharmacokinetically enhanced amoxicillin-clavulanate against Streptococcus pneumoniae with elevated amoxicillin MICs and Haemophilus influenzae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15728883/),[μg] / [ml],2/1,74471,DB01137,Levofloxacin
,15728883,MICs,"Bacterial strains included Streptococcus pneumoniae, with amoxicillin-clavulanic acid MICs of 2/1 (one strain), 4/2, or 8/4 microg/ml (three strains each), and Haemophilus influenzae, one beta-lactamase-positive strain and one beta-lactamase-negative, ampicillin-resistant strain.",Comparative bacteriological efficacy of pharmacokinetically enhanced amoxicillin-clavulanate against Streptococcus pneumoniae with elevated amoxicillin MICs and Haemophilus influenzae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15728883/),[μg] / [ml],4/2,74472,DB01137,Levofloxacin
,15728883,MICs,"Bacterial strains included Streptococcus pneumoniae, with amoxicillin-clavulanic acid MICs of 2/1 (one strain), 4/2, or 8/4 microg/ml (three strains each), and Haemophilus influenzae, one beta-lactamase-positive strain and one beta-lactamase-negative, ampicillin-resistant strain.",Comparative bacteriological efficacy of pharmacokinetically enhanced amoxicillin-clavulanate against Streptococcus pneumoniae with elevated amoxicillin MICs and Haemophilus influenzae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15728883/),[μg] / [ml],8/4,74473,DB01137,Levofloxacin
up to,15728883,MICs,"Amoxicillin-clavulanate, 2,000/125 mg twice a day, ratio 16:1, was effective against all S. pneumoniae strains tested, including those with amoxicillin-clavulanic acid MICs of up to 8/4 microg/ml and against beta-lactamase-producing and beta-lactamase-negative ampicillin-resistant H. influenzae.",Comparative bacteriological efficacy of pharmacokinetically enhanced amoxicillin-clavulanate against Streptococcus pneumoniae with elevated amoxicillin MICs and Haemophilus influenzae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15728883/),[μg] / [ml],8/4,74474,DB01137,Levofloxacin
at,15728883,MICs,"These results demonstrate the bacteriological efficacy of pharmacokinetically enhanced amoxicillin-clavulanate 2,000/125 mg twice a day (ratio 16:1) against S. pneumoniae with amoxicillin-clavulanic acid MICs of at least 4/2 microg/ml and support clavulanate 125 mg twice a day as sufficient to protect against beta-lactamase in this rat model.",Comparative bacteriological efficacy of pharmacokinetically enhanced amoxicillin-clavulanate against Streptococcus pneumoniae with elevated amoxicillin MICs and Haemophilus influenzae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15728883/),[μg] / [ml],4/2,74475,DB01137,Levofloxacin
,16304179,area under the concentration curve (AUC),"The median area under the concentration curve (AUC) of levofloxacin in interstitial lung fluid was 18.6 microg.h/ml (range, 10.1 to 33.6).",In vivo measurement of levofloxacin penetration into lung tissue after cardiac surgery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16304179/),[h·μg] / [ml],18.6,79227,DB01137,Levofloxacin
,16304179,AUC for tissue (AUC(tissue)),"The median AUC for tissue (AUC(tissue)) of unbound levofloxacin/AUC(total) in plasma was 0.6 (range, 0.4 to 0.9).",In vivo measurement of levofloxacin penetration into lung tissue after cardiac surgery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16304179/),,0.6,79228,DB01137,Levofloxacin
,16304179,unbound AUC(tissue)/MIC,"The median unbound AUC(tissue)/MIC was 2.4 (range, 1.3 to 4.2) for Pseudomonas aeruginosa.",In vivo measurement of levofloxacin penetration into lung tissue after cardiac surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16304179/),,2.4,79229,DB01137,Levofloxacin
,25936632,trough,"Mean trough and peak serum concentrations of clindamycin in the clindamycin-rifampicin arm were lower than in the clindamycin-levofloxacin arm during the time of oral antibiotic regimen (0.79 ± 0.3 μg/ml vs 4.7 ± 1.2 μg/ml, p < 0.001, and 3.48 ± 1.1 μg/ml vs 10.2 ± 1.8 μg/ml, p < 0.001, respectively).",Dramatic reduction of clindamycin serum concentration in staphylococcal osteoarticular infection patients treated with the oral clindamycin-rifampicin combination. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25936632/),[μg] / [ml],0.79,79784,DB01137,Levofloxacin
,25936632,trough,"Mean trough and peak serum concentrations of clindamycin in the clindamycin-rifampicin arm were lower than in the clindamycin-levofloxacin arm during the time of oral antibiotic regimen (0.79 ± 0.3 μg/ml vs 4.7 ± 1.2 μg/ml, p < 0.001, and 3.48 ± 1.1 μg/ml vs 10.2 ± 1.8 μg/ml, p < 0.001, respectively).",Dramatic reduction of clindamycin serum concentration in staphylococcal osteoarticular infection patients treated with the oral clindamycin-rifampicin combination. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25936632/),[μg] / [ml],4.7,79785,DB01137,Levofloxacin
,25936632,peak serum concentrations,"Mean trough and peak serum concentrations of clindamycin in the clindamycin-rifampicin arm were lower than in the clindamycin-levofloxacin arm during the time of oral antibiotic regimen (0.79 ± 0.3 μg/ml vs 4.7 ± 1.2 μg/ml, p < 0.001, and 3.48 ± 1.1 μg/ml vs 10.2 ± 1.8 μg/ml, p < 0.001, respectively).",Dramatic reduction of clindamycin serum concentration in staphylococcal osteoarticular infection patients treated with the oral clindamycin-rifampicin combination. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25936632/),[μg] / [ml],3.48,79786,DB01137,Levofloxacin
,25936632,peak serum concentrations,"Mean trough and peak serum concentrations of clindamycin in the clindamycin-rifampicin arm were lower than in the clindamycin-levofloxacin arm during the time of oral antibiotic regimen (0.79 ± 0.3 μg/ml vs 4.7 ± 1.2 μg/ml, p < 0.001, and 3.48 ± 1.1 μg/ml vs 10.2 ± 1.8 μg/ml, p < 0.001, respectively).",Dramatic reduction of clindamycin serum concentration in staphylococcal osteoarticular infection patients treated with the oral clindamycin-rifampicin combination. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25936632/),[μg] / [ml],10.2,79787,DB01137,Levofloxacin
,10471591,elimination half-lives,"Levofloxacin disposition was characterized by rapid oral absorption, with peak concentrations occurring approximately 1.5 h after dosing and elimination half-lives from 7.2 to 9.4 h.",Pharmacokinetics and safety of high-dose and extended-interval regimens of levofloxacin in human immunodeficiency virus-infected patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10471591/),h,7.2 to 9.4,81262,DB01137,Levofloxacin
,34117648,apparent clearance,"The estimated PK parameters (interindividual variability, %) were: apparent clearance 8.32 L h-1 (22.6%), apparent central volume of distribution 35.8 L (45.2%), apparent peripheral volume of distribution 39.7 L, intercompartmental clearance 40.6 L h-1 (43.8%), absorption rate constant 7.45 h-1 (150%), mean absorption transit time 0.355 h (52.4%), and total number of transit compartments 6.01 (131.9%).",Population pharmacokinetics of oral levofloxacin in healthy volunteers and dosing optimization for multidrug-resistant tuberculosis therapy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34117648/),[l] / [h],8.32,83407,DB01137,Levofloxacin
,34117648,apparent central volume of distribution,"The estimated PK parameters (interindividual variability, %) were: apparent clearance 8.32 L h-1 (22.6%), apparent central volume of distribution 35.8 L (45.2%), apparent peripheral volume of distribution 39.7 L, intercompartmental clearance 40.6 L h-1 (43.8%), absorption rate constant 7.45 h-1 (150%), mean absorption transit time 0.355 h (52.4%), and total number of transit compartments 6.01 (131.9%).",Population pharmacokinetics of oral levofloxacin in healthy volunteers and dosing optimization for multidrug-resistant tuberculosis therapy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34117648/),l,35.8,83408,DB01137,Levofloxacin
,34117648,apparent peripheral volume of distribution,"The estimated PK parameters (interindividual variability, %) were: apparent clearance 8.32 L h-1 (22.6%), apparent central volume of distribution 35.8 L (45.2%), apparent peripheral volume of distribution 39.7 L, intercompartmental clearance 40.6 L h-1 (43.8%), absorption rate constant 7.45 h-1 (150%), mean absorption transit time 0.355 h (52.4%), and total number of transit compartments 6.01 (131.9%).",Population pharmacokinetics of oral levofloxacin in healthy volunteers and dosing optimization for multidrug-resistant tuberculosis therapy. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34117648/),l,39.7,83409,DB01137,Levofloxacin
,34117648,intercompartmental clearance,"The estimated PK parameters (interindividual variability, %) were: apparent clearance 8.32 L h-1 (22.6%), apparent central volume of distribution 35.8 L (45.2%), apparent peripheral volume of distribution 39.7 L, intercompartmental clearance 40.6 L h-1 (43.8%), absorption rate constant 7.45 h-1 (150%), mean absorption transit time 0.355 h (52.4%), and total number of transit compartments 6.01 (131.9%).",Population pharmacokinetics of oral levofloxacin in healthy volunteers and dosing optimization for multidrug-resistant tuberculosis therapy. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34117648/),[l] / [h],40.6,83410,DB01137,Levofloxacin
,34117648,absorption rate constant,"The estimated PK parameters (interindividual variability, %) were: apparent clearance 8.32 L h-1 (22.6%), apparent central volume of distribution 35.8 L (45.2%), apparent peripheral volume of distribution 39.7 L, intercompartmental clearance 40.6 L h-1 (43.8%), absorption rate constant 7.45 h-1 (150%), mean absorption transit time 0.355 h (52.4%), and total number of transit compartments 6.01 (131.9%).",Population pharmacokinetics of oral levofloxacin in healthy volunteers and dosing optimization for multidrug-resistant tuberculosis therapy. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34117648/),1/[h],7.45,83411,DB01137,Levofloxacin
,34117648,mean absorption transit time,"The estimated PK parameters (interindividual variability, %) were: apparent clearance 8.32 L h-1 (22.6%), apparent central volume of distribution 35.8 L (45.2%), apparent peripheral volume of distribution 39.7 L, intercompartmental clearance 40.6 L h-1 (43.8%), absorption rate constant 7.45 h-1 (150%), mean absorption transit time 0.355 h (52.4%), and total number of transit compartments 6.01 (131.9%).",Population pharmacokinetics of oral levofloxacin in healthy volunteers and dosing optimization for multidrug-resistant tuberculosis therapy. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34117648/),h,0.355,83412,DB01137,Levofloxacin
,34117648,total number of transit compartments,"The estimated PK parameters (interindividual variability, %) were: apparent clearance 8.32 L h-1 (22.6%), apparent central volume of distribution 35.8 L (45.2%), apparent peripheral volume of distribution 39.7 L, intercompartmental clearance 40.6 L h-1 (43.8%), absorption rate constant 7.45 h-1 (150%), mean absorption transit time 0.355 h (52.4%), and total number of transit compartments 6.01 (131.9%).",Population pharmacokinetics of oral levofloxacin in healthy volunteers and dosing optimization for multidrug-resistant tuberculosis therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34117648/),,6.01,83413,DB01137,Levofloxacin
,34117648,area under the concentration-time curve/minimum inhibitory concentration (MIC),"Monte Carlo simulations using levofloxacin 750-1000 mg yielded a probability of achieving a target free area under the concentration-time curve/minimum inhibitory concentration (MIC) of 100 at greater than 90% for Mycobacterium tuberculosis with an MIC < 0.5 mg L-1 , while a dose of 1500 mg was required for strains with an MIC of 1 mg L-1 .",Population pharmacokinetics of oral levofloxacin in healthy volunteers and dosing optimization for multidrug-resistant tuberculosis therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34117648/),,100,83414,DB01137,Levofloxacin
<,34117648,MIC,"Monte Carlo simulations using levofloxacin 750-1000 mg yielded a probability of achieving a target free area under the concentration-time curve/minimum inhibitory concentration (MIC) of 100 at greater than 90% for Mycobacterium tuberculosis with an MIC < 0.5 mg L-1 , while a dose of 1500 mg was required for strains with an MIC of 1 mg L-1 .",Population pharmacokinetics of oral levofloxacin in healthy volunteers and dosing optimization for multidrug-resistant tuberculosis therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34117648/),[mg] / [l],0.5,83415,DB01137,Levofloxacin
,34117648,MIC,"Monte Carlo simulations using levofloxacin 750-1000 mg yielded a probability of achieving a target free area under the concentration-time curve/minimum inhibitory concentration (MIC) of 100 at greater than 90% for Mycobacterium tuberculosis with an MIC < 0.5 mg L-1 , while a dose of 1500 mg was required for strains with an MIC of 1 mg L-1 .",Population pharmacokinetics of oral levofloxacin in healthy volunteers and dosing optimization for multidrug-resistant tuberculosis therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34117648/),[mg] / [l],1,83416,DB01137,Levofloxacin
,17825693,AUC:MIC ratio,The probability of target attainment was determined for each regimen for an AUC:MIC ratio from 0 to 300.,Simulated comparison of the pharmacodynamics of ciprofloxacin and levofloxacin against Pseudomonas aeruginosa using pharmacokinetic data from healthy volunteers and 2002 minimum inhibitory concentration data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17825693/),,0 to 300,83660,DB01137,Levofloxacin
,17825693,AUC:MIC ratio,"For ciprofloxacin 400 mg TID and levofloxacin 750 mg QD, the AUC:MIC ratio at the corresponding 2002 Clinical Laboratory Standards Institute break points of 1 and 2 microg/mL were 33 and 34, respectively.",Simulated comparison of the pharmacodynamics of ciprofloxacin and levofloxacin against Pseudomonas aeruginosa using pharmacokinetic data from healthy volunteers and 2002 minimum inhibitory concentration data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17825693/),,33,83661,DB01137,Levofloxacin
,17825693,AUC:MIC ratio,"For ciprofloxacin 400 mg TID and levofloxacin 750 mg QD, the AUC:MIC ratio at the corresponding 2002 Clinical Laboratory Standards Institute break points of 1 and 2 microg/mL were 33 and 34, respectively.",Simulated comparison of the pharmacodynamics of ciprofloxacin and levofloxacin against Pseudomonas aeruginosa using pharmacokinetic data from healthy volunteers and 2002 minimum inhibitory concentration data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17825693/),,34,83662,DB01137,Levofloxacin
>,17825693,free,"The probabilities of target attainment for a free AUC:MIC ratio >90 (equivalent to a total AUC:MIC ratio > or =125) were 47% for ciprofloxacin 400 mg BID, 54% for ciprofloxacin 400 mg TID, and 48% for levofloxacin 750 mg QD.",Simulated comparison of the pharmacodynamics of ciprofloxacin and levofloxacin against Pseudomonas aeruginosa using pharmacokinetic data from healthy volunteers and 2002 minimum inhibitory concentration data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17825693/),,90,83663,DB01137,Levofloxacin
>,17825693,AUC:MIC ratio,"The probabilities of target attainment for a free AUC:MIC ratio >90 (equivalent to a total AUC:MIC ratio > or =125) were 47% for ciprofloxacin 400 mg BID, 54% for ciprofloxacin 400 mg TID, and 48% for levofloxacin 750 mg QD.",Simulated comparison of the pharmacodynamics of ciprofloxacin and levofloxacin against Pseudomonas aeruginosa using pharmacokinetic data from healthy volunteers and 2002 minimum inhibitory concentration data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17825693/),,90,83664,DB01137,Levofloxacin
>,17825693,total AUC:MIC ratio,"The probabilities of target attainment for a free AUC:MIC ratio >90 (equivalent to a total AUC:MIC ratio > or =125) were 47% for ciprofloxacin 400 mg BID, 54% for ciprofloxacin 400 mg TID, and 48% for levofloxacin 750 mg QD.",Simulated comparison of the pharmacodynamics of ciprofloxacin and levofloxacin against Pseudomonas aeruginosa using pharmacokinetic data from healthy volunteers and 2002 minimum inhibitory concentration data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17825693/),,125,83665,DB01137,Levofloxacin
,30373800,time span,"Only clinically suitable LSSs (maximum time span, 8 h; minimum interval, 1 h; 1 to 3 samples) were tested.",Population Pharmacokinetic Model and Limited Sampling Strategies for Personalized Dosing of Levofloxacin in Tuberculosis Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30373800/),h,8,86468,DB01137,Levofloxacin
,11109013,AUC:MIC ratios,"Monte Carlo simulation was utilized to estimate the probability of attaining AUC:MIC ratios of 30, 40, 50, 60, 70, 80, 90, 100, 110 and 120 using AUC values from patients treated with either gatifloxacin or levofloxacin and microbiologic activity against S. pneumoniae observed in 1997 SENTRY Antimicrobial Surveillance Program.",The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11109013/),,30,88729,DB01137,Levofloxacin
,11109013,AUC:MIC ratios,"Monte Carlo simulation was utilized to estimate the probability of attaining AUC:MIC ratios of 30, 40, 50, 60, 70, 80, 90, 100, 110 and 120 using AUC values from patients treated with either gatifloxacin or levofloxacin and microbiologic activity against S. pneumoniae observed in 1997 SENTRY Antimicrobial Surveillance Program.",The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11109013/),,40,88730,DB01137,Levofloxacin
,11109013,AUC:MIC ratios,"Monte Carlo simulation was utilized to estimate the probability of attaining AUC:MIC ratios of 30, 40, 50, 60, 70, 80, 90, 100, 110 and 120 using AUC values from patients treated with either gatifloxacin or levofloxacin and microbiologic activity against S. pneumoniae observed in 1997 SENTRY Antimicrobial Surveillance Program.",The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11109013/),,50,88731,DB01137,Levofloxacin
,11109013,AUC:MIC ratios,"Monte Carlo simulation was utilized to estimate the probability of attaining AUC:MIC ratios of 30, 40, 50, 60, 70, 80, 90, 100, 110 and 120 using AUC values from patients treated with either gatifloxacin or levofloxacin and microbiologic activity against S. pneumoniae observed in 1997 SENTRY Antimicrobial Surveillance Program.",The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11109013/),,60,88732,DB01137,Levofloxacin
,11109013,AUC:MIC ratios,"Monte Carlo simulation was utilized to estimate the probability of attaining AUC:MIC ratios of 30, 40, 50, 60, 70, 80, 90, 100, 110 and 120 using AUC values from patients treated with either gatifloxacin or levofloxacin and microbiologic activity against S. pneumoniae observed in 1997 SENTRY Antimicrobial Surveillance Program.",The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11109013/),,70,88733,DB01137,Levofloxacin
,11109013,AUC:MIC ratios,"Monte Carlo simulation was utilized to estimate the probability of attaining AUC:MIC ratios of 30, 40, 50, 60, 70, 80, 90, 100, 110 and 120 using AUC values from patients treated with either gatifloxacin or levofloxacin and microbiologic activity against S. pneumoniae observed in 1997 SENTRY Antimicrobial Surveillance Program.",The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11109013/),,80,88734,DB01137,Levofloxacin
,11109013,AUC:MIC ratios,"Monte Carlo simulation was utilized to estimate the probability of attaining AUC:MIC ratios of 30, 40, 50, 60, 70, 80, 90, 100, 110 and 120 using AUC values from patients treated with either gatifloxacin or levofloxacin and microbiologic activity against S. pneumoniae observed in 1997 SENTRY Antimicrobial Surveillance Program.",The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11109013/),,90,88735,DB01137,Levofloxacin
,11109013,AUC:MIC ratios,"Monte Carlo simulation was utilized to estimate the probability of attaining AUC:MIC ratios of 30, 40, 50, 60, 70, 80, 90, 100, 110 and 120 using AUC values from patients treated with either gatifloxacin or levofloxacin and microbiologic activity against S. pneumoniae observed in 1997 SENTRY Antimicrobial Surveillance Program.",The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11109013/),,120,88736,DB01137,Levofloxacin
,11109013,AUC:MIC ratios,The median AUC:MIC ratios were 120 for gatifloxacin and 50.5 for levofloxacin.,The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11109013/),,120,88737,DB01137,Levofloxacin
,11109013,AUC:MIC ratios,The median AUC:MIC ratios were 120 for gatifloxacin and 50.5 for levofloxacin.,The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11109013/),,50.5,88738,DB01137,Levofloxacin
,11109013,AUC:MIC ratios,"The probability of attaining AUC:MIC ratios of 30, 50, 70 and 100 for gatifloxacin were 94%, 86%, 78% and 62%, and for levofloxacin were 80%, 51%, 31% and 17%, respectively.",The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11109013/),,30,88739,DB01137,Levofloxacin
,11109013,AUC:MIC ratios,"The probability of attaining AUC:MIC ratios of 30, 50, 70 and 100 for gatifloxacin were 94%, 86%, 78% and 62%, and for levofloxacin were 80%, 51%, 31% and 17%, respectively.",The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11109013/),,50,88740,DB01137,Levofloxacin
,11109013,AUC:MIC ratios,"The probability of attaining AUC:MIC ratios of 30, 50, 70 and 100 for gatifloxacin were 94%, 86%, 78% and 62%, and for levofloxacin were 80%, 51%, 31% and 17%, respectively.",The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11109013/),,100,88741,DB01137,Levofloxacin
,8865312,hepatic extraction ratio,"By considering the bioavailability of levofloxacin in rat, the hepatic extraction ratio in vivo of levofloxacin was estimated to be 30%.",Local absorption kinetics of levofloxacin from intestinal tract into portal vein in conscious rat using portal-venous concentration difference. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8865312/),%,30,89543,DB01137,Levofloxacin
,8865312,local absorption time (Ta),The mean local absorption time (Ta) was 1.44 hr which coincided almost with the mean absorption time (MAT).,Local absorption kinetics of levofloxacin from intestinal tract into portal vein in conscious rat using portal-venous concentration difference. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8865312/),h,1.44,89544,DB01137,Levofloxacin
,15618751,AUC ratios,"The AUC ratios of ELF/plasma and AM/plasma after the oral administration of GPFX were 5.69 +/- 1.00 and 352 +/- 57, respectively, which were several-fold greater than those of ciprofloxacin (CPFX).","Distribution characteristics of grepafloxacin, a fluoroquinolone antibiotic, in lung epithelial lining fluid and alveolar macrophage. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15618751/),,5.69,89679,DB01137,Levofloxacin
,15618751,AUC ratios,"The AUC ratios of ELF/plasma and AM/plasma after the oral administration of GPFX were 5.69 +/- 1.00 and 352 +/- 57, respectively, which were several-fold greater than those of ciprofloxacin (CPFX).","Distribution characteristics of grepafloxacin, a fluoroquinolone antibiotic, in lung epithelial lining fluid and alveolar macrophage. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15618751/),,352,89680,DB01137,Levofloxacin
,28507117,AUC0-24,The median AUC0-24 was 98.8 mg/h/liter (IQR = 84.8 to 159.6 mg/h/liter).,Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis Patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28507117/),[mg] / [h·l],98.8,89969,DB01137,Levofloxacin
,28507117,MIC,"The MIC median value for LFX was 0.5 mg/liter with a range of 0.25 to 2.0 mg/liter, and the median fAUC0-24/MIC ratio was 109.5 (IQR = 48.5 to 399.4).",Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28507117/),[mg] / [l],0.5,89970,DB01137,Levofloxacin
,28507117,fAUC0-24/MIC ratio,"The MIC median value for LFX was 0.5 mg/liter with a range of 0.25 to 2.0 mg/liter, and the median fAUC0-24/MIC ratio was 109.5 (IQR = 48.5 to 399.4).",Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28507117/),,109.5,89971,DB01137,Levofloxacin
,28507117,MICs,"When MICs of 0.25, 0.5, 1.0, and 2.0 mg/liter were applicable, 19, 18, 3, and no patients, respectively, had an fAUC/MIC ratio that exceeded 100.",Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28507117/),[mg] / [l],0.25,89972,DB01137,Levofloxacin
,28507117,MICs,"When MICs of 0.25, 0.5, 1.0, and 2.0 mg/liter were applicable, 19, 18, 3, and no patients, respectively, had an fAUC/MIC ratio that exceeded 100.",Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28507117/),[mg] / [l],0.5,89973,DB01137,Levofloxacin
,28507117,MICs,"When MICs of 0.25, 0.5, 1.0, and 2.0 mg/liter were applicable, 19, 18, 3, and no patients, respectively, had an fAUC/MIC ratio that exceeded 100.",Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28507117/),[mg] / [l],1.0,89974,DB01137,Levofloxacin
,28507117,MICs,"When MICs of 0.25, 0.5, 1.0, and 2.0 mg/liter were applicable, 19, 18, 3, and no patients, respectively, had an fAUC/MIC ratio that exceeded 100.",Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28507117/),[mg] / [l],2.0,89975,DB01137,Levofloxacin
exceeded,28507117,fAUC/MIC ratio,"When MICs of 0.25, 0.5, 1.0, and 2.0 mg/liter were applicable, 19, 18, 3, and no patients, respectively, had an fAUC/MIC ratio that exceeded 100.",Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28507117/),,100,89976,DB01137,Levofloxacin
≥,28507117,fAUC0-24/MIC,An fAUC0-24/MIC of ≥100 was only observed when the MIC values for LFX were 0.25 to 0.5 mg/liter.,Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28507117/),,100,89977,DB01137,Levofloxacin
,28507117,MIC,An fAUC0-24/MIC of ≥100 was only observed when the MIC values for LFX were 0.25 to 0.5 mg/liter.,Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28507117/),[mg] / [l],0.25 to 0.5,89978,DB01137,Levofloxacin
more,25045247,elimination half-life,"It rapidly reaches maximum concentration Cmax 1-2 hours after oral administration in the fasting state and has a relatively long elimination half-life of more than 10 hours, which is similar to fluoroquinolones.",Review of nemonoxacin with special focus on clinical development. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25045247/),h,10,90292,DB01137,Levofloxacin
,31956998,exposure,Rifampin 15 mg/kg increased plasma and cerebrospinal fluid (CSF) exposures compared with 10 mg/kg: day 14 exposure increased from 48.2 hour·mg/L (range 18.2-93.8) to 82.5 hour·mg/L (range 8.7-161.0) in plasma and from 3.5 hour·mg/L (range 1.2-9.6) to 6.0 hour·mg/L (range 0.7-15.1) in CSF.,Pharmacokinetics and Pharmacodynamics of Intensive Antituberculosis Treatment of Tuberculous Meningitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31956998/),[h·mg] / [l],48.2,90694,DB01137,Levofloxacin
,31956998,exposure,Rifampin 15 mg/kg increased plasma and cerebrospinal fluid (CSF) exposures compared with 10 mg/kg: day 14 exposure increased from 48.2 hour·mg/L (range 18.2-93.8) to 82.5 hour·mg/L (range 8.7-161.0) in plasma and from 3.5 hour·mg/L (range 1.2-9.6) to 6.0 hour·mg/L (range 0.7-15.1) in CSF.,Pharmacokinetics and Pharmacodynamics of Intensive Antituberculosis Treatment of Tuberculous Meningitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31956998/),[h·mg] / [l],82.5,90695,DB01137,Levofloxacin
,31956998,exposure,Rifampin 15 mg/kg increased plasma and cerebrospinal fluid (CSF) exposures compared with 10 mg/kg: day 14 exposure increased from 48.2 hour·mg/L (range 18.2-93.8) to 82.5 hour·mg/L (range 8.7-161.0) in plasma and from 3.5 hour·mg/L (range 1.2-9.6) to 6.0 hour·mg/L (range 0.7-15.1) in CSF.,Pharmacokinetics and Pharmacodynamics of Intensive Antituberculosis Treatment of Tuberculous Meningitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31956998/),[h·mg] / [l],3.5,90696,DB01137,Levofloxacin
,31956998,exposure,Rifampin 15 mg/kg increased plasma and cerebrospinal fluid (CSF) exposures compared with 10 mg/kg: day 14 exposure increased from 48.2 hour·mg/L (range 18.2-93.8) to 82.5 hour·mg/L (range 8.7-161.0) in plasma and from 3.5 hour·mg/L (range 1.2-9.6) to 6.0 hour·mg/L (range 0.7-15.1) in CSF.,Pharmacokinetics and Pharmacodynamics of Intensive Antituberculosis Treatment of Tuberculous Meningitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31956998/),[h·mg] / [l],6.0,90697,DB01137,Levofloxacin
,31556716,peak plasma concentration,"After oral administration of the levofloxacin tablet, mean (coefficient of variation) peak plasma concentration was 15.5 μg/mL (23.8%), mean elimination half-life was 5.84 hours (20.0%), and mean bioavailability was 104% (29.0%).",Pharmacokinetics of levofloxacin following oral administration of a generic levofloxacin tablet and intravenous administration to dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31556716/),[μg] / [ml],15.5,91425,DB01137,Levofloxacin
,31556716,elimination half-life,"After oral administration of the levofloxacin tablet, mean (coefficient of variation) peak plasma concentration was 15.5 μg/mL (23.8%), mean elimination half-life was 5.84 hours (20.0%), and mean bioavailability was 104% (29.0%).",Pharmacokinetics of levofloxacin following oral administration of a generic levofloxacin tablet and intravenous administration to dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31556716/),h,5.84,91426,DB01137,Levofloxacin
,31556716,bioavailability,"After oral administration of the levofloxacin tablet, mean (coefficient of variation) peak plasma concentration was 15.5 μg/mL (23.8%), mean elimination half-life was 5.84 hours (20.0%), and mean bioavailability was 104% (29.0%).",Pharmacokinetics of levofloxacin following oral administration of a generic levofloxacin tablet and intravenous administration to dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31556716/),%,104,91427,DB01137,Levofloxacin
,31556716,elimination half-life,"After IV administration, mean elimination half-life (coefficient of variation) was 6.23 hours (14.7%), systemic clearance was 145.0 mL/kg/h (22.2%), and volume of distribution was 1.19 L/kg (17.1%).",Pharmacokinetics of levofloxacin following oral administration of a generic levofloxacin tablet and intravenous administration to dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31556716/),h,6.23,91428,DB01137,Levofloxacin
,31556716,systemic clearance,"After IV administration, mean elimination half-life (coefficient of variation) was 6.23 hours (14.7%), systemic clearance was 145.0 mL/kg/h (22.2%), and volume of distribution was 1.19 L/kg (17.1%).",Pharmacokinetics of levofloxacin following oral administration of a generic levofloxacin tablet and intravenous administration to dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31556716/),[ml] / [h·kg],145.0,91429,DB01137,Levofloxacin
,31556716,volume of distribution,"After IV administration, mean elimination half-life (coefficient of variation) was 6.23 hours (14.7%), systemic clearance was 145.0 mL/kg/h (22.2%), and volume of distribution was 1.19 L/kg (17.1%).",Pharmacokinetics of levofloxacin following oral administration of a generic levofloxacin tablet and intravenous administration to dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31556716/),[l] / [kg],1.19,91430,DB01137,Levofloxacin
,30496461,AUC0-24/MIC,"In the HFS-TB, the AUC0-24/MIC associated with maximal Mtb kill was 146, while that associated with suppression of resistance was 360.","Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30496461/),,146,95868,DB01137,Levofloxacin
,30496461,AUC0-24/MIC,"In the HFS-TB, the AUC0-24/MIC associated with maximal Mtb kill was 146, while that associated with suppression of resistance was 360.","Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30496461/),,360,95869,DB01137,Levofloxacin
,30496461,AUC0-24/MIC,"AI algorithms identified an AUC0-24/MIC of 160 as predictive of microbiologic cure, followed by levofloxacin 2-hour peak concentration and body weight.","Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30496461/),,160,95870,DB01137,Levofloxacin
,14506016,peak concentration of levofloxacin at steady state (C(max ss)),"The peak concentration of levofloxacin at steady state (C(max ss))was 10.45 mg/liter in plasma and 4.06 mg/liter in CSF, respectively, with the ratio of the C(max ss) in CSF to the C(max ss) in plasma being 0.47.",Levofloxacin disposition in cerebrospinal fluid in patients with external ventriculostomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14506016/),[mg] / [l],10.45,100747,DB01137,Levofloxacin
,14506016,peak concentration of levofloxacin at steady state (C(max ss)),"The peak concentration of levofloxacin at steady state (C(max ss))was 10.45 mg/liter in plasma and 4.06 mg/liter in CSF, respectively, with the ratio of the C(max ss) in CSF to the C(max ss) in plasma being 0.47.",Levofloxacin disposition in cerebrospinal fluid in patients with external ventriculostomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14506016/),[mg] / [l],4.06,100748,DB01137,Levofloxacin
,14506016,areas under the concentration-time curves during the 12-h dosing interval (AUC(0-tau)s),The areas under the concentration-time curves during the 12-h dosing interval (AUC(0-tau)s) were 47.69 mg.,Levofloxacin disposition in cerebrospinal fluid in patients with external ventriculostomy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14506016/),mg,47.69,100749,DB01137,Levofloxacin
,14506016,terminal-phase half-life,"The terminal-phase half-life of levofloxacin in CSF was longer than that in plasma (7.02 +/- 1.57 and 5.51 +/- 1.36 h, respectively; P = 0.034).",Levofloxacin disposition in cerebrospinal fluid in patients with external ventriculostomy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14506016/),h,7.02,100750,DB01137,Levofloxacin
,14506016,terminal-phase half-life,"The terminal-phase half-life of levofloxacin in CSF was longer than that in plasma (7.02 +/- 1.57 and 5.51 +/- 1.36 h, respectively; P = 0.034).",Levofloxacin disposition in cerebrospinal fluid in patients with external ventriculostomy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14506016/),h,5.51,100751,DB01137,Levofloxacin
,11396281,blood flow,"CVVHF with the following characteristics: hemofilter AN69 hollow fibers of 0.90 m2 area, blood flow 150 ml/min, ultrafiltrate flow 1.3 l/h, filtrate substitution in post-dilution mode.",Pharmacokinetics of levofloxacin during continuous veno-venous hemofiltration. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11396281/),[ml] / [min],150,103615,DB01137,Levofloxacin
,11396281,ultrafiltrate flow,"CVVHF with the following characteristics: hemofilter AN69 hollow fibers of 0.90 m2 area, blood flow 150 ml/min, ultrafiltrate flow 1.3 l/h, filtrate substitution in post-dilution mode.",Pharmacokinetics of levofloxacin during continuous veno-venous hemofiltration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11396281/),[l] / [h],1.3,103616,DB01137,Levofloxacin
,11396281,peak plasma concentrations,"Mean (range) peak plasma concentrations after levofloxacin 500 mg single dose (s.d.) and 250 mg multiple dose (m.d.) were 6.4 (2.7-9.4) and 8.2 (4.7-10.3) mg/l, trough levels 2.7 (1.4-5.0) and 2.9 (1.7-3.9) mg/l, half-life 28 (19-38) and 22 (17-31) h, volume of distribution 1.2 (0.72-1.6) l/kg and 0.91 (0.52-2.0) l/kg, respectively.",Pharmacokinetics of levofloxacin during continuous veno-venous hemofiltration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11396281/),[mg] / [l],6.4,103617,DB01137,Levofloxacin
,11396281,peak plasma concentrations,"Mean (range) peak plasma concentrations after levofloxacin 500 mg single dose (s.d.) and 250 mg multiple dose (m.d.) were 6.4 (2.7-9.4) and 8.2 (4.7-10.3) mg/l, trough levels 2.7 (1.4-5.0) and 2.9 (1.7-3.9) mg/l, half-life 28 (19-38) and 22 (17-31) h, volume of distribution 1.2 (0.72-1.6) l/kg and 0.91 (0.52-2.0) l/kg, respectively.",Pharmacokinetics of levofloxacin during continuous veno-venous hemofiltration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11396281/),[mg] / [l],8.2,103618,DB01137,Levofloxacin
,11396281,trough levels,"Mean (range) peak plasma concentrations after levofloxacin 500 mg single dose (s.d.) and 250 mg multiple dose (m.d.) were 6.4 (2.7-9.4) and 8.2 (4.7-10.3) mg/l, trough levels 2.7 (1.4-5.0) and 2.9 (1.7-3.9) mg/l, half-life 28 (19-38) and 22 (17-31) h, volume of distribution 1.2 (0.72-1.6) l/kg and 0.91 (0.52-2.0) l/kg, respectively.",Pharmacokinetics of levofloxacin during continuous veno-venous hemofiltration. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11396281/),[mg] / [l],2.7,103619,DB01137,Levofloxacin
,11396281,trough levels,"Mean (range) peak plasma concentrations after levofloxacin 500 mg single dose (s.d.) and 250 mg multiple dose (m.d.) were 6.4 (2.7-9.4) and 8.2 (4.7-10.3) mg/l, trough levels 2.7 (1.4-5.0) and 2.9 (1.7-3.9) mg/l, half-life 28 (19-38) and 22 (17-31) h, volume of distribution 1.2 (0.72-1.6) l/kg and 0.91 (0.52-2.0) l/kg, respectively.",Pharmacokinetics of levofloxacin during continuous veno-venous hemofiltration. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11396281/),[mg] / [l],2.9,103620,DB01137,Levofloxacin
,11396281,half-life,"Mean (range) peak plasma concentrations after levofloxacin 500 mg single dose (s.d.) and 250 mg multiple dose (m.d.) were 6.4 (2.7-9.4) and 8.2 (4.7-10.3) mg/l, trough levels 2.7 (1.4-5.0) and 2.9 (1.7-3.9) mg/l, half-life 28 (19-38) and 22 (17-31) h, volume of distribution 1.2 (0.72-1.6) l/kg and 0.91 (0.52-2.0) l/kg, respectively.",Pharmacokinetics of levofloxacin during continuous veno-venous hemofiltration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11396281/),h,28,103621,DB01137,Levofloxacin
,11396281,half-life,"Mean (range) peak plasma concentrations after levofloxacin 500 mg single dose (s.d.) and 250 mg multiple dose (m.d.) were 6.4 (2.7-9.4) and 8.2 (4.7-10.3) mg/l, trough levels 2.7 (1.4-5.0) and 2.9 (1.7-3.9) mg/l, half-life 28 (19-38) and 22 (17-31) h, volume of distribution 1.2 (0.72-1.6) l/kg and 0.91 (0.52-2.0) l/kg, respectively.",Pharmacokinetics of levofloxacin during continuous veno-venous hemofiltration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11396281/),h,22,103622,DB01137,Levofloxacin
,11396281,volume of distribution,"Mean (range) peak plasma concentrations after levofloxacin 500 mg single dose (s.d.) and 250 mg multiple dose (m.d.) were 6.4 (2.7-9.4) and 8.2 (4.7-10.3) mg/l, trough levels 2.7 (1.4-5.0) and 2.9 (1.7-3.9) mg/l, half-life 28 (19-38) and 22 (17-31) h, volume of distribution 1.2 (0.72-1.6) l/kg and 0.91 (0.52-2.0) l/kg, respectively.",Pharmacokinetics of levofloxacin during continuous veno-venous hemofiltration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11396281/),[l] / [kg],1.2,103623,DB01137,Levofloxacin
,11396281,volume of distribution,"Mean (range) peak plasma concentrations after levofloxacin 500 mg single dose (s.d.) and 250 mg multiple dose (m.d.) were 6.4 (2.7-9.4) and 8.2 (4.7-10.3) mg/l, trough levels 2.7 (1.4-5.0) and 2.9 (1.7-3.9) mg/l, half-life 28 (19-38) and 22 (17-31) h, volume of distribution 1.2 (0.72-1.6) l/kg and 0.91 (0.52-2.0) l/kg, respectively.",Pharmacokinetics of levofloxacin during continuous veno-venous hemofiltration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11396281/),[l] / [kg],0.91,103624,DB01137,Levofloxacin
,11396281,sieving coefficient,"The mean sieving coefficient was 0.96 (0.79-1.09), mean total clearance 47 (20-89) ml/min, and mean clearance by hemofiltration 21 (13-27) ml/min, respectively.",Pharmacokinetics of levofloxacin during continuous veno-venous hemofiltration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11396281/),,0.96,103625,DB01137,Levofloxacin
,11396281,total clearance,"The mean sieving coefficient was 0.96 (0.79-1.09), mean total clearance 47 (20-89) ml/min, and mean clearance by hemofiltration 21 (13-27) ml/min, respectively.",Pharmacokinetics of levofloxacin during continuous veno-venous hemofiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11396281/),[ml] / [min],47,103626,DB01137,Levofloxacin
,11396281,clearance,"The mean sieving coefficient was 0.96 (0.79-1.09), mean total clearance 47 (20-89) ml/min, and mean clearance by hemofiltration 21 (13-27) ml/min, respectively.",Pharmacokinetics of levofloxacin during continuous veno-venous hemofiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11396281/),[ml] / [min],21,103627,DB01137,Levofloxacin
,15358708,time to,The time to equilibration between the pleural fluid and blood antibiotic levels was more rapid for moxifloxacin (3.9 h) than for levofloxacin (4.4 h).,Penetration of newer quinolones in the empyema fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15358708/),h,3.9,104284,DB01137,Levofloxacin
,15358708,time to,The time to equilibration between the pleural fluid and blood antibiotic levels was more rapid for moxifloxacin (3.9 h) than for levofloxacin (4.4 h).,Penetration of newer quinolones in the empyema fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15358708/),h,4.4,104285,DB01137,Levofloxacin
,15358708,"peak pleural fluid concentration (Cmax,PF)","With moxifloxacin, the peak pleural fluid concentration (Cmax,PF) was 2.77 microg.",Penetration of newer quinolones in the empyema fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15358708/),μg,2.77,104286,DB01137,Levofloxacin
,15358708,"time to maximum pleural fluid concentration (Tmax,PF)","mL(-1) and occurred at a time to maximum pleural fluid concentration (Tmax,PF) of 6 h after infusion and decreased thereafter.",Penetration of newer quinolones in the empyema fluid. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15358708/),h,6,104287,DB01137,Levofloxacin
,15358708,"peak blood concentration (Cmax,blood)","The peak blood concentration (Cmax,blood) was 4.81 microg.",Penetration of newer quinolones in the empyema fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15358708/),μg,4.81,104288,DB01137,Levofloxacin
,15358708,peak pleural fluid level (Cmax,"With levofloxacin, the peak pleural fluid level (Cmax,PF=1.39 microg.mL(-1)) occurred at 6 h (Tmax,PF=6 h) after infusion.",Penetration of newer quinolones in the empyema fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15358708/),[μg] / [ml],1.39,104289,DB01137,Levofloxacin
,15358708,Tmax,"With levofloxacin, the peak pleural fluid level (Cmax,PF=1.39 microg.mL(-1)) occurred at 6 h (Tmax,PF=6 h) after infusion.",Penetration of newer quinolones in the empyema fluid. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15358708/),h,6,104290,DB01137,Levofloxacin
,15358708,"Cmax,blood","The Cmax,blood was 1.88 microg.",Penetration of newer quinolones in the empyema fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15358708/),μg,1.88,104291,DB01137,Levofloxacin
<,24041906,50% inhibitory concentrations,The two compounds inhibited the ATPase activity of GyrB and ParE with 50% inhibitory concentrations of <0.1 μg/ml.,Biological evaluation of benzothiazole ethyl urea inhibitors of bacterial type II topoisomerases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24041906/),[μg] / [ml],0.1,105887,DB01137,Levofloxacin
,24041906,MIC90s,MIC90s against clinical isolates ranged from 0.015 μg/ml for Streptococcus pneumoniae to 0.25 μg/ml for Staphylococcus aureus.,Biological evaluation of benzothiazole ethyl urea inhibitors of bacterial type II topoisomerases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24041906/),[μg] / [ml],0.015,105888,DB01137,Levofloxacin
,24041906,MIC90s,MIC90s against clinical isolates ranged from 0.015 μg/ml for Streptococcus pneumoniae to 0.25 μg/ml for Staphylococcus aureus.,Biological evaluation of benzothiazole ethyl urea inhibitors of bacterial type II topoisomerases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24041906/),[μg] / [ml],0.25,105889,DB01137,Levofloxacin
<,24041906,frequencies of spontaneous resistance,The frequencies of spontaneous resistance for S. aureus were <2.3 × 10(-10) with compound A and <5.8 × 10(-11) with compound B at concentrations equivalent to 8× the MICs.,Biological evaluation of benzothiazole ethyl urea inhibitors of bacterial type II topoisomerases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24041906/),,2.3 × 10(-10),105890,DB01137,Levofloxacin
<,24041906,frequencies of spontaneous resistance,The frequencies of spontaneous resistance for S. aureus were <2.3 × 10(-10) with compound A and <5.8 × 10(-11) with compound B at concentrations equivalent to 8× the MICs.,Biological evaluation of benzothiazole ethyl urea inhibitors of bacterial type II topoisomerases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24041906/),,5.8 × 10(-11),105891,DB01137,Levofloxacin
,24041906,oral bioavailability,The measured oral bioavailability of compound B was 47.7%.,Biological evaluation of benzothiazole ethyl urea inhibitors of bacterial type II topoisomerases. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24041906/),%,47.7,105892,DB01137,Levofloxacin
,16875808,AUC ratios,"The AUC ratios of ELF/plasma and AM/plasma of HSR-903 were 3.03+/-0.54 and 97.5+/-24.2, respectively, notably higher than those of ciprofloxacin (CPFX).","Distribution characteristics of orally administered olamufloxacin, a newly synthesized fluoroquinolone antibacterial, in lung epithelial lining fluid and alveolar macrophage in rats. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16875808/),,3.03,106946,DB01137,Levofloxacin
,16875808,AUC ratios,"The AUC ratios of ELF/plasma and AM/plasma of HSR-903 were 3.03+/-0.54 and 97.5+/-24.2, respectively, notably higher than those of ciprofloxacin (CPFX).","Distribution characteristics of orally administered olamufloxacin, a newly synthesized fluoroquinolone antibacterial, in lung epithelial lining fluid and alveolar macrophage in rats. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16875808/),,97.5,106947,DB01137,Levofloxacin
,25073403,apparent clearance (CL),"The typical population values for pharmacokinetic parameters of apparent clearance (CL) and apparent distribution volume (V) were 5.84 L/h and 43.3L, respectively.",Population pharmacokinetics of intravenous levofloxacin 500 mg/day dosage in infected patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25073403/),[l] / [h],5.84,108212,DB01137,Levofloxacin
,25073403,apparent distribution volume (V),"The typical population values for pharmacokinetic parameters of apparent clearance (CL) and apparent distribution volume (V) were 5.84 L/h and 43.3L, respectively.",Population pharmacokinetics of intravenous levofloxacin 500 mg/day dosage in infected patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25073403/),l,43.3,108213,DB01137,Levofloxacin
,9593134,CL,"The mean CL and the mean volume of distribution of the central compartment (V1) were 9.27 liters/h and 0.836 liter/kg, respectively.",Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9593134/),[l] / [h],9.27,110058,DB01137,Levofloxacin
,9593134,volume of distribution of the central compartment (V1),"The mean CL and the mean volume of distribution of the central compartment (V1) were 9.27 liters/h and 0.836 liter/kg, respectively.",Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9593134/),[l] / [kg],0.836,110059,DB01137,Levofloxacin
,9593134,rate constant from the peripheral compartment to the central compartment (Kpc),"The mean values for the intercompartmental rate constants, the rate constant from the central compartment to the peripheral compartment (Kcp) and the rate constant from the peripheral compartment to the central compartment (Kpc), were 0.487 and 0.647 h(-1), respectively.",Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9593134/),1/[h],0.647,110060,DB01137,Levofloxacin
,9593134,peak concentration,"The mean peak concentration and the mean AUC values normalized to a dosage of 500 mg every 24 h were 8.67 microg/ml and 72.53 microg x h/ml, respectively.",Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9593134/),[μg] / [ml],8.67,110061,DB01137,Levofloxacin
,9593134,AUC,"The mean peak concentration and the mean AUC values normalized to a dosage of 500 mg every 24 h were 8.67 microg/ml and 72.53 microg x h/ml, respectively.",Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9593134/),[h·μg] / [ml],72.53,110062,DB01137,Levofloxacin
,16837169,MIC(90),The maximum plasma drug concentration to minimum inhibitory concentration ratio (C(max)/MIC(90)) and the area under the drug concentration curve to minimum inhibitory concentration ratio (AUC/MIC(90)) during the dosing interval were calculated for potential respiratory pathogens with MIC(90) values from 0.03 microg/mL to 2 microg/mL.,Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16837169/),[μg] / [ml],0.03,111319,DB01137,Levofloxacin
,16837169,MIC(90),The maximum plasma drug concentration to minimum inhibitory concentration ratio (C(max)/MIC(90)) and the area under the drug concentration curve to minimum inhibitory concentration ratio (AUC/MIC(90)) during the dosing interval were calculated for potential respiratory pathogens with MIC(90) values from 0.03 microg/mL to 2 microg/mL.,Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16837169/),[μg] / [ml],2,111320,DB01137,Levofloxacin
,16837169,C(max),"In the 1000 mg dose group, the C(max) (mean+/-standard deviation (S.D.)), AUC(0-8h) and half-life were: for plasma, 9.2+/-1.9 microg/mL, 103.6 microg h/mL and 7.45 h; for ELF, 25.8+/-7.9 microg/mL, 279.1 microg h/mL and 8.10h; and for ACs, 51.8+/-26.2 microg/mL, 507.5 microg h/mL and 14.32 h.",Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16837169/),[μg] / [ml],9.2,111321,DB01137,Levofloxacin
,16837169,AUC(0-8h),"In the 1000 mg dose group, the C(max) (mean+/-standard deviation (S.D.)), AUC(0-8h) and half-life were: for plasma, 9.2+/-1.9 microg/mL, 103.6 microg h/mL and 7.45 h; for ELF, 25.8+/-7.9 microg/mL, 279.1 microg h/mL and 8.10h; and for ACs, 51.8+/-26.2 microg/mL, 507.5 microg h/mL and 14.32 h.",Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16837169/),[h·μg] / [ml],103.6,111322,DB01137,Levofloxacin
,16837169,AUC(0-8h),"In the 1000 mg dose group, the C(max) (mean+/-standard deviation (S.D.)), AUC(0-8h) and half-life were: for plasma, 9.2+/-1.9 microg/mL, 103.6 microg h/mL and 7.45 h; for ELF, 25.8+/-7.9 microg/mL, 279.1 microg h/mL and 8.10h; and for ACs, 51.8+/-26.2 microg/mL, 507.5 microg h/mL and 14.32 h.",Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16837169/),[μg] / [ml],25.8,111323,DB01137,Levofloxacin
,16837169,AUC(0-8h),"In the 1000 mg dose group, the C(max) (mean+/-standard deviation (S.D.)), AUC(0-8h) and half-life were: for plasma, 9.2+/-1.9 microg/mL, 103.6 microg h/mL and 7.45 h; for ELF, 25.8+/-7.9 microg/mL, 279.1 microg h/mL and 8.10h; and for ACs, 51.8+/-26.2 microg/mL, 507.5 microg h/mL and 14.32 h.",Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16837169/),[h·μg] / [ml],279.1,111324,DB01137,Levofloxacin
,16837169,AUC(0-8h),"In the 1000 mg dose group, the C(max) (mean+/-standard deviation (S.D.)), AUC(0-8h) and half-life were: for plasma, 9.2+/-1.9 microg/mL, 103.6 microg h/mL and 7.45 h; for ELF, 25.8+/-7.9 microg/mL, 279.1 microg h/mL and 8.10h; and for ACs, 51.8+/-26.2 microg/mL, 507.5 microg h/mL and 14.32 h.",Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16837169/),[μg] / [ml],51.8,111325,DB01137,Levofloxacin
,16837169,half-life,"In the 1000 mg dose group, the C(max) (mean+/-standard deviation (S.D.)), AUC(0-8h) and half-life were: for plasma, 9.2+/-1.9 microg/mL, 103.6 microg h/mL and 7.45 h; for ELF, 25.8+/-7.9 microg/mL, 279.1 microg h/mL and 8.10h; and for ACs, 51.8+/-26.2 microg/mL, 507.5 microg h/mL and 14.32 h.",Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16837169/),h,7.45,111326,DB01137,Levofloxacin
,16837169,half-life,"In the 1000 mg dose group, the C(max) (mean+/-standard deviation (S.D.)), AUC(0-8h) and half-life were: for plasma, 9.2+/-1.9 microg/mL, 103.6 microg h/mL and 7.45 h; for ELF, 25.8+/-7.9 microg/mL, 279.1 microg h/mL and 8.10h; and for ACs, 51.8+/-26.2 microg/mL, 507.5 microg h/mL and 14.32 h.",Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16837169/),h,8.10,111327,DB01137,Levofloxacin
,16837169,half-life,"In the 1000 mg dose group, the C(max) (mean+/-standard deviation (S.D.)), AUC(0-8h) and half-life were: for plasma, 9.2+/-1.9 microg/mL, 103.6 microg h/mL and 7.45 h; for ELF, 25.8+/-7.9 microg/mL, 279.1 microg h/mL and 8.10h; and for ACs, 51.8+/-26.2 microg/mL, 507.5 microg h/mL and 14.32 h.",Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16837169/),[μg] / [ml],51.8,111328,DB01137,Levofloxacin
,16837169,half-life,"In the 1000 mg dose group, the C(max) (mean+/-standard deviation (S.D.)), AUC(0-8h) and half-life were: for plasma, 9.2+/-1.9 microg/mL, 103.6 microg h/mL and 7.45 h; for ELF, 25.8+/-7.9 microg/mL, 279.1 microg h/mL and 8.10h; and for ACs, 51.8+/-26.2 microg/mL, 507.5 microg h/mL and 14.32 h.",Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16837169/),[h·μg] / [ml],507.5,111329,DB01137,Levofloxacin
,16837169,half-life,"In the 1000 mg dose group, the C(max) (mean+/-standard deviation (S.D.)), AUC(0-8h) and half-life were: for plasma, 9.2+/-1.9 microg/mL, 103.6 microg h/mL and 7.45 h; for ELF, 25.8+/-7.9 microg/mL, 279.1 microg h/mL and 8.10h; and for ACs, 51.8+/-26.2 microg/mL, 507.5 microg h/mL and 14.32 h.",Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16837169/),h,14.32,111330,DB01137,Levofloxacin
,16837169,C(max),"In the 750 mg dose group, the C(max) values in plasma, ELF and ACs were 5.7+/-0.4, 28.0+/-23.6 and 34.2+/-18.7 microg/mL, respectively.",Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16837169/),[μg] / [ml],5.7,111331,DB01137,Levofloxacin
,16837169,C(max),"In the 750 mg dose group, the C(max) values in plasma, ELF and ACs were 5.7+/-0.4, 28.0+/-23.6 and 34.2+/-18.7 microg/mL, respectively.",Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16837169/),[μg] / [ml],28.0,111332,DB01137,Levofloxacin
,16837169,C(max),"In the 750 mg dose group, the C(max) values in plasma, ELF and ACs were 5.7+/-0.4, 28.0+/-23.6 and 34.2+/-18.7 microg/mL, respectively.",Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16837169/),[μg] / [ml],34.2,111333,DB01137,Levofloxacin
,16837169,C(max)/MIC(90) ratios,"For pathogens commonly associated with community-acquired pneumonia, C(max)/MIC(90) ratios in ELF ranged from 12.9 for Mycoplasma pneumoniae to 859 for Haemophilus influenzae, and AUC/MIC(90) ratios ranged from 139 to 9303, respectively.",Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16837169/),,12.9,111334,DB01137,Levofloxacin
,16837169,C(max)/MIC(90) ratios,"For pathogens commonly associated with community-acquired pneumonia, C(max)/MIC(90) ratios in ELF ranged from 12.9 for Mycoplasma pneumoniae to 859 for Haemophilus influenzae, and AUC/MIC(90) ratios ranged from 139 to 9303, respectively.",Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16837169/),,859,111335,DB01137,Levofloxacin
,16837169,AUC/MIC(90) ratios,"For pathogens commonly associated with community-acquired pneumonia, C(max)/MIC(90) ratios in ELF ranged from 12.9 for Mycoplasma pneumoniae to 859 for Haemophilus influenzae, and AUC/MIC(90) ratios ranged from 139 to 9303, respectively.",Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16837169/),,139,111336,DB01137,Levofloxacin
,16837169,AUC/MIC(90) ratios,"For pathogens commonly associated with community-acquired pneumonia, C(max)/MIC(90) ratios in ELF ranged from 12.9 for Mycoplasma pneumoniae to 859 for Haemophilus influenzae, and AUC/MIC(90) ratios ranged from 139 to 9303, respectively.",Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16837169/),,9303,111337,DB01137,Levofloxacin
,16837169,C(max)/MIC(90) ratios,"The C(max)/MIC(90) ratios in ACs ranged from 25.9 for M. pneumoniae to 1727 for H. influenzae, and AUC/MIC(90) ratios ranged from 254 to 16917, respectively.",Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16837169/),,25.9,111338,DB01137,Levofloxacin
,16837169,C(max)/MIC(90) ratios,"The C(max)/MIC(90) ratios in ACs ranged from 25.9 for M. pneumoniae to 1727 for H. influenzae, and AUC/MIC(90) ratios ranged from 254 to 16917, respectively.",Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16837169/),,1727,111339,DB01137,Levofloxacin
,16837169,AUC/MIC(90) ratios,"The C(max)/MIC(90) ratios in ACs ranged from 25.9 for M. pneumoniae to 1727 for H. influenzae, and AUC/MIC(90) ratios ranged from 254 to 16917, respectively.",Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16837169/),,254,111340,DB01137,Levofloxacin
,16837169,AUC/MIC(90) ratios,"The C(max)/MIC(90) ratios in ACs ranged from 25.9 for M. pneumoniae to 1727 for H. influenzae, and AUC/MIC(90) ratios ranged from 254 to 16917, respectively.",Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16837169/),,16917,111341,DB01137,Levofloxacin
,19000258,half-lives of distribution,"The half-lives of distribution and elimination were 0.21 +/- 0.13 and 2.58 +/- 0.51 h, respectively.",Characterization of the pharmacokinetic disposition of levofloxacin in stallions after intravenous and intramuscular administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000258/),h,0.21,112131,DB01137,Levofloxacin
,19000258,elimination,"The half-lives of distribution and elimination were 0.21 +/- 0.13 and 2.58 +/- 0.51 h, respectively.",Characterization of the pharmacokinetic disposition of levofloxacin in stallions after intravenous and intramuscular administration. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000258/),h,2.58,112132,DB01137,Levofloxacin
,19000258,volume of distribution at steady-state,"The volume of distribution at steady-state was 0.81 +/- 0.26 L/kg, the total body clearance (Cl(tot)) was 0.21 +/- 0.18 L/h/kg, and the areas under the concentration-time curves (AUCs) were 18.79 +/- 4.57 microg.h/mL. Following i.m. administration, the mean t(1/2el) and AUC values were 2.94 +/- 0.78 h and 17.21 +/- 4.36 microg.h/mL.",Characterization of the pharmacokinetic disposition of levofloxacin in stallions after intravenous and intramuscular administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000258/),[l] / [kg],0.81,112133,DB01137,Levofloxacin
,19000258,total body clearance (Cl(tot)),"The volume of distribution at steady-state was 0.81 +/- 0.26 L/kg, the total body clearance (Cl(tot)) was 0.21 +/- 0.18 L/h/kg, and the areas under the concentration-time curves (AUCs) were 18.79 +/- 4.57 microg.h/mL. Following i.m. administration, the mean t(1/2el) and AUC values were 2.94 +/- 0.78 h and 17.21 +/- 4.36 microg.h/mL.",Characterization of the pharmacokinetic disposition of levofloxacin in stallions after intravenous and intramuscular administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000258/),[l] / [h·kg],0.21,112134,DB01137,Levofloxacin
,19000258,areas under the concentration-time curves (AUCs),"The volume of distribution at steady-state was 0.81 +/- 0.26 L/kg, the total body clearance (Cl(tot)) was 0.21 +/- 0.18 L/h/kg, and the areas under the concentration-time curves (AUCs) were 18.79 +/- 4.57 microg.h/mL. Following i.m. administration, the mean t(1/2el) and AUC values were 2.94 +/- 0.78 h and 17.21 +/- 4.36 microg.h/mL.",Characterization of the pharmacokinetic disposition of levofloxacin in stallions after intravenous and intramuscular administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000258/),[h·μg] / [ml],18.79,112135,DB01137,Levofloxacin
,19000258,t(1/2el),"The volume of distribution at steady-state was 0.81 +/- 0.26 L/kg, the total body clearance (Cl(tot)) was 0.21 +/- 0.18 L/h/kg, and the areas under the concentration-time curves (AUCs) were 18.79 +/- 4.57 microg.h/mL. Following i.m. administration, the mean t(1/2el) and AUC values were 2.94 +/- 0.78 h and 17.21 +/- 4.36 microg.h/mL.",Characterization of the pharmacokinetic disposition of levofloxacin in stallions after intravenous and intramuscular administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000258/),h,2.94,112136,DB01137,Levofloxacin
,19000258,AUC,"The volume of distribution at steady-state was 0.81 +/- 0.26 L/kg, the total body clearance (Cl(tot)) was 0.21 +/- 0.18 L/h/kg, and the areas under the concentration-time curves (AUCs) were 18.79 +/- 4.57 microg.h/mL. Following i.m. administration, the mean t(1/2el) and AUC values were 2.94 +/- 0.78 h and 17.21 +/- 4.36 microg.h/mL.",Characterization of the pharmacokinetic disposition of levofloxacin in stallions after intravenous and intramuscular administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000258/),[h·μg] / [ml],17.21,112137,DB01137,Levofloxacin
,19000258,bioavailability,"The bioavailability was high (91.76% +/- 12.68%), with a peak plasma mean concentration (C(max)) of 2.85 +/- 0.89 microg/mL attained at 1.56 +/- 0.71 h (T(max)).",Characterization of the pharmacokinetic disposition of levofloxacin in stallions after intravenous and intramuscular administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000258/),%,91.76,112138,DB01137,Levofloxacin
,19000258,peak plasma mean concentration (C(max)),"The bioavailability was high (91.76% +/- 12.68%), with a peak plasma mean concentration (C(max)) of 2.85 +/- 0.89 microg/mL attained at 1.56 +/- 0.71 h (T(max)).",Characterization of the pharmacokinetic disposition of levofloxacin in stallions after intravenous and intramuscular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000258/),[μg] / [ml],2.85,112139,DB01137,Levofloxacin
,19000258,T(max),"The bioavailability was high (91.76% +/- 12.68%), with a peak plasma mean concentration (C(max)) of 2.85 +/- 0.89 microg/mL attained at 1.56 +/- 0.71 h (T(max)).",Characterization of the pharmacokinetic disposition of levofloxacin in stallions after intravenous and intramuscular administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000258/),h,1.56,112140,DB01137,Levofloxacin
,19000258,protein binding percentage,The in vitro protein binding percentage was 27.84%.,Characterization of the pharmacokinetic disposition of levofloxacin in stallions after intravenous and intramuscular administration. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000258/),%,27.84,112141,DB01137,Levofloxacin
<or=,19000258,MIC,"Calculation of efficacy predictors showed that levofloxacin might have a good therapeutic profile against Gram-negative and Gram-positive bacteria, with an MIC <or= 0.1 microg/mL.",Characterization of the pharmacokinetic disposition of levofloxacin in stallions after intravenous and intramuscular administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000258/),[μg] / [ml],0.1,112142,DB01137,Levofloxacin
,1512940,AUC ratio,"The AUC ratio of sputum/serum was 0.9-1.0, indicating good sputum penetration of LVFX in these patients.",[Sputum penetration of levofloxacin and its clinical efficacy in patients with chronic lower respiratory tract infections]. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1512940/),,0.9-1.0,112187,DB01137,Levofloxacin
,10553702,elimination half-lives,"The fluoroquinolones have moderate to excellent bioavailability, moderate to long elimination half-lives (50 to 98%) and volumes of distribution >1.5 L/kg.",Pharmacokinetics and pharmacodynamics of fluoroquinolones. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10553702/),%,50 to 98,113595,DB01137,Levofloxacin
>,10553702,volumes of distribution,"The fluoroquinolones have moderate to excellent bioavailability, moderate to long elimination half-lives (50 to 98%) and volumes of distribution >1.5 L/kg.",Pharmacokinetics and pharmacodynamics of fluoroquinolones. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10553702/),[l] / [kg],1.5,113596,DB01137,Levofloxacin
,10553702,24-hour,"Animal models and human studies with ciprofloxacin, grepafloxacin and levofloxacin show that a 24-hour AUC/MIC ratio of about 100, or a Cmax/MIC ratio of about 10 gives maximum clinical and bacteriological efficacy.",Pharmacokinetics and pharmacodynamics of fluoroquinolones. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10553702/),,100,113597,DB01137,Levofloxacin
,10553702,AUC/MIC ratio,"Animal models and human studies with ciprofloxacin, grepafloxacin and levofloxacin show that a 24-hour AUC/MIC ratio of about 100, or a Cmax/MIC ratio of about 10 gives maximum clinical and bacteriological efficacy.",Pharmacokinetics and pharmacodynamics of fluoroquinolones. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10553702/),,100,113598,DB01137,Levofloxacin
,10553702,Cmax/MIC ratio,"Animal models and human studies with ciprofloxacin, grepafloxacin and levofloxacin show that a 24-hour AUC/MIC ratio of about 100, or a Cmax/MIC ratio of about 10 gives maximum clinical and bacteriological efficacy.",Pharmacokinetics and pharmacodynamics of fluoroquinolones. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10553702/),,10,113599,DB01137,Levofloxacin
,19093704,Clinical cure rates,Clinical cure rates were 89.7% versus 86.3% in the clinically evaluable population and 81.0% versus 79.7% in the clinical modified intent-to-treat population.,Tigecycline: in community-acquired pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19093704/),%,89.7,114575,DB01137,Levofloxacin
,19093704,Clinical cure rates,Clinical cure rates were 89.7% versus 86.3% in the clinically evaluable population and 81.0% versus 79.7% in the clinical modified intent-to-treat population.,Tigecycline: in community-acquired pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19093704/),%,86.3,114576,DB01137,Levofloxacin
,19093704,Clinical cure rates,Clinical cure rates were 89.7% versus 86.3% in the clinically evaluable population and 81.0% versus 79.7% in the clinical modified intent-to-treat population.,Tigecycline: in community-acquired pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19093704/),%,81.0,114577,DB01137,Levofloxacin
,19093704,Clinical cure rates,Clinical cure rates were 89.7% versus 86.3% in the clinically evaluable population and 81.0% versus 79.7% in the clinical modified intent-to-treat population.,Tigecycline: in community-acquired pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19093704/),%,79.7,114578,DB01137,Levofloxacin
,16864506,elimination half-life,The elimination half-life of levofloxacin was estimated at about 2 h.,"Pharmacokinetics, metabolism, excretion and plasma protein binding of 14C-levofloxacin after a single oral administration in the Rhesus monkey. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16864506/),h,2,114841,DB01137,Levofloxacin
,16864506,plasma protein binding,The in vitro plasma protein binding was low (on average 11.2%) and independent of concentration (1.0-10.0 microg ml-1).,"Pharmacokinetics, metabolism, excretion and plasma protein binding of 14C-levofloxacin after a single oral administration in the Rhesus monkey. ",fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16864506/),%,11.2,114842,DB01137,Levofloxacin
,16864506,half-life,The shorter half-life of levofloxacin in the Rhesus monkey relative to man (2 versus 7 h) prompted the development of an alternative dosing strategy for use in the efficacy study.,"Pharmacokinetics, metabolism, excretion and plasma protein binding of 14C-levofloxacin after a single oral administration in the Rhesus monkey. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16864506/),h,2,114843,DB01137,Levofloxacin
,16864506,half-life,The shorter half-life of levofloxacin in the Rhesus monkey relative to man (2 versus 7 h) prompted the development of an alternative dosing strategy for use in the efficacy study.,"Pharmacokinetics, metabolism, excretion and plasma protein binding of 14C-levofloxacin after a single oral administration in the Rhesus monkey. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16864506/),h,7,114844,DB01137,Levofloxacin
,15006955,concentrations,"The mean ELF concentrations at 4, 8, 12, and 24 h were as follows: MXF, 11.7 +/- 11.9, 7.8 +/- 5.1, 10.5 +/- 3.7, and 5.7 +/- 6.3 micro g/mL, respectively; LEVO, 15.2 +/- 4.5, 10.2 +/- 6.7, 6.9 +/- 4.4, and 2.9 +/- 1.7 micro g/mL, respectively; and AZI, 0.6 +/- 0.4, 0.7 +/- 0.4, 0.9 +/- 0.5, and 0.9 +/- 0.7 micro g/mL, respectively.","Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15006955/),[μg] / [ml],11.7,115518,DB01137,Levofloxacin
,15006955,concentrations,"The mean ELF concentrations at 4, 8, 12, and 24 h were as follows: MXF, 11.7 +/- 11.9, 7.8 +/- 5.1, 10.5 +/- 3.7, and 5.7 +/- 6.3 micro g/mL, respectively; LEVO, 15.2 +/- 4.5, 10.2 +/- 6.7, 6.9 +/- 4.4, and 2.9 +/- 1.7 micro g/mL, respectively; and AZI, 0.6 +/- 0.4, 0.7 +/- 0.4, 0.9 +/- 0.5, and 0.9 +/- 0.7 micro g/mL, respectively.","Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15006955/),[μg] / [ml],7.8,115519,DB01137,Levofloxacin
,15006955,concentrations,"The mean ELF concentrations at 4, 8, 12, and 24 h were as follows: MXF, 11.7 +/- 11.9, 7.8 +/- 5.1, 10.5 +/- 3.7, and 5.7 +/- 6.3 micro g/mL, respectively; LEVO, 15.2 +/- 4.5, 10.2 +/- 6.7, 6.9 +/- 4.4, and 2.9 +/- 1.7 micro g/mL, respectively; and AZI, 0.6 +/- 0.4, 0.7 +/- 0.4, 0.9 +/- 0.5, and 0.9 +/- 0.7 micro g/mL, respectively.","Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15006955/),[μg] / [ml],10.5,115520,DB01137,Levofloxacin
,15006955,concentrations,"The mean ELF concentrations at 4, 8, 12, and 24 h were as follows: MXF, 11.7 +/- 11.9, 7.8 +/- 5.1, 10.5 +/- 3.7, and 5.7 +/- 6.3 micro g/mL, respectively; LEVO, 15.2 +/- 4.5, 10.2 +/- 6.7, 6.9 +/- 4.4, and 2.9 +/- 1.7 micro g/mL, respectively; and AZI, 0.6 +/- 0.4, 0.7 +/- 0.4, 0.9 +/- 0.5, and 0.9 +/- 0.7 micro g/mL, respectively.","Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15006955/),[μg] / [ml],5.7,115521,DB01137,Levofloxacin
,15006955,concentrations,"The mean ELF concentrations at 4, 8, 12, and 24 h were as follows: MXF, 11.7 +/- 11.9, 7.8 +/- 5.1, 10.5 +/- 3.7, and 5.7 +/- 6.3 micro g/mL, respectively; LEVO, 15.2 +/- 4.5, 10.2 +/- 6.7, 6.9 +/- 4.4, and 2.9 +/- 1.7 micro g/mL, respectively; and AZI, 0.6 +/- 0.4, 0.7 +/- 0.4, 0.9 +/- 0.5, and 0.9 +/- 0.7 micro g/mL, respectively.","Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15006955/),[μg] / [ml],15.2,115522,DB01137,Levofloxacin
,15006955,concentrations,"The mean ELF concentrations at 4, 8, 12, and 24 h were as follows: MXF, 11.7 +/- 11.9, 7.8 +/- 5.1, 10.5 +/- 3.7, and 5.7 +/- 6.3 micro g/mL, respectively; LEVO, 15.2 +/- 4.5, 10.2 +/- 6.7, 6.9 +/- 4.4, and 2.9 +/- 1.7 micro g/mL, respectively; and AZI, 0.6 +/- 0.4, 0.7 +/- 0.4, 0.9 +/- 0.5, and 0.9 +/- 0.7 micro g/mL, respectively.","Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15006955/),[μg] / [ml],10.2,115523,DB01137,Levofloxacin
,15006955,concentrations,"The mean ELF concentrations at 4, 8, 12, and 24 h were as follows: MXF, 11.7 +/- 11.9, 7.8 +/- 5.1, 10.5 +/- 3.7, and 5.7 +/- 6.3 micro g/mL, respectively; LEVO, 15.2 +/- 4.5, 10.2 +/- 6.7, 6.9 +/- 4.4, and 2.9 +/- 1.7 micro g/mL, respectively; and AZI, 0.6 +/- 0.4, 0.7 +/- 0.4, 0.9 +/- 0.5, and 0.9 +/- 0.7 micro g/mL, respectively.","Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15006955/),[μg] / [ml],6.9,115524,DB01137,Levofloxacin
,15006955,concentrations,"The mean ELF concentrations at 4, 8, 12, and 24 h were as follows: MXF, 11.7 +/- 11.9, 7.8 +/- 5.1, 10.5 +/- 3.7, and 5.7 +/- 6.3 micro g/mL, respectively; LEVO, 15.2 +/- 4.5, 10.2 +/- 6.7, 6.9 +/- 4.4, and 2.9 +/- 1.7 micro g/mL, respectively; and AZI, 0.6 +/- 0.4, 0.7 +/- 0.4, 0.9 +/- 0.5, and 0.9 +/- 0.7 micro g/mL, respectively.","Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15006955/),[μg] / [ml],2.9,115525,DB01137,Levofloxacin
,15006955,concentrations,"The mean ELF concentrations at 4, 8, 12, and 24 h were as follows: MXF, 11.7 +/- 11.9, 7.8 +/- 5.1, 10.5 +/- 3.7, and 5.7 +/- 6.3 micro g/mL, respectively; LEVO, 15.2 +/- 4.5, 10.2 +/- 6.7, 6.9 +/- 4.4, and 2.9 +/- 1.7 micro g/mL, respectively; and AZI, 0.6 +/- 0.4, 0.7 +/- 0.4, 0.9 +/- 0.5, and 0.9 +/- 0.7 micro g/mL, respectively.","Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15006955/),[μg] / [ml],0.6,115526,DB01137,Levofloxacin
,15006955,concentrations,"The mean ELF concentrations at 4, 8, 12, and 24 h were as follows: MXF, 11.7 +/- 11.9, 7.8 +/- 5.1, 10.5 +/- 3.7, and 5.7 +/- 6.3 micro g/mL, respectively; LEVO, 15.2 +/- 4.5, 10.2 +/- 6.7, 6.9 +/- 4.4, and 2.9 +/- 1.7 micro g/mL, respectively; and AZI, 0.6 +/- 0.4, 0.7 +/- 0.4, 0.9 +/- 0.5, and 0.9 +/- 0.7 micro g/mL, respectively.","Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15006955/),[μg] / [ml],0.7,115527,DB01137,Levofloxacin
,15006955,concentrations,"The mean ELF concentrations at 4, 8, 12, and 24 h were as follows: MXF, 11.7 +/- 11.9, 7.8 +/- 5.1, 10.5 +/- 3.7, and 5.7 +/- 6.3 micro g/mL, respectively; LEVO, 15.2 +/- 4.5, 10.2 +/- 6.7, 6.9 +/- 4.4, and 2.9 +/- 1.7 micro g/mL, respectively; and AZI, 0.6 +/- 0.4, 0.7 +/- 0.4, 0.9 +/- 0.5, and 0.9 +/- 0.7 micro g/mL, respectively.","Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15006955/),[μg] / [ml],0.9,115528,DB01137,Levofloxacin
,15006955,concentrations,"The mean ELF concentrations at 4, 8, 12, and 24 h were as follows: MXF, 11.7 +/- 11.9, 7.8 +/- 5.1, 10.5 +/- 3.7, and 5.7 +/- 6.3 micro g/mL, respectively; LEVO, 15.2 +/- 4.5, 10.2 +/- 6.7, 6.9 +/- 4.4, and 2.9 +/- 1.7 micro g/mL, respectively; and AZI, 0.6 +/- 0.4, 0.7 +/- 0.4, 0.9 +/- 0.5, and 0.9 +/- 0.7 micro g/mL, respectively.","Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15006955/),[μg] / [ml],0.9,115529,DB01137,Levofloxacin
<,15006955,MIC(90)),The AM concentrations of all agents studied were more than adequate relative to the minimum concentration required to inhibit 90% of the organism population (MIC(90)) of the common intracellular pathogens (< 1 micro g/mL).,"Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15006955/),[μg] / [ml],1,115530,DB01137,Levofloxacin
,22024700,Km,"Ciprofloxacin increased the net renal clearance of levofloxacin by 13%, as its estimated affinity for a putative tubular reabsorption transporter was 12-fold higher (Km: 568 μM) compared to levofloxacin (Km: 6,830 μM).","Population pharmacokinetics and penetration into prostatic, seminal, and vaginal fluid for ciprofloxacin, levofloxacin, and their combination. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22024700/),μM,568,115669,DB01137,Levofloxacin
,22024700,Km,"Ciprofloxacin increased the net renal clearance of levofloxacin by 13%, as its estimated affinity for a putative tubular reabsorption transporter was 12-fold higher (Km: 568 μM) compared to levofloxacin (Km: 6,830 μM).","Population pharmacokinetics and penetration into prostatic, seminal, and vaginal fluid for ciprofloxacin, levofloxacin, and their combination. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22024700/),μM,"6,830",115670,DB01137,Levofloxacin
,10381104,area under the inhibitory curve over 24 h (AUIC24),"Levofloxacin was rapidly and significantly bactericidal against all eight strains evaluated, with eradication of six strains occurring despite area under the inhibitory curve over 24 h (AUIC24) values of only 32-64 SIT(-1) x h (serum inhibitory titre over time).",Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381104/),[h] / [sit],32-64,116896,DB01137,Levofloxacin
,10381104,serum inhibitory titre,"Levofloxacin was rapidly and significantly bactericidal against all eight strains evaluated, with eradication of six strains occurring despite area under the inhibitory curve over 24 h (AUIC24) values of only 32-64 SIT(-1) x h (serum inhibitory titre over time).",Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381104/),[h] / [sit],32-64,116897,DB01137,Levofloxacin
,10381104,AUIC24,Ciprofloxacin eradicated five strains despite having an AUIC24 of only 44 SIT(-1) x h.,Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381104/),[h] / [sit],44,116898,DB01137,Levofloxacin
below,10381104,minimum AUIC,"Furthermore, these data suggest that the minimum AUIC required for clinical efficacy against and eradication of S. pneumoniae with levofloxacin and ciprofloxacin may be well below the 125 SIT(-1) x h identified by other studies.",Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381104/),[h] / [sit],125,116899,DB01137,Levofloxacin
,32033424,effective permeability coefficient,"OLC was poorly absorbed in the intestine, as indicated by the low effective permeability coefficient (2.23 ± 3.16 × 10-5 cm/s) and apparent permeability coefficient (4.12 ± 2.33 × 10-6 cm/s) obtained relative to the values of the highly permeable reference compound levofloxacin (LEV).",Absorption and Intestinal Metabolic Profile of Oleocanthal in Rats. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32033424/),[cm] / [s],2.23,118231,DB01137,Levofloxacin
,32033424,apparent permeability coefficient,"OLC was poorly absorbed in the intestine, as indicated by the low effective permeability coefficient (2.23 ± 3.16 × 10-5 cm/s) and apparent permeability coefficient (4.12 ± 2.33 × 10-6 cm/s) obtained relative to the values of the highly permeable reference compound levofloxacin (LEV).",Absorption and Intestinal Metabolic Profile of Oleocanthal in Rats. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32033424/),[cm] / [s],4.12,118232,DB01137,Levofloxacin
,32033424,area under the mesenteric blood-time curve,"The extent of OLC absorption reflected by the area under the mesenteric blood-time curve normalized by the inlet concentration (AUC) was also lower than that of LEV (0.25 ± 0.04 vs. 0.64 ± 0.03, respectively).",Absorption and Intestinal Metabolic Profile of Oleocanthal in Rats. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32033424/),,0.25,118233,DB01137,Levofloxacin
,32033424,area under the mesenteric blood-time curve,"The extent of OLC absorption reflected by the area under the mesenteric blood-time curve normalized by the inlet concentration (AUC) was also lower than that of LEV (0.25 ± 0.04 vs. 0.64 ± 0.03, respectively).",Absorption and Intestinal Metabolic Profile of Oleocanthal in Rats. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32033424/),,0.64,118234,DB01137,Levofloxacin
,19217166,MICs,"MICs and MBCs in logarithmic and stationary phases and MPCs of levofloxacin were 0.5, 1 and 4, 0.8microg/ml, respectively, and those of moxifloxacin 0.12, 0.25 and 2, 0.25microg/ml. AUC/MIC were 234 (levofloxacin), 431 (moxifloxacin 40) and 568 (moxifloxacin 80).",High doses of levofloxacin vs moxifloxacin against staphylococcal experimental foreign-body infection: the effect of higher MIC-related pharmacokinetic parameters on efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19217166/),[μg] / [ml],0.5,120294,DB01137,Levofloxacin
,19217166,MICs,"MICs and MBCs in logarithmic and stationary phases and MPCs of levofloxacin were 0.5, 1 and 4, 0.8microg/ml, respectively, and those of moxifloxacin 0.12, 0.25 and 2, 0.25microg/ml. AUC/MIC were 234 (levofloxacin), 431 (moxifloxacin 40) and 568 (moxifloxacin 80).",High doses of levofloxacin vs moxifloxacin against staphylococcal experimental foreign-body infection: the effect of higher MIC-related pharmacokinetic parameters on efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19217166/),[μg] / [ml],1,120295,DB01137,Levofloxacin
,19217166,MICs,"MICs and MBCs in logarithmic and stationary phases and MPCs of levofloxacin were 0.5, 1 and 4, 0.8microg/ml, respectively, and those of moxifloxacin 0.12, 0.25 and 2, 0.25microg/ml. AUC/MIC were 234 (levofloxacin), 431 (moxifloxacin 40) and 568 (moxifloxacin 80).",High doses of levofloxacin vs moxifloxacin against staphylococcal experimental foreign-body infection: the effect of higher MIC-related pharmacokinetic parameters on efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19217166/),[μg] / [ml],"4, 0.8",120296,DB01137,Levofloxacin
,19217166,MICs,"MICs and MBCs in logarithmic and stationary phases and MPCs of levofloxacin were 0.5, 1 and 4, 0.8microg/ml, respectively, and those of moxifloxacin 0.12, 0.25 and 2, 0.25microg/ml. AUC/MIC were 234 (levofloxacin), 431 (moxifloxacin 40) and 568 (moxifloxacin 80).",High doses of levofloxacin vs moxifloxacin against staphylococcal experimental foreign-body infection: the effect of higher MIC-related pharmacokinetic parameters on efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19217166/),[μg] / [ml],0.12,120297,DB01137,Levofloxacin
,19217166,MBCs,"MICs and MBCs in logarithmic and stationary phases and MPCs of levofloxacin were 0.5, 1 and 4, 0.8microg/ml, respectively, and those of moxifloxacin 0.12, 0.25 and 2, 0.25microg/ml. AUC/MIC were 234 (levofloxacin), 431 (moxifloxacin 40) and 568 (moxifloxacin 80).",High doses of levofloxacin vs moxifloxacin against staphylococcal experimental foreign-body infection: the effect of higher MIC-related pharmacokinetic parameters on efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19217166/),[μg] / [ml],1,120298,DB01137,Levofloxacin
,19217166,MBCs,"MICs and MBCs in logarithmic and stationary phases and MPCs of levofloxacin were 0.5, 1 and 4, 0.8microg/ml, respectively, and those of moxifloxacin 0.12, 0.25 and 2, 0.25microg/ml. AUC/MIC were 234 (levofloxacin), 431 (moxifloxacin 40) and 568 (moxifloxacin 80).",High doses of levofloxacin vs moxifloxacin against staphylococcal experimental foreign-body infection: the effect of higher MIC-related pharmacokinetic parameters on efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19217166/),[μg] / [ml],"4, 0.8",120299,DB01137,Levofloxacin
,19217166,MBCs,"MICs and MBCs in logarithmic and stationary phases and MPCs of levofloxacin were 0.5, 1 and 4, 0.8microg/ml, respectively, and those of moxifloxacin 0.12, 0.25 and 2, 0.25microg/ml. AUC/MIC were 234 (levofloxacin), 431 (moxifloxacin 40) and 568 (moxifloxacin 80).",High doses of levofloxacin vs moxifloxacin against staphylococcal experimental foreign-body infection: the effect of higher MIC-related pharmacokinetic parameters on efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19217166/),[μg] / [ml],0.12,120300,DB01137,Levofloxacin
,19217166,MBCs,"MICs and MBCs in logarithmic and stationary phases and MPCs of levofloxacin were 0.5, 1 and 4, 0.8microg/ml, respectively, and those of moxifloxacin 0.12, 0.25 and 2, 0.25microg/ml. AUC/MIC were 234 (levofloxacin), 431 (moxifloxacin 40) and 568 (moxifloxacin 80).",High doses of levofloxacin vs moxifloxacin against staphylococcal experimental foreign-body infection: the effect of higher MIC-related pharmacokinetic parameters on efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19217166/),[μg] / [ml],0.25,120301,DB01137,Levofloxacin
,19217166,MBCs,"MICs and MBCs in logarithmic and stationary phases and MPCs of levofloxacin were 0.5, 1 and 4, 0.8microg/ml, respectively, and those of moxifloxacin 0.12, 0.25 and 2, 0.25microg/ml. AUC/MIC were 234 (levofloxacin), 431 (moxifloxacin 40) and 568 (moxifloxacin 80).",High doses of levofloxacin vs moxifloxacin against staphylococcal experimental foreign-body infection: the effect of higher MIC-related pharmacokinetic parameters on efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19217166/),[μg] / [ml],"2, 0.25",120302,DB01137,Levofloxacin
,19217166,MPCs,"MICs and MBCs in logarithmic and stationary phases and MPCs of levofloxacin were 0.5, 1 and 4, 0.8microg/ml, respectively, and those of moxifloxacin 0.12, 0.25 and 2, 0.25microg/ml. AUC/MIC were 234 (levofloxacin), 431 (moxifloxacin 40) and 568 (moxifloxacin 80).",High doses of levofloxacin vs moxifloxacin against staphylococcal experimental foreign-body infection: the effect of higher MIC-related pharmacokinetic parameters on efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19217166/),[μg] / [ml],1,120303,DB01137,Levofloxacin
,19217166,MPCs,"MICs and MBCs in logarithmic and stationary phases and MPCs of levofloxacin were 0.5, 1 and 4, 0.8microg/ml, respectively, and those of moxifloxacin 0.12, 0.25 and 2, 0.25microg/ml. AUC/MIC were 234 (levofloxacin), 431 (moxifloxacin 40) and 568 (moxifloxacin 80).",High doses of levofloxacin vs moxifloxacin against staphylococcal experimental foreign-body infection: the effect of higher MIC-related pharmacokinetic parameters on efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19217166/),[μg] / [ml],"4, 0.8",120304,DB01137,Levofloxacin
,19217166,MPCs,"MICs and MBCs in logarithmic and stationary phases and MPCs of levofloxacin were 0.5, 1 and 4, 0.8microg/ml, respectively, and those of moxifloxacin 0.12, 0.25 and 2, 0.25microg/ml. AUC/MIC were 234 (levofloxacin), 431 (moxifloxacin 40) and 568 (moxifloxacin 80).",High doses of levofloxacin vs moxifloxacin against staphylococcal experimental foreign-body infection: the effect of higher MIC-related pharmacokinetic parameters on efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19217166/),[μg] / [ml],0.12,120305,DB01137,Levofloxacin
,19217166,MPCs,"MICs and MBCs in logarithmic and stationary phases and MPCs of levofloxacin were 0.5, 1 and 4, 0.8microg/ml, respectively, and those of moxifloxacin 0.12, 0.25 and 2, 0.25microg/ml. AUC/MIC were 234 (levofloxacin), 431 (moxifloxacin 40) and 568 (moxifloxacin 80).",High doses of levofloxacin vs moxifloxacin against staphylococcal experimental foreign-body infection: the effect of higher MIC-related pharmacokinetic parameters on efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19217166/),[μg] / [ml],0.25,120306,DB01137,Levofloxacin
,19217166,MPCs,"MICs and MBCs in logarithmic and stationary phases and MPCs of levofloxacin were 0.5, 1 and 4, 0.8microg/ml, respectively, and those of moxifloxacin 0.12, 0.25 and 2, 0.25microg/ml. AUC/MIC were 234 (levofloxacin), 431 (moxifloxacin 40) and 568 (moxifloxacin 80).",High doses of levofloxacin vs moxifloxacin against staphylococcal experimental foreign-body infection: the effect of higher MIC-related pharmacokinetic parameters on efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19217166/),[μg] / [ml],"2, 0.25",120307,DB01137,Levofloxacin
,19217166,AUC/MIC,"MICs and MBCs in logarithmic and stationary phases and MPCs of levofloxacin were 0.5, 1 and 4, 0.8microg/ml, respectively, and those of moxifloxacin 0.12, 0.25 and 2, 0.25microg/ml. AUC/MIC were 234 (levofloxacin), 431 (moxifloxacin 40) and 568 (moxifloxacin 80).",High doses of levofloxacin vs moxifloxacin against staphylococcal experimental foreign-body infection: the effect of higher MIC-related pharmacokinetic parameters on efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19217166/),,234,120308,DB01137,Levofloxacin
,19217166,AUC/MIC,"MICs and MBCs in logarithmic and stationary phases and MPCs of levofloxacin were 0.5, 1 and 4, 0.8microg/ml, respectively, and those of moxifloxacin 0.12, 0.25 and 2, 0.25microg/ml. AUC/MIC were 234 (levofloxacin), 431 (moxifloxacin 40) and 568 (moxifloxacin 80).",High doses of levofloxacin vs moxifloxacin against staphylococcal experimental foreign-body infection: the effect of higher MIC-related pharmacokinetic parameters on efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19217166/),,431,120309,DB01137,Levofloxacin
,19217166,AUC/MIC,"MICs and MBCs in logarithmic and stationary phases and MPCs of levofloxacin were 0.5, 1 and 4, 0.8microg/ml, respectively, and those of moxifloxacin 0.12, 0.25 and 2, 0.25microg/ml. AUC/MIC were 234 (levofloxacin), 431 (moxifloxacin 40) and 568 (moxifloxacin 80).",High doses of levofloxacin vs moxifloxacin against staphylococcal experimental foreign-body infection: the effect of higher MIC-related pharmacokinetic parameters on efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19217166/),,568,120310,DB01137,Levofloxacin
,9758306,oral bioavailability,"It is available in an injectable form, as well as an oral formulation with virtually 100% oral bioavailability.","Levofloxacin, a second-generation fluoroquinolone. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9758306/),%,100,120914,DB01137,Levofloxacin
,9758306,plasma elimination half-life,The plasma elimination half-life ranges from 6-8 hours in individuals with normal renal function.,"Levofloxacin, a second-generation fluoroquinolone. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9758306/),h,6-8,120915,DB01137,Levofloxacin
,14613952,MIC,"The olamufloxacin MIC at which 50% of isolates are inhibited (MIC50) for 81 different Legionella spp. strains (59 type strains and 22 clinical isolates) was 0.008 mg/L, which was identical to sparfloxacin, whereas the MIC50s for erythromycin, levofloxacin and ciprofloxacin were 0.25, 0.032 and 0.032 mg/L, respectively.",In vitro and in vivo activity of olamufloxacin (HSR-903) against Legionella spp. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14613952/),[mg] / [l],0.008,123820,DB01137,Levofloxacin
,14613952,MIC50s,"The olamufloxacin MIC at which 50% of isolates are inhibited (MIC50) for 81 different Legionella spp. strains (59 type strains and 22 clinical isolates) was 0.008 mg/L, which was identical to sparfloxacin, whereas the MIC50s for erythromycin, levofloxacin and ciprofloxacin were 0.25, 0.032 and 0.032 mg/L, respectively.",In vitro and in vivo activity of olamufloxacin (HSR-903) against Legionella spp. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14613952/),[mg] / [l],0.25,123821,DB01137,Levofloxacin
,14613952,MIC50s,"The olamufloxacin MIC at which 50% of isolates are inhibited (MIC50) for 81 different Legionella spp. strains (59 type strains and 22 clinical isolates) was 0.008 mg/L, which was identical to sparfloxacin, whereas the MIC50s for erythromycin, levofloxacin and ciprofloxacin were 0.25, 0.032 and 0.032 mg/L, respectively.",In vitro and in vivo activity of olamufloxacin (HSR-903) against Legionella spp. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14613952/),[mg] / [l],0.032,123822,DB01137,Levofloxacin
,14613952,peak levels,"When olamufloxacin was given to the infected guinea pigs orally (5 mg/kg of body weight), peak levels in the lung were 3.02 mg/kg at 2 h post-administration, with a half-life of 3.41 h and an AUC0-12 of 12.31 mg.h/kg.",In vitro and in vivo activity of olamufloxacin (HSR-903) against Legionella spp. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14613952/),[mg] / [kg],3.02,123823,DB01137,Levofloxacin
,14613952,half-life,"When olamufloxacin was given to the infected guinea pigs orally (5 mg/kg of body weight), peak levels in the lung were 3.02 mg/kg at 2 h post-administration, with a half-life of 3.41 h and an AUC0-12 of 12.31 mg.h/kg.",In vitro and in vivo activity of olamufloxacin (HSR-903) against Legionella spp. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14613952/),h,3.41,123824,DB01137,Levofloxacin
,14613952,AUC0-12,"When olamufloxacin was given to the infected guinea pigs orally (5 mg/kg of body weight), peak levels in the lung were 3.02 mg/kg at 2 h post-administration, with a half-life of 3.41 h and an AUC0-12 of 12.31 mg.h/kg.",In vitro and in vivo activity of olamufloxacin (HSR-903) against Legionella spp. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14613952/),[h·mg] / [kg],12.31,123825,DB01137,Levofloxacin
,15644655,plasma,"The median (interquartile range [IQR]) plasma and epithelial lining fluid peak levofloxacin concentrations were 12.6 (IQR, 12.0-14.1) and 11.9 (IQR, 8.7-13.7) mg/L, respectively, in the once-daily group and 19.7 (IQR, 19.0-22.0) and 17.8 (IQR, 16.2-23.5) mg/L in the twice-daily group, showing a pulmonary percentage penetration of >100% in both groups.",Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15644655/),[mg] / [l],12.6,123831,DB01137,Levofloxacin
,15644655,peak levofloxacin concentrations,"The median (interquartile range [IQR]) plasma and epithelial lining fluid peak levofloxacin concentrations were 12.6 (IQR, 12.0-14.1) and 11.9 (IQR, 8.7-13.7) mg/L, respectively, in the once-daily group and 19.7 (IQR, 19.0-22.0) and 17.8 (IQR, 16.2-23.5) mg/L in the twice-daily group, showing a pulmonary percentage penetration of >100% in both groups.",Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15644655/),[mg] / [l],11.9,123832,DB01137,Levofloxacin
,15644655,peak levofloxacin concentrations,"The median (interquartile range [IQR]) plasma and epithelial lining fluid peak levofloxacin concentrations were 12.6 (IQR, 12.0-14.1) and 11.9 (IQR, 8.7-13.7) mg/L, respectively, in the once-daily group and 19.7 (IQR, 19.0-22.0) and 17.8 (IQR, 16.2-23.5) mg/L in the twice-daily group, showing a pulmonary percentage penetration of >100% in both groups.",Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15644655/),[mg] / [l],19.7,123833,DB01137,Levofloxacin
,15644655,peak levofloxacin concentrations,"The median (interquartile range [IQR]) plasma and epithelial lining fluid peak levofloxacin concentrations were 12.6 (IQR, 12.0-14.1) and 11.9 (IQR, 8.7-13.7) mg/L, respectively, in the once-daily group and 19.7 (IQR, 19.0-22.0) and 17.8 (IQR, 16.2-23.5) mg/L in the twice-daily group, showing a pulmonary percentage penetration of >100% in both groups.",Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15644655/),[mg] / [l],17.8,123834,DB01137,Levofloxacin
>,15644655,pulmonary percentage penetration,"The median (interquartile range [IQR]) plasma and epithelial lining fluid peak levofloxacin concentrations were 12.6 (IQR, 12.0-14.1) and 11.9 (IQR, 8.7-13.7) mg/L, respectively, in the once-daily group and 19.7 (IQR, 19.0-22.0) and 17.8 (IQR, 16.2-23.5) mg/L in the twice-daily group, showing a pulmonary percentage penetration of >100% in both groups.",Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15644655/),%,100,123835,DB01137,Levofloxacin
,15644655,total body exposures,"The median (IQR) total body exposures were 151 (IQR, 137-174) and 416 (IQR, 406-472) mg.hr/L, respectively, in the once-daily and twice-daily groups.",Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15644655/),[h·mg] / [l],151,123836,DB01137,Levofloxacin
,15644655,total body exposures,"The median (IQR) total body exposures were 151 (IQR, 137-174) and 416 (IQR, 406-472) mg.hr/L, respectively, in the once-daily and twice-daily groups.",Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15644655/),[h·mg] / [l],416,123837,DB01137,Levofloxacin
>,15644655,peak concentration to minimum inhibitory concentration ratio,"Our results suggest that in critically ill patients who are receiving mechanical ventilation and have severe community-acquired pneumonia and creatinine clearance of >40 mL/min, the administration of 500 mg of intravenous levofloxacin once and twice daily allows for the exceeding of pharmacodynamic thresholds predictive of outcome (i.e., peak concentration to minimum inhibitory concentration ratio of >10 or area under concentration-time curve to minimal inhibitory concentration ratio of >125 hrs) both in serum and epithelial lining fluid for pathogens with minimum inhibitory concentration values of < or =1 mg/L and >1 mg/L, respectively.",Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15644655/),,10,123838,DB01137,Levofloxacin
>,15644655,area under concentration-time curve to minimal inhibitory concentration ratio,"Our results suggest that in critically ill patients who are receiving mechanical ventilation and have severe community-acquired pneumonia and creatinine clearance of >40 mL/min, the administration of 500 mg of intravenous levofloxacin once and twice daily allows for the exceeding of pharmacodynamic thresholds predictive of outcome (i.e., peak concentration to minimum inhibitory concentration ratio of >10 or area under concentration-time curve to minimal inhibitory concentration ratio of >125 hrs) both in serum and epithelial lining fluid for pathogens with minimum inhibitory concentration values of < or =1 mg/L and >1 mg/L, respectively.",Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15644655/),h,125,123839,DB01137,Levofloxacin
<,15644655,minimum inhibitory concentration,"Our results suggest that in critically ill patients who are receiving mechanical ventilation and have severe community-acquired pneumonia and creatinine clearance of >40 mL/min, the administration of 500 mg of intravenous levofloxacin once and twice daily allows for the exceeding of pharmacodynamic thresholds predictive of outcome (i.e., peak concentration to minimum inhibitory concentration ratio of >10 or area under concentration-time curve to minimal inhibitory concentration ratio of >125 hrs) both in serum and epithelial lining fluid for pathogens with minimum inhibitory concentration values of < or =1 mg/L and >1 mg/L, respectively.",Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15644655/),[mg] / [l],1,123840,DB01137,Levofloxacin
>,15644655,minimum inhibitory concentration,"Our results suggest that in critically ill patients who are receiving mechanical ventilation and have severe community-acquired pneumonia and creatinine clearance of >40 mL/min, the administration of 500 mg of intravenous levofloxacin once and twice daily allows for the exceeding of pharmacodynamic thresholds predictive of outcome (i.e., peak concentration to minimum inhibitory concentration ratio of >10 or area under concentration-time curve to minimal inhibitory concentration ratio of >125 hrs) both in serum and epithelial lining fluid for pathogens with minimum inhibitory concentration values of < or =1 mg/L and >1 mg/L, respectively.",Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15644655/),[mg] / [l],1,123841,DB01137,Levofloxacin
,17716873,minimum inhibitory concentrations for 90%,Cmax/MIC(90) and area under the concentration-time curve for 0-24 h after the last dose (AUC(0-24 h)/MIC(90) ratios were calculated for respiratory pathogens with minimum inhibitory concentrations for 90% of the organisms (MIC(90)) of 0.03-2 microg/mL.,Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17716873/),[μg] / [ml],0.03-2,124154,DB01137,Levofloxacin
,17716873,Cmax,"The Cmax (mean+/-standard deviation), AUC(0-24h) and half-life were, respectively, 9.2+/-2.7 microg/mL, 130 microg h/mL and 8.7 h for plasma, 22.8+/-12.9 microg/mL, 260 microg h/mL and 7.0 h for ELF and 76.3+/-28.7 microg/mL, 1492 microg h/mL and 49.5 h for ACs.",Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17716873/),[μg] / [ml],9.2,124155,DB01137,Levofloxacin
,17716873,AUC(0-24h),"The Cmax (mean+/-standard deviation), AUC(0-24h) and half-life were, respectively, 9.2+/-2.7 microg/mL, 130 microg h/mL and 8.7 h for plasma, 22.8+/-12.9 microg/mL, 260 microg h/mL and 7.0 h for ELF and 76.3+/-28.7 microg/mL, 1492 microg h/mL and 49.5 h for ACs.",Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17716873/),[h·μg] / [ml],130,124156,DB01137,Levofloxacin
,17716873,AUC(0-24h),"The Cmax (mean+/-standard deviation), AUC(0-24h) and half-life were, respectively, 9.2+/-2.7 microg/mL, 130 microg h/mL and 8.7 h for plasma, 22.8+/-12.9 microg/mL, 260 microg h/mL and 7.0 h for ELF and 76.3+/-28.7 microg/mL, 1492 microg h/mL and 49.5 h for ACs.",Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17716873/),[μg] / [ml],22.8,124157,DB01137,Levofloxacin
,17716873,AUC(0-24h),"The Cmax (mean+/-standard deviation), AUC(0-24h) and half-life were, respectively, 9.2+/-2.7 microg/mL, 130 microg h/mL and 8.7 h for plasma, 22.8+/-12.9 microg/mL, 260 microg h/mL and 7.0 h for ELF and 76.3+/-28.7 microg/mL, 1492 microg h/mL and 49.5 h for ACs.",Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17716873/),[h·μg] / [ml],260,124158,DB01137,Levofloxacin
,17716873,AUC(0-24h),"The Cmax (mean+/-standard deviation), AUC(0-24h) and half-life were, respectively, 9.2+/-2.7 microg/mL, 130 microg h/mL and 8.7 h for plasma, 22.8+/-12.9 microg/mL, 260 microg h/mL and 7.0 h for ELF and 76.3+/-28.7 microg/mL, 1492 microg h/mL and 49.5 h for ACs.",Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17716873/),[μg] / [ml],76.3,124159,DB01137,Levofloxacin
,17716873,AUC(0-24h),"The Cmax (mean+/-standard deviation), AUC(0-24h) and half-life were, respectively, 9.2+/-2.7 microg/mL, 130 microg h/mL and 8.7 h for plasma, 22.8+/-12.9 microg/mL, 260 microg h/mL and 7.0 h for ELF and 76.3+/-28.7 microg/mL, 1492 microg h/mL and 49.5 h for ACs.",Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17716873/),[h·μg] / [ml],1492,124160,DB01137,Levofloxacin
,17716873,half-life,"The Cmax (mean+/-standard deviation), AUC(0-24h) and half-life were, respectively, 9.2+/-2.7 microg/mL, 130 microg h/mL and 8.7 h for plasma, 22.8+/-12.9 microg/mL, 260 microg h/mL and 7.0 h for ELF and 76.3+/-28.7 microg/mL, 1492 microg h/mL and 49.5 h for ACs.",Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17716873/),h,8.7,124161,DB01137,Levofloxacin
,17716873,half-life,"The Cmax (mean+/-standard deviation), AUC(0-24h) and half-life were, respectively, 9.2+/-2.7 microg/mL, 130 microg h/mL and 8.7 h for plasma, 22.8+/-12.9 microg/mL, 260 microg h/mL and 7.0 h for ELF and 76.3+/-28.7 microg/mL, 1492 microg h/mL and 49.5 h for ACs.",Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17716873/),[μg] / [ml],76.3,124162,DB01137,Levofloxacin
,17716873,half-life,"The Cmax (mean+/-standard deviation), AUC(0-24h) and half-life were, respectively, 9.2+/-2.7 microg/mL, 130 microg h/mL and 8.7 h for plasma, 22.8+/-12.9 microg/mL, 260 microg h/mL and 7.0 h for ELF and 76.3+/-28.7 microg/mL, 1492 microg h/mL and 49.5 h for ACs.",Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17716873/),[h·μg] / [ml],1492,124163,DB01137,Levofloxacin
,17716873,half-life,"The Cmax (mean+/-standard deviation), AUC(0-24h) and half-life were, respectively, 9.2+/-2.7 microg/mL, 130 microg h/mL and 8.7 h for plasma, 22.8+/-12.9 microg/mL, 260 microg h/mL and 7.0 h for ELF and 76.3+/-28.7 microg/mL, 1492 microg h/mL and 49.5 h for ACs.",Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17716873/),h,49.5,124164,DB01137,Levofloxacin
,17716873,Cmax/MIC(90),"Cmax/MIC(90) and AUC/MIC(90) ratios in ELF were, respectively, 11.4 and 130 for Mycoplasma pneumoniae, 22.8 and 260 for Streptococcus pneumoniae, 91.2 and 1040 for Chlamydia pneumoniae and 760 and 8667 for Haemophilus influenzae.",Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17716873/),,11.4,124165,DB01137,Levofloxacin
,17716873,Cmax/MIC(90),"Cmax/MIC(90) and AUC/MIC(90) ratios in ELF were, respectively, 11.4 and 130 for Mycoplasma pneumoniae, 22.8 and 260 for Streptococcus pneumoniae, 91.2 and 1040 for Chlamydia pneumoniae and 760 and 8667 for Haemophilus influenzae.",Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17716873/),,130,124166,DB01137,Levofloxacin
,17716873,Cmax/MIC(90),"Cmax/MIC(90) and AUC/MIC(90) ratios in ELF were, respectively, 11.4 and 130 for Mycoplasma pneumoniae, 22.8 and 260 for Streptococcus pneumoniae, 91.2 and 1040 for Chlamydia pneumoniae and 760 and 8667 for Haemophilus influenzae.",Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17716873/),,22.8,124167,DB01137,Levofloxacin
,17716873,Cmax/MIC(90),"Cmax/MIC(90) and AUC/MIC(90) ratios in ELF were, respectively, 11.4 and 130 for Mycoplasma pneumoniae, 22.8 and 260 for Streptococcus pneumoniae, 91.2 and 1040 for Chlamydia pneumoniae and 760 and 8667 for Haemophilus influenzae.",Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17716873/),,91.2,124168,DB01137,Levofloxacin
,17716873,Cmax/MIC(90),"Cmax/MIC(90) and AUC/MIC(90) ratios in ELF were, respectively, 11.4 and 130 for Mycoplasma pneumoniae, 22.8 and 260 for Streptococcus pneumoniae, 91.2 and 1040 for Chlamydia pneumoniae and 760 and 8667 for Haemophilus influenzae.",Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17716873/),,760,124169,DB01137,Levofloxacin
,17716873,AUC/MIC(90) ratios,"Cmax/MIC(90) and AUC/MIC(90) ratios in ELF were, respectively, 11.4 and 130 for Mycoplasma pneumoniae, 22.8 and 260 for Streptococcus pneumoniae, 91.2 and 1040 for Chlamydia pneumoniae and 760 and 8667 for Haemophilus influenzae.",Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17716873/),,130,124170,DB01137,Levofloxacin
,17716873,AUC/MIC(90) ratios,"Cmax/MIC(90) and AUC/MIC(90) ratios in ELF were, respectively, 11.4 and 130 for Mycoplasma pneumoniae, 22.8 and 260 for Streptococcus pneumoniae, 91.2 and 1040 for Chlamydia pneumoniae and 760 and 8667 for Haemophilus influenzae.",Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17716873/),,1040,124171,DB01137,Levofloxacin
,17716873,AUC/MIC(90) ratios,"Cmax/MIC(90) and AUC/MIC(90) ratios in ELF were, respectively, 11.4 and 130 for Mycoplasma pneumoniae, 22.8 and 260 for Streptococcus pneumoniae, 91.2 and 1040 for Chlamydia pneumoniae and 760 and 8667 for Haemophilus influenzae.",Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17716873/),,760,124172,DB01137,Levofloxacin
,17716873,AUC/MIC(90) ratios,"Cmax/MIC(90) and AUC/MIC(90) ratios in ELF were, respectively, 11.4 and 130 for Mycoplasma pneumoniae, 22.8 and 260 for Streptococcus pneumoniae, 91.2 and 1040 for Chlamydia pneumoniae and 760 and 8667 for Haemophilus influenzae.",Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17716873/),,8667,124173,DB01137,Levofloxacin
,9144740,Renal clearance,"Renal clearance was 2.56 +/- 0.42 ml/min in control, which accounted for 34% of the total body clearance.",Evaluation of renal tubular secretion and reabsorption of levofloxacin in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9144740/),[ml] / [min],2.56,126164,DB01137,Levofloxacin
,9144740,Renal clearance,"Renal clearance was significantly decreased to 0.83 +/- 0.25 ml/min by cimetidine (p < .05), corresponding to 32% of the control value.",Evaluation of renal tubular secretion and reabsorption of levofloxacin in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9144740/),[ml] / [min],0.83,126165,DB01137,Levofloxacin
,9144740,clearance ratio,"The clearance ratio of levofloxacin, which was calculated by renal clearance divided by the plasma unbound fraction and the glomerular filtration rate, was 1.60 +/- 0.38 in the control and it was decreased to 0.68 +/- 0.17 and 1.11 +/- 0.22 by cimetidine and tetraethylammonium, respectively.",Evaluation of renal tubular secretion and reabsorption of levofloxacin in rats. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9144740/),,1.60,126166,DB01137,Levofloxacin
,9144740,clearance ratio,"The clearance ratio of levofloxacin, which was calculated by renal clearance divided by the plasma unbound fraction and the glomerular filtration rate, was 1.60 +/- 0.38 in the control and it was decreased to 0.68 +/- 0.17 and 1.11 +/- 0.22 by cimetidine and tetraethylammonium, respectively.",Evaluation of renal tubular secretion and reabsorption of levofloxacin in rats. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9144740/),,0.68,126167,DB01137,Levofloxacin
,9144740,clearance ratio,"The clearance ratio of levofloxacin, which was calculated by renal clearance divided by the plasma unbound fraction and the glomerular filtration rate, was 1.60 +/- 0.38 in the control and it was decreased to 0.68 +/- 0.17 and 1.11 +/- 0.22 by cimetidine and tetraethylammonium, respectively.",Evaluation of renal tubular secretion and reabsorption of levofloxacin in rats. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9144740/),,1.11,126168,DB01137,Levofloxacin
,11837556,constant blood flow rate,"Five patients received levofloxacin 500 mg/day and one patient received levofloxacin 125 mg/day All patients received continuous renal replacement therapy: CVVHDF on day 1 and CVVH on day 2, using an acrylonitrile hollow-fiber 0.9-m2 filter, constant blood flow rate of 90 ml/minute, substitution flow rate of 1 L/hour predilution, and dialysate flow rate of 1 L/hour (CVVHDF).",Pharmacokinetics of levofloxacin during continuous venovenous hemodiafiltration and continuous venovenous hemofiltration in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11837556/),[ml] / [min],90,127092,DB01137,Levofloxacin
,11837556,substitution flow rate,"Five patients received levofloxacin 500 mg/day and one patient received levofloxacin 125 mg/day All patients received continuous renal replacement therapy: CVVHDF on day 1 and CVVH on day 2, using an acrylonitrile hollow-fiber 0.9-m2 filter, constant blood flow rate of 90 ml/minute, substitution flow rate of 1 L/hour predilution, and dialysate flow rate of 1 L/hour (CVVHDF).",Pharmacokinetics of levofloxacin during continuous venovenous hemodiafiltration and continuous venovenous hemofiltration in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11837556/),[l] / [h],1,127093,DB01137,Levofloxacin
,11837556,dial,"Five patients received levofloxacin 500 mg/day and one patient received levofloxacin 125 mg/day All patients received continuous renal replacement therapy: CVVHDF on day 1 and CVVH on day 2, using an acrylonitrile hollow-fiber 0.9-m2 filter, constant blood flow rate of 90 ml/minute, substitution flow rate of 1 L/hour predilution, and dialysate flow rate of 1 L/hour (CVVHDF).",Pharmacokinetics of levofloxacin during continuous venovenous hemodiafiltration and continuous venovenous hemofiltration in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11837556/),[l] / [h],1,127094,DB01137,Levofloxacin
,11837556,Extracorporeal clearance,Extracorporeal clearance was 26.05 +/- 4.66 ml/hour during CVVHDF and 15.71 +/- 2.73 ml/hour during CVVH (p<0.05).,Pharmacokinetics of levofloxacin during continuous venovenous hemodiafiltration and continuous venovenous hemofiltration in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11837556/),[ml] / [h],26.05,127095,DB01137,Levofloxacin
,11837556,Extracorporeal clearance,Extracorporeal clearance was 26.05 +/- 4.66 ml/hour during CVVHDF and 15.71 +/- 2.73 ml/hour during CVVH (p<0.05).,Pharmacokinetics of levofloxacin during continuous venovenous hemodiafiltration and continuous venovenous hemofiltration in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11837556/),[ml] / [h],15.71,127096,DB01137,Levofloxacin
,11837556,Elimination half-life,"Elimination half-life was 28.08 +/- 4.5 hours and 45.9 +/- 17.7 hours, and distribution volume was 1.51 +/- 0.52 L/kg and 1.42 +/- 0.42 L/kg for CVVHDF and CVVH, respectively.",Pharmacokinetics of levofloxacin during continuous venovenous hemodiafiltration and continuous venovenous hemofiltration in critically ill patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11837556/),h,28.08,127097,DB01137,Levofloxacin
,11837556,Elimination half-life,"Elimination half-life was 28.08 +/- 4.5 hours and 45.9 +/- 17.7 hours, and distribution volume was 1.51 +/- 0.52 L/kg and 1.42 +/- 0.42 L/kg for CVVHDF and CVVH, respectively.",Pharmacokinetics of levofloxacin during continuous venovenous hemodiafiltration and continuous venovenous hemofiltration in critically ill patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11837556/),h,45.9,127098,DB01137,Levofloxacin
,11837556,distribution volume,"Elimination half-life was 28.08 +/- 4.5 hours and 45.9 +/- 17.7 hours, and distribution volume was 1.51 +/- 0.52 L/kg and 1.42 +/- 0.42 L/kg for CVVHDF and CVVH, respectively.",Pharmacokinetics of levofloxacin during continuous venovenous hemodiafiltration and continuous venovenous hemofiltration in critically ill patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11837556/),[l] / [kg],1.51,127099,DB01137,Levofloxacin
,11837556,distribution volume,"Elimination half-life was 28.08 +/- 4.5 hours and 45.9 +/- 17.7 hours, and distribution volume was 1.51 +/- 0.52 L/kg and 1.42 +/- 0.42 L/kg for CVVHDF and CVVH, respectively.",Pharmacokinetics of levofloxacin during continuous venovenous hemodiafiltration and continuous venovenous hemofiltration in critically ill patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11837556/),[l] / [kg],1.42,127100,DB01137,Levofloxacin
,11837556,Saturation,Saturation was 0.76 +/- 0.13 for CVVHDF versus a sieving coefficient of 0.77 +/- 0.16 for CVVH.,Pharmacokinetics of levofloxacin during continuous venovenous hemodiafiltration and continuous venovenous hemofiltration in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11837556/),,0.76,127101,DB01137,Levofloxacin
,11837556,sieving coefficient,Saturation was 0.76 +/- 0.13 for CVVHDF versus a sieving coefficient of 0.77 +/- 0.16 for CVVH.,Pharmacokinetics of levofloxacin during continuous venovenous hemodiafiltration and continuous venovenous hemofiltration in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11837556/),,0.77,127102,DB01137,Levofloxacin
,11642690,oral bioavailability,"The pharmacokinetic characteristics of levofloxacin, moxifloxacin, and gatifloxacin include excellent oral bioavailability (90-99%), extensive penetration into tissues and body fluids, and an elimination half-life (6-12 hrs) that allows for once-daily dosing in patients with normal renal function.",Pharmacokinetics and pharmacodynamics of fluoroquinolones. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11642690/),%,90-99,127439,DB01137,Levofloxacin
,11642690,elimination half-life,"The pharmacokinetic characteristics of levofloxacin, moxifloxacin, and gatifloxacin include excellent oral bioavailability (90-99%), extensive penetration into tissues and body fluids, and an elimination half-life (6-12 hrs) that allows for once-daily dosing in patients with normal renal function.",Pharmacokinetics and pharmacodynamics of fluoroquinolones. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11642690/),h,6-12,127440,DB01137,Levofloxacin
greater,11642690,Cmax:MIC,"For gram-negative infections, a Cmax:MIC greater than or equal to 10 and AUC(0-24hr):MIC greater than or equal to 125 are associated with increased probability of a successful outcome.",Pharmacokinetics and pharmacodynamics of fluoroquinolones. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11642690/),,10,127441,DB01137,Levofloxacin
greater,11642690,AUC(0-24hr):MIC,"For gram-negative infections, a Cmax:MIC greater than or equal to 10 and AUC(0-24hr):MIC greater than or equal to 125 are associated with increased probability of a successful outcome.",Pharmacokinetics and pharmacodynamics of fluoroquinolones. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11642690/),,125,127442,DB01137,Levofloxacin
,11642690,AUC(0-24hr):MIC,"For infections caused by Streptococcus pneumoniae, an AUC(0-24hr):MIC of 30 or more is suggested for favorable clinical outcomes.",Pharmacokinetics and pharmacodynamics of fluoroquinolones. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11642690/),,30,127443,DB01137,Levofloxacin
,19572205,maximum plasma concentration (Cp(max)),The mean maximum plasma concentration (Cp(max)) of levofloxacin in febrile calves (5.28±0.32 μg/ml) did not differ significantly as compared with healthy calves (4.50±0.22 μg/ml) after single dose (20 mg/kg) oral administration.,Pharmacokinetic studies of levofloxacin after oral administration in healthy and febrile cow calves. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19572205/),[μg] / [ml],5.28,127975,DB01137,Levofloxacin
,19572205,maximum plasma concentration (Cp(max)),The mean maximum plasma concentration (Cp(max)) of levofloxacin in febrile calves (5.28±0.32 μg/ml) did not differ significantly as compared with healthy calves (4.50±0.22 μg/ml) after single dose (20 mg/kg) oral administration.,Pharmacokinetic studies of levofloxacin after oral administration in healthy and febrile cow calves. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19572205/),[μg] / [ml],4.50,127976,DB01137,Levofloxacin
,19572205,maximum urine concentration (Cu(max)),The mean maximum urine concentration (Cu(max)) in febrile (40.86±2.19 μg/ml) also did not differ significantly as compared with healthy calves (39.38±2.43 μg/ml).,Pharmacokinetic studies of levofloxacin after oral administration in healthy and febrile cow calves. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19572205/),[μg] / [ml],40.86,127977,DB01137,Levofloxacin
,19572205,maximum urine concentration (Cu(max)),The mean maximum urine concentration (Cu(max)) in febrile (40.86±2.19 μg/ml) also did not differ significantly as compared with healthy calves (39.38±2.43 μg/ml).,Pharmacokinetic studies of levofloxacin after oral administration in healthy and febrile cow calves. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19572205/),[μg] / [ml],39.38,127978,DB01137,Levofloxacin
,19572205,β,No significant difference in various pharmacokinetic parameters of plasma was observed in healthy calves ( β=0.23±0.01/h ; t½β=3.00±0.17 h and MRT=4.66±0.14 h ) and febrile calves ( β=0.23±0.01/ h; t½β=3.05±0.16 h and MRT=5.04±0.14 h).,Pharmacokinetic studies of levofloxacin after oral administration in healthy and febrile cow calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19572205/),1/[h],0.23,127979,DB01137,Levofloxacin
,19572205,t½β,No significant difference in various pharmacokinetic parameters of plasma was observed in healthy calves ( β=0.23±0.01/h ; t½β=3.00±0.17 h and MRT=4.66±0.14 h ) and febrile calves ( β=0.23±0.01/ h; t½β=3.05±0.16 h and MRT=5.04±0.14 h).,Pharmacokinetic studies of levofloxacin after oral administration in healthy and febrile cow calves. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19572205/),h,3.00,127980,DB01137,Levofloxacin
,19572205,MRT,No significant difference in various pharmacokinetic parameters of plasma was observed in healthy calves ( β=0.23±0.01/h ; t½β=3.00±0.17 h and MRT=4.66±0.14 h ) and febrile calves ( β=0.23±0.01/ h; t½β=3.05±0.16 h and MRT=5.04±0.14 h).,Pharmacokinetic studies of levofloxacin after oral administration in healthy and febrile cow calves. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19572205/),h,4.66,127981,DB01137,Levofloxacin
,19572205,β,No significant difference in various pharmacokinetic parameters of plasma was observed in healthy calves ( β=0.23±0.01/h ; t½β=3.00±0.17 h and MRT=4.66±0.14 h ) and febrile calves ( β=0.23±0.01/ h; t½β=3.05±0.16 h and MRT=5.04±0.14 h).,Pharmacokinetic studies of levofloxacin after oral administration in healthy and febrile cow calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19572205/),1/[h],0.23,127982,DB01137,Levofloxacin
,19572205,t½β,No significant difference in various pharmacokinetic parameters of plasma was observed in healthy calves ( β=0.23±0.01/h ; t½β=3.00±0.17 h and MRT=4.66±0.14 h ) and febrile calves ( β=0.23±0.01/ h; t½β=3.05±0.16 h and MRT=5.04±0.14 h).,Pharmacokinetic studies of levofloxacin after oral administration in healthy and febrile cow calves. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19572205/),h,3.05,127983,DB01137,Levofloxacin
,19572205,MRT,No significant difference in various pharmacokinetic parameters of plasma was observed in healthy calves ( β=0.23±0.01/h ; t½β=3.00±0.17 h and MRT=4.66±0.14 h ) and febrile calves ( β=0.23±0.01/ h; t½β=3.05±0.16 h and MRT=5.04±0.14 h).,Pharmacokinetic studies of levofloxacin after oral administration in healthy and febrile cow calves. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19572205/),h,5.04,127984,DB01137,Levofloxacin
,19572205,MRT,"However, the value of MRT(3.79±0.07 h) and Cl(B) (1.65±0.09 ml/kg/min) calculated in urine of febrile calves significantly (p<0.05) differ to healthy calves (MRT=3.15±0.03 h;Cl(B)=2.09±0.13 ml/kg/min).",Pharmacokinetic studies of levofloxacin after oral administration in healthy and febrile cow calves. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19572205/),h,3.79,127985,DB01137,Levofloxacin
,19572205,Cl(B),"However, the value of MRT(3.79±0.07 h) and Cl(B) (1.65±0.09 ml/kg/min) calculated in urine of febrile calves significantly (p<0.05) differ to healthy calves (MRT=3.15±0.03 h;Cl(B)=2.09±0.13 ml/kg/min).",Pharmacokinetic studies of levofloxacin after oral administration in healthy and febrile cow calves. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19572205/),[ml] / [kg·min],1.65,127986,DB01137,Levofloxacin
,19572205,MRT,"However, the value of MRT(3.79±0.07 h) and Cl(B) (1.65±0.09 ml/kg/min) calculated in urine of febrile calves significantly (p<0.05) differ to healthy calves (MRT=3.15±0.03 h;Cl(B)=2.09±0.13 ml/kg/min).",Pharmacokinetic studies of levofloxacin after oral administration in healthy and febrile cow calves. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19572205/),h,3.15,127987,DB01137,Levofloxacin
,19572205,Cl(B),"However, the value of MRT(3.79±0.07 h) and Cl(B) (1.65±0.09 ml/kg/min) calculated in urine of febrile calves significantly (p<0.05) differ to healthy calves (MRT=3.15±0.03 h;Cl(B)=2.09±0.13 ml/kg/min).",Pharmacokinetic studies of levofloxacin after oral administration in healthy and febrile cow calves. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19572205/),[ml] / [kg·min],2.09,127988,DB01137,Levofloxacin
,11328772,unbound peak plasma concentrations,"The unbound peak plasma concentrations for the three doses studied were 3.9, 6.4 and 10.3 mg/L, respectively.",Cerebrospinal fluid penetration and pharmacokinetics of levofloxacin in an experimental rabbit meningitis model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11328772/),[mg] / [l],3.9,128048,DB01137,Levofloxacin
,11328772,unbound peak plasma concentrations,"The unbound peak plasma concentrations for the three doses studied were 3.9, 6.4 and 10.3 mg/L, respectively.",Cerebrospinal fluid penetration and pharmacokinetics of levofloxacin in an experimental rabbit meningitis model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11328772/),[mg] / [l],6.4,128049,DB01137,Levofloxacin
,11328772,unbound peak plasma concentrations,"The unbound peak plasma concentrations for the three doses studied were 3.9, 6.4 and 10.3 mg/L, respectively.",Cerebrospinal fluid penetration and pharmacokinetics of levofloxacin in an experimental rabbit meningitis model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11328772/),[mg] / [l],10.3,128050,DB01137,Levofloxacin
,11328772,plasma AUC(0-8),"There was a significant increase in the plasma AUC(0-8) [29.7 +/- 6.3, 49.1 +/- 19.1 and 67.6 +/- 8.9 mg x h/L (P < 0.005)].",Cerebrospinal fluid penetration and pharmacokinetics of levofloxacin in an experimental rabbit meningitis model. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11328772/),[h·mg] / [l],29.7,128051,DB01137,Levofloxacin
,11328772,plasma AUC(0-8),"There was a significant increase in the plasma AUC(0-8) [29.7 +/- 6.3, 49.1 +/- 19.1 and 67.6 +/- 8.9 mg x h/L (P < 0.005)].",Cerebrospinal fluid penetration and pharmacokinetics of levofloxacin in an experimental rabbit meningitis model. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11328772/),[h·mg] / [l],49.1,128052,DB01137,Levofloxacin
,11328772,plasma AUC(0-8),"There was a significant increase in the plasma AUC(0-8) [29.7 +/- 6.3, 49.1 +/- 19.1 and 67.6 +/- 8.9 mg x h/L (P < 0.005)].",Cerebrospinal fluid penetration and pharmacokinetics of levofloxacin in an experimental rabbit meningitis model. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11328772/),[h·mg] / [l],67.6,128053,DB01137,Levofloxacin
,11328772,unbound peak CSF concentrations,"The unbound peak CSF concentrations were 3.8, 5.7 and 8.6 mg/L and occurred at 0-0.5 h after the administration of the dose.",Cerebrospinal fluid penetration and pharmacokinetics of levofloxacin in an experimental rabbit meningitis model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11328772/),[mg] / [l],3.8,128054,DB01137,Levofloxacin
,11328772,unbound peak CSF concentrations,"The unbound peak CSF concentrations were 3.8, 5.7 and 8.6 mg/L and occurred at 0-0.5 h after the administration of the dose.",Cerebrospinal fluid penetration and pharmacokinetics of levofloxacin in an experimental rabbit meningitis model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11328772/),[mg] / [l],5.7,128055,DB01137,Levofloxacin
,11328772,unbound peak CSF concentrations,"The unbound peak CSF concentrations were 3.8, 5.7 and 8.6 mg/L and occurred at 0-0.5 h after the administration of the dose.",Cerebrospinal fluid penetration and pharmacokinetics of levofloxacin in an experimental rabbit meningitis model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11328772/),[mg] / [l],8.6,128056,DB01137,Levofloxacin
,11328772,AUC(CSF(0-8)),"The AUC(CSF(0-8)) was significantly higher as the dose was increased (7 mg/kg, 15.8 +/- 6.6; 10.5 mg/kg, 37.3 +/- 7.8; and 14 mg/kg, 46.4 +/- 20.9 mg x h/L; P < 0.03).",Cerebrospinal fluid penetration and pharmacokinetics of levofloxacin in an experimental rabbit meningitis model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11328772/),[h·mg] / [l],15.8,128057,DB01137,Levofloxacin
,11328772,AUC(CSF(0-8)),"The AUC(CSF(0-8)) was significantly higher as the dose was increased (7 mg/kg, 15.8 +/- 6.6; 10.5 mg/kg, 37.3 +/- 7.8; and 14 mg/kg, 46.4 +/- 20.9 mg x h/L; P < 0.03).",Cerebrospinal fluid penetration and pharmacokinetics of levofloxacin in an experimental rabbit meningitis model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11328772/),[h·mg] / [l],37.3,128058,DB01137,Levofloxacin
,11328772,AUC(CSF(0-8)),"The AUC(CSF(0-8)) was significantly higher as the dose was increased (7 mg/kg, 15.8 +/- 6.6; 10.5 mg/kg, 37.3 +/- 7.8; and 14 mg/kg, 46.4 +/- 20.9 mg x h/L; P < 0.03).",Cerebrospinal fluid penetration and pharmacokinetics of levofloxacin in an experimental rabbit meningitis model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11328772/),[h·mg] / [l],46.4,128059,DB01137,Levofloxacin
,11328772,penetration,"The penetration of levofloxacin averaged 53% for the 7 mg/kg dosage group, 76% for the 10.5 mg/kg group and 68% for the 14 mg/kg group.",Cerebrospinal fluid penetration and pharmacokinetics of levofloxacin in an experimental rabbit meningitis model. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11328772/),%,53,128060,DB01137,Levofloxacin
,11328772,penetration,"The penetration of levofloxacin averaged 53% for the 7 mg/kg dosage group, 76% for the 10.5 mg/kg group and 68% for the 14 mg/kg group.",Cerebrospinal fluid penetration and pharmacokinetics of levofloxacin in an experimental rabbit meningitis model. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11328772/),%,76,128061,DB01137,Levofloxacin
,11328772,penetration,"The penetration of levofloxacin averaged 53% for the 7 mg/kg dosage group, 76% for the 10.5 mg/kg group and 68% for the 14 mg/kg group.",Cerebrospinal fluid penetration and pharmacokinetics of levofloxacin in an experimental rabbit meningitis model. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11328772/),%,68,128062,DB01137,Levofloxacin
,11328772,penetration,Our results demonstrate that levofloxacin penetration into the CSF averages 66% for the doses that would be used in clinical practice.,Cerebrospinal fluid penetration and pharmacokinetics of levofloxacin in an experimental rabbit meningitis model. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11328772/),%,66,128063,DB01137,Levofloxacin
,15561831,areas under the metronidazole plasma concentration-time curve (AUC(0-24)),"The mean (+/- standard deviation) areas under the metronidazole plasma concentration-time curve (AUC(0-24)) for 1,500-mg q24h (338 +/- 105 mg.h/liter) and 500-mg q8h (356 +/- 68 mg.h/liter) regimens were not different (P > 0.05), but both were significantly higher than the 1,000-mg q24h AUC(0-24) (P < 0.05, 227 +/- 57 mg.h/liter).",Pharmacokinetics and pharmacodynamics of intravenous levofloxacin at 750 milligrams and various doses of metronidazole in healthy adult subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15561831/),[h·mg] / [l],338,128476,DB01137,Levofloxacin
,15561831,areas under the metronidazole plasma concentration-time curve (AUC(0-24)),"The mean (+/- standard deviation) areas under the metronidazole plasma concentration-time curve (AUC(0-24)) for 1,500-mg q24h (338 +/- 105 mg.h/liter) and 500-mg q8h (356 +/- 68 mg.h/liter) regimens were not different (P > 0.05), but both were significantly higher than the 1,000-mg q24h AUC(0-24) (P < 0.05, 227 +/- 57 mg.h/liter).",Pharmacokinetics and pharmacodynamics of intravenous levofloxacin at 750 milligrams and various doses of metronidazole in healthy adult subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15561831/),[h·mg] / [l],356,128477,DB01137,Levofloxacin
,15561831,AUC(0-24),"The mean (+/- standard deviation) areas under the metronidazole plasma concentration-time curve (AUC(0-24)) for 1,500-mg q24h (338 +/- 105 mg.h/liter) and 500-mg q8h (356 +/- 68 mg.h/liter) regimens were not different (P > 0.05), but both were significantly higher than the 1,000-mg q24h AUC(0-24) (P < 0.05, 227 +/- 57 mg.h/liter).",Pharmacokinetics and pharmacodynamics of intravenous levofloxacin at 750 milligrams and various doses of metronidazole in healthy adult subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15561831/),[h·mg] / [l],227,128478,DB01137,Levofloxacin
,15561831,total body clearance,"Mean (+/- standard deviation) total body clearance and renal clearance values were similar among the 500-mg q8h, 1,000-mg q24, and 1,500-mg q24h regimens (62 +/- 7, 67 +/- 13, and 67 +/- 14 and 11 +/- 3, 12 +/- 2, and 12 +/- 5 ml/min/1.73 m2, respectively).",Pharmacokinetics and pharmacodynamics of intravenous levofloxacin at 750 milligrams and various doses of metronidazole in healthy adult subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15561831/),[ml] / [1.73·m2·min],62,128479,DB01137,Levofloxacin
,15561831,total body clearance,"Mean (+/- standard deviation) total body clearance and renal clearance values were similar among the 500-mg q8h, 1,000-mg q24, and 1,500-mg q24h regimens (62 +/- 7, 67 +/- 13, and 67 +/- 14 and 11 +/- 3, 12 +/- 2, and 12 +/- 5 ml/min/1.73 m2, respectively).",Pharmacokinetics and pharmacodynamics of intravenous levofloxacin at 750 milligrams and various doses of metronidazole in healthy adult subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15561831/),[ml] / [1.73·m2·min],67,128480,DB01137,Levofloxacin
,15561831,total body clearance,"Mean (+/- standard deviation) total body clearance and renal clearance values were similar among the 500-mg q8h, 1,000-mg q24, and 1,500-mg q24h regimens (62 +/- 7, 67 +/- 13, and 67 +/- 14 and 11 +/- 3, 12 +/- 2, and 12 +/- 5 ml/min/1.73 m2, respectively).",Pharmacokinetics and pharmacodynamics of intravenous levofloxacin at 750 milligrams and various doses of metronidazole in healthy adult subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15561831/),[ml] / [1.73·m2·min],67,128481,DB01137,Levofloxacin
,15561831,total body clearance,"Mean (+/- standard deviation) total body clearance and renal clearance values were similar among the 500-mg q8h, 1,000-mg q24, and 1,500-mg q24h regimens (62 +/- 7, 67 +/- 13, and 67 +/- 14 and 11 +/- 3, 12 +/- 2, and 12 +/- 5 ml/min/1.73 m2, respectively).",Pharmacokinetics and pharmacodynamics of intravenous levofloxacin at 750 milligrams and various doses of metronidazole in healthy adult subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15561831/),[ml] / [1.73·m2·min],11,128482,DB01137,Levofloxacin
,15561831,total body clearance,"Mean (+/- standard deviation) total body clearance and renal clearance values were similar among the 500-mg q8h, 1,000-mg q24, and 1,500-mg q24h regimens (62 +/- 7, 67 +/- 13, and 67 +/- 14 and 11 +/- 3, 12 +/- 2, and 12 +/- 5 ml/min/1.73 m2, respectively).",Pharmacokinetics and pharmacodynamics of intravenous levofloxacin at 750 milligrams and various doses of metronidazole in healthy adult subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15561831/),[ml] / [1.73·m2·min],12,128483,DB01137,Levofloxacin
,15561831,renal clearance,"Mean (+/- standard deviation) total body clearance and renal clearance values were similar among the 500-mg q8h, 1,000-mg q24, and 1,500-mg q24h regimens (62 +/- 7, 67 +/- 13, and 67 +/- 14 and 11 +/- 3, 12 +/- 2, and 12 +/- 5 ml/min/1.73 m2, respectively).",Pharmacokinetics and pharmacodynamics of intravenous levofloxacin at 750 milligrams and various doses of metronidazole in healthy adult subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15561831/),[ml] / [1.73·m2·min],67,128484,DB01137,Levofloxacin
,15561831,renal clearance,"Mean (+/- standard deviation) total body clearance and renal clearance values were similar among the 500-mg q8h, 1,000-mg q24, and 1,500-mg q24h regimens (62 +/- 7, 67 +/- 13, and 67 +/- 14 and 11 +/- 3, 12 +/- 2, and 12 +/- 5 ml/min/1.73 m2, respectively).",Pharmacokinetics and pharmacodynamics of intravenous levofloxacin at 750 milligrams and various doses of metronidazole in healthy adult subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15561831/),[ml] / [1.73·m2·min],67,128485,DB01137,Levofloxacin
,15561831,renal clearance,"Mean (+/- standard deviation) total body clearance and renal clearance values were similar among the 500-mg q8h, 1,000-mg q24, and 1,500-mg q24h regimens (62 +/- 7, 67 +/- 13, and 67 +/- 14 and 11 +/- 3, 12 +/- 2, and 12 +/- 5 ml/min/1.73 m2, respectively).",Pharmacokinetics and pharmacodynamics of intravenous levofloxacin at 750 milligrams and various doses of metronidazole in healthy adult subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15561831/),[ml] / [1.73·m2·min],11,128486,DB01137,Levofloxacin
,15561831,renal clearance,"Mean (+/- standard deviation) total body clearance and renal clearance values were similar among the 500-mg q8h, 1,000-mg q24, and 1,500-mg q24h regimens (62 +/- 7, 67 +/- 13, and 67 +/- 14 and 11 +/- 3, 12 +/- 2, and 12 +/- 5 ml/min/1.73 m2, respectively).",Pharmacokinetics and pharmacodynamics of intravenous levofloxacin at 750 milligrams and various doses of metronidazole in healthy adult subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15561831/),[ml] / [1.73·m2·min],12,128487,DB01137,Levofloxacin
,15561831,renal clearance,"Mean (+/- standard deviation) total body clearance and renal clearance values were similar among the 500-mg q8h, 1,000-mg q24, and 1,500-mg q24h regimens (62 +/- 7, 67 +/- 13, and 67 +/- 14 and 11 +/- 3, 12 +/- 2, and 12 +/- 5 ml/min/1.73 m2, respectively).",Pharmacokinetics and pharmacodynamics of intravenous levofloxacin at 750 milligrams and various doses of metronidazole in healthy adult subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15561831/),[ml] / [1.73·m2·min],12,128488,DB01137,Levofloxacin
> or =,16046101,AUC(0-24)/MIC(all),Monte Carlo simulations were then used to analyse target attainment both of gatifloxacin and levofloxacin to achieve free-drug AUC(0-24)/MIC(all)> or =30 against S. pneumoniae in patients with CAP.,Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16046101/),,30,129990,DB01137,Levofloxacin
,16046101,AUC(0-24)/MIC(all),"Monte Carlo simulations using gatifloxacin 400mg against S. pneumoniae yielded probabilities of achieving free-drug AUC(0-24)/MIC(all) of 30 of 96.6% for all patients, 92.3% for younger patients and 97.7% for elderly patients.",Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16046101/),,30,129991,DB01137,Levofloxacin
,16046101,target attainment potential,"When administered to elderly patients, a reduced dose of gatifloxacin 200mg qd could achieve a target attainment potential of 91.4%.",Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16046101/),%,91.4,129992,DB01137,Levofloxacin
,16046101,AUC(0-24)/MIC(all),"Monte Carlo simulation using levofloxacin 500 mg qd yielded probabilities of achieving free-drug AUC(0-24)/MIC(all) of 30 of 92.3% for all patients, 95.7% for elderly patients compared with 72.7% for younger patients.",Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16046101/),,30,129993,DB01137,Levofloxacin
,16046101,AUC(0-24)/MIC,"Using levofloxacin 750 mg and 1000 mg qd had probabilities of achieving free-drug AUC(0-24)/MIC(all) of 30 of 97.0% and 98.3%, 98.1% and 99.2%, and 90.1% and 95.2% for all patients, elderly patients and younger patients, respectively.",Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16046101/),,30,129994,DB01137,Levofloxacin
,16046101,AUC(0-24)/MIC(all),"The probability of achieving free-drug AUC(0-24)/MIC(all) of 100 was low both with gatifloxacin and levofloxacin, except in the case of elderly patients receiving levofloxacin in a dose of 1000 mg qd (78.5%).",Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16046101/),,100,129995,DB01137,Levofloxacin
,12878504,concentrations,"The respective mean (+/- standard deviation) concentrations at 4, 12, and 24 h in ELF for 500 mg of levofloxacin were 11.01 +/- 4.52, 2.50 +/- 0.97, and 1.24 +/- 0.55 micro g/ml; those for 750 mg of levofloxacin were 12.94 +/- 1.21, 6.04 +/- 0.39, and 1.73 +/- 0.78 micro g/ml; and those for azithromycin were 1.70 +/- 0.74, 1.27 +/- 0.47, and 2.86 +/- 1.75 micro g/ml.",Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878504/),[μg] / [ml],11.01,130438,DB01137,Levofloxacin
,12878504,concentrations,"The respective mean (+/- standard deviation) concentrations at 4, 12, and 24 h in ELF for 500 mg of levofloxacin were 11.01 +/- 4.52, 2.50 +/- 0.97, and 1.24 +/- 0.55 micro g/ml; those for 750 mg of levofloxacin were 12.94 +/- 1.21, 6.04 +/- 0.39, and 1.73 +/- 0.78 micro g/ml; and those for azithromycin were 1.70 +/- 0.74, 1.27 +/- 0.47, and 2.86 +/- 1.75 micro g/ml.",Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878504/),[μg] / [ml],2.50,130439,DB01137,Levofloxacin
,12878504,concentrations,"The respective mean (+/- standard deviation) concentrations at 4, 12, and 24 h in ELF for 500 mg of levofloxacin were 11.01 +/- 4.52, 2.50 +/- 0.97, and 1.24 +/- 0.55 micro g/ml; those for 750 mg of levofloxacin were 12.94 +/- 1.21, 6.04 +/- 0.39, and 1.73 +/- 0.78 micro g/ml; and those for azithromycin were 1.70 +/- 0.74, 1.27 +/- 0.47, and 2.86 +/- 1.75 micro g/ml.",Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878504/),[μg] / [ml],1.24,130440,DB01137,Levofloxacin
,12878504,concentrations,"The respective mean (+/- standard deviation) concentrations at 4, 12, and 24 h in ELF for 500 mg of levofloxacin were 11.01 +/- 4.52, 2.50 +/- 0.97, and 1.24 +/- 0.55 micro g/ml; those for 750 mg of levofloxacin were 12.94 +/- 1.21, 6.04 +/- 0.39, and 1.73 +/- 0.78 micro g/ml; and those for azithromycin were 1.70 +/- 0.74, 1.27 +/- 0.47, and 2.86 +/- 1.75 micro g/ml.",Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878504/),[μg] / [ml],12.94,130441,DB01137,Levofloxacin
,12878504,concentrations,"The respective mean (+/- standard deviation) concentrations at 4, 12, and 24 h in ELF for 500 mg of levofloxacin were 11.01 +/- 4.52, 2.50 +/- 0.97, and 1.24 +/- 0.55 micro g/ml; those for 750 mg of levofloxacin were 12.94 +/- 1.21, 6.04 +/- 0.39, and 1.73 +/- 0.78 micro g/ml; and those for azithromycin were 1.70 +/- 0.74, 1.27 +/- 0.47, and 2.86 +/- 1.75 micro g/ml.",Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878504/),[μg] / [ml],6.04,130442,DB01137,Levofloxacin
,12878504,concentrations,"The respective mean (+/- standard deviation) concentrations at 4, 12, and 24 h in ELF for 500 mg of levofloxacin were 11.01 +/- 4.52, 2.50 +/- 0.97, and 1.24 +/- 0.55 micro g/ml; those for 750 mg of levofloxacin were 12.94 +/- 1.21, 6.04 +/- 0.39, and 1.73 +/- 0.78 micro g/ml; and those for azithromycin were 1.70 +/- 0.74, 1.27 +/- 0.47, and 2.86 +/- 1.75 micro g/ml.",Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878504/),[μg] / [ml],1.73,130443,DB01137,Levofloxacin
,12878504,concentrations,"The respective mean (+/- standard deviation) concentrations at 4, 12, and 24 h in ELF for 500 mg of levofloxacin were 11.01 +/- 4.52, 2.50 +/- 0.97, and 1.24 +/- 0.55 micro g/ml; those for 750 mg of levofloxacin were 12.94 +/- 1.21, 6.04 +/- 0.39, and 1.73 +/- 0.78 micro g/ml; and those for azithromycin were 1.70 +/- 0.74, 1.27 +/- 0.47, and 2.86 +/- 1.75 micro g/ml.",Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878504/),[μg] / [ml],1.70,130444,DB01137,Levofloxacin
,12878504,concentrations,"The respective mean (+/- standard deviation) concentrations at 4, 12, and 24 h in ELF for 500 mg of levofloxacin were 11.01 +/- 4.52, 2.50 +/- 0.97, and 1.24 +/- 0.55 micro g/ml; those for 750 mg of levofloxacin were 12.94 +/- 1.21, 6.04 +/- 0.39, and 1.73 +/- 0.78 micro g/ml; and those for azithromycin were 1.70 +/- 0.74, 1.27 +/- 0.47, and 2.86 +/- 1.75 micro g/ml.",Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878504/),[μg] / [ml],1.27,130445,DB01137,Levofloxacin
,12878504,concentrations,"The respective mean (+/- standard deviation) concentrations at 4, 12, and 24 h in ELF for 500 mg of levofloxacin were 11.01 +/- 4.52, 2.50 +/- 0.97, and 1.24 +/- 0.55 micro g/ml; those for 750 mg of levofloxacin were 12.94 +/- 1.21, 6.04 +/- 0.39, and 1.73 +/- 0.78 micro g/ml; and those for azithromycin were 1.70 +/- 0.74, 1.27 +/- 0.47, and 2.86 +/- 1.75 micro g/ml.",Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878504/),[μg] / [ml],2.86,130446,DB01137,Levofloxacin
,12878504,concentrations,"The respective concentrations in AM for 500 mg of levofloxacin were 83.9 +/- 53.2, 18.3 +/- 6.7, and 5.6 +/- 3.2 micro g/ml; those for 750 mg of levofloxacin were 81.7 +/- 37.0, 78.2 +/- 55.4, and 13.3 +/- 6.5 micro g/ml; and those for azithromycin were 650 +/- 259, 669 +/- 311, and 734 +/- 770 micro g/ml.",Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878504/),[μg] / [ml],83.9,130447,DB01137,Levofloxacin
,12878504,concentrations,"The respective concentrations in AM for 500 mg of levofloxacin were 83.9 +/- 53.2, 18.3 +/- 6.7, and 5.6 +/- 3.2 micro g/ml; those for 750 mg of levofloxacin were 81.7 +/- 37.0, 78.2 +/- 55.4, and 13.3 +/- 6.5 micro g/ml; and those for azithromycin were 650 +/- 259, 669 +/- 311, and 734 +/- 770 micro g/ml.",Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878504/),[μg] / [ml],18.3,130448,DB01137,Levofloxacin
,12878504,concentrations,"The respective concentrations in AM for 500 mg of levofloxacin were 83.9 +/- 53.2, 18.3 +/- 6.7, and 5.6 +/- 3.2 micro g/ml; those for 750 mg of levofloxacin were 81.7 +/- 37.0, 78.2 +/- 55.4, and 13.3 +/- 6.5 micro g/ml; and those for azithromycin were 650 +/- 259, 669 +/- 311, and 734 +/- 770 micro g/ml.",Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878504/),[μg] / [ml],5.6,130449,DB01137,Levofloxacin
,12878504,concentrations,"The respective concentrations in AM for 500 mg of levofloxacin were 83.9 +/- 53.2, 18.3 +/- 6.7, and 5.6 +/- 3.2 micro g/ml; those for 750 mg of levofloxacin were 81.7 +/- 37.0, 78.2 +/- 55.4, and 13.3 +/- 6.5 micro g/ml; and those for azithromycin were 650 +/- 259, 669 +/- 311, and 734 +/- 770 micro g/ml.",Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878504/),[μg] / [ml],81.7,130450,DB01137,Levofloxacin
,12878504,concentrations,"The respective concentrations in AM for 500 mg of levofloxacin were 83.9 +/- 53.2, 18.3 +/- 6.7, and 5.6 +/- 3.2 micro g/ml; those for 750 mg of levofloxacin were 81.7 +/- 37.0, 78.2 +/- 55.4, and 13.3 +/- 6.5 micro g/ml; and those for azithromycin were 650 +/- 259, 669 +/- 311, and 734 +/- 770 micro g/ml.",Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878504/),[μg] / [ml],78.2,130451,DB01137,Levofloxacin
,12878504,concentrations,"The respective concentrations in AM for 500 mg of levofloxacin were 83.9 +/- 53.2, 18.3 +/- 6.7, and 5.6 +/- 3.2 micro g/ml; those for 750 mg of levofloxacin were 81.7 +/- 37.0, 78.2 +/- 55.4, and 13.3 +/- 6.5 micro g/ml; and those for azithromycin were 650 +/- 259, 669 +/- 311, and 734 +/- 770 micro g/ml.",Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878504/),[μg] / [ml],13.3,130452,DB01137,Levofloxacin
,12878504,concentrations,"The respective concentrations in AM for 500 mg of levofloxacin were 83.9 +/- 53.2, 18.3 +/- 6.7, and 5.6 +/- 3.2 micro g/ml; those for 750 mg of levofloxacin were 81.7 +/- 37.0, 78.2 +/- 55.4, and 13.3 +/- 6.5 micro g/ml; and those for azithromycin were 650 +/- 259, 669 +/- 311, and 734 +/- 770 micro g/ml.",Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878504/),[μg] / [ml],650,130453,DB01137,Levofloxacin
,12878504,concentrations,"The respective concentrations in AM for 500 mg of levofloxacin were 83.9 +/- 53.2, 18.3 +/- 6.7, and 5.6 +/- 3.2 micro g/ml; those for 750 mg of levofloxacin were 81.7 +/- 37.0, 78.2 +/- 55.4, and 13.3 +/- 6.5 micro g/ml; and those for azithromycin were 650 +/- 259, 669 +/- 311, and 734 +/- 770 micro g/ml.",Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878504/),[μg] / [ml],669,130454,DB01137,Levofloxacin
,12878504,concentrations,"The respective concentrations in AM for 500 mg of levofloxacin were 83.9 +/- 53.2, 18.3 +/- 6.7, and 5.6 +/- 3.2 micro g/ml; those for 750 mg of levofloxacin were 81.7 +/- 37.0, 78.2 +/- 55.4, and 13.3 +/- 6.5 micro g/ml; and those for azithromycin were 650 +/- 259, 669 +/- 311, and 734 +/- 770 micro g/ml.",Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878504/),[μg] / [ml],734,130455,DB01137,Levofloxacin
,17674322,survivorship,"For gentamicin, survivorship of mice receiving drug every 24, 12, and 6 h was, respectively, 80%, 80%, and 90% for normal mice and 80%, 100%, and 70% for neutropenic mice.",Comparison of 2 antibiotics that inhibit protein synthesis for the treatment of infection with Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17674322/),%,80,131317,DB01137,Levofloxacin
,17674322,survivorship,"For gentamicin, survivorship of mice receiving drug every 24, 12, and 6 h was, respectively, 80%, 80%, and 90% for normal mice and 80%, 100%, and 70% for neutropenic mice.",Comparison of 2 antibiotics that inhibit protein synthesis for the treatment of infection with Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17674322/),%,90,131318,DB01137,Levofloxacin
,17674322,survivorship,"For gentamicin, survivorship of mice receiving drug every 24, 12, and 6 h was, respectively, 80%, 80%, and 90% for normal mice and 80%, 100%, and 70% for neutropenic mice.",Comparison of 2 antibiotics that inhibit protein synthesis for the treatment of infection with Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17674322/),%,100,131319,DB01137,Levofloxacin
,17674322,survivorship,"For gentamicin, survivorship of mice receiving drug every 24, 12, and 6 h was, respectively, 80%, 80%, and 90% for normal mice and 80%, 100%, and 70% for neutropenic mice.",Comparison of 2 antibiotics that inhibit protein synthesis for the treatment of infection with Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17674322/),%,70,131320,DB01137,Levofloxacin
,33565110,absorption,"In the levofloxacin intramuscular administration group, the absorption and elimination half-lives of the drug were determined to be 0.123 (range: 0.02) hr and 5.402 (range: 0.70) hr, respectively.",Pharmacokinetics of levofloxacin mesylate in healthy adult giant panda after single-dose administration via different routes. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33565110/),h,0.123,131685,DB01137,Levofloxacin
,33565110,elimination half-lives,"In the levofloxacin intramuscular administration group, the absorption and elimination half-lives of the drug were determined to be 0.123 (range: 0.02) hr and 5.402 (range: 0.70) hr, respectively.",Pharmacokinetics of levofloxacin mesylate in healthy adult giant panda after single-dose administration via different routes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33565110/),h,5.402,131686,DB01137,Levofloxacin
,33565110,absorption,"In the levofloxacin oral administration group, the absorption and elimination half-lives were determined to be 0.325 (range: 0.02) hr and 7.143 (range: 0.63) hr, respectively.",Pharmacokinetics of levofloxacin mesylate in healthy adult giant panda after single-dose administration via different routes. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33565110/),h,0.325,131687,DB01137,Levofloxacin
,33565110,elimination half-lives,"In the levofloxacin oral administration group, the absorption and elimination half-lives were determined to be 0.325 (range: 0.02) hr and 7.143 (range: 0.63) hr, respectively.",Pharmacokinetics of levofloxacin mesylate in healthy adult giant panda after single-dose administration via different routes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33565110/),h,7.143,131688,DB01137,Levofloxacin
,8902431,Maximum serum concentration (Cmax),"Maximum serum concentration (Cmax) of levofloxacin after the administration of 200 mg of the levo-isomer was 2.42 mg/l (chiral derivatization HPLC, mean values); the corresponding area under the serum concentration-time curve (AUC0-28) was 17.0 mg x h/l.",Pharmacokinetics of levofloxacin in comparison to the racemic mixture of ofloxacin in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8902431/),[mg] / [l],2.42,131709,DB01137,Levofloxacin
,8902431,area under the serum concentration-time curve (AUC0-28),"Maximum serum concentration (Cmax) of levofloxacin after the administration of 200 mg of the levo-isomer was 2.42 mg/l (chiral derivatization HPLC, mean values); the corresponding area under the serum concentration-time curve (AUC0-28) was 17.0 mg x h/l.",Pharmacokinetics of levofloxacin in comparison to the racemic mixture of ofloxacin in man. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8902431/),[h·mg] / [l],17.0,131710,DB01137,Levofloxacin
,8902431,Cmax,"The corresponding Cmax values after the administration of 400 mg (+/-)-isomer (chiral derivatization HPLC and reversed phased HPLC, mean values) were 2.05 mg/l, 1.98 mg/l and 4.41 mg/l for (-)-, (+)- and (+/-) isomer, respectively.",Pharmacokinetics of levofloxacin in comparison to the racemic mixture of ofloxacin in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8902431/),[mg] / [l],2.05,131711,DB01137,Levofloxacin
,8902431,Cmax,"The corresponding Cmax values after the administration of 400 mg (+/-)-isomer (chiral derivatization HPLC and reversed phased HPLC, mean values) were 2.05 mg/l, 1.98 mg/l and 4.41 mg/l for (-)-, (+)- and (+/-) isomer, respectively.",Pharmacokinetics of levofloxacin in comparison to the racemic mixture of ofloxacin in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8902431/),[mg] / [l],1.98,131712,DB01137,Levofloxacin
,8902431,Cmax,"The corresponding Cmax values after the administration of 400 mg (+/-)-isomer (chiral derivatization HPLC and reversed phased HPLC, mean values) were 2.05 mg/l, 1.98 mg/l and 4.41 mg/l for (-)-, (+)- and (+/-) isomer, respectively.",Pharmacokinetics of levofloxacin in comparison to the racemic mixture of ofloxacin in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8902431/),[mg] / [l],4.41,131713,DB01137,Levofloxacin
,8902431,AUCS0-28,"The AUCS0-28 were 17.0, 14.6 and 32.7 mg x h/l, respectively.",Pharmacokinetics of levofloxacin in comparison to the racemic mixture of ofloxacin in man. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8902431/),[h·mg] / [l],17.0,131714,DB01137,Levofloxacin
,8902431,AUCS0-28,"The AUCS0-28 were 17.0, 14.6 and 32.7 mg x h/l, respectively.",Pharmacokinetics of levofloxacin in comparison to the racemic mixture of ofloxacin in man. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8902431/),[h·mg] / [l],14.6,131715,DB01137,Levofloxacin
,8902431,AUCS0-28,"The AUCS0-28 were 17.0, 14.6 and 32.7 mg x h/l, respectively.",Pharmacokinetics of levofloxacin in comparison to the racemic mixture of ofloxacin in man. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8902431/),[h·mg] / [l],32.7,131716,DB01137,Levofloxacin
,12380635,tear concentration,"At 5 minutes after administration of a single topical dose of levofloxacin, the mean tear concentration was 49.19 +/- 26.73 microg/mL.",Tear concentrations of levofloxacin following topical administration of a single dose of 0.5% levofloxacin ophthalmic solution in healthy volunteers. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12380635/),[μg] / [ml],49.19,133503,DB01137,Levofloxacin
,12380635,peak concentration,"The mean peak concentration of levofloxacin in the tear film, 221.06 +/- 256.68 microg/mL, was reached at 15 minutes after administration.",Tear concentrations of levofloxacin following topical administration of a single dose of 0.5% levofloxacin ophthalmic solution in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12380635/),[μg] / [ml],221.06,133504,DB01137,Levofloxacin
,12380635,tear concentration,"At 4 hours after administration, the mean tear concentration of levofloxacin was 17.04 +/- 15.13 microg/mL.",Tear concentrations of levofloxacin following topical administration of a single dose of 0.5% levofloxacin ophthalmic solution in healthy volunteers. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12380635/),[μg] / [ml],17.04,133505,DB01137,Levofloxacin
<,12380635,minimum inhibitory concentration,"Levofloxacin concentrations in the tear fluid after a single topical dose (1 drop) reached high levels quickly and remained above the minimum inhibitory concentration for most suspected ophthalmic pathogens (< or = 2 microg/mL) for at least 6 hours in most healthy volunteers, and for up to 24 hours in some volunteers.",Tear concentrations of levofloxacin following topical administration of a single dose of 0.5% levofloxacin ophthalmic solution in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12380635/),[μg] / [ml],2,133506,DB01137,Levofloxacin
,11062191,T:1/2,"With each organism, a series of monoexponential pharmacokinetic profiles of single doses of moxifloxacin (T:1/2 = 12.1 h) and levofloxacin (T:(1/2) = 6.8 h) were simulated.",Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11062191/),h,12.1,133707,DB01137,Levofloxacin
,11062191,T:(1/2),"With each organism, a series of monoexponential pharmacokinetic profiles of single doses of moxifloxacin (T:1/2 = 12.1 h) and levofloxacin (T:(1/2) = 6.8 h) were simulated.",Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11062191/),h,6.8,133708,DB01137,Levofloxacin
,11062191,ratios of area under the concentration-time curve (AUC) to the MIC,The respective eight-fold ranges of the ratios of area under the concentration-time curve (AUC) to the MIC were 58-475 and 114-934.,Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11062191/),,58-475,133709,DB01137,Levofloxacin
,11062191,ratios of area under the concentration-time curve (AUC) to the MIC,The respective eight-fold ranges of the ratios of area under the concentration-time curve (AUC) to the MIC were 58-475 and 114-934.,Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11062191/),,114-934,133710,DB01137,Levofloxacin
,11062191,AUC/MIC ratios,"The predicted AUC/MIC ratios for moxifloxacin and levofloxacin that might be equivalent to Schentag's AUC/MIC breakpoint for ciprofloxacin (125) were estimated at 80 and 130, respectively.",Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11062191/),,80,133711,DB01137,Levofloxacin
,11062191,AUC/MIC ratios,"The predicted AUC/MIC ratios for moxifloxacin and levofloxacin that might be equivalent to Schentag's AUC/MIC breakpoint for ciprofloxacin (125) were estimated at 80 and 130, respectively.",Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11062191/),,130,133712,DB01137,Levofloxacin
,11062191,MIC,The respective equivalent MIC breakpoints were 0.41 mg/L (for a 400 mg dose of moxifloxacin) and 0.35 mg/L (for a 500 mg dose of levofloxacin).,Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11062191/),[mg] / [l],0.41,133713,DB01137,Levofloxacin
,11062191,MIC,The respective equivalent MIC breakpoints were 0.41 mg/L (for a 400 mg dose of moxifloxacin) and 0.35 mg/L (for a 500 mg dose of levofloxacin).,Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11062191/),[mg] / [l],0.35,133714,DB01137,Levofloxacin
,11062191,I:(E),"To provide an 'acceptable' I:(E) = 200 (log cfu/mL)*h, the D:(24)s of moxifloxacin for all three organisms were much lower (150, 30 and 60 mg, respectively) than the clinically proposed 400 mg dose.",Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11062191/),,200,133715,DB01137,Levofloxacin
,16857688,AUC/MIC,It appears that the critical AUC/MIC necessary to prevent the acquisition of resistance for levofloxacin is 200 and approximately 400 for moxifloxacin.,Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16857688/),,200,134702,DB01137,Levofloxacin
,16857688,AUC/MIC,It appears that the critical AUC/MIC necessary to prevent the acquisition of resistance for levofloxacin is 200 and approximately 400 for moxifloxacin.,Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16857688/),,400,134703,DB01137,Levofloxacin
,16236860,peak concentration,"The mean peak concentration in serum (6.5 mg/L) was found 1 h after administration, and at 4 h after administration in sputum (5.1 mg/L).",Pharmacodynamics of levofloxacin in patients with acute exacerbation of chronic bronchitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236860/),[mg] / [l],6.5,137898,DB01137,Levofloxacin
,16236860,peak concentration,"The mean peak concentration in serum (6.5 mg/L) was found 1 h after administration, and at 4 h after administration in sputum (5.1 mg/L).",Pharmacodynamics of levofloxacin in patients with acute exacerbation of chronic bronchitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236860/),[mg] / [l],5.1,137899,DB01137,Levofloxacin
>,16236860,AUC(0-24)/MIC ratio,"Treatment was successful in eight patients when the AUC(0-24)/MIC ratio was > 40 for serum, and in nine patients when it was > 30 for sputum.",Pharmacodynamics of levofloxacin in patients with acute exacerbation of chronic bronchitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236860/),,40,137900,DB01137,Levofloxacin
>,16236860,AUC(0-24)/MIC ratio,"Treatment was successful in eight patients when the AUC(0-24)/MIC ratio was > 40 for serum, and in nine patients when it was > 30 for sputum.",Pharmacodynamics of levofloxacin in patients with acute exacerbation of chronic bronchitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236860/),,30,137901,DB01137,Levofloxacin
>,16236860,Cmax/MIC ratio,"Treatment was also successful in seven patients when the Cmax/MIC ratio was > 5.01 for serum, and in nine patients when the Cmax/MIC ratio was > 4.01 for sputum.",Pharmacodynamics of levofloxacin in patients with acute exacerbation of chronic bronchitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236860/),,5.01,137902,DB01137,Levofloxacin
>,16236860,Cmax/MIC ratio,"Treatment was also successful in seven patients when the Cmax/MIC ratio was > 5.01 for serum, and in nine patients when the Cmax/MIC ratio was > 4.01 for sputum.",Pharmacodynamics of levofloxacin in patients with acute exacerbation of chronic bronchitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236860/),,4.01,137903,DB01137,Levofloxacin
>,16236860,AUC(0-24)/MIC ratio,"Treatment was successful in 90% (27 of 30 patients) when the AUC(0-24)/MIC ratio was > 125 for serum and > 100 for sputum, and when Cmax/MIC was > 10.01 for serum and > 8.01 for sputum following the first dose.",Pharmacodynamics of levofloxacin in patients with acute exacerbation of chronic bronchitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236860/),,125,137904,DB01137,Levofloxacin
>,16236860,AUC(0-24)/MIC ratio,"Treatment was successful in 90% (27 of 30 patients) when the AUC(0-24)/MIC ratio was > 125 for serum and > 100 for sputum, and when Cmax/MIC was > 10.01 for serum and > 8.01 for sputum following the first dose.",Pharmacodynamics of levofloxacin in patients with acute exacerbation of chronic bronchitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236860/),,100,137905,DB01137,Levofloxacin
>,16236860,Cmax/MIC,"Treatment was successful in 90% (27 of 30 patients) when the AUC(0-24)/MIC ratio was > 125 for serum and > 100 for sputum, and when Cmax/MIC was > 10.01 for serum and > 8.01 for sputum following the first dose.",Pharmacodynamics of levofloxacin in patients with acute exacerbation of chronic bronchitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236860/),,10.01,137906,DB01137,Levofloxacin
>,16236860,Cmax/MIC,"Treatment was successful in 90% (27 of 30 patients) when the AUC(0-24)/MIC ratio was > 125 for serum and > 100 for sputum, and when Cmax/MIC was > 10.01 for serum and > 8.01 for sputum following the first dose.",Pharmacodynamics of levofloxacin in patients with acute exacerbation of chronic bronchitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236860/),,8.01,137907,DB01137,Levofloxacin
,11083664,maximum concentration in serum,"Pharmacokinetic data were as follows: maximum concentration in serum, 6.36 +/- 0.57 mg/liter; area under the concentration-time curve, 43.6 +/- 6.23 mg.",Levofloxacin pharmacokinetics and serum bactericidal activities against five enterobacterial species. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11083664/),[mg] / [l],6.36,138717,DB01137,Levofloxacin
,11083664,area under the concentration-time curve,"Pharmacokinetic data were as follows: maximum concentration in serum, 6.36 +/- 0.57 mg/liter; area under the concentration-time curve, 43.6 +/- 6.23 mg.",Levofloxacin pharmacokinetics and serum bactericidal activities against five enterobacterial species. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11083664/),mg,43.6,138718,DB01137,Levofloxacin
,11083664,elimination half-life,h/liter; elimination half-life 4.23 +/- 0.87 h.,Levofloxacin pharmacokinetics and serum bactericidal activities against five enterobacterial species. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11083664/),h,4.23,138719,DB01137,Levofloxacin
,9333057,times to the maximum concentration,"Study C indicated that levofloxacin was rapidly and completely absorbed from the oral tablets, with mean times to the maximum concentration of drug in serum of approximately 1.5 h and mean absolute bioavailability of > or =99%.",Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333057/),h,1.5,139821,DB01137,Levofloxacin
> or =,9333057,absolute bioavailability,"Study C indicated that levofloxacin was rapidly and completely absorbed from the oral tablets, with mean times to the maximum concentration of drug in serum of approximately 1.5 h and mean absolute bioavailability of > or =99%.",Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333057/),%,99,139822,DB01137,Levofloxacin
≥,28031199,AUC24/MIC ratio,"The identified cutoff AUC24/MIC ratio (≥95.7) was the only covariate that correlated with a favorable clinical outcome in multivariate regression analysis (odds ratio [OR], 20.85; 95% confidence interval [CI], 1.56 to 186.73).",Population Pharmacokinetics and Pharmacodynamics of Levofloxacin in Acutely Hospitalized Older Patients with Various Degrees of Renal Function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28031199/),,95.7,140831,DB01137,Levofloxacin
≤,28031199,MIC,"The levofloxacin doses defined in our study may be effective for the treatment of infections due to bacterial pathogens, with an MIC of ≤0.5 mg/liter in older patients with various degrees of renal function, while minimizing the toxicity risk.",Population Pharmacokinetics and Pharmacodynamics of Levofloxacin in Acutely Hospitalized Older Patients with Various Degrees of Renal Function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28031199/),[mg] / [l],0.5,140832,DB01137,Levofloxacin
,11861816,apparent oral clearance,"The apparent oral clearance of grepafloxacin was decreased to 33% of the control, and the bioavailability of grepafloxacin was increased to 95% by cyclosporin A from 53% in the controls.",Pharmacokinetic role of P-glycoprotein in oral bioavailability and intestinal secretion of grepafloxacin in vivo. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11861816/),,33,144031,DB01137,Levofloxacin
,11861816,bioavailability,"The apparent oral clearance of grepafloxacin was decreased to 33% of the control, and the bioavailability of grepafloxacin was increased to 95% by cyclosporin A from 53% in the controls.",Pharmacokinetic role of P-glycoprotein in oral bioavailability and intestinal secretion of grepafloxacin in vivo. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11861816/),,95,144032,DB01137,Levofloxacin
,11861816,bioavailability,"The apparent oral clearance of grepafloxacin was decreased to 33% of the control, and the bioavailability of grepafloxacin was increased to 95% by cyclosporin A from 53% in the controls.",Pharmacokinetic role of P-glycoprotein in oral bioavailability and intestinal secretion of grepafloxacin in vivo. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11861816/),%,53,144033,DB01137,Levofloxacin
,10418754,percent survival,"For example, percent survival following levofloxacin treatment recorded at day 4 postinfection with SP 22, SP 28 and SP 46 were 41, 90 and 30%, respectively, while the corresponding values after ciprofloxacin treatment were 27, 75 and 16%, respectively.",Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10418754/),%,41,144034,DB01137,Levofloxacin
,10418754,percent survival,"For example, percent survival following levofloxacin treatment recorded at day 4 postinfection with SP 22, SP 28 and SP 46 were 41, 90 and 30%, respectively, while the corresponding values after ciprofloxacin treatment were 27, 75 and 16%, respectively.",Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10418754/),%,90,144035,DB01137,Levofloxacin
,10418754,percent survival,"For example, percent survival following levofloxacin treatment recorded at day 4 postinfection with SP 22, SP 28 and SP 46 were 41, 90 and 30%, respectively, while the corresponding values after ciprofloxacin treatment were 27, 75 and 16%, respectively.",Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10418754/),%,30,144036,DB01137,Levofloxacin
,10418754,percent survival,"For example, percent survival following levofloxacin treatment recorded at day 4 postinfection with SP 22, SP 28 and SP 46 were 41, 90 and 30%, respectively, while the corresponding values after ciprofloxacin treatment were 27, 75 and 16%, respectively.",Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10418754/),%,27,144037,DB01137,Levofloxacin
,10418754,percent survival,"For example, percent survival following levofloxacin treatment recorded at day 4 postinfection with SP 22, SP 28 and SP 46 were 41, 90 and 30%, respectively, while the corresponding values after ciprofloxacin treatment were 27, 75 and 16%, respectively.",Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10418754/),%,75,144038,DB01137,Levofloxacin
,10418754,percent survival,"For example, percent survival following levofloxacin treatment recorded at day 4 postinfection with SP 22, SP 28 and SP 46 were 41, 90 and 30%, respectively, while the corresponding values after ciprofloxacin treatment were 27, 75 and 16%, respectively.",Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10418754/),%,16,144039,DB01137,Levofloxacin
,19356395,AUClast,"The means (test and reference) for AUClast were 58.869 and 56.297 microg x h/ml, for AUC yen were 63.456 and 60.748 microg x h/ml and for Cmax were 8.691 and 8.445 microg/ml.",Comparative bioavailability of two oral formulations of levofloxacin in healthy Mexican volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19356395/),[h·μg] / [ml],58.869,145165,DB01137,Levofloxacin
,19356395,AUClast,"The means (test and reference) for AUClast were 58.869 and 56.297 microg x h/ml, for AUC yen were 63.456 and 60.748 microg x h/ml and for Cmax were 8.691 and 8.445 microg/ml.",Comparative bioavailability of two oral formulations of levofloxacin in healthy Mexican volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19356395/),[h·μg] / [ml],56.297,145166,DB01137,Levofloxacin
,19356395,AUC yen,"The means (test and reference) for AUClast were 58.869 and 56.297 microg x h/ml, for AUC yen were 63.456 and 60.748 microg x h/ml and for Cmax were 8.691 and 8.445 microg/ml.",Comparative bioavailability of two oral formulations of levofloxacin in healthy Mexican volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19356395/),[h·μg] / [ml],63.456,145167,DB01137,Levofloxacin
,19356395,AUC yen,"The means (test and reference) for AUClast were 58.869 and 56.297 microg x h/ml, for AUC yen were 63.456 and 60.748 microg x h/ml and for Cmax were 8.691 and 8.445 microg/ml.",Comparative bioavailability of two oral formulations of levofloxacin in healthy Mexican volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19356395/),[h·μg] / [ml],60.748,145168,DB01137,Levofloxacin
,19356395,Cmax,"The means (test and reference) for AUClast were 58.869 and 56.297 microg x h/ml, for AUC yen were 63.456 and 60.748 microg x h/ml and for Cmax were 8.691 and 8.445 microg/ml.",Comparative bioavailability of two oral formulations of levofloxacin in healthy Mexican volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19356395/),[μg] / [ml],8.691,145169,DB01137,Levofloxacin
,19356395,Cmax,"The means (test and reference) for AUClast were 58.869 and 56.297 microg x h/ml, for AUC yen were 63.456 and 60.748 microg x h/ml and for Cmax were 8.691 and 8.445 microg/ml.",Comparative bioavailability of two oral formulations of levofloxacin in healthy Mexican volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19356395/),[μg] / [ml],8.445,145170,DB01137,Levofloxacin
>,22653817,fAUC/MIC,The probability of reaching an fAUC/MIC >100 was calculated for each regimen.,Evaluation of fluoroquinolone reduced dosage regimens in elderly patients by using pharmacokinetic modelling and Monte Carlo simulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22653817/),,100,145526,DB01137,Levofloxacin
<,22653817,MICs,"For MICs <1 mg/L, all simulated patients reach the efficacy target.",Evaluation of fluoroquinolone reduced dosage regimens in elderly patients by using pharmacokinetic modelling and Monte Carlo simulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22653817/),[mg] / [l],1,145527,DB01137,Levofloxacin
,22653817,MIC,"However, with higher values of MIC, the proposed regimens were inefficient for patients with moderate or severe renal impairment: 3.4% and 30.2% of patients with moderate renal impairment reached the efficacy target for ciprofloxacin and ofloxacin, respectively, for an MIC of 2 mg/L.",Evaluation of fluoroquinolone reduced dosage regimens in elderly patients by using pharmacokinetic modelling and Monte Carlo simulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22653817/),[mg] / [l],2,145528,DB01137,Levofloxacin
low,22653817,MIC,"For ciprofloxacin, more than 80% of patients with severe renal impairment were unable to reach the target fAUC/MIC with an MIC as low as 1 mg/L, whereas for levofloxacin, all simulated patients reached the efficacy target until an MIC of 4 mg/L.",Evaluation of fluoroquinolone reduced dosage regimens in elderly patients by using pharmacokinetic modelling and Monte Carlo simulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22653817/),[mg] / [l],1,145529,DB01137,Levofloxacin
,22653817,MIC,"For ciprofloxacin, more than 80% of patients with severe renal impairment were unable to reach the target fAUC/MIC with an MIC as low as 1 mg/L, whereas for levofloxacin, all simulated patients reached the efficacy target until an MIC of 4 mg/L.",Evaluation of fluoroquinolone reduced dosage regimens in elderly patients by using pharmacokinetic modelling and Monte Carlo simulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22653817/),[mg] / [l],4,145530,DB01137,Levofloxacin
,28113087,terminal half-life,"Mean values of terminal half-life for IV and PO groups were 6.93 and 8.09h, respectively.",Ex vivo antibacterial activity of levofloxacin against Escherichia coli and its pharmacokinetic profile following intravenous and oral administrations in broilers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28113087/),h,6.93,146219,DB01137,Levofloxacin
,28113087,terminal half-life,"Mean values of terminal half-life for IV and PO groups were 6.93 and 8.09h, respectively.",Ex vivo antibacterial activity of levofloxacin against Escherichia coli and its pharmacokinetic profile following intravenous and oral administrations in broilers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28113087/),h,8.09,146220,DB01137,Levofloxacin
,28113087,Tmax,"Following oral administration, the peak plasma concentration was achieved at 0.88h (Tmax).",Ex vivo antibacterial activity of levofloxacin against Escherichia coli and its pharmacokinetic profile following intravenous and oral administrations in broilers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28113087/),h,0.88,146221,DB01137,Levofloxacin
,28113087,oral bioavailability,Mean value of oral bioavailability was 123.25%.,Ex vivo antibacterial activity of levofloxacin against Escherichia coli and its pharmacokinetic profile following intravenous and oral administrations in broilers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28113087/),%,123.25,146222,DB01137,Levofloxacin
,28113087,MIC,"Also, simulated optimal dose based on the ex vivo PK/PD approach was 2.9mg/kg/day (bactericidal) to 4.3mg/kg/day (eradication) PO against E. coli (MIC=0.125μg/ml).",Ex vivo antibacterial activity of levofloxacin against Escherichia coli and its pharmacokinetic profile following intravenous and oral administrations in broilers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28113087/),[μg] / [ml],0.125,146223,DB01137,Levofloxacin
,11210403,AUC,"There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens.",Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210403/),,48.59,147172,DB01137,Levofloxacin
,11210403,AUC,"There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens.",Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210403/),,49.9,147173,DB01137,Levofloxacin
,11210403,Cmax,"There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens.",Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210403/),,7.73,147174,DB01137,Levofloxacin
,11210403,Cmax,"There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens.",Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210403/),,6.6,147175,DB01137,Levofloxacin
,11210403,tmax,"There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens.",Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210403/),,1.1,147176,DB01137,Levofloxacin
,11210403,tmax,"There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus levofloxacin/oxycodone regimens.",Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210403/),,1.6,147177,DB01137,Levofloxacin
,19263265,zeta potential,The formulated liposomes were found to be relatively uniform in size (7.424 +/- 0.689 microm) with a positive zeta potential (+13.11 +/- 1.08 mV).,Targeted delivery of levofloxacin-liposomes for the treatment of pulmonary inflammation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19263265/),m,13.,149351,DB01137,Levofloxacin
,19263265,entrapment efficiency,The entrapment efficiency of levofloxacin-loaded liposomes ranged from 82.19% to 86.23%.,Targeted delivery of levofloxacin-liposomes for the treatment of pulmonary inflammation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19263265/),%,82.19,149352,DB01137,Levofloxacin
,19263265,entrapment efficiency,The entrapment efficiency of levofloxacin-loaded liposomes ranged from 82.19% to 86.23%.,Targeted delivery of levofloxacin-liposomes for the treatment of pulmonary inflammation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19263265/),%,86.23,149353,DB01137,Levofloxacin
,17699357,blood,Treatment lasted 8 h; blood and dialysate flow rates were 160 ml/min.,Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17699357/),[ml] / [min],160,149543,DB01137,Levofloxacin
,17699357,dialysate flow rates,Treatment lasted 8 h; blood and dialysate flow rates were 160 ml/min.,Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17699357/),[ml] / [min],160,149544,DB01137,Levofloxacin
,11679556,MIC(50),"The BMS-284756 MIC(50) of 22 different Legionella spp. strains was 0.008 mg/L, compared with 0.016 and 0.125 mg/L for levofloxacin and azithromycin, respectively.","BMS-284756 (T-3811ME) a new fluoroquinolone: in vitro activity against Legionella, efficacy in a guinea pig model of L. pneumophila pneumonia and pharmacokinetics in guinea pigs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11679556/),[mg] / [l],0.008,150059,DB01137,Levofloxacin
,11679556,MIC(50),"The BMS-284756 MIC(50) of 22 different Legionella spp. strains was 0.008 mg/L, compared with 0.016 and 0.125 mg/L for levofloxacin and azithromycin, respectively.","BMS-284756 (T-3811ME) a new fluoroquinolone: in vitro activity against Legionella, efficacy in a guinea pig model of L. pneumophila pneumonia and pharmacokinetics in guinea pigs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11679556/),[mg] / [l],0.016,150060,DB01137,Levofloxacin
,11679556,MIC(50),"The BMS-284756 MIC(50) of 22 different Legionella spp. strains was 0.008 mg/L, compared with 0.016 and 0.125 mg/L for levofloxacin and azithromycin, respectively.","BMS-284756 (T-3811ME) a new fluoroquinolone: in vitro activity against Legionella, efficacy in a guinea pig model of L. pneumophila pneumonia and pharmacokinetics in guinea pigs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11679556/),[mg] / [l],0.125,150061,DB01137,Levofloxacin
,11679556,peak plasma levels,"In infected guinea pigs given BMS-284756 10 mg/kg ip, mean peak plasma levels were 1.8 mg/L at 0.5 h and 0.7 mg/L at 1 h post-dose.","BMS-284756 (T-3811ME) a new fluoroquinolone: in vitro activity against Legionella, efficacy in a guinea pig model of L. pneumophila pneumonia and pharmacokinetics in guinea pigs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11679556/),[mg] / [l],1.8,150062,DB01137,Levofloxacin
,11679556,peak plasma levels,"In infected guinea pigs given BMS-284756 10 mg/kg ip, mean peak plasma levels were 1.8 mg/L at 0.5 h and 0.7 mg/L at 1 h post-dose.","BMS-284756 (T-3811ME) a new fluoroquinolone: in vitro activity against Legionella, efficacy in a guinea pig model of L. pneumophila pneumonia and pharmacokinetics in guinea pigs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11679556/),[mg] / [l],0.7,150063,DB01137,Levofloxacin
,11679556,elimination half-life,"The elimination half-life in plasma was 0.5 h, and the AUC(0-24 )was 1.7 mg*h/L, about 2% of the AUC(0-24 )for a single 400 mg oral dose in man.","BMS-284756 (T-3811ME) a new fluoroquinolone: in vitro activity against Legionella, efficacy in a guinea pig model of L. pneumophila pneumonia and pharmacokinetics in guinea pigs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11679556/),h,0.5,150064,DB01137,Levofloxacin
,11679556,AUC(0-24 ),"The elimination half-life in plasma was 0.5 h, and the AUC(0-24 )was 1.7 mg*h/L, about 2% of the AUC(0-24 )for a single 400 mg oral dose in man.","BMS-284756 (T-3811ME) a new fluoroquinolone: in vitro activity against Legionella, efficacy in a guinea pig model of L. pneumophila pneumonia and pharmacokinetics in guinea pigs. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11679556/),[h·mg] / [l],1.7,150065,DB01137,Levofloxacin
,24217697,unbound AUC0-∞),"Unbound prostate tissue concentrations represented 78% of unbound plasma levels over a period of 12 h by comparing the extent of exposure (unbound AUC0-∞) of 6.4 and 4.8 h·μg/ml in plasma and tissue, respectively.",Population pharmacokinetic modeling of the unbound levofloxacin concentrations in rat plasma and prostate tissue measured by microdialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24217697/),[h·μg] / [ml],6.4,150810,DB01137,Levofloxacin
,24217697,unbound AUC0-∞),"Unbound prostate tissue concentrations represented 78% of unbound plasma levels over a period of 12 h by comparing the extent of exposure (unbound AUC0-∞) of 6.4 and 4.8 h·μg/ml in plasma and tissue, respectively.",Population pharmacokinetic modeling of the unbound levofloxacin concentrations in rat plasma and prostate tissue measured by microdialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24217697/),[h·μg] / [ml],4.8,150811,DB01137,Levofloxacin
,24217697,V1,"The following parameter values were estimated by the population model: V1 (0.38 liter; where V1 represents the volume of the central compartment), CL (0.22 liter/h), k12 (2.27 h(-1)), k21 (1.44 h(-1)), k13 (0.69 h(-1)), Vmax (7.19 μg/h), kM (0.35 μg/ml), V3/fuprostate (0.05 liter; where fuprostate represents the fraction unbound in the prostate), and k31 (3.67 h(-1)).",Population pharmacokinetic modeling of the unbound levofloxacin concentrations in rat plasma and prostate tissue measured by microdialysis. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24217697/),l,0.38,150812,DB01137,Levofloxacin
,24217697,CL,"The following parameter values were estimated by the population model: V1 (0.38 liter; where V1 represents the volume of the central compartment), CL (0.22 liter/h), k12 (2.27 h(-1)), k21 (1.44 h(-1)), k13 (0.69 h(-1)), Vmax (7.19 μg/h), kM (0.35 μg/ml), V3/fuprostate (0.05 liter; where fuprostate represents the fraction unbound in the prostate), and k31 (3.67 h(-1)).",Population pharmacokinetic modeling of the unbound levofloxacin concentrations in rat plasma and prostate tissue measured by microdialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24217697/),[l] / [h],0.22,150813,DB01137,Levofloxacin
,24217697,k12,"The following parameter values were estimated by the population model: V1 (0.38 liter; where V1 represents the volume of the central compartment), CL (0.22 liter/h), k12 (2.27 h(-1)), k21 (1.44 h(-1)), k13 (0.69 h(-1)), Vmax (7.19 μg/h), kM (0.35 μg/ml), V3/fuprostate (0.05 liter; where fuprostate represents the fraction unbound in the prostate), and k31 (3.67 h(-1)).",Population pharmacokinetic modeling of the unbound levofloxacin concentrations in rat plasma and prostate tissue measured by microdialysis. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24217697/),1/[h],2.27,150814,DB01137,Levofloxacin
,24217697,k21,"The following parameter values were estimated by the population model: V1 (0.38 liter; where V1 represents the volume of the central compartment), CL (0.22 liter/h), k12 (2.27 h(-1)), k21 (1.44 h(-1)), k13 (0.69 h(-1)), Vmax (7.19 μg/h), kM (0.35 μg/ml), V3/fuprostate (0.05 liter; where fuprostate represents the fraction unbound in the prostate), and k31 (3.67 h(-1)).",Population pharmacokinetic modeling of the unbound levofloxacin concentrations in rat plasma and prostate tissue measured by microdialysis. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24217697/),1/[h],1.44,150815,DB01137,Levofloxacin
,24217697,k13,"The following parameter values were estimated by the population model: V1 (0.38 liter; where V1 represents the volume of the central compartment), CL (0.22 liter/h), k12 (2.27 h(-1)), k21 (1.44 h(-1)), k13 (0.69 h(-1)), Vmax (7.19 μg/h), kM (0.35 μg/ml), V3/fuprostate (0.05 liter; where fuprostate represents the fraction unbound in the prostate), and k31 (3.67 h(-1)).",Population pharmacokinetic modeling of the unbound levofloxacin concentrations in rat plasma and prostate tissue measured by microdialysis. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24217697/),1/[h],0.69,150816,DB01137,Levofloxacin
,24217697,Vmax,"The following parameter values were estimated by the population model: V1 (0.38 liter; where V1 represents the volume of the central compartment), CL (0.22 liter/h), k12 (2.27 h(-1)), k21 (1.44 h(-1)), k13 (0.69 h(-1)), Vmax (7.19 μg/h), kM (0.35 μg/ml), V3/fuprostate (0.05 liter; where fuprostate represents the fraction unbound in the prostate), and k31 (3.67 h(-1)).",Population pharmacokinetic modeling of the unbound levofloxacin concentrations in rat plasma and prostate tissue measured by microdialysis. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24217697/),[μg] / [h],7.19,150817,DB01137,Levofloxacin
,24217697,kM,"The following parameter values were estimated by the population model: V1 (0.38 liter; where V1 represents the volume of the central compartment), CL (0.22 liter/h), k12 (2.27 h(-1)), k21 (1.44 h(-1)), k13 (0.69 h(-1)), Vmax (7.19 μg/h), kM (0.35 μg/ml), V3/fuprostate (0.05 liter; where fuprostate represents the fraction unbound in the prostate), and k31 (3.67 h(-1)).",Population pharmacokinetic modeling of the unbound levofloxacin concentrations in rat plasma and prostate tissue measured by microdialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24217697/),[μg] / [ml],0.35,150818,DB01137,Levofloxacin
,24217697,V3/fuprostate,"The following parameter values were estimated by the population model: V1 (0.38 liter; where V1 represents the volume of the central compartment), CL (0.22 liter/h), k12 (2.27 h(-1)), k21 (1.44 h(-1)), k13 (0.69 h(-1)), Vmax (7.19 μg/h), kM (0.35 μg/ml), V3/fuprostate (0.05 liter; where fuprostate represents the fraction unbound in the prostate), and k31 (3.67 h(-1)).",Population pharmacokinetic modeling of the unbound levofloxacin concentrations in rat plasma and prostate tissue measured by microdialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24217697/),l,0.05,150819,DB01137,Levofloxacin
,24217697,k31,"The following parameter values were estimated by the population model: V1 (0.38 liter; where V1 represents the volume of the central compartment), CL (0.22 liter/h), k12 (2.27 h(-1)), k21 (1.44 h(-1)), k13 (0.69 h(-1)), Vmax (7.19 μg/h), kM (0.35 μg/ml), V3/fuprostate (0.05 liter; where fuprostate represents the fraction unbound in the prostate), and k31 (3.67 h(-1)).",Population pharmacokinetic modeling of the unbound levofloxacin concentrations in rat plasma and prostate tissue measured by microdialysis. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24217697/),1/[h],3.67,150820,DB01137,Levofloxacin
,9257757,time to maximum plasma concentration,"Levofloxacin was rapidly absorbed (time to maximum plasma concentration, approximately 1.0 h) and extensively distributed in the body with an apparent volume of distribution of approximately 104 liters (approximately 1.34 liters/kg).",Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257757/),h,1.0,152520,DB01137,Levofloxacin
,9257757,apparent volume of distribution,"Levofloxacin was rapidly absorbed (time to maximum plasma concentration, approximately 1.0 h) and extensively distributed in the body with an apparent volume of distribution of approximately 104 liters (approximately 1.34 liters/kg).",Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257757/),l,104,152521,DB01137,Levofloxacin
,9257757,apparent volume of distribution,"Levofloxacin was rapidly absorbed (time to maximum plasma concentration, approximately 1.0 h) and extensively distributed in the body with an apparent volume of distribution of approximately 104 liters (approximately 1.34 liters/kg).",Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257757/),[l] / [kg],1.34,152522,DB01137,Levofloxacin
,9257757,steady-state peak plasma concentration,"Mean average steady-state peak plasma concentration, plasma levofloxacin concentration at the end of the dosing interval, AUC(0-8), terminal half-life, and total body clearance were 7.06 microg/ml, 3.62 microg/ml, 37.4 microg x h/ml, 7.2 h, and 9.4 liters/h (0.12 liters/h/kg), respectively.",Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257757/),[μg] / [ml],7.06,152523,DB01137,Levofloxacin
,9257757,total body clearance,"Mean average steady-state peak plasma concentration, plasma levofloxacin concentration at the end of the dosing interval, AUC(0-8), terminal half-life, and total body clearance were 7.06 microg/ml, 3.62 microg/ml, 37.4 microg x h/ml, 7.2 h, and 9.4 liters/h (0.12 liters/h/kg), respectively.",Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257757/),[l] / [h],9.4,152524,DB01137,Levofloxacin
,9257757,total body clearance,"Mean average steady-state peak plasma concentration, plasma levofloxacin concentration at the end of the dosing interval, AUC(0-8), terminal half-life, and total body clearance were 7.06 microg/ml, 3.62 microg/ml, 37.4 microg x h/ml, 7.2 h, and 9.4 liters/h (0.12 liters/h/kg), respectively.",Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257757/),[l] / [h·kg],0.12,152525,DB01137,Levofloxacin
,23609512,ƒAUC(0-24)/MIC,The mean ƒAUC(0-24)/MIC was 41.3 ± 18.8 in the patients with DCS and 585.4 ± 219 in patients with a CS isolate.,Decreased ciprofloxacin susceptibility in Salmonella Typhi and Paratyphi infections in ill-returned travellers: the impact on clinical outcome and future treatment options. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23609512/),,41.3,153420,DB01137,Levofloxacin
,23609512,ƒAUC(0-24)/MIC,The mean ƒAUC(0-24)/MIC was 41.3 ± 18.8 in the patients with DCS and 585.4 ± 219 in patients with a CS isolate.,Decreased ciprofloxacin susceptibility in Salmonella Typhi and Paratyphi infections in ill-returned travellers: the impact on clinical outcome and future treatment options. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23609512/),,585.4,153421,DB01137,Levofloxacin
,23609512,ƒAUC0-24/MIC,"For DCS isolates, the mean ƒAUC0-24/MIC for levofloxacin was 60.5 ± 28.7 and for gatifloxacin, it was 97.9 ± 28.0.",Decreased ciprofloxacin susceptibility in Salmonella Typhi and Paratyphi infections in ill-returned travellers: the impact on clinical outcome and future treatment options. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23609512/),,60.5,153422,DB01137,Levofloxacin
,23609512,ƒAUC0-24/MIC,"For DCS isolates, the mean ƒAUC0-24/MIC for levofloxacin was 60.5 ± 28.7 and for gatifloxacin, it was 97.9 ± 28.0.",Decreased ciprofloxacin susceptibility in Salmonella Typhi and Paratyphi infections in ill-returned travellers: the impact on clinical outcome and future treatment options. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23609512/),,97.9,153423,DB01137,Levofloxacin
,28089362,maximum concentrations (Cmax),"For LVFX, the simulated curves estimated the following: maximum concentrations (Cmax) of 8.84 μg/ml in serum and 14.1 μg/g in epididymal tissue and area under the concentration-time curve for 24 h (AUC24) of 68.5 μg h/ml in serum and 108.9 μg h/g in epididymal tissue.",Clinical pharmacokinetics of oral levofloxacin and sitafloxacin in epididymal tissue. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28089362/),[μg] / [ml],8.84,155374,DB01137,Levofloxacin
,28089362,maximum concentrations (Cmax),"For LVFX, the simulated curves estimated the following: maximum concentrations (Cmax) of 8.84 μg/ml in serum and 14.1 μg/g in epididymal tissue and area under the concentration-time curve for 24 h (AUC24) of 68.5 μg h/ml in serum and 108.9 μg h/g in epididymal tissue.",Clinical pharmacokinetics of oral levofloxacin and sitafloxacin in epididymal tissue. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28089362/),[μg] / [g],14.1,155375,DB01137,Levofloxacin
,28089362,area under the concentration-time curve for 24 h (AUC24),"For LVFX, the simulated curves estimated the following: maximum concentrations (Cmax) of 8.84 μg/ml in serum and 14.1 μg/g in epididymal tissue and area under the concentration-time curve for 24 h (AUC24) of 68.5 μg h/ml in serum and 108.9 μg h/g in epididymal tissue.",Clinical pharmacokinetics of oral levofloxacin and sitafloxacin in epididymal tissue. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28089362/),[h·μg] / [ml],68.5,155376,DB01137,Levofloxacin
,28089362,area under the concentration-time curve for 24 h (AUC24),"For LVFX, the simulated curves estimated the following: maximum concentrations (Cmax) of 8.84 μg/ml in serum and 14.1 μg/g in epididymal tissue and area under the concentration-time curve for 24 h (AUC24) of 68.5 μg h/ml in serum and 108.9 μg h/g in epididymal tissue.",Clinical pharmacokinetics of oral levofloxacin and sitafloxacin in epididymal tissue. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28089362/),[h·μg] / [g],108.9,155377,DB01137,Levofloxacin
,28089362,Cmax,"For STFX, the Cmax was 1.22 μg/ml in serum and 1.66 μg/g in epididymal tissue, and the AUC24 was 9.58 μg h/ml in serum and 13.1 μg h/g in epididymal tissue.",Clinical pharmacokinetics of oral levofloxacin and sitafloxacin in epididymal tissue. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28089362/),[μg] / [ml],1.22,155378,DB01137,Levofloxacin
,28089362,Cmax,"For STFX, the Cmax was 1.22 μg/ml in serum and 1.66 μg/g in epididymal tissue, and the AUC24 was 9.58 μg h/ml in serum and 13.1 μg h/g in epididymal tissue.",Clinical pharmacokinetics of oral levofloxacin and sitafloxacin in epididymal tissue. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28089362/),[μg] / [g],1.66,155379,DB01137,Levofloxacin
,28089362,AUC24,"For STFX, the Cmax was 1.22 μg/ml in serum and 1.66 μg/g in epididymal tissue, and the AUC24 was 9.58 μg h/ml in serum and 13.1 μg h/g in epididymal tissue.",Clinical pharmacokinetics of oral levofloxacin and sitafloxacin in epididymal tissue. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28089362/),[h·μg] / [ml],9.58,155380,DB01137,Levofloxacin
,28089362,AUC24,"For STFX, the Cmax was 1.22 μg/ml in serum and 1.66 μg/g in epididymal tissue, and the AUC24 was 9.58 μg h/ml in serum and 13.1 μg h/g in epididymal tissue.",Clinical pharmacokinetics of oral levofloxacin and sitafloxacin in epididymal tissue. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28089362/),[h·μg] / [g],13.1,155381,DB01137,Levofloxacin
,25218157,AUCprostate,"Moxifloxacin showed a significant tissue distribution in the prostate (AUCprostate,ISF/fu·AUCplasma=1.24±0.37), 59% higher than the value obtained for levofloxacin in a previous study.",Enhanced penetration of moxifloxacin into rat prostate tissue evidenced by microdialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25218157/),,1.24,156262,DB01137,Levofloxacin
> or,11764770,bioavailability,"Recent analysis of the pharmacokinetic and pharmacodynamic properties of the new fluoroquinolones (gatifloxacin, gemifloxacin, levofloxacin and moxifloxacin) have shown high bioavailability (> or = 70%) and long serum half-lives (> or = 7 h), allowing for once-daily dosing.",Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11764770/),%,70,156773,DB01137,Levofloxacin
> or =,11764770,serum half-lives,"Recent analysis of the pharmacokinetic and pharmacodynamic properties of the new fluoroquinolones (gatifloxacin, gemifloxacin, levofloxacin and moxifloxacin) have shown high bioavailability (> or = 70%) and long serum half-lives (> or = 7 h), allowing for once-daily dosing.",Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11764770/),h,7,156774,DB01137,Levofloxacin
,10590278,MIC(90)s,"The MIC(90)s of levofloxacin and ciprofloxacin for 20 independent isolates of such bacteria were 1 and 8 mg/L, respectively.",Efficacy of levofloxacin in the treatment of experimental endocarditis caused by viridans group streptococci. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10590278/),[mg] / [l],1,158593,DB01137,Levofloxacin
,10590278,MIC(90)s,"The MIC(90)s of levofloxacin and ciprofloxacin for 20 independent isolates of such bacteria were 1 and 8 mg/L, respectively.",Efficacy of levofloxacin in the treatment of experimental endocarditis caused by viridans group streptococci. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10590278/),[mg] / [l],8,158594,DB01137,Levofloxacin
<,10590278,MIC,Rats were infected with two types of organism: either fully susceptible to levofloxacin MIC < or = 0.5 mg/L) or borderline susceptible (MIC 1-2 mg/L).,Efficacy of levofloxacin in the treatment of experimental endocarditis caused by viridans group streptococci. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10590278/),[mg] / [l],0.5,158595,DB01137,Levofloxacin
,10590278,MIC,Rats were infected with two types of organism: either fully susceptible to levofloxacin MIC < or = 0.5 mg/L) or borderline susceptible (MIC 1-2 mg/L).,Efficacy of levofloxacin in the treatment of experimental endocarditis caused by viridans group streptococci. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10590278/),[mg] / [l],1-2,158596,DB01137,Levofloxacin
,10590278,MIC,"Fully levofloxacin-susceptible bacteria comprised one penicillin-susceptible (MIC 0.004 mg/L) Streptococcus gordonii, and one penicillin-tolerant as well as one intermediate penicillin-resistant (MIC 0.125 mg/L) isogenic strains.",Efficacy of levofloxacin in the treatment of experimental endocarditis caused by viridans group streptococci. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10590278/),[mg] / [l],0.004,158597,DB01137,Levofloxacin
,10590278,MIC,"Fully levofloxacin-susceptible bacteria comprised one penicillin-susceptible (MIC 0.004 mg/L) Streptococcus gordonii, and one penicillin-tolerant as well as one intermediate penicillin-resistant (MIC 0.125 mg/L) isogenic strains.",Efficacy of levofloxacin in the treatment of experimental endocarditis caused by viridans group streptococci. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10590278/),[mg] / [l],0.125,158598,DB01137,Levofloxacin
,10590278,MIC,Borderline levofloxacin-susceptible bacteria comprised one penicillin-susceptible Streptococcus sanguis and one highly penicillin-resistant Streptococcus mitis (MIC 2 mg/L).,Efficacy of levofloxacin in the treatment of experimental endocarditis caused by viridans group streptococci. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10590278/),[mg] / [l],2,158599,DB01137,Levofloxacin
,20545503,relative bioavailability,"Unsuccessful in vivo-in vitro correlation was shown in Eudragit® NE30D-coated pellets with a relative bioavailability of only 41.5%, whereas Surelease-coated pellets achieved best sustained-release feature both in vitro and in vivo with a relative bioavailability of 103.0%.",In vitro and in vivo evaluation of levofloxacin sustained-release capsules. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20545503/),%,41.5,159238,DB01137,Levofloxacin
,20545503,relative bioavailability,"Unsuccessful in vivo-in vitro correlation was shown in Eudragit® NE30D-coated pellets with a relative bioavailability of only 41.5%, whereas Surelease-coated pellets achieved best sustained-release feature both in vitro and in vivo with a relative bioavailability of 103.0%.",In vitro and in vivo evaluation of levofloxacin sustained-release capsules. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20545503/),%,103.0,159239,DB01137,Levofloxacin
> or =,15116294,area under the curve: minimum inhibitory concentration ratio,Multivariate logistic regression analysis (n=47 patients) demonstrated that only the age of the patient and the achievement of an area under the curve: minimum inhibitory concentration ratio of > or =87 had a significant effect on eradication of the pathogen (P<.001).,"Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15116294/),,87,159640,DB01137,Levofloxacin
over,14755314,Minimal inhibitory concentration,"Minimal inhibitory concentration values for viridans group (VG) streptococci tended to increase, in four patients over 8 mg/l, indicating resistance to levofloxacin.",Pharmacokinetics and effects on bowel and throat microflora of oral levofloxacin as antibacterial prophylaxis in neutropenic patients with haematological malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14755314/),[mg] / [l],8,161249,DB01137,Levofloxacin
,25726443,volume of central compartment,"Mean±S.D. model parameters for plasma in infected patients were similar to uninfected patients (volume of central compartment, 68.4±36.3 vs. 50.2±17.3L; clearance, 6.0±2.5 vs. 6.8±3.3L/h; and absorption rate, 5.4±2.5 vs. 4.7±2.7h(-1)), resulting in similar simulated AUC in plasma (infected, 140.5±54.8 vs. uninfected, 133.7±61.6μgh/mL).",Presence of infection influences the epithelial lining fluid penetration of oral levofloxacin in adult patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25726443/),l,68.4,162054,DB01137,Levofloxacin
,25726443,volume of central compartment,"Mean±S.D. model parameters for plasma in infected patients were similar to uninfected patients (volume of central compartment, 68.4±36.3 vs. 50.2±17.3L; clearance, 6.0±2.5 vs. 6.8±3.3L/h; and absorption rate, 5.4±2.5 vs. 4.7±2.7h(-1)), resulting in similar simulated AUC in plasma (infected, 140.5±54.8 vs. uninfected, 133.7±61.6μgh/mL).",Presence of infection influences the epithelial lining fluid penetration of oral levofloxacin in adult patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25726443/),l,50.2,162055,DB01137,Levofloxacin
,25726443,clearance,"Mean±S.D. model parameters for plasma in infected patients were similar to uninfected patients (volume of central compartment, 68.4±36.3 vs. 50.2±17.3L; clearance, 6.0±2.5 vs. 6.8±3.3L/h; and absorption rate, 5.4±2.5 vs. 4.7±2.7h(-1)), resulting in similar simulated AUC in plasma (infected, 140.5±54.8 vs. uninfected, 133.7±61.6μgh/mL).",Presence of infection influences the epithelial lining fluid penetration of oral levofloxacin in adult patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25726443/),[l] / [h],6.0,162056,DB01137,Levofloxacin
,25726443,clearance,"Mean±S.D. model parameters for plasma in infected patients were similar to uninfected patients (volume of central compartment, 68.4±36.3 vs. 50.2±17.3L; clearance, 6.0±2.5 vs. 6.8±3.3L/h; and absorption rate, 5.4±2.5 vs. 4.7±2.7h(-1)), resulting in similar simulated AUC in plasma (infected, 140.5±54.8 vs. uninfected, 133.7±61.6μgh/mL).",Presence of infection influences the epithelial lining fluid penetration of oral levofloxacin in adult patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25726443/),[l] / [h],6.8,162057,DB01137,Levofloxacin
,25726443,absorption rate,"Mean±S.D. model parameters for plasma in infected patients were similar to uninfected patients (volume of central compartment, 68.4±36.3 vs. 50.2±17.3L; clearance, 6.0±2.5 vs. 6.8±3.3L/h; and absorption rate, 5.4±2.5 vs. 4.7±2.7h(-1)), resulting in similar simulated AUC in plasma (infected, 140.5±54.8 vs. uninfected, 133.7±61.6μgh/mL).",Presence of infection influences the epithelial lining fluid penetration of oral levofloxacin in adult patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25726443/),1/[h],5.4,162058,DB01137,Levofloxacin
,25726443,absorption rate,"Mean±S.D. model parameters for plasma in infected patients were similar to uninfected patients (volume of central compartment, 68.4±36.3 vs. 50.2±17.3L; clearance, 6.0±2.5 vs. 6.8±3.3L/h; and absorption rate, 5.4±2.5 vs. 4.7±2.7h(-1)), resulting in similar simulated AUC in plasma (infected, 140.5±54.8 vs. uninfected, 133.7±61.6μgh/mL).",Presence of infection influences the epithelial lining fluid penetration of oral levofloxacin in adult patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25726443/),1/[h],4.7,162059,DB01137,Levofloxacin
,25726443,AUC,"Mean±S.D. model parameters for plasma in infected patients were similar to uninfected patients (volume of central compartment, 68.4±36.3 vs. 50.2±17.3L; clearance, 6.0±2.5 vs. 6.8±3.3L/h; and absorption rate, 5.4±2.5 vs. 4.7±2.7h(-1)), resulting in similar simulated AUC in plasma (infected, 140.5±54.8 vs. uninfected, 133.7±61.6μgh/mL).",Presence of infection influences the epithelial lining fluid penetration of oral levofloxacin in adult patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25726443/),[μgh] / [ml],140.5,162060,DB01137,Levofloxacin
,25726443,AUC,"Mean±S.D. model parameters for plasma in infected patients were similar to uninfected patients (volume of central compartment, 68.4±36.3 vs. 50.2±17.3L; clearance, 6.0±2.5 vs. 6.8±3.3L/h; and absorption rate, 5.4±2.5 vs. 4.7±2.7h(-1)), resulting in similar simulated AUC in plasma (infected, 140.5±54.8 vs. uninfected, 133.7±61.6μgh/mL).",Presence of infection influences the epithelial lining fluid penetration of oral levofloxacin in adult patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25726443/),[μgh] / [ml],133.7,162061,DB01137,Levofloxacin
,25726443,volume,"The volume of ELF was 57.2±25.0 and 14.8±9.0L in infected and uninfected patients, respectively, resulting in a lower simulated AUCELF exposure for infected patients (189.1±210.5 vs. 461.0±558.7μgh/mL).",Presence of infection influences the epithelial lining fluid penetration of oral levofloxacin in adult patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25726443/),l,57.2,162062,DB01137,Levofloxacin
,25726443,volume,"The volume of ELF was 57.2±25.0 and 14.8±9.0L in infected and uninfected patients, respectively, resulting in a lower simulated AUCELF exposure for infected patients (189.1±210.5 vs. 461.0±558.7μgh/mL).",Presence of infection influences the epithelial lining fluid penetration of oral levofloxacin in adult patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25726443/),l,14.8,162063,DB01137,Levofloxacin
,25726443,AUCELF exposure,"The volume of ELF was 57.2±25.0 and 14.8±9.0L in infected and uninfected patients, respectively, resulting in a lower simulated AUCELF exposure for infected patients (189.1±210.5 vs. 461.0±558.7μgh/mL).",Presence of infection influences the epithelial lining fluid penetration of oral levofloxacin in adult patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25726443/),[μgh] / [ml],189.1,162064,DB01137,Levofloxacin
,25726443,AUCELF exposure,"The volume of ELF was 57.2±25.0 and 14.8±9.0L in infected and uninfected patients, respectively, resulting in a lower simulated AUCELF exposure for infected patients (189.1±210.5 vs. 461.0±558.7μgh/mL).",Presence of infection influences the epithelial lining fluid penetration of oral levofloxacin in adult patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25726443/),[μgh] / [ml],461.0,162065,DB01137,Levofloxacin
,25726443,Penetration ratios,"Penetration ratios for infected and uninfected patients were, respectively, 1.4±1.8 and 3.5±3.7, with median values of 0.9 and 2.4.",Presence of infection influences the epithelial lining fluid penetration of oral levofloxacin in adult patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25726443/),,1.4,162066,DB01137,Levofloxacin
,25726443,Penetration ratios,"Penetration ratios for infected and uninfected patients were, respectively, 1.4±1.8 and 3.5±3.7, with median values of 0.9 and 2.4.",Presence of infection influences the epithelial lining fluid penetration of oral levofloxacin in adult patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25726443/),,3.5,162067,DB01137,Levofloxacin
,25726443,Penetration ratios,"Penetration ratios for infected and uninfected patients were, respectively, 1.4±1.8 and 3.5±3.7, with median values of 0.9 and 2.4.",Presence of infection influences the epithelial lining fluid penetration of oral levofloxacin in adult patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25726443/),,0.9,162068,DB01137,Levofloxacin
,25726443,Penetration ratios,"Penetration ratios for infected and uninfected patients were, respectively, 1.4±1.8 and 3.5±3.7, with median values of 0.9 and 2.4.",Presence of infection influences the epithelial lining fluid penetration of oral levofloxacin in adult patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25726443/),,2.4,162069,DB01137,Levofloxacin
,19856067,Q/F,Q/F (l/h) = 0.351.,Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19856067/),[l] / [h],0.,162309,DB01137,Levofloxacin
,19856067,V2/F (l),V2/F (l) = 6.81.,Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19856067/),,6.81,162310,DB01137,Levofloxacin
,19856067,C(max),"Based on the population PK model, mean C(max) and AUC(0-24h) in CALRTI patients were estimated as 5.13 microg/ml and 58.98 microg.h/ml, respectively.",Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19856067/),[μg] / [ml],5.13,162311,DB01137,Levofloxacin
,19856067,AUC(0-24h),"Based on the population PK model, mean C(max) and AUC(0-24h) in CALRTI patients were estimated as 5.13 microg/ml and 58.98 microg.h/ml, respectively.",Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19856067/),[h·μg] / [ml],58.98,162312,DB01137,Levofloxacin
,19856067,C(max)/MIC ratio,"In addition, the C(max)/MIC ratio reached 5 for Streptococcus pneumoniae, indicating that the emergence of LVFX-resistant S. pneumoniae could be prevented during the therapy with this dosage regimen.",Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19856067/),,5,162313,DB01137,Levofloxacin
,12389872,half-life,"Mean +/- SD levofloxacin half-life, clearance at steady state, and volume of distribution in all 28 patients were 8.0 +/- 1.7 hours, 134 +/- 35 ml/minute, and 1.2 +/- 0.3 L/kg, respectively Maximum and minimum serum concentrations (Cmax and Cmin) and area under the serum concentration-time curve from 0-24 hours (AUC(0-24)) in patients receiving levofloxacin 500 mg intravenously were 7.5 +/- 0.8 mg/L, 1.0 +/- 0.5 mg/L, and 66.1 +/- 15.7 mg x hour/L, respectively Observed Cmax, Cmin, and time at which maximum concentration was achieved after oral doses of levofloxacin 500 mg were 5.5 +/- 1.1 mg/L, 0.8 +/- 0.4 mg/L, and 1.3 +/- 0.4 hours, respectively.",Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12389872/),h,8.0,162941,DB01137,Levofloxacin
,12389872,clearance at steady state,"Mean +/- SD levofloxacin half-life, clearance at steady state, and volume of distribution in all 28 patients were 8.0 +/- 1.7 hours, 134 +/- 35 ml/minute, and 1.2 +/- 0.3 L/kg, respectively Maximum and minimum serum concentrations (Cmax and Cmin) and area under the serum concentration-time curve from 0-24 hours (AUC(0-24)) in patients receiving levofloxacin 500 mg intravenously were 7.5 +/- 0.8 mg/L, 1.0 +/- 0.5 mg/L, and 66.1 +/- 15.7 mg x hour/L, respectively Observed Cmax, Cmin, and time at which maximum concentration was achieved after oral doses of levofloxacin 500 mg were 5.5 +/- 1.1 mg/L, 0.8 +/- 0.4 mg/L, and 1.3 +/- 0.4 hours, respectively.",Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12389872/),[ml] / [min],134,162942,DB01137,Levofloxacin
,12389872,volume of distribution,"Mean +/- SD levofloxacin half-life, clearance at steady state, and volume of distribution in all 28 patients were 8.0 +/- 1.7 hours, 134 +/- 35 ml/minute, and 1.2 +/- 0.3 L/kg, respectively Maximum and minimum serum concentrations (Cmax and Cmin) and area under the serum concentration-time curve from 0-24 hours (AUC(0-24)) in patients receiving levofloxacin 500 mg intravenously were 7.5 +/- 0.8 mg/L, 1.0 +/- 0.5 mg/L, and 66.1 +/- 15.7 mg x hour/L, respectively Observed Cmax, Cmin, and time at which maximum concentration was achieved after oral doses of levofloxacin 500 mg were 5.5 +/- 1.1 mg/L, 0.8 +/- 0.4 mg/L, and 1.3 +/- 0.4 hours, respectively.",Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12389872/),[l] / [kg],1.2,162943,DB01137,Levofloxacin
,12389872,Maximum,"Mean +/- SD levofloxacin half-life, clearance at steady state, and volume of distribution in all 28 patients were 8.0 +/- 1.7 hours, 134 +/- 35 ml/minute, and 1.2 +/- 0.3 L/kg, respectively Maximum and minimum serum concentrations (Cmax and Cmin) and area under the serum concentration-time curve from 0-24 hours (AUC(0-24)) in patients receiving levofloxacin 500 mg intravenously were 7.5 +/- 0.8 mg/L, 1.0 +/- 0.5 mg/L, and 66.1 +/- 15.7 mg x hour/L, respectively Observed Cmax, Cmin, and time at which maximum concentration was achieved after oral doses of levofloxacin 500 mg were 5.5 +/- 1.1 mg/L, 0.8 +/- 0.4 mg/L, and 1.3 +/- 0.4 hours, respectively.",Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12389872/),[mg] / [l],7.5,162944,DB01137,Levofloxacin
,12389872,minimum serum concentrations (Cmax,"Mean +/- SD levofloxacin half-life, clearance at steady state, and volume of distribution in all 28 patients were 8.0 +/- 1.7 hours, 134 +/- 35 ml/minute, and 1.2 +/- 0.3 L/kg, respectively Maximum and minimum serum concentrations (Cmax and Cmin) and area under the serum concentration-time curve from 0-24 hours (AUC(0-24)) in patients receiving levofloxacin 500 mg intravenously were 7.5 +/- 0.8 mg/L, 1.0 +/- 0.5 mg/L, and 66.1 +/- 15.7 mg x hour/L, respectively Observed Cmax, Cmin, and time at which maximum concentration was achieved after oral doses of levofloxacin 500 mg were 5.5 +/- 1.1 mg/L, 0.8 +/- 0.4 mg/L, and 1.3 +/- 0.4 hours, respectively.",Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12389872/),[mg] / [l],7.5,162945,DB01137,Levofloxacin
,12389872,Cmin,"Mean +/- SD levofloxacin half-life, clearance at steady state, and volume of distribution in all 28 patients were 8.0 +/- 1.7 hours, 134 +/- 35 ml/minute, and 1.2 +/- 0.3 L/kg, respectively Maximum and minimum serum concentrations (Cmax and Cmin) and area under the serum concentration-time curve from 0-24 hours (AUC(0-24)) in patients receiving levofloxacin 500 mg intravenously were 7.5 +/- 0.8 mg/L, 1.0 +/- 0.5 mg/L, and 66.1 +/- 15.7 mg x hour/L, respectively Observed Cmax, Cmin, and time at which maximum concentration was achieved after oral doses of levofloxacin 500 mg were 5.5 +/- 1.1 mg/L, 0.8 +/- 0.4 mg/L, and 1.3 +/- 0.4 hours, respectively.",Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12389872/),[mg] / [l],7.5,162946,DB01137,Levofloxacin
,12389872,Cmin,"Mean +/- SD levofloxacin half-life, clearance at steady state, and volume of distribution in all 28 patients were 8.0 +/- 1.7 hours, 134 +/- 35 ml/minute, and 1.2 +/- 0.3 L/kg, respectively Maximum and minimum serum concentrations (Cmax and Cmin) and area under the serum concentration-time curve from 0-24 hours (AUC(0-24)) in patients receiving levofloxacin 500 mg intravenously were 7.5 +/- 0.8 mg/L, 1.0 +/- 0.5 mg/L, and 66.1 +/- 15.7 mg x hour/L, respectively Observed Cmax, Cmin, and time at which maximum concentration was achieved after oral doses of levofloxacin 500 mg were 5.5 +/- 1.1 mg/L, 0.8 +/- 0.4 mg/L, and 1.3 +/- 0.4 hours, respectively.",Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12389872/),[mg] / [l],1.0,162947,DB01137,Levofloxacin
,12389872,area under the serum concentration-time curve from 0-24 hours (AUC(0-24)),"Mean +/- SD levofloxacin half-life, clearance at steady state, and volume of distribution in all 28 patients were 8.0 +/- 1.7 hours, 134 +/- 35 ml/minute, and 1.2 +/- 0.3 L/kg, respectively Maximum and minimum serum concentrations (Cmax and Cmin) and area under the serum concentration-time curve from 0-24 hours (AUC(0-24)) in patients receiving levofloxacin 500 mg intravenously were 7.5 +/- 0.8 mg/L, 1.0 +/- 0.5 mg/L, and 66.1 +/- 15.7 mg x hour/L, respectively Observed Cmax, Cmin, and time at which maximum concentration was achieved after oral doses of levofloxacin 500 mg were 5.5 +/- 1.1 mg/L, 0.8 +/- 0.4 mg/L, and 1.3 +/- 0.4 hours, respectively.",Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12389872/),[h·mg] / [l],66.1,162948,DB01137,Levofloxacin
,12389872,Cmax,"Mean +/- SD levofloxacin half-life, clearance at steady state, and volume of distribution in all 28 patients were 8.0 +/- 1.7 hours, 134 +/- 35 ml/minute, and 1.2 +/- 0.3 L/kg, respectively Maximum and minimum serum concentrations (Cmax and Cmin) and area under the serum concentration-time curve from 0-24 hours (AUC(0-24)) in patients receiving levofloxacin 500 mg intravenously were 7.5 +/- 0.8 mg/L, 1.0 +/- 0.5 mg/L, and 66.1 +/- 15.7 mg x hour/L, respectively Observed Cmax, Cmin, and time at which maximum concentration was achieved after oral doses of levofloxacin 500 mg were 5.5 +/- 1.1 mg/L, 0.8 +/- 0.4 mg/L, and 1.3 +/- 0.4 hours, respectively.",Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12389872/),[mg] / [l],5.5,162949,DB01137,Levofloxacin
,12389872,Cmin,"Mean +/- SD levofloxacin half-life, clearance at steady state, and volume of distribution in all 28 patients were 8.0 +/- 1.7 hours, 134 +/- 35 ml/minute, and 1.2 +/- 0.3 L/kg, respectively Maximum and minimum serum concentrations (Cmax and Cmin) and area under the serum concentration-time curve from 0-24 hours (AUC(0-24)) in patients receiving levofloxacin 500 mg intravenously were 7.5 +/- 0.8 mg/L, 1.0 +/- 0.5 mg/L, and 66.1 +/- 15.7 mg x hour/L, respectively Observed Cmax, Cmin, and time at which maximum concentration was achieved after oral doses of levofloxacin 500 mg were 5.5 +/- 1.1 mg/L, 0.8 +/- 0.4 mg/L, and 1.3 +/- 0.4 hours, respectively.",Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12389872/),[mg] / [l],0.8,162950,DB01137,Levofloxacin
,12389872,time at which maximum concentration,"Mean +/- SD levofloxacin half-life, clearance at steady state, and volume of distribution in all 28 patients were 8.0 +/- 1.7 hours, 134 +/- 35 ml/minute, and 1.2 +/- 0.3 L/kg, respectively Maximum and minimum serum concentrations (Cmax and Cmin) and area under the serum concentration-time curve from 0-24 hours (AUC(0-24)) in patients receiving levofloxacin 500 mg intravenously were 7.5 +/- 0.8 mg/L, 1.0 +/- 0.5 mg/L, and 66.1 +/- 15.7 mg x hour/L, respectively Observed Cmax, Cmin, and time at which maximum concentration was achieved after oral doses of levofloxacin 500 mg were 5.5 +/- 1.1 mg/L, 0.8 +/- 0.4 mg/L, and 1.3 +/- 0.4 hours, respectively.",Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12389872/),[mg] / [l],0.8,162951,DB01137,Levofloxacin
,12389872,time at which maximum concentration,"Mean +/- SD levofloxacin half-life, clearance at steady state, and volume of distribution in all 28 patients were 8.0 +/- 1.7 hours, 134 +/- 35 ml/minute, and 1.2 +/- 0.3 L/kg, respectively Maximum and minimum serum concentrations (Cmax and Cmin) and area under the serum concentration-time curve from 0-24 hours (AUC(0-24)) in patients receiving levofloxacin 500 mg intravenously were 7.5 +/- 0.8 mg/L, 1.0 +/- 0.5 mg/L, and 66.1 +/- 15.7 mg x hour/L, respectively Observed Cmax, Cmin, and time at which maximum concentration was achieved after oral doses of levofloxacin 500 mg were 5.5 +/- 1.1 mg/L, 0.8 +/- 0.4 mg/L, and 1.3 +/- 0.4 hours, respectively.",Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12389872/),h,1.3,162952,DB01137,Levofloxacin
,17189094,AUC(0-infinity),"The median AUC(0-infinity) of free levofloxacin in lung (2267mg x min/L, 1980-2355) was about 2-fold and 1.5-fold lower compared with skeletal muscle (4381mg x min/L, range 1720-8195) and adipose tissue (3492mg x min/L, range 1323-6420) of healthy controls, respectively.",A pilot study testing whether concentrations of levofloxacin in interstitial space fluid of soft tissues may serve as a surrogate for predicting its pharmacokinetics in lung. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17189094/),[mg·min] / [l],2267,163308,DB01137,Levofloxacin
,17189094,AUC(0-infinity),"The median AUC(0-infinity) of free levofloxacin in lung (2267mg x min/L, 1980-2355) was about 2-fold and 1.5-fold lower compared with skeletal muscle (4381mg x min/L, range 1720-8195) and adipose tissue (3492mg x min/L, range 1323-6420) of healthy controls, respectively.",A pilot study testing whether concentrations of levofloxacin in interstitial space fluid of soft tissues may serve as a surrogate for predicting its pharmacokinetics in lung. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17189094/),[mg·min] / [l],4381,163309,DB01137,Levofloxacin
,17189094,AUC(0-infinity),"The median AUC(0-infinity) of free levofloxacin in lung (2267mg x min/L, 1980-2355) was about 2-fold and 1.5-fold lower compared with skeletal muscle (4381mg x min/L, range 1720-8195) and adipose tissue (3492mg x min/L, range 1323-6420) of healthy controls, respectively.",A pilot study testing whether concentrations of levofloxacin in interstitial space fluid of soft tissues may serve as a surrogate for predicting its pharmacokinetics in lung. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17189094/),[mg·min] / [l],3492,163310,DB01137,Levofloxacin
,17334064,target attainment rates ofAUC/MIC,"For S. pneumoniae, target attainment rates ofAUC/MIC; 30 were 47.18%, 75.54%, 89.16%, 93.63% and 98.63% for LVFX 100mgx3, LVFX 200mgx2, LVFX 500mgxl, TFLX 150mgx3 and TFLX 300mgx2, respectively.",[Evaluation of efficacy of oral quinolone against Streptococcus pneumoniae AND Haemophilus influenzae with the use of Monte Carlo simulation]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17334064/),%,47.18,163829,DB01137,Levofloxacin
,17334064,target attainment rates ofAUC/MIC,"For S. pneumoniae, target attainment rates ofAUC/MIC; 30 were 47.18%, 75.54%, 89.16%, 93.63% and 98.63% for LVFX 100mgx3, LVFX 200mgx2, LVFX 500mgxl, TFLX 150mgx3 and TFLX 300mgx2, respectively.",[Evaluation of efficacy of oral quinolone against Streptococcus pneumoniae AND Haemophilus influenzae with the use of Monte Carlo simulation]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17334064/),%,75.54,163830,DB01137,Levofloxacin
,17334064,target attainment rates ofAUC/MIC,"For S. pneumoniae, target attainment rates ofAUC/MIC; 30 were 47.18%, 75.54%, 89.16%, 93.63% and 98.63% for LVFX 100mgx3, LVFX 200mgx2, LVFX 500mgxl, TFLX 150mgx3 and TFLX 300mgx2, respectively.",[Evaluation of efficacy of oral quinolone against Streptococcus pneumoniae AND Haemophilus influenzae with the use of Monte Carlo simulation]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17334064/),%,89.16,163831,DB01137,Levofloxacin
,17334064,target attainment rates ofAUC/MIC,"For S. pneumoniae, target attainment rates ofAUC/MIC; 30 were 47.18%, 75.54%, 89.16%, 93.63% and 98.63% for LVFX 100mgx3, LVFX 200mgx2, LVFX 500mgxl, TFLX 150mgx3 and TFLX 300mgx2, respectively.",[Evaluation of efficacy of oral quinolone against Streptococcus pneumoniae AND Haemophilus influenzae with the use of Monte Carlo simulation]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17334064/),%,93.63,163832,DB01137,Levofloxacin
,17334064,target attainment rates ofAUC/MIC,"For S. pneumoniae, target attainment rates ofAUC/MIC; 30 were 47.18%, 75.54%, 89.16%, 93.63% and 98.63% for LVFX 100mgx3, LVFX 200mgx2, LVFX 500mgxl, TFLX 150mgx3 and TFLX 300mgx2, respectively.",[Evaluation of efficacy of oral quinolone against Streptococcus pneumoniae AND Haemophilus influenzae with the use of Monte Carlo simulation]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17334064/),%,98.63,163833,DB01137,Levofloxacin
,17334064,target attainment rates of AUC/MIC; 125,"For H. influenzae, target attainment rates of AUC/MIC; 125 were 99.20%, 99.05%, 99.54%, 99.66% and 100% for LVFX 100mgx3, LVFX 200mgx2, LVFX 500mgxl, TFLX 150mgx3 and TFLX 300mgx2, respectively.",[Evaluation of efficacy of oral quinolone against Streptococcus pneumoniae AND Haemophilus influenzae with the use of Monte Carlo simulation]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17334064/),%,99.20,163834,DB01137,Levofloxacin
,17334064,target attainment rates of AUC/MIC; 125,"For H. influenzae, target attainment rates of AUC/MIC; 125 were 99.20%, 99.05%, 99.54%, 99.66% and 100% for LVFX 100mgx3, LVFX 200mgx2, LVFX 500mgxl, TFLX 150mgx3 and TFLX 300mgx2, respectively.",[Evaluation of efficacy of oral quinolone against Streptococcus pneumoniae AND Haemophilus influenzae with the use of Monte Carlo simulation]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17334064/),%,99.05,163835,DB01137,Levofloxacin
,17334064,target attainment rates of AUC/MIC; 125,"For H. influenzae, target attainment rates of AUC/MIC; 125 were 99.20%, 99.05%, 99.54%, 99.66% and 100% for LVFX 100mgx3, LVFX 200mgx2, LVFX 500mgxl, TFLX 150mgx3 and TFLX 300mgx2, respectively.",[Evaluation of efficacy of oral quinolone against Streptococcus pneumoniae AND Haemophilus influenzae with the use of Monte Carlo simulation]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17334064/),%,99.54,163836,DB01137,Levofloxacin
,17334064,target attainment rates of AUC/MIC; 125,"For H. influenzae, target attainment rates of AUC/MIC; 125 were 99.20%, 99.05%, 99.54%, 99.66% and 100% for LVFX 100mgx3, LVFX 200mgx2, LVFX 500mgxl, TFLX 150mgx3 and TFLX 300mgx2, respectively.",[Evaluation of efficacy of oral quinolone against Streptococcus pneumoniae AND Haemophilus influenzae with the use of Monte Carlo simulation]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17334064/),%,99.66,163837,DB01137,Levofloxacin
,17334064,target attainment rates of AUC/MIC; 125,"For H. influenzae, target attainment rates of AUC/MIC; 125 were 99.20%, 99.05%, 99.54%, 99.66% and 100% for LVFX 100mgx3, LVFX 200mgx2, LVFX 500mgxl, TFLX 150mgx3 and TFLX 300mgx2, respectively.",[Evaluation of efficacy of oral quinolone against Streptococcus pneumoniae AND Haemophilus influenzae with the use of Monte Carlo simulation]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17334064/),%,100,163838,DB01137,Levofloxacin
,24061442,flow rate,"After protein precipitation with acetonitrile:methanol (1:1, vol/vol), satisfactory separation was achieved on a Hypersil BDS C18 column (250 × 4.6 mm, 5 μm) using a mobile phase comprising 20 mM sodium dihydrogen phosphate-2 hydrate (pH = 3.2) and acetonitrile at a ratio of 75:25, vol/vol; the elution was isocratic at ambient temperature with a flow rate of 1.5 mL/min.","Simultaneous quantification of linezolid, tinidazole, norfloxacin, moxifloxacin, levofloxacin, and gatifloxacin in human plasma for therapeutic drug monitoring and pharmacokinetic studies in human volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24061442/),[ml] / [min],1.5,165179,DB01137,Levofloxacin
,18240275,CL/F,Antofloxacin hydrochloride demonstrated linear pharmacokinetic characteristics with mean pharmacokinetic values varying from 0.09 to 0.10 l/h/kg for CL/F and from 2.75-3.00 l/kg for V/F.,"Pharmacokinetics of antofloxacin hydrochloride, a new fluoroquinolone antibiotic, after single oral dose administration in Chinese healthy male volunteers. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18240275/),[l] / [h·kg],0.09 to 0.10,165869,DB01137,Levofloxacin
,18240275,V/F,Antofloxacin hydrochloride demonstrated linear pharmacokinetic characteristics with mean pharmacokinetic values varying from 0.09 to 0.10 l/h/kg for CL/F and from 2.75-3.00 l/kg for V/F.,"Pharmacokinetics of antofloxacin hydrochloride, a new fluoroquinolone antibiotic, after single oral dose administration in Chinese healthy male volunteers. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18240275/),[l] / [kg],2.75-3.00,165870,DB01137,Levofloxacin
,18240275,t(1/2beta),The t(1/2beta) was around 20 h and the mean fraction of dose excreted in urine varied from 0.40 to 0.46.,"Pharmacokinetics of antofloxacin hydrochloride, a new fluoroquinolone antibiotic, after single oral dose administration in Chinese healthy male volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18240275/),h,20,165871,DB01137,Levofloxacin
,18240275,fraction of dose excreted in urine,The t(1/2beta) was around 20 h and the mean fraction of dose excreted in urine varied from 0.40 to 0.46.,"Pharmacokinetics of antofloxacin hydrochloride, a new fluoroquinolone antibiotic, after single oral dose administration in Chinese healthy male volunteers. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18240275/),,0.40 to 0.46,165872,DB01137,Levofloxacin
,29133560,CL,"CL in a typical child (weight, 12 kg; age, 2 years) was 4.7 liters/h.",Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant Tuberculosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29133560/),[l] / [h],4.7,169298,DB01137,Levofloxacin
≥,22088660,ratios of area under the plasma concentration-time curve over 24h to minimum inhibitory concentration (AUC(0-24)/MIC),"Garenoxacin showed excellent bactericidal activity against S. pneumoniae, including quinolone-resistant S. pneumoniae (QRSP), achieving ratios of area under the plasma concentration-time curve over 24h to minimum inhibitory concentration (AUC(0-24)/MIC) ≥ 26.3, without emerging resistant subpopulations.",In vitro pharmacodynamic evaluation of garenoxacin against quinolone-resistant Streptococcus pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22088660/),,26.3,171426,DB01137,Levofloxacin
,19188391,urinary excretion,Doripenem and levofloxacin show comparable urinary excretion of approximately 80% and are therefore registered for the treatment of UTIs.,Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19188391/),%,80,172020,DB01137,Levofloxacin
,19188391,UBTs (AUBTs),"Median UBTs (AUBTs) of doripenem for the uropathogens tested ranged between 1.5 and 65,536 (224 and 909,312) and were significantly higher than median UBTs (AUBTs) of levofloxacin, ranging between 0 and 128 (0 and 2,208).",Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19188391/),,"1.5 and 65,536",172021,DB01137,Levofloxacin
,19188391,UBTs (AUBTs),"Median UBTs (AUBTs) of doripenem for the uropathogens tested ranged between 1.5 and 65,536 (224 and 909,312) and were significantly higher than median UBTs (AUBTs) of levofloxacin, ranging between 0 and 128 (0 and 2,208).",Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19188391/),,224,172022,DB01137,Levofloxacin
,19188391,UBTs (AUBTs),"Median UBTs (AUBTs) of doripenem for the uropathogens tested ranged between 1.5 and 65,536 (224 and 909,312) and were significantly higher than median UBTs (AUBTs) of levofloxacin, ranging between 0 and 128 (0 and 2,208).",Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19188391/),,90,172023,DB01137,Levofloxacin
,19188391,UBTs (AUBTs),"Median UBTs (AUBTs) of doripenem for the uropathogens tested ranged between 1.5 and 65,536 (224 and 909,312) and were significantly higher than median UBTs (AUBTs) of levofloxacin, ranging between 0 and 128 (0 and 2,208).",Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19188391/),,0 and 128,172024,DB01137,Levofloxacin
,19188391,UBTs (AUBTs),"Median UBTs (AUBTs) of doripenem for the uropathogens tested ranged between 1.5 and 65,536 (224 and 909,312) and were significantly higher than median UBTs (AUBTs) of levofloxacin, ranging between 0 and 128 (0 and 2,208).",Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19188391/),,"0 and 2,208",172025,DB01137,Levofloxacin
,19188391,UBTs,"From this study, a calculated target attainment rate for levofloxacin predicting therapeutic success in patients with UTIs approximated mean UBTs of 100 over 24 h or AUBTs of 2,240.",Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19188391/),24·h·over,100,172026,DB01137,Levofloxacin
,19188391,AUBTs,"From this study, a calculated target attainment rate for levofloxacin predicting therapeutic success in patients with UTIs approximated mean UBTs of 100 over 24 h or AUBTs of 2,240.",Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19188391/),,"2,240",172027,DB01137,Levofloxacin
,14693523,peak,"To simulate the kinetics of drugs in humans, rats were infused intravenously with garenoxacin every 24 h (peak and trough levels in serum, 6.1 and 1.0 mg/liter, respectively; area under the concentration-time curve [AUC], 63.4 mg.",Efficacy of garenoxacin in treatment of experimental endocarditis due to Staphylococcus aureus or viridans group streptococci. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14693523/),[mg] / [l],6.1,172211,DB01137,Levofloxacin
,14693523,trough levels,"To simulate the kinetics of drugs in humans, rats were infused intravenously with garenoxacin every 24 h (peak and trough levels in serum, 6.1 and 1.0 mg/liter, respectively; area under the concentration-time curve [AUC], 63.4 mg.",Efficacy of garenoxacin in treatment of experimental endocarditis due to Staphylococcus aureus or viridans group streptococci. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14693523/),[mg] / [l],6.1,172212,DB01137,Levofloxacin
,14693523,trough levels,"To simulate the kinetics of drugs in humans, rats were infused intravenously with garenoxacin every 24 h (peak and trough levels in serum, 6.1 and 1.0 mg/liter, respectively; area under the concentration-time curve [AUC], 63.4 mg.",Efficacy of garenoxacin in treatment of experimental endocarditis due to Staphylococcus aureus or viridans group streptococci. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14693523/),[mg] / [l],1.0,172213,DB01137,Levofloxacin
,14693523,area under the concentration-time curve [AUC],"To simulate the kinetics of drugs in humans, rats were infused intravenously with garenoxacin every 24 h (peak and trough levels in serum, 6.1 and 1.0 mg/liter, respectively; area under the concentration-time curve [AUC], 63.4 mg.",Efficacy of garenoxacin in treatment of experimental endocarditis due to Staphylococcus aureus or viridans group streptococci. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14693523/),mg,63.4,172214,DB01137,Levofloxacin
,14693523,peak,"h/liter) or levofloxacin every 12 h (peak and trough levels in serum, 7.3 and 1.5 mg/liter, respectively; AUC, 55.6 mg.",Efficacy of garenoxacin in treatment of experimental endocarditis due to Staphylococcus aureus or viridans group streptococci. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14693523/),[mg] / [l],7.3,172215,DB01137,Levofloxacin
,14693523,trough levels,"h/liter) or levofloxacin every 12 h (peak and trough levels in serum, 7.3 and 1.5 mg/liter, respectively; AUC, 55.6 mg.",Efficacy of garenoxacin in treatment of experimental endocarditis due to Staphylococcus aureus or viridans group streptococci. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14693523/),[mg] / [l],1.5,172216,DB01137,Levofloxacin
,14693523,AUC,"h/liter) or levofloxacin every 12 h (peak and trough levels in serum, 7.3 and 1.5 mg/liter, respectively; AUC, 55.6 mg.",Efficacy of garenoxacin in treatment of experimental endocarditis due to Staphylococcus aureus or viridans group streptococci. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14693523/),mg,55.6,172217,DB01137,Levofloxacin
,14693523,cure rate,"Garenoxacin and vancomycin also sterilized 70% of the vegetations infected with ciprofloxacin-resistant MRSA isolate P8-4, whereas treatment with levofloxacin failed against this organism (cure rate, 0%; P < 0.05 versus the results obtained with the comparator drugs).",Efficacy of garenoxacin in treatment of experimental endocarditis due to Staphylococcus aureus or viridans group streptococci. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14693523/),%,0,172218,DB01137,Levofloxacin
≥,33012583,AUC24h/MIC,Levofloxacin concentration-time profiles were calculated to determine the efficacy based on the probability of target attainment (PTA) of AUC24h/MIC ≥50 for Gram-positive and AUC24h/MIC ≥125 for Gram-negative infections.,Optimal levofloxacin dosing regimens in critically ill patients with acute kidney injury receiving continuous renal replacement therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33012583/),,50,172842,DB01137,Levofloxacin
≥,33012583,AUC24h/MIC,Levofloxacin concentration-time profiles were calculated to determine the efficacy based on the probability of target attainment (PTA) of AUC24h/MIC ≥50 for Gram-positive and AUC24h/MIC ≥125 for Gram-negative infections.,Optimal levofloxacin dosing regimens in critically ill patients with acute kidney injury receiving continuous renal replacement therapy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33012583/),,125,172843,DB01137,Levofloxacin
,33012583,MIC,"No conventional, FDA approved regimens achieved at least 90% of PTA for Gram-negative infection with Pseudomonas aeruginosa at MIC of 2 mg/L.",Optimal levofloxacin dosing regimens in critically ill patients with acute kidney injury receiving continuous renal replacement therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33012583/),[mg] / [l],2,172844,DB01137,Levofloxacin
,33012583,MIC,"For Gram-positive infections, a levofloxacin 750 mg q 24 h was sufficient to attain PTA target of ~90% at the MIC of 2 mg/L for Streptococcus pneumoniae.",Optimal levofloxacin dosing regimens in critically ill patients with acute kidney injury receiving continuous renal replacement therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33012583/),[mg] / [l],2,172845,DB01137,Levofloxacin
,16343856,cumulative renal excretion,"The median proportions of cumulative renal excretion of the administered dose of the parent drug up to 36 h were 43.1% for ciprofloxacin XR (range, 13.7-50.8%; mean +/- standard deviation (S.D.), 40.5 +/- 9.9%) and 79.8% for levofloxacin (range, 74.0-88.2%; mean +/- S.D., 80.4 +/- 5.5%).",Pharmacokinetics of ciprofloxacin XR (1000 mg) versus levofloxacin (500 mg) in plasma and urine of male and female healthy volunteers receiving a single oral dose. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16343856/),%,43.1,172916,DB01137,Levofloxacin
,16343856,cumulative renal excretion,"The median proportions of cumulative renal excretion of the administered dose of the parent drug up to 36 h were 43.1% for ciprofloxacin XR (range, 13.7-50.8%; mean +/- standard deviation (S.D.), 40.5 +/- 9.9%) and 79.8% for levofloxacin (range, 74.0-88.2%; mean +/- S.D., 80.4 +/- 5.5%).",Pharmacokinetics of ciprofloxacin XR (1000 mg) versus levofloxacin (500 mg) in plasma and urine of male and female healthy volunteers receiving a single oral dose. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16343856/),%,40.5,172917,DB01137,Levofloxacin
,16343856,cumulative renal excretion,"The median proportions of cumulative renal excretion of the administered dose of the parent drug up to 36 h were 43.1% for ciprofloxacin XR (range, 13.7-50.8%; mean +/- standard deviation (S.D.), 40.5 +/- 9.9%) and 79.8% for levofloxacin (range, 74.0-88.2%; mean +/- S.D., 80.4 +/- 5.5%).",Pharmacokinetics of ciprofloxacin XR (1000 mg) versus levofloxacin (500 mg) in plasma and urine of male and female healthy volunteers receiving a single oral dose. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16343856/),%,79.8,172918,DB01137,Levofloxacin
,16343856,cumulative renal excretion,"The median proportions of cumulative renal excretion of the administered dose of the parent drug up to 36 h were 43.1% for ciprofloxacin XR (range, 13.7-50.8%; mean +/- standard deviation (S.D.), 40.5 +/- 9.9%) and 79.8% for levofloxacin (range, 74.0-88.2%; mean +/- S.D., 80.4 +/- 5.5%).",Pharmacokinetics of ciprofloxacin XR (1000 mg) versus levofloxacin (500 mg) in plasma and urine of male and female healthy volunteers receiving a single oral dose. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16343856/),%,80.4,172919,DB01137,Levofloxacin
,23398423,distribution at steady state (Vd(ss)),"2. Following intravenous administration, the mean value of distribution at steady state (Vd(ss)), total body clearance (Cl(tot)) and mean residence time (MRT) of levofloxacin were 1·25 l/kg, 0·39 l/h/kg and 2·72 h, respectively.",Pharmacokinetics of levofloxacin in Japanese quails (Coturnix japonica) following intravenous and oral administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23398423/),[l] / [kg],1·25,173409,DB01137,Levofloxacin
,23398423,total body clearance (Cl(tot)),"2. Following intravenous administration, the mean value of distribution at steady state (Vd(ss)), total body clearance (Cl(tot)) and mean residence time (MRT) of levofloxacin were 1·25 l/kg, 0·39 l/h/kg and 2·72 h, respectively.",Pharmacokinetics of levofloxacin in Japanese quails (Coturnix japonica) following intravenous and oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23398423/),[l] / [h·kg],0·39,173410,DB01137,Levofloxacin
,23398423,mean residence time (MRT),"2. Following intravenous administration, the mean value of distribution at steady state (Vd(ss)), total body clearance (Cl(tot)) and mean residence time (MRT) of levofloxacin were 1·25 l/kg, 0·39 l/h/kg and 2·72 h, respectively.",Pharmacokinetics of levofloxacin in Japanese quails (Coturnix japonica) following intravenous and oral administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23398423/),h,2·72,173411,DB01137,Levofloxacin
,23398423,peak plasma concentration (C(max)),"3. Following oral administration of levofloxacin, the peak plasma concentration (C(max)) was 3·31 µg/ml and was achieved at a maximum time (T(max)) of 2 h.",Pharmacokinetics of levofloxacin in Japanese quails (Coturnix japonica) following intravenous and oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23398423/),[μg] / [ml],3·31,173412,DB01137,Levofloxacin
,23398423,maximum time (T(max)),"3. Following oral administration of levofloxacin, the peak plasma concentration (C(max)) was 3·31 µg/ml and was achieved at a maximum time (T(max)) of 2 h.",Pharmacokinetics of levofloxacin in Japanese quails (Coturnix japonica) following intravenous and oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23398423/),h,2,173413,DB01137,Levofloxacin
,23398423,Mean residence time (MRT),"Mean residence time (MRT), mean absorption time (MAT) and bioavailability were 4·26 h, 1·54 h and 69·01%, respectively.",Pharmacokinetics of levofloxacin in Japanese quails (Coturnix japonica) following intravenous and oral administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23398423/),h,4·26,173414,DB01137,Levofloxacin
,23398423,mean absorption time (MAT),"Mean residence time (MRT), mean absorption time (MAT) and bioavailability were 4·26 h, 1·54 h and 69·01%, respectively.",Pharmacokinetics of levofloxacin in Japanese quails (Coturnix japonica) following intravenous and oral administration. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23398423/),h,1·54,173415,DB01137,Levofloxacin
,23398423,bioavailability,"Mean residence time (MRT), mean absorption time (MAT) and bioavailability were 4·26 h, 1·54 h and 69·01%, respectively.",Pharmacokinetics of levofloxacin in Japanese quails (Coturnix japonica) following intravenous and oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23398423/),%,69·01,173416,DB01137,Levofloxacin
,23398423,plasma protein binding,In vitro plasma protein binding of levofloxacin was 23·52%.,Pharmacokinetics of levofloxacin in Japanese quails (Coturnix japonica) following intravenous and oral administration. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23398423/),%,23·52,173417,DB01137,Levofloxacin
,22404324,dose-normalized C(max),"For levofloxacin, the mean values for dose-normalized C(max) and AUC(last) with the two doses were as follows: therapeutic dose, 15.2 ± 4.6 ng/ml/mg and 103.6 ± 15.5 ng·h/ml/mg, respectively; low dose, 17.1 ± 6.5 ng/ml/mg and 72.6 ± 8.7 ng·h/ml/mg, respectively.",Assessment of pharmacokinetic proportionality of levofloxacin and cyclosporine over a 100-fold dose range in healthy human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22404324/),[ng] / [mg·ml],15.2,173962,DB01137,Levofloxacin
,22404324,dose-normalized C(max),"For levofloxacin, the mean values for dose-normalized C(max) and AUC(last) with the two doses were as follows: therapeutic dose, 15.2 ± 4.6 ng/ml/mg and 103.6 ± 15.5 ng·h/ml/mg, respectively; low dose, 17.1 ± 6.5 ng/ml/mg and 72.6 ± 8.7 ng·h/ml/mg, respectively.",Assessment of pharmacokinetic proportionality of levofloxacin and cyclosporine over a 100-fold dose range in healthy human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22404324/),[ng] / [mg·ml],17.1,173963,DB01137,Levofloxacin
,22404324,AUC(last),"For levofloxacin, the mean values for dose-normalized C(max) and AUC(last) with the two doses were as follows: therapeutic dose, 15.2 ± 4.6 ng/ml/mg and 103.6 ± 15.5 ng·h/ml/mg, respectively; low dose, 17.1 ± 6.5 ng/ml/mg and 72.6 ± 8.7 ng·h/ml/mg, respectively.",Assessment of pharmacokinetic proportionality of levofloxacin and cyclosporine over a 100-fold dose range in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22404324/),[h·ng] / [mg·ml],103.6,173964,DB01137,Levofloxacin
,22404324,AUC(last),"For levofloxacin, the mean values for dose-normalized C(max) and AUC(last) with the two doses were as follows: therapeutic dose, 15.2 ± 4.6 ng/ml/mg and 103.6 ± 15.5 ng·h/ml/mg, respectively; low dose, 17.1 ± 6.5 ng/ml/mg and 72.6 ± 8.7 ng·h/ml/mg, respectively.",Assessment of pharmacokinetic proportionality of levofloxacin and cyclosporine over a 100-fold dose range in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22404324/),[ng] / [mg·ml],17.1,173965,DB01137,Levofloxacin
,22404324,AUC(last),"For levofloxacin, the mean values for dose-normalized C(max) and AUC(last) with the two doses were as follows: therapeutic dose, 15.2 ± 4.6 ng/ml/mg and 103.6 ± 15.5 ng·h/ml/mg, respectively; low dose, 17.1 ± 6.5 ng/ml/mg and 72.6 ± 8.7 ng·h/ml/mg, respectively.",Assessment of pharmacokinetic proportionality of levofloxacin and cyclosporine over a 100-fold dose range in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22404324/),[h·ng] / [mg·ml],72.6,173966,DB01137,Levofloxacin
,22404324,dose-normalized C(max),"For cyclosporine, the mean values for dose-normalized C(max) and AUC(last) were as follows: therapeutic dose, 4.9 ± 1.5 ng/ml/mg and 15.4 ± 4.9 ng·h/ml/mg, respectively; low dose, 1.6 ± 0.6 ng/ml/mg and 9.3 ± 7.3 ng·h/ml/mg, respectively.",Assessment of pharmacokinetic proportionality of levofloxacin and cyclosporine over a 100-fold dose range in healthy human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22404324/),[ng] / [mg·ml],4.9,173967,DB01137,Levofloxacin
,22404324,dose-normalized C(max),"For cyclosporine, the mean values for dose-normalized C(max) and AUC(last) were as follows: therapeutic dose, 4.9 ± 1.5 ng/ml/mg and 15.4 ± 4.9 ng·h/ml/mg, respectively; low dose, 1.6 ± 0.6 ng/ml/mg and 9.3 ± 7.3 ng·h/ml/mg, respectively.",Assessment of pharmacokinetic proportionality of levofloxacin and cyclosporine over a 100-fold dose range in healthy human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22404324/),[ng] / [mg·ml],1.6,173968,DB01137,Levofloxacin
,22404324,AUC(last),"For cyclosporine, the mean values for dose-normalized C(max) and AUC(last) were as follows: therapeutic dose, 4.9 ± 1.5 ng/ml/mg and 15.4 ± 4.9 ng·h/ml/mg, respectively; low dose, 1.6 ± 0.6 ng/ml/mg and 9.3 ± 7.3 ng·h/ml/mg, respectively.",Assessment of pharmacokinetic proportionality of levofloxacin and cyclosporine over a 100-fold dose range in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22404324/),[ng] / [mg·ml],4.9,173969,DB01137,Levofloxacin
,22404324,AUC(last),"For cyclosporine, the mean values for dose-normalized C(max) and AUC(last) were as follows: therapeutic dose, 4.9 ± 1.5 ng/ml/mg and 15.4 ± 4.9 ng·h/ml/mg, respectively; low dose, 1.6 ± 0.6 ng/ml/mg and 9.3 ± 7.3 ng·h/ml/mg, respectively.",Assessment of pharmacokinetic proportionality of levofloxacin and cyclosporine over a 100-fold dose range in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22404324/),[h·ng] / [mg·ml],15.4,173970,DB01137,Levofloxacin
,22404324,AUC(last),"For cyclosporine, the mean values for dose-normalized C(max) and AUC(last) were as follows: therapeutic dose, 4.9 ± 1.5 ng/ml/mg and 15.4 ± 4.9 ng·h/ml/mg, respectively; low dose, 1.6 ± 0.6 ng/ml/mg and 9.3 ± 7.3 ng·h/ml/mg, respectively.",Assessment of pharmacokinetic proportionality of levofloxacin and cyclosporine over a 100-fold dose range in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22404324/),[ng] / [mg·ml],1.6,173971,DB01137,Levofloxacin
,22404324,AUC(last),"For cyclosporine, the mean values for dose-normalized C(max) and AUC(last) were as follows: therapeutic dose, 4.9 ± 1.5 ng/ml/mg and 15.4 ± 4.9 ng·h/ml/mg, respectively; low dose, 1.6 ± 0.6 ng/ml/mg and 9.3 ± 7.3 ng·h/ml/mg, respectively.",Assessment of pharmacokinetic proportionality of levofloxacin and cyclosporine over a 100-fold dose range in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22404324/),[h·ng] / [mg·ml],9.3,173972,DB01137,Levofloxacin
,27036073,minimum inhibitory concentrations (MICs),"We used S. epidermidis conjunctival sac isolates [minimum inhibitory concentrations (MICs) of LVFX, 0.125 μg/mL].",The antibacterial activity of levofloxacin eye drops against staphylococci using an in vitro pharmacokinetic model in the bulbar conjunctiva. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27036073/),[μg] / [ml],0.125,175583,DB01137,Levofloxacin
≥,27036073,MICs,"The MICs of LVFX for the resistant isolates were 2-32 times higher than the parental strain, and those with MICs ≥2 ug/mL had mutations in the quinolone resistance-determining region.",The antibacterial activity of levofloxacin eye drops against staphylococci using an in vitro pharmacokinetic model in the bulbar conjunctiva. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27036073/),[ug] / [ml],2,175584,DB01137,Levofloxacin
,27036073,MICs,"The PK model simulation predicts that 1.5% LVFX exerts bactericidal and bacteriostatic effects against strains with MICs of 0.125-2 and 4 μg/mL, respectively, whereas 0.5% LVFX would only be effective against strains with MICs of 0.125-1 μg/mL.",The antibacterial activity of levofloxacin eye drops against staphylococci using an in vitro pharmacokinetic model in the bulbar conjunctiva. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27036073/),[μg] / [ml],0.125-2,175585,DB01137,Levofloxacin
,27036073,MICs,"The PK model simulation predicts that 1.5% LVFX exerts bactericidal and bacteriostatic effects against strains with MICs of 0.125-2 and 4 μg/mL, respectively, whereas 0.5% LVFX would only be effective against strains with MICs of 0.125-1 μg/mL.",The antibacterial activity of levofloxacin eye drops against staphylococci using an in vitro pharmacokinetic model in the bulbar conjunctiva. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27036073/),[μg] / [ml],4,175586,DB01137,Levofloxacin
,27036073,MICs,"The PK model simulation predicts that 1.5% LVFX exerts bactericidal and bacteriostatic effects against strains with MICs of 0.125-2 and 4 μg/mL, respectively, whereas 0.5% LVFX would only be effective against strains with MICs of 0.125-1 μg/mL.",The antibacterial activity of levofloxacin eye drops against staphylococci using an in vitro pharmacokinetic model in the bulbar conjunctiva. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27036073/),[μg] / [ml],0.125-1,175587,DB01137,Levofloxacin
at,10424513,peak plasma concentration/MIC ratio,"When the peak concentrations for both agents were compared to standard twofold dilution minimum inhibitory concentration (MIC) values for pneumococcal isolates, it was discovered that the breakpoint MIC value at which each compound would no longer achieve a peak plasma concentration/MIC ratio of at least 12:1 was 0.5 mg/L for levofloxacin and 0.25 mg/L for alatrofloxacin.","A randomized, crossover design study of the pharmacology of extended-spectrum fluoroquinolones for pneumococcal infections. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424513/),[mg] / [l],12:1,177798,DB01137,Levofloxacin
,10424513,peak plasma concentration/MIC ratio,"When the peak concentrations for both agents were compared to standard twofold dilution minimum inhibitory concentration (MIC) values for pneumococcal isolates, it was discovered that the breakpoint MIC value at which each compound would no longer achieve a peak plasma concentration/MIC ratio of at least 12:1 was 0.5 mg/L for levofloxacin and 0.25 mg/L for alatrofloxacin.","A randomized, crossover design study of the pharmacology of extended-spectrum fluoroquinolones for pneumococcal infections. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424513/),[mg] / [l],0.5,177799,DB01137,Levofloxacin
,10424513,peak plasma concentration/MIC ratio,"When the peak concentrations for both agents were compared to standard twofold dilution minimum inhibitory concentration (MIC) values for pneumococcal isolates, it was discovered that the breakpoint MIC value at which each compound would no longer achieve a peak plasma concentration/MIC ratio of at least 12:1 was 0.5 mg/L for levofloxacin and 0.25 mg/L for alatrofloxacin.","A randomized, crossover design study of the pharmacology of extended-spectrum fluoroquinolones for pneumococcal infections. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424513/),[mg] / [l],0.25,177800,DB01137,Levofloxacin
,10424513,MIC,"Based on the MIC that inhibits 90% of isolates of Streptococcus pneumoniae for both of these agents (1.0 to 2.0 mg/L for levofloxacin and 0.125 to 0.25 mg/L for trovafloxacin), our results indicate that although the once-daily regimen of alatrofloxacin appears to be appropriate for this pathogen, a more aggressive regimen may need to be investigated to optimize the clinical and microbiological effects of levofloxacin.","A randomized, crossover design study of the pharmacology of extended-spectrum fluoroquinolones for pneumococcal infections. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424513/),[mg] / [l],1.0 to 2.0,177801,DB01137,Levofloxacin
,10424513,MIC,"Based on the MIC that inhibits 90% of isolates of Streptococcus pneumoniae for both of these agents (1.0 to 2.0 mg/L for levofloxacin and 0.125 to 0.25 mg/L for trovafloxacin), our results indicate that although the once-daily regimen of alatrofloxacin appears to be appropriate for this pathogen, a more aggressive regimen may need to be investigated to optimize the clinical and microbiological effects of levofloxacin.","A randomized, crossover design study of the pharmacology of extended-spectrum fluoroquinolones for pneumococcal infections. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424513/),[mg] / [l],0.125 to 0.25,177802,DB01137,Levofloxacin
,24250583,Cmax,"In healthy volunteers, the average pharmacokinetic parameters were as Cmax (6.79 μg/mL), Tmax (1.84 h), T(½) (10.03 h), Ka (2.23 h(-1)), AUC (110.09 μgh/mL), Vd (85.84 L), Cl (4.57 L/h) and in typhoid patients were Cmax (6.90 μg/mL), Tmax (1.82 h), T(½) (9.42 h), Ka (2.21 h(-1)), AUC (105.55 μgh/mL), Vd (64.31 L), Cl (4.75 L/h).",Comparative pharmacokinetics of levofloxacin in healthy volunteers and in patients suffering from typhoid Fever. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24250583/),[μg] / [ml],6.79,178217,DB01137,Levofloxacin
,24250583,Tmax,"In healthy volunteers, the average pharmacokinetic parameters were as Cmax (6.79 μg/mL), Tmax (1.84 h), T(½) (10.03 h), Ka (2.23 h(-1)), AUC (110.09 μgh/mL), Vd (85.84 L), Cl (4.57 L/h) and in typhoid patients were Cmax (6.90 μg/mL), Tmax (1.82 h), T(½) (9.42 h), Ka (2.21 h(-1)), AUC (105.55 μgh/mL), Vd (64.31 L), Cl (4.75 L/h).",Comparative pharmacokinetics of levofloxacin in healthy volunteers and in patients suffering from typhoid Fever. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24250583/),h,1.84,178218,DB01137,Levofloxacin
,24250583,T(½),"In healthy volunteers, the average pharmacokinetic parameters were as Cmax (6.79 μg/mL), Tmax (1.84 h), T(½) (10.03 h), Ka (2.23 h(-1)), AUC (110.09 μgh/mL), Vd (85.84 L), Cl (4.57 L/h) and in typhoid patients were Cmax (6.90 μg/mL), Tmax (1.82 h), T(½) (9.42 h), Ka (2.21 h(-1)), AUC (105.55 μgh/mL), Vd (64.31 L), Cl (4.75 L/h).",Comparative pharmacokinetics of levofloxacin in healthy volunteers and in patients suffering from typhoid Fever. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24250583/),h,10.03,178219,DB01137,Levofloxacin
,24250583,Ka,"In healthy volunteers, the average pharmacokinetic parameters were as Cmax (6.79 μg/mL), Tmax (1.84 h), T(½) (10.03 h), Ka (2.23 h(-1)), AUC (110.09 μgh/mL), Vd (85.84 L), Cl (4.57 L/h) and in typhoid patients were Cmax (6.90 μg/mL), Tmax (1.82 h), T(½) (9.42 h), Ka (2.21 h(-1)), AUC (105.55 μgh/mL), Vd (64.31 L), Cl (4.75 L/h).",Comparative pharmacokinetics of levofloxacin in healthy volunteers and in patients suffering from typhoid Fever. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24250583/),1/[h],2.23,178220,DB01137,Levofloxacin
,24250583,AUC,"In healthy volunteers, the average pharmacokinetic parameters were as Cmax (6.79 μg/mL), Tmax (1.84 h), T(½) (10.03 h), Ka (2.23 h(-1)), AUC (110.09 μgh/mL), Vd (85.84 L), Cl (4.57 L/h) and in typhoid patients were Cmax (6.90 μg/mL), Tmax (1.82 h), T(½) (9.42 h), Ka (2.21 h(-1)), AUC (105.55 μgh/mL), Vd (64.31 L), Cl (4.75 L/h).",Comparative pharmacokinetics of levofloxacin in healthy volunteers and in patients suffering from typhoid Fever. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24250583/),[μgh] / [ml],110.09,178221,DB01137,Levofloxacin
,24250583,Vd,"In healthy volunteers, the average pharmacokinetic parameters were as Cmax (6.79 μg/mL), Tmax (1.84 h), T(½) (10.03 h), Ka (2.23 h(-1)), AUC (110.09 μgh/mL), Vd (85.84 L), Cl (4.57 L/h) and in typhoid patients were Cmax (6.90 μg/mL), Tmax (1.82 h), T(½) (9.42 h), Ka (2.21 h(-1)), AUC (105.55 μgh/mL), Vd (64.31 L), Cl (4.75 L/h).",Comparative pharmacokinetics of levofloxacin in healthy volunteers and in patients suffering from typhoid Fever. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24250583/),l,85.84,178222,DB01137,Levofloxacin
,24250583,Cl,"In healthy volunteers, the average pharmacokinetic parameters were as Cmax (6.79 μg/mL), Tmax (1.84 h), T(½) (10.03 h), Ka (2.23 h(-1)), AUC (110.09 μgh/mL), Vd (85.84 L), Cl (4.57 L/h) and in typhoid patients were Cmax (6.90 μg/mL), Tmax (1.82 h), T(½) (9.42 h), Ka (2.21 h(-1)), AUC (105.55 μgh/mL), Vd (64.31 L), Cl (4.75 L/h).",Comparative pharmacokinetics of levofloxacin in healthy volunteers and in patients suffering from typhoid Fever. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24250583/),[l] / [h],4.57,178223,DB01137,Levofloxacin
,24250583,Cmax,"In healthy volunteers, the average pharmacokinetic parameters were as Cmax (6.79 μg/mL), Tmax (1.84 h), T(½) (10.03 h), Ka (2.23 h(-1)), AUC (110.09 μgh/mL), Vd (85.84 L), Cl (4.57 L/h) and in typhoid patients were Cmax (6.90 μg/mL), Tmax (1.82 h), T(½) (9.42 h), Ka (2.21 h(-1)), AUC (105.55 μgh/mL), Vd (64.31 L), Cl (4.75 L/h).",Comparative pharmacokinetics of levofloxacin in healthy volunteers and in patients suffering from typhoid Fever. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24250583/),[μg] / [ml],6.90,178224,DB01137,Levofloxacin
,24250583,Tmax,"In healthy volunteers, the average pharmacokinetic parameters were as Cmax (6.79 μg/mL), Tmax (1.84 h), T(½) (10.03 h), Ka (2.23 h(-1)), AUC (110.09 μgh/mL), Vd (85.84 L), Cl (4.57 L/h) and in typhoid patients were Cmax (6.90 μg/mL), Tmax (1.82 h), T(½) (9.42 h), Ka (2.21 h(-1)), AUC (105.55 μgh/mL), Vd (64.31 L), Cl (4.75 L/h).",Comparative pharmacokinetics of levofloxacin in healthy volunteers and in patients suffering from typhoid Fever. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24250583/),h,1.82,178225,DB01137,Levofloxacin
,24250583,T(½),"In healthy volunteers, the average pharmacokinetic parameters were as Cmax (6.79 μg/mL), Tmax (1.84 h), T(½) (10.03 h), Ka (2.23 h(-1)), AUC (110.09 μgh/mL), Vd (85.84 L), Cl (4.57 L/h) and in typhoid patients were Cmax (6.90 μg/mL), Tmax (1.82 h), T(½) (9.42 h), Ka (2.21 h(-1)), AUC (105.55 μgh/mL), Vd (64.31 L), Cl (4.75 L/h).",Comparative pharmacokinetics of levofloxacin in healthy volunteers and in patients suffering from typhoid Fever. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24250583/),h,9.42,178226,DB01137,Levofloxacin
,24250583,Ka,"In healthy volunteers, the average pharmacokinetic parameters were as Cmax (6.79 μg/mL), Tmax (1.84 h), T(½) (10.03 h), Ka (2.23 h(-1)), AUC (110.09 μgh/mL), Vd (85.84 L), Cl (4.57 L/h) and in typhoid patients were Cmax (6.90 μg/mL), Tmax (1.82 h), T(½) (9.42 h), Ka (2.21 h(-1)), AUC (105.55 μgh/mL), Vd (64.31 L), Cl (4.75 L/h).",Comparative pharmacokinetics of levofloxacin in healthy volunteers and in patients suffering from typhoid Fever. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24250583/),1/[h],2.21,178227,DB01137,Levofloxacin
,24250583,AUC,"In healthy volunteers, the average pharmacokinetic parameters were as Cmax (6.79 μg/mL), Tmax (1.84 h), T(½) (10.03 h), Ka (2.23 h(-1)), AUC (110.09 μgh/mL), Vd (85.84 L), Cl (4.57 L/h) and in typhoid patients were Cmax (6.90 μg/mL), Tmax (1.82 h), T(½) (9.42 h), Ka (2.21 h(-1)), AUC (105.55 μgh/mL), Vd (64.31 L), Cl (4.75 L/h).",Comparative pharmacokinetics of levofloxacin in healthy volunteers and in patients suffering from typhoid Fever. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24250583/),[μgh] / [ml],105.55,178228,DB01137,Levofloxacin
,24250583,Vd,"In healthy volunteers, the average pharmacokinetic parameters were as Cmax (6.79 μg/mL), Tmax (1.84 h), T(½) (10.03 h), Ka (2.23 h(-1)), AUC (110.09 μgh/mL), Vd (85.84 L), Cl (4.57 L/h) and in typhoid patients were Cmax (6.90 μg/mL), Tmax (1.82 h), T(½) (9.42 h), Ka (2.21 h(-1)), AUC (105.55 μgh/mL), Vd (64.31 L), Cl (4.75 L/h).",Comparative pharmacokinetics of levofloxacin in healthy volunteers and in patients suffering from typhoid Fever. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24250583/),l,64.31,178229,DB01137,Levofloxacin
,24250583,Cl,"In healthy volunteers, the average pharmacokinetic parameters were as Cmax (6.79 μg/mL), Tmax (1.84 h), T(½) (10.03 h), Ka (2.23 h(-1)), AUC (110.09 μgh/mL), Vd (85.84 L), Cl (4.57 L/h) and in typhoid patients were Cmax (6.90 μg/mL), Tmax (1.82 h), T(½) (9.42 h), Ka (2.21 h(-1)), AUC (105.55 μgh/mL), Vd (64.31 L), Cl (4.75 L/h).",Comparative pharmacokinetics of levofloxacin in healthy volunteers and in patients suffering from typhoid Fever. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24250583/),[l] / [h],4.75,178230,DB01137,Levofloxacin
,28756357,flow rate,"After solid phase extraction process using Evolute® ABN 96 fixed well plate; levofloxacin and internal standard-enoxacin were separated using a mobile phase consisting of phosphate buffer 10mM with 0.025% triethylamine pH 3.0 - acetonitrile (88:12, v/v) on a Purosphere RP-8e column (5μm, 125×4.0mm) at a flow rate of 1.2mL/min at 35°C.",High-performance liquid chromatography with time-programmed fluorescence detection for the quantification of Levofloxacin in human plasma and cerebrospinal fluid in adults with tuberculous meningitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28756357/),[ml] / [min],1.2,180176,DB01137,Levofloxacin
,28756357,excitation/emission wavelengths,"The excitation/emission wavelengths were set to 269/400nm and 294/500nm, for enoxacin and levofloxacin, respectively.",High-performance liquid chromatography with time-programmed fluorescence detection for the quantification of Levofloxacin in human plasma and cerebrospinal fluid in adults with tuberculous meningitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28756357/),nm,269/400,180177,DB01137,Levofloxacin
,28756357,excitation/emission wavelengths,"The excitation/emission wavelengths were set to 269/400nm and 294/500nm, for enoxacin and levofloxacin, respectively.",High-performance liquid chromatography with time-programmed fluorescence detection for the quantification of Levofloxacin in human plasma and cerebrospinal fluid in adults with tuberculous meningitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28756357/),n,294,180178,DB01137,Levofloxacin
,28756357,limit of detection,The method was linear over the concentration range of 0.02 to 20.0μg/mL with a limit of detection of 0.01μg/mL.,High-performance liquid chromatography with time-programmed fluorescence detection for the quantification of Levofloxacin in human plasma and cerebrospinal fluid in adults with tuberculous meningitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28756357/),[μg] / [ml],0.01,180179,DB01137,Levofloxacin
,19364849,AUC/MIC ratios,"AUC/MIC ratios of 12.4, 31.2, 62.8, and 127.6 were required to drive these bacterial responses.",Pharmacodynamics of levofloxacin in a murine pneumonia model of Pseudomonas aeruginosa infection: determination of epithelial lining fluid targets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19364849/),,12.4,181793,DB01137,Levofloxacin
,19364849,AUC/MIC ratios,"AUC/MIC ratios of 12.4, 31.2, 62.8, and 127.6 were required to drive these bacterial responses.",Pharmacodynamics of levofloxacin in a murine pneumonia model of Pseudomonas aeruginosa infection: determination of epithelial lining fluid targets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19364849/),,31.2,181794,DB01137,Levofloxacin
,19364849,AUC/MIC ratios,"AUC/MIC ratios of 12.4, 31.2, 62.8, and 127.6 were required to drive these bacterial responses.",Pharmacodynamics of levofloxacin in a murine pneumonia model of Pseudomonas aeruginosa infection: determination of epithelial lining fluid targets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19364849/),,62.8,181795,DB01137,Levofloxacin
,19364849,AUC/MIC ratios,"AUC/MIC ratios of 12.4, 31.2, 62.8, and 127.6 were required to drive these bacterial responses.",Pharmacodynamics of levofloxacin in a murine pneumonia model of Pseudomonas aeruginosa infection: determination of epithelial lining fluid targets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19364849/),,127.6,181796,DB01137,Levofloxacin
,19364849,target,"With a 750-mg levofloxacin dose, target attainment rates fell below 90% at 4 mg/liter, 1 mg/liter, and 0.5 mg/liter for 1-, 2-, and 3-log kills, respectively.",Pharmacodynamics of levofloxacin in a murine pneumonia model of Pseudomonas aeruginosa infection: determination of epithelial lining fluid targets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19364849/),,1,181797,DB01137,Levofloxacin
,19364849,target,"With a 750-mg levofloxacin dose, target attainment rates fell below 90% at 4 mg/liter, 1 mg/liter, and 0.5 mg/liter for 1-, 2-, and 3-log kills, respectively.",Pharmacodynamics of levofloxacin in a murine pneumonia model of Pseudomonas aeruginosa infection: determination of epithelial lining fluid targets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19364849/),,0,181798,DB01137,Levofloxacin
,17101261,maximum concentration,The median maximum concentration of levofloxacin in plasma was 6.1 mg/L and that of ciprofloxacin was 2.3 mg/L.,"Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17101261/),[mg] / [l],6.1,182004,DB01137,Levofloxacin
,17101261,maximum concentration,The median maximum concentration of levofloxacin in plasma was 6.1 mg/L and that of ciprofloxacin was 2.3 mg/L.,"Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17101261/),[mg] / [l],2.3,182005,DB01137,Levofloxacin
,17101261,cumulative level of renal excretion,The median cumulative level of renal excretion of the administered dose of the parent drug was 81.2% for levofloxacin and 36.2% for ciprofloxacin.,"Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17101261/),%,81.2,182006,DB01137,Levofloxacin
,17101261,cumulative level of renal excretion,The median cumulative level of renal excretion of the administered dose of the parent drug was 81.2% for levofloxacin and 36.2% for ciprofloxacin.,"Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17101261/),%,36.2,182007,DB01137,Levofloxacin
,17101261,UBTs,"The median UBTs of both quinolones measured within the first 12h were between 0 and 1:> or =1024, correlating with the minimum inhibitory concentrations (MICs) of the strains.","Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17101261/),,0 and 1:> or =,182008,DB01137,Levofloxacin
,17101261,UBTs,"The median UBTs of both quinolones measured within the first 12h were between 0 and 1:> or =1024, correlating with the minimum inhibitory concentrations (MICs) of the strains.","Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17101261/),,1024,182009,DB01137,Levofloxacin
>,15519481,AUC(0-24)/MIC(all),"Monte Carlo simulations were then used to analyse target attainment of levofloxacin using doses of 500 mg, 750 mg and 1000 mg once daily to achieve free drug AUC(0-24)/MIC(all) >/= 30-100 versus S. pneumoniae in patients with CAP.","Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP). ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15519481/),,30-100,182372,DB01137,Levofloxacin
,15519481,t(1/2),Levofloxacin t(1/2) values were longer in elderly patients (9.8 +/- 2.5h) than younger patients with CAP (7.4 +/- 2.5h).,"Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15519481/),h,9.8,182373,DB01137,Levofloxacin
,15519481,t(1/2),Levofloxacin t(1/2) values were longer in elderly patients (9.8 +/- 2.5h) than younger patients with CAP (7.4 +/- 2.5h).,"Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15519481/),h,7.4,182374,DB01137,Levofloxacin
,15519481,AUC(0-24)/MIC,Monte Carlo simulation using levofloxacin 500 mg yielded probabilities of achieving free-drug AUC(0-24)/MIC(all) of 30 in P and ELF (95.7% and 98.1%) in elderly and younger patients (72.7% and 80.6%) respectively.,"Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15519481/),,30,182375,DB01137,Levofloxacin
,15519481,AUC(0-24)/MIC,"Levofloxacin 750 mg and 1000 mg once daily had probability of achieving free-drug AUC(0-24)/MIC(all) of 30 in P/ELF of 98.1%/98.6% and 99.2%/99.0%, respectively, in elderly patients compared with 89.9%/94.1% and 95.2%/96.5%, respectively, for younger patients.","Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15519481/),,30,182376,DB01137,Levofloxacin
,15519481,AUC(0-24)/MIC(all),Probability of achieving of AUC(0-24)/MIC(all) of 100 in P or ELF was very low in both patient populations at different doses except in the case of elderly patients receiving levofloxacin in a dose of 1000 mg once daily P/ELF of 78.5%/87.0%.,"Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15519481/),,100,182377,DB01137,Levofloxacin
,15519481,AUC(0-24)/MIC(all),Levofloxacin 750 mg OD provides high probabilities of achieving free-drug AUC(0-24)/MIC(all) of 30 in both plasma and epithelial lining fluid in patients with CAP including younger patients.,"Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15519481/),,30,182378,DB01137,Levofloxacin
,15519481,AUC(0-24)/MIC,"Levofloxacin 500 mg OD provides high probabilities of achieving free-drug AUC(0-24)/MIC(all) of 30 in elderly patients with CAP, although we favour the 750 mg dosing in these patients as well.","Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15519481/),,30,182379,DB01137,Levofloxacin
,12878526,peak,"Therapeutic regimens (moxifloxacin: peak, 4.5 micro g/ml; half-life [t(1/2)], 12 h; and levofloxacin: peak, 6 micro g/ml; t(1/2), 6 h) were tested against two fluoroquinolone-susceptible isolates (strains 79 and ATCC 49619) and KD2138 and KD2139 (parC and gyrA mutants, respectively, of ATCC 49619).",Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878526/),[μg] / [ml],4.5,183949,DB01137,Levofloxacin
,12878526,half-life [t(1/2)],"Therapeutic regimens (moxifloxacin: peak, 4.5 micro g/ml; half-life [t(1/2)], 12 h; and levofloxacin: peak, 6 micro g/ml; t(1/2), 6 h) were tested against two fluoroquinolone-susceptible isolates (strains 79 and ATCC 49619) and KD2138 and KD2139 (parC and gyrA mutants, respectively, of ATCC 49619).",Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878526/),h,12,183950,DB01137,Levofloxacin
,12878526,peak,"Therapeutic regimens (moxifloxacin: peak, 4.5 micro g/ml; half-life [t(1/2)], 12 h; and levofloxacin: peak, 6 micro g/ml; t(1/2), 6 h) were tested against two fluoroquinolone-susceptible isolates (strains 79 and ATCC 49619) and KD2138 and KD2139 (parC and gyrA mutants, respectively, of ATCC 49619).",Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878526/),[μg] / [ml],6,183951,DB01137,Levofloxacin
,12878526,t(1/2),"Therapeutic regimens (moxifloxacin: peak, 4.5 micro g/ml; half-life [t(1/2)], 12 h; and levofloxacin: peak, 6 micro g/ml; t(1/2), 6 h) were tested against two fluoroquinolone-susceptible isolates (strains 79 and ATCC 49619) and KD2138 and KD2139 (parC and gyrA mutants, respectively, of ATCC 49619).",Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878526/),h,6,183952,DB01137,Levofloxacin
,12878526,MICs,"Moxifloxacin MICs and MPCs (MIC/MPC) for isolates 79, ATCC 49619, KD2138, and KD2139, respectively, were 0.125 and 0.5, 0.125 and 0.5, 0.25 and 8, and 0.25 and 4 micro g/ml.",Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878526/),[μg] / [ml],0.125,183953,DB01137,Levofloxacin
,12878526,MICs,"Moxifloxacin MICs and MPCs (MIC/MPC) for isolates 79, ATCC 49619, KD2138, and KD2139, respectively, were 0.125 and 0.5, 0.125 and 0.5, 0.25 and 8, and 0.25 and 4 micro g/ml.",Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878526/),[μg] / [ml],0.25,183954,DB01137,Levofloxacin
,12878526,MPCs (MIC/MPC),"Moxifloxacin MICs and MPCs (MIC/MPC) for isolates 79, ATCC 49619, KD2138, and KD2139, respectively, were 0.125 and 0.5, 0.125 and 0.5, 0.25 and 8, and 0.25 and 4 micro g/ml.",Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878526/),[μg] / [ml],0.125,183955,DB01137,Levofloxacin
,12878526,MPCs (MIC/MPC),"Moxifloxacin MICs and MPCs (MIC/MPC) for isolates 79, ATCC 49619, KD2138, and KD2139, respectively, were 0.125 and 0.5, 0.125 and 0.5, 0.25 and 8, and 0.25 and 4 micro g/ml.",Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878526/),[μg] / [ml],0.25,183956,DB01137,Levofloxacin
,12878526,MPCs (MIC/MPC),"Moxifloxacin MICs and MPCs (MIC/MPC) for isolates 79, ATCC 49619, KD2138, and KD2139, respectively, were 0.125 and 0.5, 0.125 and 0.5, 0.25 and 8, and 0.25 and 4 micro g/ml.",Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878526/),[μg] / [ml],8,183957,DB01137,Levofloxacin
,12878526,MPCs (MIC/MPC),"Moxifloxacin MICs and MPCs (MIC/MPC) for isolates 79, ATCC 49619, KD2138, and KD2139, respectively, were 0.125 and 0.5, 0.125 and 0.5, 0.25 and 8, and 0.25 and 4 micro g/ml.",Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878526/),[μg] / [ml],4,183958,DB01137,Levofloxacin
,12878526,MICs,"Levofloxacin MICs and MPCs for the same isolates were 1 and 4, 0.5 and 2, 1 and 64, and 0.5 and 32 micro g/ml, respectively.",Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878526/),[μg] / [ml],1,183959,DB01137,Levofloxacin
,12878526,MICs,"Levofloxacin MICs and MPCs for the same isolates were 1 and 4, 0.5 and 2, 1 and 64, and 0.5 and 32 micro g/ml, respectively.",Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878526/),[μg] / [ml],4,183960,DB01137,Levofloxacin
,12878526,MICs,"Levofloxacin MICs and MPCs for the same isolates were 1 and 4, 0.5 and 2, 1 and 64, and 0.5 and 32 micro g/ml, respectively.",Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878526/),[μg] / [ml],0.5,183961,DB01137,Levofloxacin
,12878526,MPCs,"Levofloxacin MICs and MPCs for the same isolates were 1 and 4, 0.5 and 2, 1 and 64, and 0.5 and 32 micro g/ml, respectively.",Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878526/),[μg] / [ml],4,183962,DB01137,Levofloxacin
,12878526,MPCs,"Levofloxacin MICs and MPCs for the same isolates were 1 and 4, 0.5 and 2, 1 and 64, and 0.5 and 32 micro g/ml, respectively.",Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878526/),[μg] / [ml],0.5,183963,DB01137,Levofloxacin
,12878526,MPCs,"Levofloxacin MICs and MPCs for the same isolates were 1 and 4, 0.5 and 2, 1 and 64, and 0.5 and 32 micro g/ml, respectively.",Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878526/),[μg] / [ml],2,183964,DB01137,Levofloxacin
,12878526,MPCs,"Levofloxacin MICs and MPCs for the same isolates were 1 and 4, 0.5 and 2, 1 and 64, and 0.5 and 32 micro g/ml, respectively.",Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878526/),[μg] / [ml],1,183965,DB01137,Levofloxacin
,12878526,MPCs,"Levofloxacin MICs and MPCs for the same isolates were 1 and 4, 0.5 and 2, 1 and 64, and 0.5 and 32 micro g/ml, respectively.",Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878526/),[μg] / [ml],64,183966,DB01137,Levofloxacin
,12878526,MPCs,"Levofloxacin MICs and MPCs for the same isolates were 1 and 4, 0.5 and 2, 1 and 64, and 0.5 and 32 micro g/ml, respectively.",Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878526/),[μg] / [ml],32,183967,DB01137,Levofloxacin
,12878526,peak,"MPC-targeted moxifloxacin (lower-than-normal peak = 0.75 to 1.5 micro g/ml, administered at levofloxacin's t(1/2)) caused growth of a GyrA variant (S81Y) of KD2138 and a ParC variant (S79Y) of KD2139, while no mutants of ATCC 49619 were recovered.",Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878526/),[μg] / [ml],0.75 to 1.5,183968,DB01137,Levofloxacin
,12878526,peak,"MPC-targeted levofloxacin (higher-than-normal peak = 14.5 to 29.5 micro g/ml, administered at moxifloxacin's t(1/2)) against KD2138 and KD2139 did not prevent the development of the mutations observed in therapeutic regimens, but resistance in the fluoroquinolone-susceptible ATCC 49619 was no longer noted.",Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12878526/),[μg] / [ml],14.5 to 29.5,183969,DB01137,Levofloxacin
,25362196,penetrations,"Meropenem and levofloxacin penetrations into epithelial lining fluid were 39.3% and 64.3%, respectively.",Combination treatment with meropenem plus levofloxacin is synergistic against Pseudomonas aeruginosa infection in a murine model of pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25362196/),%,39.3,184078,DB01137,Levofloxacin
,25362196,penetrations,"Meropenem and levofloxacin penetrations into epithelial lining fluid were 39.3% and 64.3%, respectively.",Combination treatment with meropenem plus levofloxacin is synergistic against Pseudomonas aeruginosa infection in a murine model of pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25362196/),%,64.3,184079,DB01137,Levofloxacin
,27423043,limit of detection,"The limit of detection and the limit of quantification for human plasma were 0.01μg/mL and 0.03μg/mL, respectively.",Ultra-high performance liquid chromatographic determination of levofloxacin in human plasma and prostate tissue with use of experimental design optimization procedures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27423043/),[μg] / [ml],0.01,184526,DB01137,Levofloxacin
,27423043,limit of quantification,"The limit of detection and the limit of quantification for human plasma were 0.01μg/mL and 0.03μg/mL, respectively.",Ultra-high performance liquid chromatographic determination of levofloxacin in human plasma and prostate tissue with use of experimental design optimization procedures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27423043/),[μg] / [ml],0.03,184527,DB01137,Levofloxacin
,27423043,limit,"For the prostate tissue, the limit of detection and the limit of quantification were 0.1μg/g and 0.3μg/g, respectively.",Ultra-high performance liquid chromatographic determination of levofloxacin in human plasma and prostate tissue with use of experimental design optimization procedures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27423043/),[μg] / [g],0.1,184528,DB01137,Levofloxacin
,27423043,recoveries,The average recoveries of levofloxacin were in the range from 99 to 106%.,Ultra-high performance liquid chromatographic determination of levofloxacin in human plasma and prostate tissue with use of experimental design optimization procedures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27423043/),%,99 to 106,184529,DB01137,Levofloxacin
,27423043,concentration,The mean (±SD) LVF concentration in prostate was 6.22±3.52μg/g and in plasma 2.54±1.14μg/mL.,Ultra-high performance liquid chromatographic determination of levofloxacin in human plasma and prostate tissue with use of experimental design optimization procedures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27423043/),[μg] / [g],6.22,184530,DB01137,Levofloxacin
,27423043,concentration,The mean (±SD) LVF concentration in prostate was 6.22±3.52μg/g and in plasma 2.54±1.14μg/mL.,Ultra-high performance liquid chromatographic determination of levofloxacin in human plasma and prostate tissue with use of experimental design optimization procedures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27423043/),μ,2.54,184531,DB01137,Levofloxacin
,33345607,encapsulation,"Ethionamide and levofloxacin loaded nanoparticles were 312 ± 64 nm and 245 ± 24 nm in size respectively and drug encapsulation was 35.2 ± 3.1% w/w and 45.6 ± 9.4% w/w, respectively.",In vitro and in vivo evaluation of clastogenicity of second-line antitubercular drug loaded PLGA nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33345607/),[%·w] / [w],35.2,185928,DB01137,Levofloxacin
,33345607,encapsulation,"Ethionamide and levofloxacin loaded nanoparticles were 312 ± 64 nm and 245 ± 24 nm in size respectively and drug encapsulation was 35.2 ± 3.1% w/w and 45.6 ± 9.4% w/w, respectively.",In vitro and in vivo evaluation of clastogenicity of second-line antitubercular drug loaded PLGA nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33345607/),[%·w] / [w],45.6,185929,DB01137,Levofloxacin
,33345607,frequencies,"For in vitro, micronucleus assay frequencies of micronuclei per thousand bi-nucleated cells (MN-BN/1000 BN) was 188.3 ± 20.20 and 148 ± 20.42 for ethionamide and levofloxacin nanoparticles as compared to 232.6 ± 16.04 (p = 0.52) and 175 ± 5.56 (p = 0.45) for free ethionamide and levofloxacin, respectively.",In vitro and in vivo evaluation of clastogenicity of second-line antitubercular drug loaded PLGA nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33345607/),,188.3,185930,DB01137,Levofloxacin
,33345607,frequencies,"For in vitro, micronucleus assay frequencies of micronuclei per thousand bi-nucleated cells (MN-BN/1000 BN) was 188.3 ± 20.20 and 148 ± 20.42 for ethionamide and levofloxacin nanoparticles as compared to 232.6 ± 16.04 (p = 0.52) and 175 ± 5.56 (p = 0.45) for free ethionamide and levofloxacin, respectively.",In vitro and in vivo evaluation of clastogenicity of second-line antitubercular drug loaded PLGA nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33345607/),,148,185931,DB01137,Levofloxacin
,33345607,frequencies,"For in vitro, micronucleus assay frequencies of micronuclei per thousand bi-nucleated cells (MN-BN/1000 BN) was 188.3 ± 20.20 and 148 ± 20.42 for ethionamide and levofloxacin nanoparticles as compared to 232.6 ± 16.04 (p = 0.52) and 175 ± 5.56 (p = 0.45) for free ethionamide and levofloxacin, respectively.",In vitro and in vivo evaluation of clastogenicity of second-line antitubercular drug loaded PLGA nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33345607/),,232.6,185932,DB01137,Levofloxacin
,33345607,frequencies,"For in vitro, micronucleus assay frequencies of micronuclei per thousand bi-nucleated cells (MN-BN/1000 BN) was 188.3 ± 20.20 and 148 ± 20.42 for ethionamide and levofloxacin nanoparticles as compared to 232.6 ± 16.04 (p = 0.52) and 175 ± 5.56 (p = 0.45) for free ethionamide and levofloxacin, respectively.",In vitro and in vivo evaluation of clastogenicity of second-line antitubercular drug loaded PLGA nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33345607/),,175,185933,DB01137,Levofloxacin
,33345607,number of SCE,"The average number of SCE per cell for nanoformulation of ethionamide were not different from that of free drug (4.9 ± 0.51 vs 4.1 ± 0.55, p = 0.86).",In vitro and in vivo evaluation of clastogenicity of second-line antitubercular drug loaded PLGA nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33345607/),,4.9,185934,DB01137,Levofloxacin
,33345607,number of SCE,"The average number of SCE per cell for nanoformulation of ethionamide were not different from that of free drug (4.9 ± 0.51 vs 4.1 ± 0.55, p = 0.86).",In vitro and in vivo evaluation of clastogenicity of second-line antitubercular drug loaded PLGA nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33345607/),,4.1,185935,DB01137,Levofloxacin
,33345607,SCE per,"The SCE per cells were not significant difference for nanoformulation of levofloxacin (2.33 ± 1.36 vs 5.46 ± 0.25, p = 0.88).",In vitro and in vivo evaluation of clastogenicity of second-line antitubercular drug loaded PLGA nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33345607/),,2.33,185936,DB01137,Levofloxacin
,33345607,SCE per,"The SCE per cells were not significant difference for nanoformulation of levofloxacin (2.33 ± 1.36 vs 5.46 ± 0.25, p = 0.88).",In vitro and in vivo evaluation of clastogenicity of second-line antitubercular drug loaded PLGA nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33345607/),,5.46,185937,DB01137,Levofloxacin
,11751113,area under the curve (AUC)/MIC ratios,Previous studies have demonstrated that fluoroquinolone area under the curve (AUC)/MIC ratios of 30 to 50 are sufficient to eradicate pneumococci from in vitro pharmacokinetic models (IVPMs).,Pharmacodynamics of gatifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model: impact of area under the curve/MIC ratios on eradication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11751113/),,30 to 50,186435,DB01137,Levofloxacin
,11751113,MICs,"Gatifloxacin MICs were 0.4 to 1 microg/ml, whereas levofloxacin MICs were 1.8 to 3.2 microg/ml.",Pharmacodynamics of gatifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model: impact of area under the curve/MIC ratios on eradication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11751113/),[μg] / [ml],0.4 to 1,186436,DB01137,Levofloxacin
,11751113,MICs,"Gatifloxacin MICs were 0.4 to 1 microg/ml, whereas levofloxacin MICs were 1.8 to 3.2 microg/ml.",Pharmacodynamics of gatifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model: impact of area under the curve/MIC ratios on eradication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11751113/),[μg] / [ml],1.8 to 3.2,186437,DB01137,Levofloxacin
,11751113,peak/MIC ratios,"Since both peak concentration/MIC (peak/MIC) and AUC/MIC ratios affect fluoroquinolone pharmacodynamics, logarithmic-phase cultures (5 x 10(7) CFU/ml) were exposed to gatifloxacin at constant peak/MIC ratios of 2:1 to 3:1 at 0 and 24 h, elimination half-lives were varied to provide a range of AUC/MIC ratios, and changes in viable counts were measured over 30 h.",Pharmacodynamics of gatifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model: impact of area under the curve/MIC ratios on eradication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11751113/),,2:,186438,DB01137,Levofloxacin
,11751113,peak/MIC ratios,"Since both peak concentration/MIC (peak/MIC) and AUC/MIC ratios affect fluoroquinolone pharmacodynamics, logarithmic-phase cultures (5 x 10(7) CFU/ml) were exposed to gatifloxacin at constant peak/MIC ratios of 2:1 to 3:1 at 0 and 24 h, elimination half-lives were varied to provide a range of AUC/MIC ratios, and changes in viable counts were measured over 30 h.",Pharmacodynamics of gatifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model: impact of area under the curve/MIC ratios on eradication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11751113/),,1,186439,DB01137,Levofloxacin
,11751113,peak/MIC ratios,"Since both peak concentration/MIC (peak/MIC) and AUC/MIC ratios affect fluoroquinolone pharmacodynamics, logarithmic-phase cultures (5 x 10(7) CFU/ml) were exposed to gatifloxacin at constant peak/MIC ratios of 2:1 to 3:1 at 0 and 24 h, elimination half-lives were varied to provide a range of AUC/MIC ratios, and changes in viable counts were measured over 30 h.",Pharmacodynamics of gatifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model: impact of area under the curve/MIC ratios on eradication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11751113/),,3:,186440,DB01137,Levofloxacin
,11751113,AUC/MIC ratios,"As a comparison, levofloxacin was evaluated at similar peak/MIC ratios and at AUC/MIC ratios of 30 to 38.",Pharmacodynamics of gatifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model: impact of area under the curve/MIC ratios on eradication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11751113/),,30 to 38,186441,DB01137,Levofloxacin
,11751113,AUC/MIC ratios,"However, continued killing and eradication were observed only when gatifloxacin AUC/MIC ratios were 27 to 48.",Pharmacodynamics of gatifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model: impact of area under the curve/MIC ratios on eradication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11751113/),,27 to 48,186442,DB01137,Levofloxacin
,11751113,AUC/MIC ratios,"In contrast, substantial regrowth was observed in most experiments when gatifloxacin AUC/MIC ratios were 9 to 24.",Pharmacodynamics of gatifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model: impact of area under the curve/MIC ratios on eradication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11751113/),,9 to 24,186443,DB01137,Levofloxacin
,11751113,AUC/MIC ratios,These data provide further support that fluoroquinolone AUC/MIC ratios of approximately 30 or higher can be sufficient for eradication of pneumococci from IVPMs.,Pharmacodynamics of gatifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model: impact of area under the curve/MIC ratios on eradication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11751113/),,30,186444,DB01137,Levofloxacin
,28141813,recovery,The mean recovery was 96.84%.,Determination of plasma concentrations of levofloxacin by high performance liquid chromatography for use at a multidrug-resistant tuberculosis hospital in Tanzania. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28141813/),%,96.84,186989,DB01137,Levofloxacin
,28141813,eCmax,Only 13 (32%) patients had any plasma concentration that reached the lower range of the expected literature derived Cmax with the median eCmax being 5.86 (3.33-9.08 μg/ml).,Determination of plasma concentrations of levofloxacin by high performance liquid chromatography for use at a multidrug-resistant tuberculosis hospital in Tanzania. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28141813/),[μg] / [ml],5.86,186990,DB01137,Levofloxacin
≥,28141813,eCmax,"Using Classification and Regression Tree analysis, an eCmax ≥7.55 μg/mL was identified as the threshold which best predicted cure.",Determination of plasma concentrations of levofloxacin by high performance liquid chromatography for use at a multidrug-resistant tuberculosis hospital in Tanzania. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28141813/),[μg] / [ml],7.55,186991,DB01137,Levofloxacin
,28141813,time to sputum culture conversion,"Analyzing this CART derived threshold on treatment outcome, the time to sputum culture conversion was 38.3 ± 22.7 days vs. 47.8 ± 26.5 days (p = 0.27) and a greater proportion were cured, in 10 out of 15 (66.7%) vs. 6 out of 18 (33.3%) (p = 0.06) respectively.",Determination of plasma concentrations of levofloxacin by high performance liquid chromatography for use at a multidrug-resistant tuberculosis hospital in Tanzania. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28141813/),d,38.3,186992,DB01137,Levofloxacin
,28141813,time to sputum culture conversion,"Analyzing this CART derived threshold on treatment outcome, the time to sputum culture conversion was 38.3 ± 22.7 days vs. 47.8 ± 26.5 days (p = 0.27) and a greater proportion were cured, in 10 out of 15 (66.7%) vs. 6 out of 18 (33.3%) (p = 0.06) respectively.",Determination of plasma concentrations of levofloxacin by high performance liquid chromatography for use at a multidrug-resistant tuberculosis hospital in Tanzania. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28141813/),d,47.8,186993,DB01137,Levofloxacin
,28141813,eCmax/minimum inhibitory concentration (MIC),"Furthermore, one patient with an eCmax/minimum inhibitory concentration (MIC) of only 1.13 acquired extensively drug resistant (XDR)-TB while undergoing treatment.",Determination of plasma concentrations of levofloxacin by high performance liquid chromatography for use at a multidrug-resistant tuberculosis hospital in Tanzania. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28141813/),,1.13,186994,DB01137,Levofloxacin
,22944286,AUC(0-6h),"The average AUC(0-6h) for levofloxacin was 46.59 mg.h/l, the average Cmax 10.7 mg/l, the average AUIC 932, and the average Cmax/MIC 107.5.",Pharmacokinetic and dynamic study of levofloxacin and rifampicin in bone and joint infections. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22944286/),[h·mg] / [l],46.59,187163,DB01137,Levofloxacin
,22944286,Cmax,"The average AUC(0-6h) for levofloxacin was 46.59 mg.h/l, the average Cmax 10.7 mg/l, the average AUIC 932, and the average Cmax/MIC 107.5.",Pharmacokinetic and dynamic study of levofloxacin and rifampicin in bone and joint infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22944286/),[mg] / [l],10.7,187164,DB01137,Levofloxacin
,22944286,AUIC,"The average AUC(0-6h) for levofloxacin was 46.59 mg.h/l, the average Cmax 10.7 mg/l, the average AUIC 932, and the average Cmax/MIC 107.5.",Pharmacokinetic and dynamic study of levofloxacin and rifampicin in bone and joint infections. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22944286/),,932,187165,DB01137,Levofloxacin
,22944286,Cmax/MIC,"The average AUC(0-6h) for levofloxacin was 46.59 mg.h/l, the average Cmax 10.7 mg/l, the average AUIC 932, and the average Cmax/MIC 107.5.",Pharmacokinetic and dynamic study of levofloxacin and rifampicin in bone and joint infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22944286/),,107.5,187166,DB01137,Levofloxacin
,31778853,peak plasma concentration,LFX administered orally was rapidly absorbed with a peak plasma concentration of 2866 ± 239 ng/mL and an absolute oral bioavailability of 114 ± 27.7%.,Pharmacokinetic and tissue analyses of levofloxacin in sheep (Ovis aries Linnaeus) after multiple-dose administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31778853/),[ng] / [ml],2866,188923,DB01137,Levofloxacin
,31778853,absolute oral bioavailability,LFX administered orally was rapidly absorbed with a peak plasma concentration of 2866 ± 239 ng/mL and an absolute oral bioavailability of 114 ± 27.7%.,Pharmacokinetic and tissue analyses of levofloxacin in sheep (Ovis aries Linnaeus) after multiple-dose administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31778853/),%,114,188924,DB01137,Levofloxacin
,31778853,area under the curve / minimum inhibitory concentration,"According to the pharmacokinetic/pharmacodynamic surrogate index (area under the curve / minimum inhibitory concentration) of 100-125, LFX has the potential to be an effective treatment for infections caused by bacteria with a MIC of 0.049-0.061 μg/mL.",Pharmacokinetic and tissue analyses of levofloxacin in sheep (Ovis aries Linnaeus) after multiple-dose administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31778853/),,100-125,188925,DB01137,Levofloxacin
,31778853,MIC,"According to the pharmacokinetic/pharmacodynamic surrogate index (area under the curve / minimum inhibitory concentration) of 100-125, LFX has the potential to be an effective treatment for infections caused by bacteria with a MIC of 0.049-0.061 μg/mL.",Pharmacokinetic and tissue analyses of levofloxacin in sheep (Ovis aries Linnaeus) after multiple-dose administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31778853/),[μg] / [ml],0.049-0.061,188926,DB01137,Levofloxacin
lower,31778853,AUCtissue/plasma ratio,The AUCtissue/plasma ratio was lower than 1 in all tissues indicating absence of LFX tissue accumulation.,Pharmacokinetic and tissue analyses of levofloxacin in sheep (Ovis aries Linnaeus) after multiple-dose administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31778853/),,1,188927,DB01137,Levofloxacin
,29463539,peak concentration (Cmax),The peak concentration (Cmax) of LFX was significantly higher in female than male children (11.5 μg/ml versus 7.3 μg/ml; P = 0.017).,Pharmacokinetics of Second-Line Antituberculosis Drugs in Children with Multidrug-Resistant Tuberculosis in India. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29463539/),[μg] / [ml],11.5,189537,DB01137,Levofloxacin
,29463539,peak concentration (Cmax),The peak concentration (Cmax) of LFX was significantly higher in female than male children (11.5 μg/ml versus 7.3 μg/ml; P = 0.017).,Pharmacokinetics of Second-Line Antituberculosis Drugs in Children with Multidrug-Resistant Tuberculosis in India. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29463539/),[μg] / [ml],7.3,189538,DB01137,Levofloxacin
,29463539,area under the concentration-time curve from 0 to 8 h [AUC0-8],Children below 12 years of age had significantly higher ETH exposure (area under the concentration-time curve from 0 to 8 h [AUC0-8]) than those above 12 years of age (17.5 μg/ml · h versus 9.4 μg/ml; P = 0.030).,Pharmacokinetics of Second-Line Antituberculosis Drugs in Children with Multidrug-Resistant Tuberculosis in India. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29463539/),[μg] / [h·ml],17.5,189539,DB01137,Levofloxacin
,29463539,area under the concentration-time curve from 0 to 8 h [AUC0-8],Children below 12 years of age had significantly higher ETH exposure (area under the concentration-time curve from 0 to 8 h [AUC0-8]) than those above 12 years of age (17.5 μg/ml · h versus 9.4 μg/ml; P = 0.030).,Pharmacokinetics of Second-Line Antituberculosis Drugs in Children with Multidrug-Resistant Tuberculosis in India. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29463539/),[μg] / [ml],9.4,189540,DB01137,Levofloxacin
,9869571,peak plasma levels,"When HMR 3647 was given (10 mg/kg of body weight) by the intraperitoneal route to infected guinea pigs, mean peak plasma levels were 1.4 microg/ml at 0.5 h and 1.0 microg/ml at 1 h postinjection.","In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9869571/),[μg] / [ml],1.4,190855,DB01137,Levofloxacin
,9869571,peak plasma levels,"When HMR 3647 was given (10 mg/kg of body weight) by the intraperitoneal route to infected guinea pigs, mean peak plasma levels were 1.4 microg/ml at 0.5 h and 1.0 microg/ml at 1 h postinjection.","In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9869571/),[μg] / [ml],1.0,190856,DB01137,Levofloxacin
,9869571,terminal half-life phase of elimination,The terminal half-life phase of elimination from plasma was 1.4 h.,"In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9869571/),h,1.4,190857,DB01137,Levofloxacin
,22003841,C(max),"The increase was significant when a single dose of levofloxacin was administered with steady-state level of lithium (C(max) of lithium: 2.54 ± 0.15 vs 2.79 ± 0.12 mm, P < 0.001 and AUC(0-α) of lithium: 24.36 ± 3.68 vs 31.88 ± 4.83 mmol/mL h, P < 0.001).",Effect of levofloxacin on lithium - a pharmacokinetic study in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22003841/),mm,2.54,192444,DB01137,Levofloxacin
,22003841,C(max),"The increase was significant when a single dose of levofloxacin was administered with steady-state level of lithium (C(max) of lithium: 2.54 ± 0.15 vs 2.79 ± 0.12 mm, P < 0.001 and AUC(0-α) of lithium: 24.36 ± 3.68 vs 31.88 ± 4.83 mmol/mL h, P < 0.001).",Effect of levofloxacin on lithium - a pharmacokinetic study in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22003841/),mm,2.79,192445,DB01137,Levofloxacin
,22003841,AUC(0-α),"The increase was significant when a single dose of levofloxacin was administered with steady-state level of lithium (C(max) of lithium: 2.54 ± 0.15 vs 2.79 ± 0.12 mm, P < 0.001 and AUC(0-α) of lithium: 24.36 ± 3.68 vs 31.88 ± 4.83 mmol/mL h, P < 0.001).",Effect of levofloxacin on lithium - a pharmacokinetic study in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22003841/),[mM] / [h·ml],24.36,192446,DB01137,Levofloxacin
,22003841,AUC(0-α),"The increase was significant when a single dose of levofloxacin was administered with steady-state level of lithium (C(max) of lithium: 2.54 ± 0.15 vs 2.79 ± 0.12 mm, P < 0.001 and AUC(0-α) of lithium: 24.36 ± 3.68 vs 31.88 ± 4.83 mmol/mL h, P < 0.001).",Effect of levofloxacin on lithium - a pharmacokinetic study in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22003841/),[mM] / [h·ml],31.88,192447,DB01137,Levofloxacin
,22003841,C(max),"The increase in lithium levels was also significant when levofloxacin was coprescribed for 3 days after lithium steady-state levels were achieved (C(max) increased from 2.72 ± 0.29 to 3.96 ± 0.29 mm, P < 0.001 and AUC(0-α) increased from 27.1 ± 4.96 to 42.64 ± 4.94 mmol/mL h).",Effect of levofloxacin on lithium - a pharmacokinetic study in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22003841/),mm,2.72,192448,DB01137,Levofloxacin
,22003841,C(max),"The increase in lithium levels was also significant when levofloxacin was coprescribed for 3 days after lithium steady-state levels were achieved (C(max) increased from 2.72 ± 0.29 to 3.96 ± 0.29 mm, P < 0.001 and AUC(0-α) increased from 27.1 ± 4.96 to 42.64 ± 4.94 mmol/mL h).",Effect of levofloxacin on lithium - a pharmacokinetic study in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22003841/),mm,3.96,192449,DB01137,Levofloxacin
,22003841,AUC(0-α),"The increase in lithium levels was also significant when levofloxacin was coprescribed for 3 days after lithium steady-state levels were achieved (C(max) increased from 2.72 ± 0.29 to 3.96 ± 0.29 mm, P < 0.001 and AUC(0-α) increased from 27.1 ± 4.96 to 42.64 ± 4.94 mmol/mL h).",Effect of levofloxacin on lithium - a pharmacokinetic study in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22003841/),[mM] / [h·ml],27.1,192450,DB01137,Levofloxacin
,22003841,AUC(0-α),"The increase in lithium levels was also significant when levofloxacin was coprescribed for 3 days after lithium steady-state levels were achieved (C(max) increased from 2.72 ± 0.29 to 3.96 ± 0.29 mm, P < 0.001 and AUC(0-α) increased from 27.1 ± 4.96 to 42.64 ± 4.94 mmol/mL h).",Effect of levofloxacin on lithium - a pharmacokinetic study in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22003841/),[mM] / [h·ml],42.64,192451,DB01137,Levofloxacin
,22392918,charge,"After lyophilization of levofloxacin-loaded nanoparticles, the average size, charge, and polydispersity index were 268 ± 18 nm, -10.2 ± 1.5 mV, and 0.15 ± 0.03, respectively.","Optimization, in vitro-in vivo evaluation, and short-term tolerability of novel levofloxacin-loaded PLGA nanoparticle formulation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22392918/),mv,-,192810,DB01137,Levofloxacin
,22392918,polydispersity index,"After lyophilization of levofloxacin-loaded nanoparticles, the average size, charge, and polydispersity index were 268 ± 18 nm, -10.2 ± 1.5 mV, and 0.15 ± 0.03, respectively.","Optimization, in vitro-in vivo evaluation, and short-term tolerability of novel levofloxacin-loaded PLGA nanoparticle formulation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22392918/),mv,10.2,192811,DB01137,Levofloxacin
,22392918,polydispersity index,"After lyophilization of levofloxacin-loaded nanoparticles, the average size, charge, and polydispersity index were 268 ± 18 nm, -10.2 ± 1.5 mV, and 0.15 ± 0.03, respectively.","Optimization, in vitro-in vivo evaluation, and short-term tolerability of novel levofloxacin-loaded PLGA nanoparticle formulation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22392918/),,0.15,192812,DB01137,Levofloxacin
,22392918,maximum drug encapsulation efficiency,"The maximum drug encapsulation efficiency and loading capacity were 36.9 ± 6.1% (w/w) and 7.2 ± 1.2 mg/100 mg nanopowder, respectively.","Optimization, in vitro-in vivo evaluation, and short-term tolerability of novel levofloxacin-loaded PLGA nanoparticle formulation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22392918/),%,36.9,192813,DB01137,Levofloxacin
,22392918,loading capacity,"The maximum drug encapsulation efficiency and loading capacity were 36.9 ± 6.1% (w/w) and 7.2 ± 1.2 mg/100 mg nanopowder, respectively.","Optimization, in vitro-in vivo evaluation, and short-term tolerability of novel levofloxacin-loaded PLGA nanoparticle formulation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22392918/),mg,7.2,192814,DB01137,Levofloxacin
,28566592,AUC0→24,"The estimated PK parameters of MFLX were as follows: AUC0→24, 61.04±17.74 μg h/mL; Cmax, 5.25±1.12 μg/mL; and Ctrough, 1.15±0.45 μg/mL.","A Prospective Study of the Efficacy, Safety and Pharmacokinetics of Enteral Moxifloxacin in the Treatment of Hemodialysis Patients with Pneumonia. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28566592/),[h·μg] / [ml],61.04,193106,DB01137,Levofloxacin
,28566592,Cmax,"The estimated PK parameters of MFLX were as follows: AUC0→24, 61.04±17.74 μg h/mL; Cmax, 5.25±1.12 μg/mL; and Ctrough, 1.15±0.45 μg/mL.","A Prospective Study of the Efficacy, Safety and Pharmacokinetics of Enteral Moxifloxacin in the Treatment of Hemodialysis Patients with Pneumonia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28566592/),[μg] / [ml],5.25,193107,DB01137,Levofloxacin
,28566592,Ctrough,"The estimated PK parameters of MFLX were as follows: AUC0→24, 61.04±17.74 μg h/mL; Cmax, 5.25±1.12 μg/mL; and Ctrough, 1.15±0.45 μg/mL.","A Prospective Study of the Efficacy, Safety and Pharmacokinetics of Enteral Moxifloxacin in the Treatment of Hemodialysis Patients with Pneumonia. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28566592/),[μg] / [ml],1.15,193108,DB01137,Levofloxacin
,9559783,rates of survival,"In accord with the pulmonary clearance results, the rates of survival for mice treated with HSR-903, sparfloxacin, levofloxacin, ciprofloxacin, and benzylpenicillin were 50, 30, 10, 0, and 0%, respectively, 14 days after being infected with penicillin-resistant S. pneumoniae.","In vivo activity of HSR-903, a new fluoroquinolone, against respiratory pathogens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559783/),%,50,193204,DB01137,Levofloxacin
,9559783,rates of survival,"In accord with the pulmonary clearance results, the rates of survival for mice treated with HSR-903, sparfloxacin, levofloxacin, ciprofloxacin, and benzylpenicillin were 50, 30, 10, 0, and 0%, respectively, 14 days after being infected with penicillin-resistant S. pneumoniae.","In vivo activity of HSR-903, a new fluoroquinolone, against respiratory pathogens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559783/),%,30,193205,DB01137,Levofloxacin
,9559783,rates of survival,"In accord with the pulmonary clearance results, the rates of survival for mice treated with HSR-903, sparfloxacin, levofloxacin, ciprofloxacin, and benzylpenicillin were 50, 30, 10, 0, and 0%, respectively, 14 days after being infected with penicillin-resistant S. pneumoniae.","In vivo activity of HSR-903, a new fluoroquinolone, against respiratory pathogens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559783/),%,10,193206,DB01137,Levofloxacin
,9559783,rates of survival,"In accord with the pulmonary clearance results, the rates of survival for mice treated with HSR-903, sparfloxacin, levofloxacin, ciprofloxacin, and benzylpenicillin were 50, 30, 10, 0, and 0%, respectively, 14 days after being infected with penicillin-resistant S. pneumoniae.","In vivo activity of HSR-903, a new fluoroquinolone, against respiratory pathogens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559783/),%,0,193207,DB01137,Levofloxacin
,26260983,plasma area under the curve (AUC)0-24,A population PK/pharmacodynamic (PD) model using adult data defined rifampin target exposures (plasma area under the curve (AUC)0-24 = 92 mg*h/L).,Pediatric tuberculous meningitis: Model-based approach to determining optimal doses of the anti-tuberculosis drugs rifampin and levofloxacin for children. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26260983/),[h·mg] / [l],92,193505,DB01137,Levofloxacin
,10659442,penetration ratio,The penetration ratio of LVFX into lung tissue was 217.2% and that into sputum was 4.05%.,"[Levofloxacin concentrations in serum, sputum and lung tissue: evaluation of its efficacy according to breakpoint]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10659442/),%,217.2,193532,DB01137,Levofloxacin
,10659442,penetration ratio,The penetration ratio of LVFX into lung tissue was 217.2% and that into sputum was 4.05%.,"[Levofloxacin concentrations in serum, sputum and lung tissue: evaluation of its efficacy according to breakpoint]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10659442/),%,4.05,193533,DB01137,Levofloxacin
,10659442,breakpoints,"Based on the results of this study, the breakpoints (BPs) of LVFX for pneumonia and chronic respiratory tract infections were calculated to be 4 micrograms/ml and 1 microgram/ml, respectively.","[Levofloxacin concentrations in serum, sputum and lung tissue: evaluation of its efficacy according to breakpoint]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10659442/),,4,193534,DB01137,Levofloxacin
,10659442,breakpoints,"Based on the results of this study, the breakpoints (BPs) of LVFX for pneumonia and chronic respiratory tract infections were calculated to be 4 micrograms/ml and 1 microgram/ml, respectively.","[Levofloxacin concentrations in serum, sputum and lung tissue: evaluation of its efficacy according to breakpoint]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10659442/),,1,193535,DB01137,Levofloxacin
,25779583,concentration in serum (Cmax),"The median levofloxacin concentration in serum (Cmax) was 6.5 μg/ml, and it was <2 μg/ml in 3 (25%) patients.",Cavitary penetration of levofloxacin among patients with multidrug-resistant tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25779583/),[μg] / [ml],6.5,194543,DB01137,Levofloxacin
<,25779583,concentration in serum (Cmax),"The median levofloxacin concentration in serum (Cmax) was 6.5 μg/ml, and it was <2 μg/ml in 3 (25%) patients.",Cavitary penetration of levofloxacin among patients with multidrug-resistant tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25779583/),[μg] / [ml],2,194544,DB01137,Levofloxacin
,25779583,cavitary concentration,"Among 11 patients with complete data, the median cavitary concentration of levofloxacin was 4.36 μg/ml (range, 0.46 to 8.82).",Cavitary penetration of levofloxacin among patients with multidrug-resistant tuberculosis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25779583/),[μg] / [ml],4.36,194545,DB01137,Levofloxacin
,25779583,cavitary/serum levofloxacin ratio,"The median cavitary/serum levofloxacin ratio was 1.33 (range, 0.63 to 2.36), and 7 patients (64%) had a ratio of >1.",Cavitary penetration of levofloxacin among patients with multidrug-resistant tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25779583/),,1.33,194546,DB01137,Levofloxacin
>,25779583,ratio,"The median cavitary/serum levofloxacin ratio was 1.33 (range, 0.63 to 2.36), and 7 patients (64%) had a ratio of >1.",Cavitary penetration of levofloxacin among patients with multidrug-resistant tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25779583/),,1,194547,DB01137,Levofloxacin
<,10974576,AUC/MIC(24),LVX AUC/MIC(24) of </=20 CFU/ml.,"In vitro characterization of fluoroquinolone concentration/MIC antimicrobial activity and resistance while simulating clinical pharmacokinetics of levofloxacin, ofloxacin, or ciprofloxacin against Streptococcus pneumoniae. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10974576/),[cfu] / [ml],20,195484,DB01137,Levofloxacin
<,10974576,C(max)/MIC,Selection of fluoroquinolone resistance only occurred at C(max)/MIC < 5.0 (p = 0.03).,"In vitro characterization of fluoroquinolone concentration/MIC antimicrobial activity and resistance while simulating clinical pharmacokinetics of levofloxacin, ofloxacin, or ciprofloxacin against Streptococcus pneumoniae. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10974576/),,5.0,195485,DB01137,Levofloxacin
,15767227,peak levofloxacin exposure,"At steady state, peak levofloxacin exposure in breast milk was 8.2 microg/ml at 5 hours after dosing.",Levofloxacin secretion in breast milk: a case report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15767227/),[μg] / [ml],8.2,196076,DB01137,Levofloxacin
,12900817,systemic clearance,"Median systemic clearance, volume of distribution at steady state, elimination half-life, and C(max) were 37.0 mL/min (range, 12.8 to 42.7 mL/min), 103.3 L (range, 39.8 to 139.3 L), 34.4 hours (range, 28.4 to 39.3 hours), and 5.2 microg/mL (range, 4.1 to 11.3 microg/mL), respectively.",Levofloxacin pharmacokinetics in ESRD and removal by the cellulose acetate high performance-210 hemodialyzer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12900817/),[ml] / [min],37.0,197163,DB01137,Levofloxacin
,12900817,C(max),"Median systemic clearance, volume of distribution at steady state, elimination half-life, and C(max) were 37.0 mL/min (range, 12.8 to 42.7 mL/min), 103.3 L (range, 39.8 to 139.3 L), 34.4 hours (range, 28.4 to 39.3 hours), and 5.2 microg/mL (range, 4.1 to 11.3 microg/mL), respectively.",Levofloxacin pharmacokinetics in ESRD and removal by the cellulose acetate high performance-210 hemodialyzer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12900817/),h,34.4,197164,DB01137,Levofloxacin
,12900817,C(max),"Median systemic clearance, volume of distribution at steady state, elimination half-life, and C(max) were 37.0 mL/min (range, 12.8 to 42.7 mL/min), 103.3 L (range, 39.8 to 139.3 L), 34.4 hours (range, 28.4 to 39.3 hours), and 5.2 microg/mL (range, 4.1 to 11.3 microg/mL), respectively.",Levofloxacin pharmacokinetics in ESRD and removal by the cellulose acetate high performance-210 hemodialyzer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12900817/),[μg] / [ml],5.2,197165,DB01137,Levofloxacin
,12900817,dialytic clearance,"Median dialytic clearance and levofloxacin reduction ratios were 84.4 mL/min (range, 61.8 to 107.6 mL/min) and 0.244 (range, 0.181 to 0.412), respectively.",Levofloxacin pharmacokinetics in ESRD and removal by the cellulose acetate high performance-210 hemodialyzer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12900817/),[ml] / [min],84.4,197166,DB01137,Levofloxacin
,12900817,reduction ratios,"Median dialytic clearance and levofloxacin reduction ratios were 84.4 mL/min (range, 61.8 to 107.6 mL/min) and 0.244 (range, 0.181 to 0.412), respectively.",Levofloxacin pharmacokinetics in ESRD and removal by the cellulose acetate high performance-210 hemodialyzer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12900817/),,0.244,197167,DB01137,Levofloxacin
,12900817,C(max)-MIC90 ratios,"Median C(max)-MIC90 ratios were 10 or greater for Haemophilus influenzae, Moraxella catarrhalis, Enterobacter cloacae, and Klebsiella pneumoniae, approximately 5 for Streptococcus pneumoniae, and less than 1 for Pseudomonas aeruginosa.",Levofloxacin pharmacokinetics in ESRD and removal by the cellulose acetate high performance-210 hemodialyzer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12900817/),,10,197168,DB01137,Levofloxacin
,12900817,C(max)-MIC90 ratios,"Median C(max)-MIC90 ratios were 10 or greater for Haemophilus influenzae, Moraxella catarrhalis, Enterobacter cloacae, and Klebsiella pneumoniae, approximately 5 for Streptococcus pneumoniae, and less than 1 for Pseudomonas aeruginosa.",Levofloxacin pharmacokinetics in ESRD and removal by the cellulose acetate high performance-210 hemodialyzer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12900817/),,5,197169,DB01137,Levofloxacin
less,12900817,C(max)-MIC90 ratios,"Median C(max)-MIC90 ratios were 10 or greater for Haemophilus influenzae, Moraxella catarrhalis, Enterobacter cloacae, and Klebsiella pneumoniae, approximately 5 for Streptococcus pneumoniae, and less than 1 for Pseudomonas aeruginosa.",Levofloxacin pharmacokinetics in ESRD and removal by the cellulose acetate high performance-210 hemodialyzer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12900817/),,1,197170,DB01137,Levofloxacin
,12900817,MICs,"The administration of levofloxacin to patients with ESRD as 500 mg initially, followed by 250 mg every 48 hours, will provide adequate C(max)-MIC ratios after the first and subsequent doses for most patients with respiratory tract infections caused by organisms with levofloxacin MICs of 1 microg/mL or less.",Levofloxacin pharmacokinetics in ESRD and removal by the cellulose acetate high performance-210 hemodialyzer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12900817/),[μg] / [ml],1,197171,DB01137,Levofloxacin
,12673102,half-lives,"The respective half-lives were 4, 7.4, 6.8 and 12.1 h, and the AUC/MICs were 730, 1,130, 920 and 690 h.",Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12673102/),h,4,198508,DB01137,Levofloxacin
,12673102,half-lives,"The respective half-lives were 4, 7.4, 6.8 and 12.1 h, and the AUC/MICs were 730, 1,130, 920 and 690 h.",Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12673102/),h,7.4,198509,DB01137,Levofloxacin
,12673102,half-lives,"The respective half-lives were 4, 7.4, 6.8 and 12.1 h, and the AUC/MICs were 730, 1,130, 920 and 690 h.",Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12673102/),h,6.8,198510,DB01137,Levofloxacin
,12673102,half-lives,"The respective half-lives were 4, 7.4, 6.8 and 12.1 h, and the AUC/MICs were 730, 1,130, 920 and 690 h.",Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12673102/),h,12.1,198511,DB01137,Levofloxacin
,12673102,AUC/MICs,"The respective half-lives were 4, 7.4, 6.8 and 12.1 h, and the AUC/MICs were 730, 1,130, 920 and 690 h.",Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12673102/),h,730,198512,DB01137,Levofloxacin
,12673102,AUC/MICs,"The respective half-lives were 4, 7.4, 6.8 and 12.1 h, and the AUC/MICs were 730, 1,130, 920 and 690 h.",Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12673102/),h,1,198513,DB01137,Levofloxacin
,12673102,AUC/MICs,"The respective half-lives were 4, 7.4, 6.8 and 12.1 h, and the AUC/MICs were 730, 1,130, 920 and 690 h.",Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12673102/),h,130,198514,DB01137,Levofloxacin
,12673102,AUC/MICs,"The respective half-lives were 4, 7.4, 6.8 and 12.1 h, and the AUC/MICs were 730, 1,130, 920 and 690 h.",Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12673102/),h,920,198515,DB01137,Levofloxacin
,12673102,AUC/MICs,"The respective half-lives were 4, 7.4, 6.8 and 12.1 h, and the AUC/MICs were 730, 1,130, 920 and 690 h.",Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12673102/),h,690,198516,DB01137,Levofloxacin
,24937382,Size,Size of the microspheres after freeze-drying was 4.96 ± 0.76 μm and well-distributed.,Preparation oral levofloxacin colon-specific microspheres delivery: in vitro and in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24937382/),μm,4.96,199250,DB01137,Levofloxacin
,24937382,zeta potential,The zeta potential of microspheres was -29.3 ± 2.1 mV.,Preparation oral levofloxacin colon-specific microspheres delivery: in vitro and in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24937382/),mv,-29.3,199251,DB01137,Levofloxacin
,24937382,drug loading,An average drug loading of 9.3 ± 0.4% and encapsulation efficiency of 81.1 ± 4.7% of levofloxacin microspheres were obtained with the optimized preparation parameters.,Preparation oral levofloxacin colon-specific microspheres delivery: in vitro and in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24937382/),%,9.3,199252,DB01137,Levofloxacin
,24937382,encapsulation efficiency,An average drug loading of 9.3 ± 0.4% and encapsulation efficiency of 81.1 ± 4.7% of levofloxacin microspheres were obtained with the optimized preparation parameters.,Preparation oral levofloxacin colon-specific microspheres delivery: in vitro and in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24937382/),%,81.1,199253,DB01137,Levofloxacin
,25753830,C max,"In the plasma concentration-versus-time profile of levofloxacin in rats, C max was 23.570 μg/ml at 5 min after intravenous injection, and t1/2 was 2.38 h.",Prediction of the pharmacokinetics and tissue distribution of levofloxacin in humans based on an extrapolated PBPK model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25753830/),[μg] / [ml],23.570,199296,DB01137,Levofloxacin
,25753830,t1/2,"In the plasma concentration-versus-time profile of levofloxacin in rats, C max was 23.570 μg/ml at 5 min after intravenous injection, and t1/2 was 2.38 h.",Prediction of the pharmacokinetics and tissue distribution of levofloxacin in humans based on an extrapolated PBPK model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25753830/),h,2.38,199297,DB01137,Levofloxacin
,25753830,tissue-to-plasma concentration ratios,The predicted tissue-to-plasma concentration ratios in abdominal viscera were between 1.9 and 2.3.,Prediction of the pharmacokinetics and tissue distribution of levofloxacin in humans based on an extrapolated PBPK model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25753830/),,1.9 and 2.3,199298,DB01137,Levofloxacin
,27886514,polydispersity index (PDI),Vesicles were spherical in shape and the size was 190.31 ± 4.51 nm with a polydispersity index (PDI) of 0.29 ± 0.03.,Sugar-based novel niosomal nanocarrier system for enhanced oral bioavailability of levofloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27886514/),,0.29,199607,DB01137,Levofloxacin
,27886514,EE,The drug EE in niosomes was 68.28 ± 3.45%.,Sugar-based novel niosomal nanocarrier system for enhanced oral bioavailability of levofloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27886514/),%,68.28,199608,DB01137,Levofloxacin
at,9440662,Peak/MIC ratio,Both clinical and microbiological outcomes were most likely to be favorable if the Peak/MIC ratio was at least 12.2.,Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9440662/),,12.2,201589,DB01137,Levofloxacin
,15060787,maximum concentration,"The maximum concentration in the aqueous humor of normal rabbit eyes was 2.09 +/- 1.56 microg/ml (60 min, OFLX), 2.57 +/- 1.00 microg/ml (30 min, LVFX), and 0.42 +/- 0.12 microg/ml (120 min, NFLX).",The effect of the corneal epithelium on the intraocular penetration of fluoroquinolone ophthalmic solution. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15060787/),[μg] / [ml],2.09,201865,DB01137,Levofloxacin
,15060787,maximum concentration,"The maximum concentration in the aqueous humor of normal rabbit eyes was 2.09 +/- 1.56 microg/ml (60 min, OFLX), 2.57 +/- 1.00 microg/ml (30 min, LVFX), and 0.42 +/- 0.12 microg/ml (120 min, NFLX).",The effect of the corneal epithelium on the intraocular penetration of fluoroquinolone ophthalmic solution. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15060787/),[μg] / [ml],2.57,201866,DB01137,Levofloxacin
,15060787,maximum concentration,"The maximum concentration in the aqueous humor of normal rabbit eyes was 2.09 +/- 1.56 microg/ml (60 min, OFLX), 2.57 +/- 1.00 microg/ml (30 min, LVFX), and 0.42 +/- 0.12 microg/ml (120 min, NFLX).",The effect of the corneal epithelium on the intraocular penetration of fluoroquinolone ophthalmic solution. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15060787/),[μg] / [ml],0.42,201867,DB01137,Levofloxacin
,15060787,drug concentration,"The drug concentration in the aqueous humor of eyes with intentionally removed corneal epithelium was 12.50 +/- 5.62 microg/ml (30 min, OFLX), 9.02 +/- 2.45 microg/ml (60 min, LVFX), and 8.54 +/- 5.17 microg/ml (30 min, NFLX).",The effect of the corneal epithelium on the intraocular penetration of fluoroquinolone ophthalmic solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15060787/),[μg] / [ml],12.50,201868,DB01137,Levofloxacin
,15060787,drug concentration,"The drug concentration in the aqueous humor of eyes with intentionally removed corneal epithelium was 12.50 +/- 5.62 microg/ml (30 min, OFLX), 9.02 +/- 2.45 microg/ml (60 min, LVFX), and 8.54 +/- 5.17 microg/ml (30 min, NFLX).",The effect of the corneal epithelium on the intraocular penetration of fluoroquinolone ophthalmic solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15060787/),[μg] / [ml],9.02,201869,DB01137,Levofloxacin
,15060787,drug concentration,"The drug concentration in the aqueous humor of eyes with intentionally removed corneal epithelium was 12.50 +/- 5.62 microg/ml (30 min, OFLX), 9.02 +/- 2.45 microg/ml (60 min, LVFX), and 8.54 +/- 5.17 microg/ml (30 min, NFLX).",The effect of the corneal epithelium on the intraocular penetration of fluoroquinolone ophthalmic solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15060787/),[μg] / [ml],8.54,201870,DB01137,Levofloxacin
,11939681,total AUC:MIC ratios,"With use of composite data, total AUC:MIC ratios associated with 50%, 90%, and 99% of Emax were 34:1, 56:1, and 95:1, respectively",Evaluation of survival and pharmacodynamic relationships for five fluoroquinolones in a neutropenic murine model of pneumococcal lung infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11939681/),,34:1,202408,DB01137,Levofloxacin
,11939681,total AUC:MIC ratios,"With use of composite data, total AUC:MIC ratios associated with 50%, 90%, and 99% of Emax were 34:1, 56:1, and 95:1, respectively",Evaluation of survival and pharmacodynamic relationships for five fluoroquinolones in a neutropenic murine model of pneumococcal lung infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11939681/),,56:,202409,DB01137,Levofloxacin
,11939681,total AUC:MIC ratios,"With use of composite data, total AUC:MIC ratios associated with 50%, 90%, and 99% of Emax were 34:1, 56:1, and 95:1, respectively",Evaluation of survival and pharmacodynamic relationships for five fluoroquinolones in a neutropenic murine model of pneumococcal lung infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11939681/),:,95,202410,DB01137,Levofloxacin
,15848296,AUC/MIC ratios,With S. pneumoniae ATCC 49619 eight-fold ranging AUC/MIC ratios (60-500 h) were simulated for each quinolone.,Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848296/),h,60-500,204555,DB01137,Levofloxacin
,15848296,AUC/MICs,"In addition, two larger AUC/MICs, i.e., 1080 and 2150 h for ABT492 and 1460 and 3660 h for levofloxacin which correspond to 100 and 200 mg doses of ABT492 and 200 and 500 mg doses of levofloxacin, respectively, were mimicked.",Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848296/),h,1080,204556,DB01137,Levofloxacin
,15848296,AUC/MICs,"In addition, two larger AUC/MICs, i.e., 1080 and 2150 h for ABT492 and 1460 and 3660 h for levofloxacin which correspond to 100 and 200 mg doses of ABT492 and 200 and 500 mg doses of levofloxacin, respectively, were mimicked.",Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848296/),h,2150,204557,DB01137,Levofloxacin
,15848296,AUC/MICs,"In addition, two larger AUC/MICs, i.e., 1080 and 2150 h for ABT492 and 1460 and 3660 h for levofloxacin which correspond to 100 and 200 mg doses of ABT492 and 200 and 500 mg doses of levofloxacin, respectively, were mimicked.",Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848296/),h,1460,204558,DB01137,Levofloxacin
,15848296,AUC/MICs,"In addition, two larger AUC/MICs, i.e., 1080 and 2150 h for ABT492 and 1460 and 3660 h for levofloxacin which correspond to 100 and 200 mg doses of ABT492 and 200 and 500 mg doses of levofloxacin, respectively, were mimicked.",Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848296/),h,3660,204559,DB01137,Levofloxacin
,15848296,AUC/MIC ratios,Each ciprofloxacin-resistant organism was exposed to the clinical doses of ABT492 (400 mg) and levofloxacin (500 mg); the respective AUC/MIC ratios were from 580 to 3470 h and from 28 to 110 h.,Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848296/),h,580 to 3470,204560,DB01137,Levofloxacin
,15848296,AUC/MIC ratios,Each ciprofloxacin-resistant organism was exposed to the clinical doses of ABT492 (400 mg) and levofloxacin (500 mg); the respective AUC/MIC ratios were from 580 to 3470 h and from 28 to 110 h.,Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848296/),h,28 to 110,204561,DB01137,Levofloxacin
,15848296,AUC/MICs,"At comparable AUC/MICs (from 60 to 500 h), regrowth of S. pneumoniae ATCC 49619 followed initial killing, and the times to regrowth were longer with levofloxacin than ABT492.",Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848296/),h,60 to 500,204562,DB01137,Levofloxacin
,15848296,AUC/MICs,"However, no regrowth of S. pneumoniae ATCC 49619 occurred at the higher AUC/MICs of ABT492 (1080 and 2150 h) and levofloxacin (1460 and 3660 h).",Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848296/),h,1080,204563,DB01137,Levofloxacin
,15848296,AUC/MICs,"However, no regrowth of S. pneumoniae ATCC 49619 occurred at the higher AUC/MICs of ABT492 (1080 and 2150 h) and levofloxacin (1460 and 3660 h).",Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848296/),h,2150,204564,DB01137,Levofloxacin
,15848296,AUC/MICs,"However, no regrowth of S. pneumoniae ATCC 49619 occurred at the higher AUC/MICs of ABT492 (1080 and 2150 h) and levofloxacin (1460 and 3660 h).",Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848296/),h,1460,204565,DB01137,Levofloxacin
,15848296,AUC/MICs,"However, no regrowth of S. pneumoniae ATCC 49619 occurred at the higher AUC/MICs of ABT492 (1080 and 2150 h) and levofloxacin (1460 and 3660 h).",Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848296/),h,3660,204566,DB01137,Levofloxacin
,15848296,AUC/MIC,"Killing of S. pneumoniae 1149, 391 and 79 without bacterial regrowth, was provided by ABT492 (AUC/MIC 3470, 2310 and 1160 h, respectively) but not levofloxacin (AUC/MIC 55, 110 and 28 h, respectively).",Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848296/),h,3470,204567,DB01137,Levofloxacin
,15848296,AUC/MIC,"Killing of S. pneumoniae 1149, 391 and 79 without bacterial regrowth, was provided by ABT492 (AUC/MIC 3470, 2310 and 1160 h, respectively) but not levofloxacin (AUC/MIC 55, 110 and 28 h, respectively).",Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848296/),h,2310,204568,DB01137,Levofloxacin
,15848296,AUC/MIC,"Killing of S. pneumoniae 1149, 391 and 79 without bacterial regrowth, was provided by ABT492 (AUC/MIC 3470, 2310 and 1160 h, respectively) but not levofloxacin (AUC/MIC 55, 110 and 28 h, respectively).",Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848296/),h,1160,204569,DB01137,Levofloxacin
,15848296,AUC/MIC,"Killing of S. pneumoniae 1149, 391 and 79 without bacterial regrowth, was provided by ABT492 (AUC/MIC 3470, 2310 and 1160 h, respectively) but not levofloxacin (AUC/MIC 55, 110 and 28 h, respectively).",Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848296/),h,55,204570,DB01137,Levofloxacin
,15848296,AUC/MIC,"Killing of S. pneumoniae 1149, 391 and 79 without bacterial regrowth, was provided by ABT492 (AUC/MIC 3470, 2310 and 1160 h, respectively) but not levofloxacin (AUC/MIC 55, 110 and 28 h, respectively).",Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848296/),h,110,204571,DB01137,Levofloxacin
,15848296,AUC/MIC,"Killing of S. pneumoniae 1149, 391 and 79 without bacterial regrowth, was provided by ABT492 (AUC/MIC 3470, 2310 and 1160 h, respectively) but not levofloxacin (AUC/MIC 55, 110 and 28 h, respectively).",Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848296/),h,28,204572,DB01137,Levofloxacin
,15848296,AUC/MIC,"Regrowth of S. pneumoniae 804 was observed with both ABT492 and levofloxacin (AUC/MIC 580 and 55 h, respectively).",Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848296/),h,580,204573,DB01137,Levofloxacin
,15848296,AUC/MIC,"Regrowth of S. pneumoniae 804 was observed with both ABT492 and levofloxacin (AUC/MIC 580 and 55 h, respectively).",Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848296/),h,55,204574,DB01137,Levofloxacin
,11796385,penetration ratio (ELF/plasma),Evaluation from the population mean values demonstrated a penetration ratio (ELF/plasma) of 1.16.,Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and monte carlo simulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11796385/),,1.16,205498,DB01137,Levofloxacin
,12654762,T > MIC,Antibacterial effects were bacteriostatic when T > MIC was 48% and bactericidal when values exceeded 55%.,AUC(0-t)/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12654762/),%,48,205830,DB01137,Levofloxacin
,12654762,AUC0-t/MICs,"Bactericidal activity and bacterial eradication were associated with AUC0-t/MICs of 28 and 135, respectively.",AUC(0-t)/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12654762/),,28,205831,DB01137,Levofloxacin
,12654762,AUC0-t/MICs,"Bactericidal activity and bacterial eradication were associated with AUC0-t/MICs of 28 and 135, respectively.",AUC(0-t)/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12654762/),,135,205832,DB01137,Levofloxacin
,12654762,AUC0-t/MIC,"AUC0-t/MIC was also highly predictive of bacterial kill curves produced by simulated clinical doses of moxifloxacin and levofloxacin (precision 0.36 log10 cfu/mL, bias 0.02 log10 cfu/mL).",AUC(0-t)/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12654762/),,0,205833,DB01137,Levofloxacin
,14998081,urinary,"Mean (+/- SD) levofloxacin urinary concentrations were 329.1 +/- 159.9, 388.6 +/- 143.5, 266.0 +/- 102.8 and 168.1 +/- 93.3mg/L at 0-2h, 2-4h, 4-8h and 8-12h, respectively, with urinary AUC0-tau of 3171.4 +/- 1192.1mg/L x h.",Urinary pharmacokinetics and theoretical pharmacodynamics of intravenous levofloxacin in intensive care unit patients treated with 500 mg b.i.d. for ventilator-associated pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14998081/),[mg] / [l],329.1,206198,DB01137,Levofloxacin
,14998081,urinary,"Mean (+/- SD) levofloxacin urinary concentrations were 329.1 +/- 159.9, 388.6 +/- 143.5, 266.0 +/- 102.8 and 168.1 +/- 93.3mg/L at 0-2h, 2-4h, 4-8h and 8-12h, respectively, with urinary AUC0-tau of 3171.4 +/- 1192.1mg/L x h.",Urinary pharmacokinetics and theoretical pharmacodynamics of intravenous levofloxacin in intensive care unit patients treated with 500 mg b.i.d. for ventilator-associated pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14998081/),[mg] / [l],388.6,206199,DB01137,Levofloxacin
,14998081,urinary,"Mean (+/- SD) levofloxacin urinary concentrations were 329.1 +/- 159.9, 388.6 +/- 143.5, 266.0 +/- 102.8 and 168.1 +/- 93.3mg/L at 0-2h, 2-4h, 4-8h and 8-12h, respectively, with urinary AUC0-tau of 3171.4 +/- 1192.1mg/L x h.",Urinary pharmacokinetics and theoretical pharmacodynamics of intravenous levofloxacin in intensive care unit patients treated with 500 mg b.i.d. for ventilator-associated pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14998081/),[mg] / [l],266.0,206200,DB01137,Levofloxacin
,14998081,urinary,"Mean (+/- SD) levofloxacin urinary concentrations were 329.1 +/- 159.9, 388.6 +/- 143.5, 266.0 +/- 102.8 and 168.1 +/- 93.3mg/L at 0-2h, 2-4h, 4-8h and 8-12h, respectively, with urinary AUC0-tau of 3171.4 +/- 1192.1mg/L x h.",Urinary pharmacokinetics and theoretical pharmacodynamics of intravenous levofloxacin in intensive care unit patients treated with 500 mg b.i.d. for ventilator-associated pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14998081/),[mg] / [l],168.1,206201,DB01137,Levofloxacin
,14998081,concentrations,"Mean (+/- SD) levofloxacin urinary concentrations were 329.1 +/- 159.9, 388.6 +/- 143.5, 266.0 +/- 102.8 and 168.1 +/- 93.3mg/L at 0-2h, 2-4h, 4-8h and 8-12h, respectively, with urinary AUC0-tau of 3171.4 +/- 1192.1mg/L x h.",Urinary pharmacokinetics and theoretical pharmacodynamics of intravenous levofloxacin in intensive care unit patients treated with 500 mg b.i.d. for ventilator-associated pneumonia. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14998081/),[mg] / [l],329.1,206202,DB01137,Levofloxacin
,14998081,concentrations,"Mean (+/- SD) levofloxacin urinary concentrations were 329.1 +/- 159.9, 388.6 +/- 143.5, 266.0 +/- 102.8 and 168.1 +/- 93.3mg/L at 0-2h, 2-4h, 4-8h and 8-12h, respectively, with urinary AUC0-tau of 3171.4 +/- 1192.1mg/L x h.",Urinary pharmacokinetics and theoretical pharmacodynamics of intravenous levofloxacin in intensive care unit patients treated with 500 mg b.i.d. for ventilator-associated pneumonia. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14998081/),[mg] / [l],388.6,206203,DB01137,Levofloxacin
,14998081,concentrations,"Mean (+/- SD) levofloxacin urinary concentrations were 329.1 +/- 159.9, 388.6 +/- 143.5, 266.0 +/- 102.8 and 168.1 +/- 93.3mg/L at 0-2h, 2-4h, 4-8h and 8-12h, respectively, with urinary AUC0-tau of 3171.4 +/- 1192.1mg/L x h.",Urinary pharmacokinetics and theoretical pharmacodynamics of intravenous levofloxacin in intensive care unit patients treated with 500 mg b.i.d. for ventilator-associated pneumonia. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14998081/),[mg] / [l],266.0,206204,DB01137,Levofloxacin
,14998081,concentrations,"Mean (+/- SD) levofloxacin urinary concentrations were 329.1 +/- 159.9, 388.6 +/- 143.5, 266.0 +/- 102.8 and 168.1 +/- 93.3mg/L at 0-2h, 2-4h, 4-8h and 8-12h, respectively, with urinary AUC0-tau of 3171.4 +/- 1192.1mg/L x h.",Urinary pharmacokinetics and theoretical pharmacodynamics of intravenous levofloxacin in intensive care unit patients treated with 500 mg b.i.d. for ventilator-associated pneumonia. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14998081/),[mg] / [l],168.1,206205,DB01137,Levofloxacin
,14998081,AUC0-tau,"Mean (+/- SD) levofloxacin urinary concentrations were 329.1 +/- 159.9, 388.6 +/- 143.5, 266.0 +/- 102.8 and 168.1 +/- 93.3mg/L at 0-2h, 2-4h, 4-8h and 8-12h, respectively, with urinary AUC0-tau of 3171.4 +/- 1192.1mg/L x h.",Urinary pharmacokinetics and theoretical pharmacodynamics of intravenous levofloxacin in intensive care unit patients treated with 500 mg b.i.d. for ventilator-associated pneumonia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14998081/),[mg] / [h·l],3171.4,206206,DB01137,Levofloxacin
,14998081,excretion rates,"Mean (+/- SD) levofloxacin excretion rates were 44.1 +/- 20.7, 42.8 +/- 8.2, 31.7 +/- 5.8 and 19.8 +/- 4.2 mg/h during the 0-2h, 2-4, 4-8h and 8-12h interval, respectively.",Urinary pharmacokinetics and theoretical pharmacodynamics of intravenous levofloxacin in intensive care unit patients treated with 500 mg b.i.d. for ventilator-associated pneumonia. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14998081/),[mg] / [h],44.1,206207,DB01137,Levofloxacin
,14998081,excretion rates,"Mean (+/- SD) levofloxacin excretion rates were 44.1 +/- 20.7, 42.8 +/- 8.2, 31.7 +/- 5.8 and 19.8 +/- 4.2 mg/h during the 0-2h, 2-4, 4-8h and 8-12h interval, respectively.",Urinary pharmacokinetics and theoretical pharmacodynamics of intravenous levofloxacin in intensive care unit patients treated with 500 mg b.i.d. for ventilator-associated pneumonia. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14998081/),[mg] / [h],42.8,206208,DB01137,Levofloxacin
,14998081,excretion rates,"Mean (+/- SD) levofloxacin excretion rates were 44.1 +/- 20.7, 42.8 +/- 8.2, 31.7 +/- 5.8 and 19.8 +/- 4.2 mg/h during the 0-2h, 2-4, 4-8h and 8-12h interval, respectively.",Urinary pharmacokinetics and theoretical pharmacodynamics of intravenous levofloxacin in intensive care unit patients treated with 500 mg b.i.d. for ventilator-associated pneumonia. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14998081/),[mg] / [h],31.7,206209,DB01137,Levofloxacin
,14998081,excretion rates,"Mean (+/- SD) levofloxacin excretion rates were 44.1 +/- 20.7, 42.8 +/- 8.2, 31.7 +/- 5.8 and 19.8 +/- 4.2 mg/h during the 0-2h, 2-4, 4-8h and 8-12h interval, respectively.",Urinary pharmacokinetics and theoretical pharmacodynamics of intravenous levofloxacin in intensive care unit patients treated with 500 mg b.i.d. for ventilator-associated pneumonia. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14998081/),[mg] / [h],19.8,206210,DB01137,Levofloxacin
>,14998081,CU/MIC,"Considering the major pharmacodynamic determinants for the concentration-dependent bactericidal activity of levofloxacin as applicable at the urinary level (CU/MIC of >12.2 and/or AUC24h U /MIC of >125h), this high dosage regimen may ensure optimal exposure for the treatment of catheter-related and severe lower UTIs not only against sensitive microorganisms, but probably also whenever microorganisms usually considered as intermediate susceptible or resistant to levofloxacin may be involved.",Urinary pharmacokinetics and theoretical pharmacodynamics of intravenous levofloxacin in intensive care unit patients treated with 500 mg b.i.d. for ventilator-associated pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14998081/),,12.2,206211,DB01137,Levofloxacin
>,14998081,AUC24h U /MIC,"Considering the major pharmacodynamic determinants for the concentration-dependent bactericidal activity of levofloxacin as applicable at the urinary level (CU/MIC of >12.2 and/or AUC24h U /MIC of >125h), this high dosage regimen may ensure optimal exposure for the treatment of catheter-related and severe lower UTIs not only against sensitive microorganisms, but probably also whenever microorganisms usually considered as intermediate susceptible or resistant to levofloxacin may be involved.",Urinary pharmacokinetics and theoretical pharmacodynamics of intravenous levofloxacin in intensive care unit patients treated with 500 mg b.i.d. for ventilator-associated pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14998081/),h,125,206212,DB01137,Levofloxacin
,15099441,maximum value (C(max)),The uveal tract concentrations reached the maximum value (C(max)) of 26.33 +/- 0.75 microg eq.,"Absorption, distribution and excretion of 14C-levofloxacin after single oral administration in albino and pigmented rats: binding characteristics of levofloxacin-related radioactivity to melanin in vivo. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15099441/),eq·μg,26.33,206672,DB01137,Levofloxacin
,15099441,terminal half-life,g(-1) at 24 h after dosing and declined slowly with a terminal half-life of 468.1 h (19.5 days).,"Absorption, distribution and excretion of 14C-levofloxacin after single oral administration in albino and pigmented rats: binding characteristics of levofloxacin-related radioactivity to melanin in vivo. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15099441/),h,468.1,206673,DB01137,Levofloxacin
,15099441,uveal tract concentration,"The uveal tract concentration at 12 weeks was 0.73+/- 0.12 microg eq. g(-1), which is c. 1/36 of C(max).","Absorption, distribution and excretion of 14C-levofloxacin after single oral administration in albino and pigmented rats: binding characteristics of levofloxacin-related radioactivity to melanin in vivo. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15099441/),[eq·μg] / [g],0.73,206674,DB01137,Levofloxacin
,15099441,AUC(0- infinity ),The AUC(0- infinity ) for the uveal tract was 12.58 mg h(-1) g(-1).,"Absorption, distribution and excretion of 14C-levofloxacin after single oral administration in albino and pigmented rats: binding characteristics of levofloxacin-related radioactivity to melanin in vivo. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15099441/),[mg] / [g·h],12.58,206675,DB01137,Levofloxacin
,9378847,peak plasma concentrations (Cmax),"Mean (+/-SD) values for theophylline pharmacokinetic parameters for the levofloxacin and placebo treatments, respectively, were peak plasma concentrations (Cmax) of 11.4 (1.8) micrograms/mL and 10.7 (1.3) micrograms/mL; areas under the concentration time curve from time 0 extrapolated to infinity (AUCzero-infinity) of 124 (32) micrograms.hr/mL and 126 (30) micrograms.hr/mL; volumes of distribution at steady state (Vdss) 31.7 (3.5) L and 32.0 (3.9) L; clearances (Cl) of 48.6 (11.6) mL/min and 47.4 (10.3) mL/min; and half-lives (t1/2) of 8.1 (1.9) hours and 8.2 (1.8) hours.",Absence of a pharmacokinetic interaction between intravenous theophylline and orally administered levofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9378847/),[μg] / [ml],11.4,207580,DB01137,Levofloxacin
,9378847,peak plasma concentrations (Cmax),"Mean (+/-SD) values for theophylline pharmacokinetic parameters for the levofloxacin and placebo treatments, respectively, were peak plasma concentrations (Cmax) of 11.4 (1.8) micrograms/mL and 10.7 (1.3) micrograms/mL; areas under the concentration time curve from time 0 extrapolated to infinity (AUCzero-infinity) of 124 (32) micrograms.hr/mL and 126 (30) micrograms.hr/mL; volumes of distribution at steady state (Vdss) 31.7 (3.5) L and 32.0 (3.9) L; clearances (Cl) of 48.6 (11.6) mL/min and 47.4 (10.3) mL/min; and half-lives (t1/2) of 8.1 (1.9) hours and 8.2 (1.8) hours.",Absence of a pharmacokinetic interaction between intravenous theophylline and orally administered levofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9378847/),[μg] / [ml],10.7,207581,DB01137,Levofloxacin
,9378847,areas under the concentration time curve from time 0 extrapolated to infinity (AUCzero-infinity),"Mean (+/-SD) values for theophylline pharmacokinetic parameters for the levofloxacin and placebo treatments, respectively, were peak plasma concentrations (Cmax) of 11.4 (1.8) micrograms/mL and 10.7 (1.3) micrograms/mL; areas under the concentration time curve from time 0 extrapolated to infinity (AUCzero-infinity) of 124 (32) micrograms.hr/mL and 126 (30) micrograms.hr/mL; volumes of distribution at steady state (Vdss) 31.7 (3.5) L and 32.0 (3.9) L; clearances (Cl) of 48.6 (11.6) mL/min and 47.4 (10.3) mL/min; and half-lives (t1/2) of 8.1 (1.9) hours and 8.2 (1.8) hours.",Absence of a pharmacokinetic interaction between intravenous theophylline and orally administered levofloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9378847/),[h·μg] / [ml],124,207582,DB01137,Levofloxacin
,9378847,areas under the concentration time curve from time 0 extrapolated to infinity (AUCzero-infinity),"Mean (+/-SD) values for theophylline pharmacokinetic parameters for the levofloxacin and placebo treatments, respectively, were peak plasma concentrations (Cmax) of 11.4 (1.8) micrograms/mL and 10.7 (1.3) micrograms/mL; areas under the concentration time curve from time 0 extrapolated to infinity (AUCzero-infinity) of 124 (32) micrograms.hr/mL and 126 (30) micrograms.hr/mL; volumes of distribution at steady state (Vdss) 31.7 (3.5) L and 32.0 (3.9) L; clearances (Cl) of 48.6 (11.6) mL/min and 47.4 (10.3) mL/min; and half-lives (t1/2) of 8.1 (1.9) hours and 8.2 (1.8) hours.",Absence of a pharmacokinetic interaction between intravenous theophylline and orally administered levofloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9378847/),[h·μg] / [ml],126,207583,DB01137,Levofloxacin
,9378847,volumes of distribution at steady state (Vdss),"Mean (+/-SD) values for theophylline pharmacokinetic parameters for the levofloxacin and placebo treatments, respectively, were peak plasma concentrations (Cmax) of 11.4 (1.8) micrograms/mL and 10.7 (1.3) micrograms/mL; areas under the concentration time curve from time 0 extrapolated to infinity (AUCzero-infinity) of 124 (32) micrograms.hr/mL and 126 (30) micrograms.hr/mL; volumes of distribution at steady state (Vdss) 31.7 (3.5) L and 32.0 (3.9) L; clearances (Cl) of 48.6 (11.6) mL/min and 47.4 (10.3) mL/min; and half-lives (t1/2) of 8.1 (1.9) hours and 8.2 (1.8) hours.",Absence of a pharmacokinetic interaction between intravenous theophylline and orally administered levofloxacin. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9378847/),l,31.7,207584,DB01137,Levofloxacin
,9378847,volumes of distribution at steady state (Vdss),"Mean (+/-SD) values for theophylline pharmacokinetic parameters for the levofloxacin and placebo treatments, respectively, were peak plasma concentrations (Cmax) of 11.4 (1.8) micrograms/mL and 10.7 (1.3) micrograms/mL; areas under the concentration time curve from time 0 extrapolated to infinity (AUCzero-infinity) of 124 (32) micrograms.hr/mL and 126 (30) micrograms.hr/mL; volumes of distribution at steady state (Vdss) 31.7 (3.5) L and 32.0 (3.9) L; clearances (Cl) of 48.6 (11.6) mL/min and 47.4 (10.3) mL/min; and half-lives (t1/2) of 8.1 (1.9) hours and 8.2 (1.8) hours.",Absence of a pharmacokinetic interaction between intravenous theophylline and orally administered levofloxacin. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9378847/),l,32.0,207585,DB01137,Levofloxacin
,9378847,clearances (Cl),"Mean (+/-SD) values for theophylline pharmacokinetic parameters for the levofloxacin and placebo treatments, respectively, were peak plasma concentrations (Cmax) of 11.4 (1.8) micrograms/mL and 10.7 (1.3) micrograms/mL; areas under the concentration time curve from time 0 extrapolated to infinity (AUCzero-infinity) of 124 (32) micrograms.hr/mL and 126 (30) micrograms.hr/mL; volumes of distribution at steady state (Vdss) 31.7 (3.5) L and 32.0 (3.9) L; clearances (Cl) of 48.6 (11.6) mL/min and 47.4 (10.3) mL/min; and half-lives (t1/2) of 8.1 (1.9) hours and 8.2 (1.8) hours.",Absence of a pharmacokinetic interaction between intravenous theophylline and orally administered levofloxacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9378847/),[ml] / [min],48.6,207586,DB01137,Levofloxacin
,9378847,clearances (Cl),"Mean (+/-SD) values for theophylline pharmacokinetic parameters for the levofloxacin and placebo treatments, respectively, were peak plasma concentrations (Cmax) of 11.4 (1.8) micrograms/mL and 10.7 (1.3) micrograms/mL; areas under the concentration time curve from time 0 extrapolated to infinity (AUCzero-infinity) of 124 (32) micrograms.hr/mL and 126 (30) micrograms.hr/mL; volumes of distribution at steady state (Vdss) 31.7 (3.5) L and 32.0 (3.9) L; clearances (Cl) of 48.6 (11.6) mL/min and 47.4 (10.3) mL/min; and half-lives (t1/2) of 8.1 (1.9) hours and 8.2 (1.8) hours.",Absence of a pharmacokinetic interaction between intravenous theophylline and orally administered levofloxacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9378847/),[ml] / [min],47.4,207587,DB01137,Levofloxacin
,9378847,half-lives (t1/2),"Mean (+/-SD) values for theophylline pharmacokinetic parameters for the levofloxacin and placebo treatments, respectively, were peak plasma concentrations (Cmax) of 11.4 (1.8) micrograms/mL and 10.7 (1.3) micrograms/mL; areas under the concentration time curve from time 0 extrapolated to infinity (AUCzero-infinity) of 124 (32) micrograms.hr/mL and 126 (30) micrograms.hr/mL; volumes of distribution at steady state (Vdss) 31.7 (3.5) L and 32.0 (3.9) L; clearances (Cl) of 48.6 (11.6) mL/min and 47.4 (10.3) mL/min; and half-lives (t1/2) of 8.1 (1.9) hours and 8.2 (1.8) hours.",Absence of a pharmacokinetic interaction between intravenous theophylline and orally administered levofloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9378847/),h,8.1,207588,DB01137,Levofloxacin
,9378847,half-lives (t1/2),"Mean (+/-SD) values for theophylline pharmacokinetic parameters for the levofloxacin and placebo treatments, respectively, were peak plasma concentrations (Cmax) of 11.4 (1.8) micrograms/mL and 10.7 (1.3) micrograms/mL; areas under the concentration time curve from time 0 extrapolated to infinity (AUCzero-infinity) of 124 (32) micrograms.hr/mL and 126 (30) micrograms.hr/mL; volumes of distribution at steady state (Vdss) 31.7 (3.5) L and 32.0 (3.9) L; clearances (Cl) of 48.6 (11.6) mL/min and 47.4 (10.3) mL/min; and half-lives (t1/2) of 8.1 (1.9) hours and 8.2 (1.8) hours.",Absence of a pharmacokinetic interaction between intravenous theophylline and orally administered levofloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9378847/),h,8.2,207589,DB01137,Levofloxacin
,17106223,peak plasma level,Appreciable plasma concentration of levofloxacin (0.38+/-0.06 microgram/ml) was detected at 1 min after injection and the peak plasma level of 3.07+/-0.08 microgram/ml was observed at 1 h.,"Pharmacokinetics, urinary excretion and dosage regimen of levofloxacin following a single intramuscular administration in cross bred calves. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17106223/),[μg] / [ml],3.07,207668,DB01137,Levofloxacin
,17106223,absorption rate constant,Rapid absorption of the drug was also evident by the high value of the absorption rate constant (2.14+/-0.24 /h).,"Pharmacokinetics, urinary excretion and dosage regimen of levofloxacin following a single intramuscular administration in cross bred calves. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17106223/),1/[h],2.14,207669,DB01137,Levofloxacin
,17106223,overall systemic bioavailability,"The overall systemic bioavailability of levofloxacin, after intramuscular administration, was 56.6+/-12.4%.","Pharmacokinetics, urinary excretion and dosage regimen of levofloxacin following a single intramuscular administration in cross bred calves. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17106223/),%,56.6,207670,DB01137,Levofloxacin
,17106223,AUC,The high value of AUC (7.66+/-0.72 mg.h/ml) reflected the vast area of body covered by drug concentration.,"Pharmacokinetics, urinary excretion and dosage regimen of levofloxacin following a single intramuscular administration in cross bred calves. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17106223/),[h·mg] / [ml],7.66,207671,DB01137,Levofloxacin
,17106223,Vd(area),Extensive distribution of the drug into various body fluids and tissues was noted by the high value of Vd(area) (1.02+/-0.05 l/kg).,"Pharmacokinetics, urinary excretion and dosage regimen of levofloxacin following a single intramuscular administration in cross bred calves. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17106223/),[l] / [kg],1.02,207672,DB01137,Levofloxacin
,17106223,ratio of AUC/MIC,The high ratio of AUC/MIC (76.6+/-7.25) obtained in this study indicated excellent clinical and bacteriological efficacy of levofloxacin in calves.,"Pharmacokinetics, urinary excretion and dosage regimen of levofloxacin following a single intramuscular administration in cross bred calves. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17106223/),,76.6,207673,DB01137,Levofloxacin
,17106223,elimination half-life,"The elimination half-life and MRT were 3.67+/-0.4 h and 5.57+/-0.51 h, respectively.","Pharmacokinetics, urinary excretion and dosage regimen of levofloxacin following a single intramuscular administration in cross bred calves. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17106223/),h,3.67,207674,DB01137,Levofloxacin
,17106223,MRT,"The elimination half-life and MRT were 3.67+/-0.4 h and 5.57+/-0.51 h, respectively.","Pharmacokinetics, urinary excretion and dosage regimen of levofloxacin following a single intramuscular administration in cross bred calves. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17106223/),h,5.57,207675,DB01137,Levofloxacin
,17106223,total body clearance (Cl(B)),The total body clearance (Cl(B)) was 204.9+/-22.6 ml/kg/h.,"Pharmacokinetics, urinary excretion and dosage regimen of levofloxacin following a single intramuscular administration in cross bred calves. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17106223/),[ml] / [h·kg],204.9,207676,DB01137,Levofloxacin
more,19101632,extractive recovery,The extractive recovery of itopride hydrochloride from the biological matrix was more than 80.77%.,Determination of itopride hydrochloride in human plasma by RP-HPLC with fluorescence detection and its use in bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19101632/),%,80.77,207689,DB01137,Levofloxacin
,18655224,flow rate,"The resolution of peaks was achieved with phosphate buffer (pH 2.5)-acetonitrile (80:20, v/v) at a flow rate of 1 mL/min on a Kromasil C(18) column.","Development and validation of a HPLC method for simultaneous quantitation of gatifloxacin, sparfloxacin and moxifloxacin using levofloxacin as internal standard in human plasma: application to a clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18655224/),[ml] / [min],1,208521,DB01137,Levofloxacin
,18655224,total chromatographic run time,"The total chromatographic run time was 18.0 min and the simultaneous elution of GFC, SFC, MFC and IS occurred at approximately 10.8, 12.8, 17.0 and 6.0 min, respectively.","Development and validation of a HPLC method for simultaneous quantitation of gatifloxacin, sparfloxacin and moxifloxacin using levofloxacin as internal standard in human plasma: application to a clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18655224/),min,18.0,208522,DB01137,Levofloxacin
,30012767,areas under the concentration-time curve from 0 to 24 h (AUC0-24),"Respective median areas under the concentration-time curve from 0 to 24 h (AUC0-24) were 109.49, 97.86, 145.33, and 207.04 μg · h/ml.",Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30012767/),[h·μg] / [ml],109.49,210180,DB01137,Levofloxacin
,30012767,areas under the concentration-time curve from 0 to 24 h (AUC0-24),"Respective median areas under the concentration-time curve from 0 to 24 h (AUC0-24) were 109.49, 97.86, 145.33, and 207.04 μg · h/ml.",Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30012767/),[h·μg] / [ml],97.86,210181,DB01137,Levofloxacin
,30012767,areas under the concentration-time curve from 0 to 24 h (AUC0-24),"Respective median areas under the concentration-time curve from 0 to 24 h (AUC0-24) were 109.49, 97.86, 145.33, and 207.04 μg · h/ml.",Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30012767/),[h·μg] / [ml],145.33,210182,DB01137,Levofloxacin
,30012767,areas under the concentration-time curve from 0 to 24 h (AUC0-24),"Respective median areas under the concentration-time curve from 0 to 24 h (AUC0-24) were 109.49, 97.86, 145.33, and 207.04 μg · h/ml.",Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30012767/),[h·μg] / [ml],207.04,210183,DB01137,Levofloxacin
,30012767,maximum plasma concentration (Cmax),"Median maximum plasma concentration (Cmax) were 11.90, 12.02, 14.86, and 19.17 μg/ml, respectively.",Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30012767/),[μg] / [ml],11.90,210184,DB01137,Levofloxacin
,30012767,maximum plasma concentration (Cmax),"Median maximum plasma concentration (Cmax) were 11.90, 12.02, 14.86, and 19.17 μg/ml, respectively.",Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30012767/),[μg] / [ml],12.02,210185,DB01137,Levofloxacin
,30012767,maximum plasma concentration (Cmax),"Median maximum plasma concentration (Cmax) were 11.90, 12.02, 14.86, and 19.17 μg/ml, respectively.",Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30012767/),[μg] / [ml],14.86,210186,DB01137,Levofloxacin
,30012767,maximum plasma concentration (Cmax),"Median maximum plasma concentration (Cmax) were 11.90, 12.02, 14.86, and 19.17 μg/ml, respectively.",Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30012767/),[μg] / [ml],19.17,210187,DB01137,Levofloxacin
,10659548,Cmax,"Mean +/- SEM of Cmax after 300 mg and 500 mg dose was 4.83 +/- 0.33 and 7.75 +/- 0.71 micrograms/mL, respectively.",Pharmacokinetics of levofloxacin in healthy Thai male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10659548/),[μg] / [ml],4.83,210793,DB01137,Levofloxacin
,10659548,Cmax,"Mean +/- SEM of Cmax after 300 mg and 500 mg dose was 4.83 +/- 0.33 and 7.75 +/- 0.71 micrograms/mL, respectively.",Pharmacokinetics of levofloxacin in healthy Thai male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10659548/),[μg] / [ml],7.75,210794,DB01137,Levofloxacin
,10659548,Tmax,Tmax ranged from 0.7 to 0.8 hours for both doses.,Pharmacokinetics of levofloxacin in healthy Thai male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10659548/),h,0.7 to 0.8,210795,DB01137,Levofloxacin
,10659548,AUC0-infinity,Mean +/- SEM of AUC0-infinity was 35.77 +/- 2.06 micrograms x h/mL for 300 mg dose and 61.57 +/- 2.84 micrograms x h/mL for 500 mg dose.,Pharmacokinetics of levofloxacin in healthy Thai male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10659548/),[h·μg] / [ml],35.77,210796,DB01137,Levofloxacin
,10659548,AUC0-infinity,Mean +/- SEM of AUC0-infinity was 35.77 +/- 2.06 micrograms x h/mL for 300 mg dose and 61.57 +/- 2.84 micrograms x h/mL for 500 mg dose.,Pharmacokinetics of levofloxacin in healthy Thai male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10659548/),[h·μg] / [ml],61.57,210797,DB01137,Levofloxacin
,10659548,VSS/F,High distribution with VSS/F value of approximately 1.5 L/kg was demonstrated after both doses.,Pharmacokinetics of levofloxacin in healthy Thai male volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10659548/),[l] / [kg],1.5,210798,DB01137,Levofloxacin
,10659548,CL/F,"Mean +/- SEM of CL/F value was 8.64 +/- 0.41 L/h and 8.31 +/- 0.37 L/h for a 300-mg and a 500-mg dose, respectively.",Pharmacokinetics of levofloxacin in healthy Thai male volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10659548/),[l] / [h],8.64,210799,DB01137,Levofloxacin
,10659548,CL/F,"Mean +/- SEM of CL/F value was 8.64 +/- 0.41 L/h and 8.31 +/- 0.37 L/h for a 300-mg and a 500-mg dose, respectively.",Pharmacokinetics of levofloxacin in healthy Thai male volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10659548/),[l] / [h],8.31,210800,DB01137,Levofloxacin
,10659548,t1/2 beta,"Long t1/2 beta of 7 to 8 hours with the mean residence time of 10.43 +/- 0.43 hours and 10.49 +/- 0.38 hours after 300 mg and 500 mg dose, respectively, was observed.",Pharmacokinetics of levofloxacin in healthy Thai male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10659548/),h,7 to 8,210801,DB01137,Levofloxacin
,10659548,mean residence time,"Long t1/2 beta of 7 to 8 hours with the mean residence time of 10.43 +/- 0.43 hours and 10.49 +/- 0.38 hours after 300 mg and 500 mg dose, respectively, was observed.",Pharmacokinetics of levofloxacin in healthy Thai male volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10659548/),h,10.43,210802,DB01137,Levofloxacin
,10659548,mean residence time,"Long t1/2 beta of 7 to 8 hours with the mean residence time of 10.43 +/- 0.43 hours and 10.49 +/- 0.38 hours after 300 mg and 500 mg dose, respectively, was observed.",Pharmacokinetics of levofloxacin in healthy Thai male volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10659548/),h,10.49,210803,DB01137,Levofloxacin
,10659548,MIC90,The results suggested that an oral 300 mg dose once daily provides sufficient Cmax to cover most Gram-negative and atypical bacteria (median MIC90 0.032-0.5 microgram/mL) common in mild to moderate respiratory tract infections or complicated urinary tract infections and Gram-positive bacteria (median MIC90 0.5 microgram/mL) common in skin and soft tissue infections.,Pharmacokinetics of levofloxacin in healthy Thai male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10659548/),[μg] / [ml],0.032-0.5,210804,DB01137,Levofloxacin
,10659548,MIC90,The results suggested that an oral 300 mg dose once daily provides sufficient Cmax to cover most Gram-negative and atypical bacteria (median MIC90 0.032-0.5 microgram/mL) common in mild to moderate respiratory tract infections or complicated urinary tract infections and Gram-positive bacteria (median MIC90 0.5 microgram/mL) common in skin and soft tissue infections.,Pharmacokinetics of levofloxacin in healthy Thai male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10659548/),[μg] / [ml],0.5,210805,DB01137,Levofloxacin
,10659548,MIC90,"For severe cases or Streptococcus pneumoniae (MIC90 2 micrograms/mL) infection, a 500-mg dose should be recommended.",Pharmacokinetics of levofloxacin in healthy Thai male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10659548/),[μg] / [ml],2,210806,DB01137,Levofloxacin
,18715762,minimum inhibitory concentrations,"Bactericidal titres in urine were determined against E. coli isolates with minimum inhibitory concentrations of 0.125, 4, 8, 16, 32 and 64microg/mL for levofloxacin.","Urinary bactericidal activity of single doses (250, 500, 750 and 1000 mg) of levofloxacin against fluoroquinolone-resistant strains of Escherichia coli. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18715762/),[μg] / [ml],0.125,211466,DB01137,Levofloxacin
,18715762,minimum inhibitory concentrations,"Bactericidal titres in urine were determined against E. coli isolates with minimum inhibitory concentrations of 0.125, 4, 8, 16, 32 and 64microg/mL for levofloxacin.","Urinary bactericidal activity of single doses (250, 500, 750 and 1000 mg) of levofloxacin against fluoroquinolone-resistant strains of Escherichia coli. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18715762/),[μg] / [ml],4,211467,DB01137,Levofloxacin
,18715762,minimum inhibitory concentrations,"Bactericidal titres in urine were determined against E. coli isolates with minimum inhibitory concentrations of 0.125, 4, 8, 16, 32 and 64microg/mL for levofloxacin.","Urinary bactericidal activity of single doses (250, 500, 750 and 1000 mg) of levofloxacin against fluoroquinolone-resistant strains of Escherichia coli. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18715762/),[μg] / [ml],8,211468,DB01137,Levofloxacin
,18715762,minimum inhibitory concentrations,"Bactericidal titres in urine were determined against E. coli isolates with minimum inhibitory concentrations of 0.125, 4, 8, 16, 32 and 64microg/mL for levofloxacin.","Urinary bactericidal activity of single doses (250, 500, 750 and 1000 mg) of levofloxacin against fluoroquinolone-resistant strains of Escherichia coli. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18715762/),[μg] / [ml],16,211469,DB01137,Levofloxacin
,18715762,minimum inhibitory concentrations,"Bactericidal titres in urine were determined against E. coli isolates with minimum inhibitory concentrations of 0.125, 4, 8, 16, 32 and 64microg/mL for levofloxacin.","Urinary bactericidal activity of single doses (250, 500, 750 and 1000 mg) of levofloxacin against fluoroquinolone-resistant strains of Escherichia coli. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18715762/),[μg] / [ml],32,211470,DB01137,Levofloxacin
,18715762,minimum inhibitory concentrations,"Bactericidal titres in urine were determined against E. coli isolates with minimum inhibitory concentrations of 0.125, 4, 8, 16, 32 and 64microg/mL for levofloxacin.","Urinary bactericidal activity of single doses (250, 500, 750 and 1000 mg) of levofloxacin against fluoroquinolone-resistant strains of Escherichia coli. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18715762/),[μg] / [ml],64,211471,DB01137,Levofloxacin
,18715762,peak urinary concentrations (0-1.5h),"The mean peak urinary concentrations (0-1.5h) were 210, 347, 620 and 536microg/mL for the 250, 500, 750 and 1000 mg dose, respectively.","Urinary bactericidal activity of single doses (250, 500, 750 and 1000 mg) of levofloxacin against fluoroquinolone-resistant strains of Escherichia coli. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18715762/),[μg] / [ml],210,211472,DB01137,Levofloxacin
,18715762,peak urinary concentrations (0-1.5h),"The mean peak urinary concentrations (0-1.5h) were 210, 347, 620 and 536microg/mL for the 250, 500, 750 and 1000 mg dose, respectively.","Urinary bactericidal activity of single doses (250, 500, 750 and 1000 mg) of levofloxacin against fluoroquinolone-resistant strains of Escherichia coli. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18715762/),[μg] / [ml],347,211473,DB01137,Levofloxacin
,18715762,peak urinary concentrations (0-1.5h),"The mean peak urinary concentrations (0-1.5h) were 210, 347, 620 and 536microg/mL for the 250, 500, 750 and 1000 mg dose, respectively.","Urinary bactericidal activity of single doses (250, 500, 750 and 1000 mg) of levofloxacin against fluoroquinolone-resistant strains of Escherichia coli. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18715762/),[μg] / [ml],620,211474,DB01137,Levofloxacin
,18715762,peak urinary concentrations (0-1.5h),"The mean peak urinary concentrations (0-1.5h) were 210, 347, 620 and 536microg/mL for the 250, 500, 750 and 1000 mg dose, respectively.","Urinary bactericidal activity of single doses (250, 500, 750 and 1000 mg) of levofloxacin against fluoroquinolone-resistant strains of Escherichia coli. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18715762/),[μg] / [ml],536,211475,DB01137,Levofloxacin
<or=,18715762,MICs,Each dose of levofloxacin exhibited early (0-1.5h time period) bactericidal activity in urine in virtually all subjects against E. coli strains with MICs<or=32microg/mL.,"Urinary bactericidal activity of single doses (250, 500, 750 and 1000 mg) of levofloxacin against fluoroquinolone-resistant strains of Escherichia coli. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18715762/),[μg] / [ml],32,211476,DB01137,Levofloxacin
up to,18715762,MICs,"Moreover, high-dose (750 mg and 1000 mg) levofloxacin provided prolonged (8-12h time period) bactericidal activity in 9/10 subjects against E. coli isolates with MICs up to 32microg/mL.","Urinary bactericidal activity of single doses (250, 500, 750 and 1000 mg) of levofloxacin against fluoroquinolone-resistant strains of Escherichia coli. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18715762/),[μg] / [ml],32,211477,DB01137,Levofloxacin
,10934671,"area under the concentration-time curve, AUC0-infinity","For pharmacokinetic parameters, the authors found small but statistically significant differences (p < 0.05) in the area under the concentration-time curve, AUC0-infinity (22.30 +/- 2.72 mg h/L for S-(-)-ofloxacin vs. 20.50 +/- 2.06 mg h/L for R-(+)-ofloxacin), and in the clearance (0.15 +/- 0.04 L/h/Kg for S-(-)-ofloxacin vs. 0.16 +/- 0.04 L/h/Kg for R-(+)-ofloxacin).",Pharmacokinetics of ofloxacin enantiomers after intravenous administration for antibiotic prophylaxis in biliary surgery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10934671/),[h·mg] / [l],22.30,213396,DB01137,Levofloxacin
,10934671,"area under the concentration-time curve, AUC0-infinity","For pharmacokinetic parameters, the authors found small but statistically significant differences (p < 0.05) in the area under the concentration-time curve, AUC0-infinity (22.30 +/- 2.72 mg h/L for S-(-)-ofloxacin vs. 20.50 +/- 2.06 mg h/L for R-(+)-ofloxacin), and in the clearance (0.15 +/- 0.04 L/h/Kg for S-(-)-ofloxacin vs. 0.16 +/- 0.04 L/h/Kg for R-(+)-ofloxacin).",Pharmacokinetics of ofloxacin enantiomers after intravenous administration for antibiotic prophylaxis in biliary surgery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10934671/),[h·mg] / [l],20.50,213397,DB01137,Levofloxacin
,10934671,clearance,"For pharmacokinetic parameters, the authors found small but statistically significant differences (p < 0.05) in the area under the concentration-time curve, AUC0-infinity (22.30 +/- 2.72 mg h/L for S-(-)-ofloxacin vs. 20.50 +/- 2.06 mg h/L for R-(+)-ofloxacin), and in the clearance (0.15 +/- 0.04 L/h/Kg for S-(-)-ofloxacin vs. 0.16 +/- 0.04 L/h/Kg for R-(+)-ofloxacin).",Pharmacokinetics of ofloxacin enantiomers after intravenous administration for antibiotic prophylaxis in biliary surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10934671/),[l] / [h·kg],0.15,213398,DB01137,Levofloxacin
,10934671,clearance,"For pharmacokinetic parameters, the authors found small but statistically significant differences (p < 0.05) in the area under the concentration-time curve, AUC0-infinity (22.30 +/- 2.72 mg h/L for S-(-)-ofloxacin vs. 20.50 +/- 2.06 mg h/L for R-(+)-ofloxacin), and in the clearance (0.15 +/- 0.04 L/h/Kg for S-(-)-ofloxacin vs. 0.16 +/- 0.04 L/h/Kg for R-(+)-ofloxacin).",Pharmacokinetics of ofloxacin enantiomers after intravenous administration for antibiotic prophylaxis in biliary surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10934671/),[l] / [h·kg],0.16,213399,DB01137,Levofloxacin
,1512922,Peak levels,"Peak levels of LVFX were from 2.22 to 4.02 micrograms/ml of plasma at 2-4 hours after the oral administration, and from 7.5 to 11.3 micrograms/ml of bile at 2-6 hours.","Efficacy of a new quinolone, levofloxacin in patients with surgical infections. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1512922/),[μg] / [ml],2.22 to 4.02,214268,DB01137,Levofloxacin
,1512922,Peak levels,"Peak levels of LVFX were from 2.22 to 4.02 micrograms/ml of plasma at 2-4 hours after the oral administration, and from 7.5 to 11.3 micrograms/ml of bile at 2-6 hours.","Efficacy of a new quinolone, levofloxacin in patients with surgical infections. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1512922/),[μg] / [ml],7.5 to 11.3,214269,DB01137,Levofloxacin
,16723549,systemic clearance,"Mean systemic clearance, half-life, and area under the concentration-time curve over 24 h after levofloxacin at 750 mg were 9.0 +/- 3.2 liters/h, 7.8 +/- 1.6 h, and 93 +/- 31 mg .",Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16723549/),[l] / [h],9.0,214848,DB01137,Levofloxacin
,16723549,half-life,"Mean systemic clearance, half-life, and area under the concentration-time curve over 24 h after levofloxacin at 750 mg were 9.0 +/- 3.2 liters/h, 7.8 +/- 1.6 h, and 93 +/- 31 mg .",Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16723549/),h,7.8,214849,DB01137,Levofloxacin
,16723549,area under the concentration-time curve,"Mean systemic clearance, half-life, and area under the concentration-time curve over 24 h after levofloxacin at 750 mg were 9.0 +/- 3.2 liters/h, 7.8 +/- 1.6 h, and 93 +/- 31 mg .",Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16723549/),h,7.8,214850,DB01137,Levofloxacin
,16723549,area under the concentration-time curve,"Mean systemic clearance, half-life, and area under the concentration-time curve over 24 h after levofloxacin at 750 mg were 9.0 +/- 3.2 liters/h, 7.8 +/- 1.6 h, and 93 +/- 31 mg .",Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16723549/),mg,93,214851,DB01137,Levofloxacin
<,16723549,MICs,"Levofloxacin at 750 mg achieved >90% PTA for gram-negative and gram-positive pathogens with MICs of < or =0.5 microg/ml and MICs of < or =1 microg/ml, respectively.",Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16723549/),[μg] / [ml],0.5,214852,DB01137,Levofloxacin
<,16723549,MICs,"Levofloxacin at 750 mg achieved >90% PTA for gram-negative and gram-positive pathogens with MICs of < or =0.5 microg/ml and MICs of < or =1 microg/ml, respectively.",Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16723549/),[μg] / [ml],1,214853,DB01137,Levofloxacin
,16723549,MICs,"However, satisfactory PTA was not obtained with less-susceptible gram-negative organisms with MICs of 1 microg/ml or any organism with a MIC of > or =2 microg/ml.",Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16723549/),[μg] / [ml],1,214854,DB01137,Levofloxacin
> or =,16723549,MIC,"However, satisfactory PTA was not obtained with less-susceptible gram-negative organisms with MICs of 1 microg/ml or any organism with a MIC of > or =2 microg/ml.",Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16723549/),[μg] / [ml],2,214855,DB01137,Levofloxacin
,16723549,MICs,"However, even 750 mg/day may be inadequate for gram-negative organisms with MICs of 1 to 2 microg/ml even though they are defined as susceptible.",Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16723549/),[μg] / [ml],1 to 2,214856,DB01137,Levofloxacin
,20625157,half-life,"On day 7 of a twice-daily dosing regimen of 40 mg/kg, the levofloxacin half-life, maximum concentration, and area under the curve in marmoset plasma were 2.3 h, 20.9 microg/ml, and 81.4 microg/liter/h, respectively.",Bioavailability and efficacy of levofloxacin against Francisella tularensis in the common marmoset (Callithrix jacchus). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20625157/),h,2.3,217010,DB01137,Levofloxacin
,20625157,maximum concentration,"On day 7 of a twice-daily dosing regimen of 40 mg/kg, the levofloxacin half-life, maximum concentration, and area under the curve in marmoset plasma were 2.3 h, 20.9 microg/ml, and 81.4 microg/liter/h, respectively.",Bioavailability and efficacy of levofloxacin against Francisella tularensis in the common marmoset (Callithrix jacchus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20625157/),[μg] / [ml],20.9,217011,DB01137,Levofloxacin
,20625157,area under the curve,"On day 7 of a twice-daily dosing regimen of 40 mg/kg, the levofloxacin half-life, maximum concentration, and area under the curve in marmoset plasma were 2.3 h, 20.9 microg/ml, and 81.4 microg/liter/h, respectively.",Bioavailability and efficacy of levofloxacin against Francisella tularensis in the common marmoset (Callithrix jacchus). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20625157/),[μg] / [h·l],81.4,217012,DB01137,Levofloxacin
,27194905,Cmax,"Concentrations of the drug in the aqueous humor, as described by mean Cmax and pooled AUC0-6 values, were greater for levofloxacin than moxifloxacin (Cmax: 1.43, 0.87 μg/ml, respectively, P=0.008; AUC0-6 6.1, 3.8 μg·min/ml, P<0.001 respectively).",Pharmacokinetics and aqueous humor penetration of levofloxacin 1.5% and moxifloxacin 0.5% in patients undergoing cataract surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27194905/),[μg] / [ml],1.43,218335,DB01137,Levofloxacin
,27194905,Cmax,"Concentrations of the drug in the aqueous humor, as described by mean Cmax and pooled AUC0-6 values, were greater for levofloxacin than moxifloxacin (Cmax: 1.43, 0.87 μg/ml, respectively, P=0.008; AUC0-6 6.1, 3.8 μg·min/ml, P<0.001 respectively).",Pharmacokinetics and aqueous humor penetration of levofloxacin 1.5% and moxifloxacin 0.5% in patients undergoing cataract surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27194905/),[μg] / [ml],0.87,218336,DB01137,Levofloxacin
,27194905,AUC0-6,"Concentrations of the drug in the aqueous humor, as described by mean Cmax and pooled AUC0-6 values, were greater for levofloxacin than moxifloxacin (Cmax: 1.43, 0.87 μg/ml, respectively, P=0.008; AUC0-6 6.1, 3.8 μg·min/ml, P<0.001 respectively).",Pharmacokinetics and aqueous humor penetration of levofloxacin 1.5% and moxifloxacin 0.5% in patients undergoing cataract surgery. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27194905/),[min·μg] / [ml],6.1,218337,DB01137,Levofloxacin
,27194905,AUC0-6,"Concentrations of the drug in the aqueous humor, as described by mean Cmax and pooled AUC0-6 values, were greater for levofloxacin than moxifloxacin (Cmax: 1.43, 0.87 μg/ml, respectively, P=0.008; AUC0-6 6.1, 3.8 μg·min/ml, P<0.001 respectively).",Pharmacokinetics and aqueous humor penetration of levofloxacin 1.5% and moxifloxacin 0.5% in patients undergoing cataract surgery. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27194905/),[min·μg] / [ml],3.8,218338,DB01137,Levofloxacin
,14759229,MICs,"In line with PK/PD predictions, simulation of human pharmacokinetics in in-vitro kinetic models and in a rat model of pneumonia, amoxicillin/clavulanate 2000/125 mg twice daily was highly effective against S. pneumoniae strains with amoxicillin MICs of 4 or 8 mg/L.",Proof of concept: performance testing in models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14759229/),[mg] / [l],4,218479,DB01137,Levofloxacin
,14759229,MICs,"In line with PK/PD predictions, simulation of human pharmacokinetics in in-vitro kinetic models and in a rat model of pneumonia, amoxicillin/clavulanate 2000/125 mg twice daily was highly effective against S. pneumoniae strains with amoxicillin MICs of 4 or 8 mg/L.",Proof of concept: performance testing in models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14759229/),[mg] / [l],8,218480,DB01137,Levofloxacin
,14759229,MICs,"Against strains with amoxicillin MICs of 4 mg/L, amoxicillin/clavulanate 2000/125 mg twice daily was significantly more effective than the conventional 875/125 mg twice daily formulation, azithromycin and levofloxacin, even though all levofloxacin MICs were < or = 1 mg/L.",Proof of concept: performance testing in models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14759229/),[mg] / [l],4,218481,DB01137,Levofloxacin
< or =,14759229,MICs,"Against strains with amoxicillin MICs of 4 mg/L, amoxicillin/clavulanate 2000/125 mg twice daily was significantly more effective than the conventional 875/125 mg twice daily formulation, azithromycin and levofloxacin, even though all levofloxacin MICs were < or = 1 mg/L.",Proof of concept: performance testing in models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14759229/),[mg] / [l],1,218482,DB01137,Levofloxacin
,14759229,MICs,"Following infection with S. pneumoniae strains with amoxicillin MICs of 8 mg/L, the amoxicillin/clavulanate 2000/125 mg twice daily formulation was more effective than the conventional amoxicillin/clavulanate formulations of 875/125 mg twice daily and three times daily and 1000/125 mg three times daily, and had similar or better efficacy than azithromycin and levofloxacin, depending on the strain.",Proof of concept: performance testing in models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14759229/),[mg] / [l],8,218483,DB01137,Levofloxacin
>,25450804,ratios of fAUC0-24h/MIC90,"Monte Carlo simulations were used with LFX 500 mg every 24h (q24 h) or every 12h (q12h), LFX 750 mg q24 h and MOX 400mg q24 h in non-compliance scenarios to derive the proportion of patients achieving target ratios of fAUC0-24h/MIC90>33.8 for Streptococcus pneumoniae and >100 for Haemophilus influenzae and Moraxella catarrhalis (PTA>90%).",Impact of poor compliance with levofloxacin and moxifloxacin on respiratory tract infection antimicrobial efficacy: a pharmacokinetic/pharmacodynamic simulation study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25450804/),,33.8,221176,DB01137,Levofloxacin
>,25450804,ratios of fAUC0-24h/MIC90,"Monte Carlo simulations were used with LFX 500 mg every 24h (q24 h) or every 12h (q12h), LFX 750 mg q24 h and MOX 400mg q24 h in non-compliance scenarios to derive the proportion of patients achieving target ratios of fAUC0-24h/MIC90>33.8 for Streptococcus pneumoniae and >100 for Haemophilus influenzae and Moraxella catarrhalis (PTA>90%).",Impact of poor compliance with levofloxacin and moxifloxacin on respiratory tract infection antimicrobial efficacy: a pharmacokinetic/pharmacodynamic simulation study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25450804/),,100,221177,DB01137,Levofloxacin
,15917572,aqueous-to-plasma ratios,"The mean aqueous humor concentrations persisted above 1.5 mg/liter between 1.5 and 6.0 h after the second dose, with average aqueous-to-plasma ratios ranging between 0.33 and 0.57.",Levofloxacin disposition over time in aqueous humor of patients undergoing cataract surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917572/),,0.,222618,DB01137,Levofloxacin
,15917572,aqueous-to-plasma ratios,"The mean aqueous humor concentrations persisted above 1.5 mg/liter between 1.5 and 6.0 h after the second dose, with average aqueous-to-plasma ratios ranging between 0.33 and 0.57.",Levofloxacin disposition over time in aqueous humor of patients undergoing cataract surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917572/),,0,222619,DB01137,Levofloxacin
,32664317,absorption rate constant (Ka),"Mean parameter estimates (% interindividual variability) were 0.895 h-1 for the absorption rate constant (Ka), 6.10 L/h (40%) for the apparent clearance (CL/F), 90.6 L (25%) for the apparent distribution volume (V/F).",Influence of Renal Function and Age on the Pharmacokinetics of Levofloxacin in Patients with Bone and Joint Infections. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32664317/),1/[h],0.895,222808,DB01137,Levofloxacin
,32664317,apparent clearance (CL/F),"Mean parameter estimates (% interindividual variability) were 0.895 h-1 for the absorption rate constant (Ka), 6.10 L/h (40%) for the apparent clearance (CL/F), 90.6 L (25%) for the apparent distribution volume (V/F).",Influence of Renal Function and Age on the Pharmacokinetics of Levofloxacin in Patients with Bone and Joint Infections. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32664317/),[l] / [h],6.10,222809,DB01137,Levofloxacin
,32664317,apparent distribution volume (V/F),"Mean parameter estimates (% interindividual variability) were 0.895 h-1 for the absorption rate constant (Ka), 6.10 L/h (40%) for the apparent clearance (CL/F), 90.6 L (25%) for the apparent distribution volume (V/F).",Influence of Renal Function and Age on the Pharmacokinetics of Levofloxacin in Patients with Bone and Joint Infections. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32664317/),l,90.6,222810,DB01137,Levofloxacin
≥,32664317,AUC/ minimum inhibitory concentration (MIC),"Based on this model, a 750 mg dose should provide an optimal exposure (AUC/ minimum inhibitory concentration (MIC) ≥100), with the possible exception of patients older than 60 years and with GFR <70 mL/min/m² who may necessitate a dose reduction, and patients with infections caused by bacteria with MIC close to 1 mg/L who may need an increase in the dose.",Influence of Renal Function and Age on the Pharmacokinetics of Levofloxacin in Patients with Bone and Joint Infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32664317/),,100,222811,DB01137,Levofloxacin
close,32664317,MIC,"Based on this model, a 750 mg dose should provide an optimal exposure (AUC/ minimum inhibitory concentration (MIC) ≥100), with the possible exception of patients older than 60 years and with GFR <70 mL/min/m² who may necessitate a dose reduction, and patients with infections caused by bacteria with MIC close to 1 mg/L who may need an increase in the dose.",Influence of Renal Function and Age on the Pharmacokinetics of Levofloxacin in Patients with Bone and Joint Infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32664317/),[mg] / [l],1,222812,DB01137,Levofloxacin
,30782999,areas under the concentration-time curve from 0 to 24 h (AUC0-24),"During the first month, the median (interquartile range [IQR]) areas under the concentration-time curve from 0 to 24 h (AUC0-24) were 67.09 (53.93 to 98.37) mg ⋅ h/liter in saliva and 99.91 (76.80 to 129.70) mg ⋅ h/liter in plasma, and the saliva plasma (S/P) ratio was 0.69 (0.53 to 0.99).",Evaluation of Saliva as a Potential Alternative Sampling Matrix for Therapeutic Drug Monitoring of Levofloxacin in Patients with Multidrug-Resistant Tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30782999/),[h·mg] / [l],67.09,223362,DB01137,Levofloxacin
,30782999,areas under the concentration-time curve from 0 to 24 h (AUC0-24),"During the first month, the median (interquartile range [IQR]) areas under the concentration-time curve from 0 to 24 h (AUC0-24) were 67.09 (53.93 to 98.37) mg ⋅ h/liter in saliva and 99.91 (76.80 to 129.70) mg ⋅ h/liter in plasma, and the saliva plasma (S/P) ratio was 0.69 (0.53 to 0.99).",Evaluation of Saliva as a Potential Alternative Sampling Matrix for Therapeutic Drug Monitoring of Levofloxacin in Patients with Multidrug-Resistant Tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30782999/),[h·mg] / [l],99.91,223363,DB01137,Levofloxacin
,30782999,AUC0-24,"Similarly, during the second month, the median (IQR) AUC0-24 were 75.63 (61.45 to 125.5) mg ⋅ h/liter in saliva and 102.7 (84.46 to 131.9) mg ⋅ h/liter in plasma, with an S/P ratio of 0.73 (0.66 to 1.18).",Evaluation of Saliva as a Potential Alternative Sampling Matrix for Therapeutic Drug Monitoring of Levofloxacin in Patients with Multidrug-Resistant Tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30782999/),[h·mg] / [l],75.63,223364,DB01137,Levofloxacin
,30782999,AUC0-24,"Similarly, during the second month, the median (IQR) AUC0-24 were 75.63 (61.45 to 125.5) mg ⋅ h/liter in saliva and 102.7 (84.46 to 131.9) mg ⋅ h/liter in plasma, with an S/P ratio of 0.73 (0.66 to 1.18).",Evaluation of Saliva as a Potential Alternative Sampling Matrix for Therapeutic Drug Monitoring of Levofloxacin in Patients with Multidrug-Resistant Tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30782999/),[h·mg] / [l],102.7,223365,DB01137,Levofloxacin
≥,23701411,fC(max) /MIC,"Taking fC(max) /MIC ≥5 and fAUC(24 h) /MIC ≥30 as a target, the cumulative fraction of response (CFR) of levofloxacin 750 mg for treatment of community-acquired pneumonia (CAP) was calculated using Monte Carlo simulation.",Pharmacokinetics and pharmacodynamics of levofloxacin injection in healthy Chinese volunteers and dosing regimen optimization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23701411/),,5,223632,DB01137,Levofloxacin
≥,23701411,fAUC(24 h) /MIC,"Taking fC(max) /MIC ≥5 and fAUC(24 h) /MIC ≥30 as a target, the cumulative fraction of response (CFR) of levofloxacin 750 mg for treatment of community-acquired pneumonia (CAP) was calculated using Monte Carlo simulation.",Pharmacokinetics and pharmacodynamics of levofloxacin injection in healthy Chinese volunteers and dosing regimen optimization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23701411/),,30,223633,DB01137,Levofloxacin
,23701411,C(max),The results of PK study showed that the C(max) and AUC(0-∞) of levofloxacin were 14·94 μg/mL and 80·14 μg h/mL following single-dose infusion of levofloxacin.,Pharmacokinetics and pharmacodynamics of levofloxacin injection in healthy Chinese volunteers and dosing regimen optimization. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23701411/),[μg] / [ml],14·94,223634,DB01137,Levofloxacin
,23701411,AUC(0-∞),The results of PK study showed that the C(max) and AUC(0-∞) of levofloxacin were 14·94 μg/mL and 80·14 μg h/mL following single-dose infusion of levofloxacin.,Pharmacokinetics and pharmacodynamics of levofloxacin injection in healthy Chinese volunteers and dosing regimen optimization. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23701411/),[h·μg] / [ml],80·14,223635,DB01137,Levofloxacin
,23701411,half-life,"The half-life and average cumulative urine excretion ratio within 72 h post-dosing were 7·75 h and 86·95%, respectively.",Pharmacokinetics and pharmacodynamics of levofloxacin injection in healthy Chinese volunteers and dosing regimen optimization. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23701411/),h,7·75,223636,DB01137,Levofloxacin
,23701411,cumulative urine excretion ratio,"The half-life and average cumulative urine excretion ratio within 72 h post-dosing were 7·75 h and 86·95%, respectively.",Pharmacokinetics and pharmacodynamics of levofloxacin injection in healthy Chinese volunteers and dosing regimen optimization. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23701411/),%,86·95,223637,DB01137,Levofloxacin
,23701411,"C(ss,max)","The mean C(ss,max), C(ss,min) and AUC(0-τ) of levofloxacin at steady state following multiple doses were 13·31 μg/mL, 0·031 μg/mL and 103·7 μg h/mL, respectively.",Pharmacokinetics and pharmacodynamics of levofloxacin injection in healthy Chinese volunteers and dosing regimen optimization. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23701411/),[μg] / [ml],13·31,223638,DB01137,Levofloxacin
,23701411,"C(ss,min)","The mean C(ss,max), C(ss,min) and AUC(0-τ) of levofloxacin at steady state following multiple doses were 13·31 μg/mL, 0·031 μg/mL and 103·7 μg h/mL, respectively.",Pharmacokinetics and pharmacodynamics of levofloxacin injection in healthy Chinese volunteers and dosing regimen optimization. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23701411/),[μg] / [ml],0·031,223639,DB01137,Levofloxacin
,23701411,AUC(0-τ),"The mean C(ss,max), C(ss,min) and AUC(0-τ) of levofloxacin at steady state following multiple doses were 13·31 μg/mL, 0·031 μg/mL and 103·7 μg h/mL, respectively.",Pharmacokinetics and pharmacodynamics of levofloxacin injection in healthy Chinese volunteers and dosing regimen optimization. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23701411/),[h·μg] / [ml],103·7,223640,DB01137,Levofloxacin
,23701411,accumulation coefficient,The accumulation coefficient was 1·22.,Pharmacokinetics and pharmacodynamics of levofloxacin injection in healthy Chinese volunteers and dosing regimen optimization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23701411/),,1·22,223641,DB01137,Levofloxacin
,19032129,maximum concentrations,"The concentration of MFLX was the highest in each tissue, with maximum concentrations of MFLX in the aqueous humor (10.16 +/- 1.59 microg/mL) at 30 min after instillation, cornea (156.07 +/- 95.97 microg/g) and iris/ciliary body (11.92 +/- 4.00 microg/g) at 10 min after instillation, and vitreous body (0.099 +/- 0.033 microg/mL) at 30 min after instillation.",Calculation of AQCmax: comparison of five ophthalmic fluoroquinolone solutions*. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19032129/),[μg] / [ml],10.16,223793,DB01137,Levofloxacin
,19032129,maximum concentrations,"The concentration of MFLX was the highest in each tissue, with maximum concentrations of MFLX in the aqueous humor (10.16 +/- 1.59 microg/mL) at 30 min after instillation, cornea (156.07 +/- 95.97 microg/g) and iris/ciliary body (11.92 +/- 4.00 microg/g) at 10 min after instillation, and vitreous body (0.099 +/- 0.033 microg/mL) at 30 min after instillation.",Calculation of AQCmax: comparison of five ophthalmic fluoroquinolone solutions*. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19032129/),[μg] / [g],156.07,223794,DB01137,Levofloxacin
,19032129,maximum concentrations,"The concentration of MFLX was the highest in each tissue, with maximum concentrations of MFLX in the aqueous humor (10.16 +/- 1.59 microg/mL) at 30 min after instillation, cornea (156.07 +/- 95.97 microg/g) and iris/ciliary body (11.92 +/- 4.00 microg/g) at 10 min after instillation, and vitreous body (0.099 +/- 0.033 microg/mL) at 30 min after instillation.",Calculation of AQCmax: comparison of five ophthalmic fluoroquinolone solutions*. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19032129/),[μg] / [g],11.92,223795,DB01137,Levofloxacin
,19032129,maximum concentrations,"The concentration of MFLX was the highest in each tissue, with maximum concentrations of MFLX in the aqueous humor (10.16 +/- 1.59 microg/mL) at 30 min after instillation, cornea (156.07 +/- 95.97 microg/g) and iris/ciliary body (11.92 +/- 4.00 microg/g) at 10 min after instillation, and vitreous body (0.099 +/- 0.033 microg/mL) at 30 min after instillation.",Calculation of AQCmax: comparison of five ophthalmic fluoroquinolone solutions*. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19032129/),[μg] / [ml],0.099,223796,DB01137,Levofloxacin
,19032129,max : MIC(90) ratio,"AQCmax : MIC(90) ratio for S. aureus was 150.67 for MFLX, 10.6 for LVFX, 9.69 for GFLX, 3.48 for OFLX, and could not be determined for TFLX.",Calculation of AQCmax: comparison of five ophthalmic fluoroquinolone solutions*. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19032129/),,150.67,223797,DB01137,Levofloxacin
,19032129,max : MIC(90) ratio,"AQCmax : MIC(90) ratio for S. aureus was 150.67 for MFLX, 10.6 for LVFX, 9.69 for GFLX, 3.48 for OFLX, and could not be determined for TFLX.",Calculation of AQCmax: comparison of five ophthalmic fluoroquinolone solutions*. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19032129/),,10.6,223798,DB01137,Levofloxacin
,19032129,max : MIC(90) ratio,"AQCmax : MIC(90) ratio for S. aureus was 150.67 for MFLX, 10.6 for LVFX, 9.69 for GFLX, 3.48 for OFLX, and could not be determined for TFLX.",Calculation of AQCmax: comparison of five ophthalmic fluoroquinolone solutions*. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19032129/),,9.69,223799,DB01137,Levofloxacin
,19032129,max : MIC(90) ratio,"AQCmax : MIC(90) ratio for S. aureus was 150.67 for MFLX, 10.6 for LVFX, 9.69 for GFLX, 3.48 for OFLX, and could not be determined for TFLX.",Calculation of AQCmax: comparison of five ophthalmic fluoroquinolone solutions*. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19032129/),,3,223800,DB01137,Levofloxacin
,24954796,running time,The extraction procedure included a protein precipitation technique and a short chromatographic running time (4.5 min).,Rapid and sensitive determination of levofloxacin in microsamples of human plasma by high-performance liquid chromatography and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24954796/),min,4.5,224873,DB01137,Levofloxacin
,24954796,absolute recovery,The average absolute recovery was 93.59%.,Rapid and sensitive determination of levofloxacin in microsamples of human plasma by high-performance liquid chromatography and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24954796/),%,93.59,224874,DB01137,Levofloxacin
,7742805,CL,The CL with normal renal function was 0.178 (l/h/kg).,Premarketing population pharmacokinetic study of levofloxacin in normal subjects and patients with infectious diseases. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7742805/),[l] / [h·kg],0.178,225026,DB01137,Levofloxacin
,7742805,apparent volume of distribution (Vd),The apparent volume of distribution (Vd) was calculated to be 1.46 (l/kg).,Premarketing population pharmacokinetic study of levofloxacin in normal subjects and patients with infectious diseases. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7742805/),[l] / [kg],1.46,225027,DB01137,Levofloxacin
,32565928,peak concentration,The peak concentration of levofloxacin was 7.0±1.2 µg/g in lung tissues and 9.4±2.1 µg/g in bronchial mucosa.,Pharmacokinetics and pharmacodynamics of levofloxacin in bronchial mucosa and lung tissue of patients undergoing pulmonary operation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32565928/),[μg] / [g],7.0,225049,DB01137,Levofloxacin
,32565928,peak concentration,The peak concentration of levofloxacin was 7.0±1.2 µg/g in lung tissues and 9.4±2.1 µg/g in bronchial mucosa.,Pharmacokinetics and pharmacodynamics of levofloxacin in bronchial mucosa and lung tissue of patients undergoing pulmonary operation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32565928/),[μg] / [g],9.4,225050,DB01137,Levofloxacin
,32565928,area under the curve between 0 and 24 h (AUC0-24),The corresponding area under the curve between 0 and 24 h (AUC0-24) was 85.7±8.5 and 137.3±19.4 µg h/g.,Pharmacokinetics and pharmacodynamics of levofloxacin in bronchial mucosa and lung tissue of patients undergoing pulmonary operation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32565928/),[h·μg] / [g],85.7,225051,DB01137,Levofloxacin
,32565928,area under the curve between 0 and 24 h (AUC0-24),The corresponding area under the curve between 0 and 24 h (AUC0-24) was 85.7±8.5 and 137.3±19.4 µg h/g.,Pharmacokinetics and pharmacodynamics of levofloxacin in bronchial mucosa and lung tissue of patients undergoing pulmonary operation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32565928/),[h·μg] / [g],137.3,225052,DB01137,Levofloxacin
,32565928,permeability,The mean permeability of levofloxacin (ratio of concentration in tissue to that in plasma) was 2.4 in lung tissue and 4.4 in the bronchial mucosa.,Pharmacokinetics and pharmacodynamics of levofloxacin in bronchial mucosa and lung tissue of patients undergoing pulmonary operation. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32565928/),,2.4,225053,DB01137,Levofloxacin
,32565928,permeability,The mean permeability of levofloxacin (ratio of concentration in tissue to that in plasma) was 2.4 in lung tissue and 4.4 in the bronchial mucosa.,Pharmacokinetics and pharmacodynamics of levofloxacin in bronchial mucosa and lung tissue of patients undergoing pulmonary operation. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32565928/),,4.4,225054,DB01137,Levofloxacin
≤,32565928,MIC,"Streptococcus pneumoniae in the lung and bronchial mucosa was maintained at 100% when MIC ≤1 mg/l, while the cumulative fraction of fAUC0-24/MIC in the corresponding tissues was 94.4 and 98.1%, respectively.",Pharmacokinetics and pharmacodynamics of levofloxacin in bronchial mucosa and lung tissue of patients undergoing pulmonary operation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32565928/),[mg] / [l],1,225055,DB01137,Levofloxacin
,32565928,cumulative fraction of fAUC0-24/MIC,"Streptococcus pneumoniae in the lung and bronchial mucosa was maintained at 100% when MIC ≤1 mg/l, while the cumulative fraction of fAUC0-24/MIC in the corresponding tissues was 94.4 and 98.1%, respectively.",Pharmacokinetics and pharmacodynamics of levofloxacin in bronchial mucosa and lung tissue of patients undergoing pulmonary operation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32565928/),%,94.4,225056,DB01137,Levofloxacin
,32565928,cumulative fraction of fAUC0-24/MIC,"Streptococcus pneumoniae in the lung and bronchial mucosa was maintained at 100% when MIC ≤1 mg/l, while the cumulative fraction of fAUC0-24/MIC in the corresponding tissues was 94.4 and 98.1%, respectively.",Pharmacokinetics and pharmacodynamics of levofloxacin in bronchial mucosa and lung tissue of patients undergoing pulmonary operation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32565928/),%,98.1,225057,DB01137,Levofloxacin
,18931471,minimum inhibitory concentrations (MICs),Six isolates with levofloxacin minimum inhibitory concentrations (MICs) of 2 to 4 microg/mL were selected for this study.,Pharmacodynamics of levofloxacin against characterized ciprofloxacin-resistant Streptococcus pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18931471/),[μg] / [ml],2 to 4,232273,DB01137,Levofloxacin
,33121260,Tmax,Levofloxacin was rapidly absorbed after oral administration (Tmax = 0.38 h) showing high bioavailability (95.57 ± 20.61%).,Levofloxacin pharmacokinetics and tissue residue concentrations after oral administration in Bilgorajska geese. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33121260/),h,0.38,235146,DB01137,Levofloxacin
,33121260,bioavailability,Levofloxacin was rapidly absorbed after oral administration (Tmax = 0.38 h) showing high bioavailability (95.57 ± 20.61%).,Levofloxacin pharmacokinetics and tissue residue concentrations after oral administration in Bilgorajska geese. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33121260/),%,95.57,235147,DB01137,Levofloxacin
,33121260,volume of distribution,The drug showed a moderate volume of distribution (1.40 ± 0.28 ml/g) and rapid clearance (0.28 ± 0.06 ml/g/h).,Levofloxacin pharmacokinetics and tissue residue concentrations after oral administration in Bilgorajska geese. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33121260/),[ml] / [g],1.40,235148,DB01137,Levofloxacin
,33121260,clearance,The drug showed a moderate volume of distribution (1.40 ± 0.28 ml/g) and rapid clearance (0.28 ± 0.06 ml/g/h).,Levofloxacin pharmacokinetics and tissue residue concentrations after oral administration in Bilgorajska geese. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33121260/),[ml] / [g·h],0.28,235149,DB01137,Levofloxacin
>,33121260,minimum inhibitory concentration (MIC),According to the pharmacokinetic/pharmacodynamic surrogate index (AUC/MIC) the levofloxacin dose regimen (after oral administration) used in the present study could be active against bacteria at a minimum inhibitory concentration (MIC) > 0.24 μg/ml in geese.,Levofloxacin pharmacokinetics and tissue residue concentrations after oral administration in Bilgorajska geese. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33121260/),[μg] / [ml],0.24,235150,DB01137,Levofloxacin
,20035039,peak concentrations,"The mean peak concentrations of LVFX in plasma and ELF were achieved at 1.5 hours (4.07 mg/L) and 1 hour (3.44 mg/L), respectively.",Permeability and concentration of levofloxacin in epithelial lining fluid in patients with lower respiratory tract infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20035039/),[mg] / [l],4.07,236191,DB01137,Levofloxacin
,20035039,peak concentrations,"The mean peak concentrations of LVFX in plasma and ELF were achieved at 1.5 hours (4.07 mg/L) and 1 hour (3.44 mg/L), respectively.",Permeability and concentration of levofloxacin in epithelial lining fluid in patients with lower respiratory tract infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20035039/),[mg] / [l],3.44,236192,DB01137,Levofloxacin
,20035039,AUC(24h),The AUC(24h) samples were 50.12 mg .,Permeability and concentration of levofloxacin in epithelial lining fluid in patients with lower respiratory tract infections. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20035039/),mg,50.12,236193,DB01137,Levofloxacin
,1512924,tissue levels (Cmax),"Tissue penetration of LVFX was found to be good, with its tissue levels (Cmax) of 1.17-2.16 micrograms/ml or g after inhalation anaesthesia and 1.15-2.17 micrograms/ml or g after lumbar spinal anaesthesia.",[Pharmacokinetic and clinical evaluation of levofloxacin in obstetrics and gynecology]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1512924/),[μg] / [g·ml·or],1.17-2.16,236204,DB01137,Levofloxacin
,1512924,tissue levels (Cmax),"Tissue penetration of LVFX was found to be good, with its tissue levels (Cmax) of 1.17-2.16 micrograms/ml or g after inhalation anaesthesia and 1.15-2.17 micrograms/ml or g after lumbar spinal anaesthesia.",[Pharmacokinetic and clinical evaluation of levofloxacin in obstetrics and gynecology]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1512924/),[μg] / [g·ml·or],1.15-2.17,236205,DB01137,Levofloxacin
,8031049,area under the concentration-time curve,"Mean +/- standard deviation levofloxacin pharmacokinetic parameters (by noncompartmental moment method) after multiple dosing were as follows: area under the concentration-time curve, 31.24 +/- 5.60 mg.h/liter; apparent total body clearance, 11.18 +/- 1.76 liters/h; renal clearance, 8.63 +/- 2.82 liters/h; steady-state volume of distribution, 104.10 +/- 12.48 liters; and effective half-life, 6.50 +/- 0.51 h.",Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8031049/),[h·mg] / [l],31.24,237964,DB01137,Levofloxacin
,8031049,apparent total body clearance,"Mean +/- standard deviation levofloxacin pharmacokinetic parameters (by noncompartmental moment method) after multiple dosing were as follows: area under the concentration-time curve, 31.24 +/- 5.60 mg.h/liter; apparent total body clearance, 11.18 +/- 1.76 liters/h; renal clearance, 8.63 +/- 2.82 liters/h; steady-state volume of distribution, 104.10 +/- 12.48 liters; and effective half-life, 6.50 +/- 0.51 h.",Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8031049/),[l] / [h],11.18,237965,DB01137,Levofloxacin
,8031049,renal clearance,"Mean +/- standard deviation levofloxacin pharmacokinetic parameters (by noncompartmental moment method) after multiple dosing were as follows: area under the concentration-time curve, 31.24 +/- 5.60 mg.h/liter; apparent total body clearance, 11.18 +/- 1.76 liters/h; renal clearance, 8.63 +/- 2.82 liters/h; steady-state volume of distribution, 104.10 +/- 12.48 liters; and effective half-life, 6.50 +/- 0.51 h.",Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8031049/),[l] / [h],8.63,237966,DB01137,Levofloxacin
,8031049,steady-state volume of distribution,"Mean +/- standard deviation levofloxacin pharmacokinetic parameters (by noncompartmental moment method) after multiple dosing were as follows: area under the concentration-time curve, 31.24 +/- 5.60 mg.h/liter; apparent total body clearance, 11.18 +/- 1.76 liters/h; renal clearance, 8.63 +/- 2.82 liters/h; steady-state volume of distribution, 104.10 +/- 12.48 liters; and effective half-life, 6.50 +/- 0.51 h.",Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8031049/),l,104.10,237967,DB01137,Levofloxacin
,8031049,effective half-life,"Mean +/- standard deviation levofloxacin pharmacokinetic parameters (by noncompartmental moment method) after multiple dosing were as follows: area under the concentration-time curve, 31.24 +/- 5.60 mg.h/liter; apparent total body clearance, 11.18 +/- 1.76 liters/h; renal clearance, 8.63 +/- 2.82 liters/h; steady-state volume of distribution, 104.10 +/- 12.48 liters; and effective half-life, 6.50 +/- 0.51 h.",Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8031049/),h,6.50,237968,DB01137,Levofloxacin
,8031049,peak concentrations,"Single-dose parameters were not significantly different from the multiple-dose parameters, with the exception of peak concentrations in plasma, which were 4.79 +/- 1.00 and 6.92 +/- 1.56 mg/liter for single- and multiple-dose data, respectively.",Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8031049/),[mg] / [l],4.79,237969,DB01137,Levofloxacin
,8031049,peak concentrations,"Single-dose parameters were not significantly different from the multiple-dose parameters, with the exception of peak concentrations in plasma, which were 4.79 +/- 1.00 and 6.92 +/- 1.56 mg/liter for single- and multiple-dose data, respectively.",Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8031049/),[mg] / [l],6.92,237970,DB01137,Levofloxacin
,11211780,MIC90s,"The MIC90s were as follows: 0.39 microgram/ml for M. tuberculosis, > 50 micrograms/ml for M. avium, > 50 micrograms/ml for M. intracellulare, 0.39 microgram/ml for M. kansasii, 0.39 microgram/ml for M. fortuitum, > 50 micrograms/ml for M. abscessus, and 50 micrograms/ml for M. chelonae.","[In vitro antimycobacterial activities of a new quinolone, balofloxacin]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11211780/),[μg] / [ml],0.39,239330,DB01137,Levofloxacin
,11211780,MIC90s,"The MIC90s were as follows: 0.39 microgram/ml for M. tuberculosis, > 50 micrograms/ml for M. avium, > 50 micrograms/ml for M. intracellulare, 0.39 microgram/ml for M. kansasii, 0.39 microgram/ml for M. fortuitum, > 50 micrograms/ml for M. abscessus, and 50 micrograms/ml for M. chelonae.","[In vitro antimycobacterial activities of a new quinolone, balofloxacin]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11211780/),[μg] / [ml],50,239331,DB01137,Levofloxacin
>,11211780,MIC90s,"The MIC90s were as follows: 0.39 microgram/ml for M. tuberculosis, > 50 micrograms/ml for M. avium, > 50 micrograms/ml for M. intracellulare, 0.39 microgram/ml for M. kansasii, 0.39 microgram/ml for M. fortuitum, > 50 micrograms/ml for M. abscessus, and 50 micrograms/ml for M. chelonae.","[In vitro antimycobacterial activities of a new quinolone, balofloxacin]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11211780/),[μg] / [ml],50,239332,DB01137,Levofloxacin
,16854570,circulating concentrations,"Four doses of levofloxacin (5, 25, 50 and 100 mg) were used, resulting in circulating concentrations of levofloxacin at 120 min of 3.56+/-0.14, 15.84+/-2.08, 31.42+/-1.95 and 58.23+/-1.10 mg/L, respectively.",Effect of drug concentration on adsorption of levofloxacin by polyacrylonitrile haemofilters. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16854570/),[mg] / [l],3.56,239584,DB01137,Levofloxacin
,16854570,circulating concentrations,"Four doses of levofloxacin (5, 25, 50 and 100 mg) were used, resulting in circulating concentrations of levofloxacin at 120 min of 3.56+/-0.14, 15.84+/-2.08, 31.42+/-1.95 and 58.23+/-1.10 mg/L, respectively.",Effect of drug concentration on adsorption of levofloxacin by polyacrylonitrile haemofilters. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16854570/),[mg] / [l],15.84,239585,DB01137,Levofloxacin
,16854570,circulating concentrations,"Four doses of levofloxacin (5, 25, 50 and 100 mg) were used, resulting in circulating concentrations of levofloxacin at 120 min of 3.56+/-0.14, 15.84+/-2.08, 31.42+/-1.95 and 58.23+/-1.10 mg/L, respectively.",Effect of drug concentration on adsorption of levofloxacin by polyacrylonitrile haemofilters. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16854570/),[mg] / [l],31.42,239586,DB01137,Levofloxacin
,16854570,circulating concentrations,"Four doses of levofloxacin (5, 25, 50 and 100 mg) were used, resulting in circulating concentrations of levofloxacin at 120 min of 3.56+/-0.14, 15.84+/-2.08, 31.42+/-1.95 and 58.23+/-1.10 mg/L, respectively.",Effect of drug concentration on adsorption of levofloxacin by polyacrylonitrile haemofilters. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16854570/),[mg] / [l],58.23,239587,DB01137,Levofloxacin
,16854570,Adsorption,"Adsorption at 2 h was 0.65+/-0.17, 5.99+/-2.49, 12.30+/-2.34 and 30.13+/-1.32 mg, respectively (P<0.001).",Effect of drug concentration on adsorption of levofloxacin by polyacrylonitrile haemofilters. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16854570/),mg,0.65,239588,DB01137,Levofloxacin
,16854570,Adsorption,"Adsorption at 2 h was 0.65+/-0.17, 5.99+/-2.49, 12.30+/-2.34 and 30.13+/-1.32 mg, respectively (P<0.001).",Effect of drug concentration on adsorption of levofloxacin by polyacrylonitrile haemofilters. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16854570/),mg,5.99,239589,DB01137,Levofloxacin
,16854570,Adsorption,"Adsorption at 2 h was 0.65+/-0.17, 5.99+/-2.49, 12.30+/-2.34 and 30.13+/-1.32 mg, respectively (P<0.001).",Effect of drug concentration on adsorption of levofloxacin by polyacrylonitrile haemofilters. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16854570/),mg,12.30,239590,DB01137,Levofloxacin
,16854570,Adsorption,"Adsorption at 2 h was 0.65+/-0.17, 5.99+/-2.49, 12.30+/-2.34 and 30.13+/-1.32 mg, respectively (P<0.001).",Effect of drug concentration on adsorption of levofloxacin by polyacrylonitrile haemofilters. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16854570/),mg,30.13,239591,DB01137,Levofloxacin
,16854570,adsorption,"When the concentration was decreased from 3.55+/-0.13 mg/L at 4h to 2.16+/-0.11 mg/L at 5 h by addition of lactated Ringer's solution, adsorption decreased from 0.67+/-0.16 mg to 0.21+/-0.25 mg (P<0.05).",Effect of drug concentration on adsorption of levofloxacin by polyacrylonitrile haemofilters. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16854570/),mg,0.67,239592,DB01137,Levofloxacin
,16854570,adsorption,"When the concentration was decreased from 3.55+/-0.13 mg/L at 4h to 2.16+/-0.11 mg/L at 5 h by addition of lactated Ringer's solution, adsorption decreased from 0.67+/-0.16 mg to 0.21+/-0.25 mg (P<0.05).",Effect of drug concentration on adsorption of levofloxacin by polyacrylonitrile haemofilters. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16854570/),mg,0.21,239593,DB01137,Levofloxacin
,24247125,C2/MIC ratios,"Three subjects with the lowest TDA result (<1.5, a finding indicative of poor killing) had significantly lower kanamycin C2/MIC ratios than subjects with a TDA of ≥1.5 (9.8 ± 8.7 versus 27.0 ± 19.1; P = 0.04).",Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24247125/),,9.8,240091,DB01137,Levofloxacin
,24247125,C2/MIC ratios,"Three subjects with the lowest TDA result (<1.5, a finding indicative of poor killing) had significantly lower kanamycin C2/MIC ratios than subjects with a TDA of ≥1.5 (9.8 ± 8.7 versus 27.0 ± 19.1; P = 0.04).",Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24247125/),,27.0,240092,DB01137,Levofloxacin
,24247125,TDAs,The mean TDAs were 2.52 ± 0.76 in subjects converting to negative in ≤2 months and 1.88 ± 0.57 in subjects converting to negative in >2 months (P = 0.08).,Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24247125/),,2.52,240093,DB01137,Levofloxacin
,24247125,TDAs,The mean TDAs were 2.52 ± 0.76 in subjects converting to negative in ≤2 months and 1.88 ± 0.57 in subjects converting to negative in >2 months (P = 0.08).,Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24247125/),,1.88,240094,DB01137,Levofloxacin
,17549677,flow rate,"Levofloxacin and terazosin (internal standard, IS) were chromatographically separated on a C(18) column with a mobile phase containing phosphate buffer (pH 3.0, 10 mm), acetonitrile and triethylamine (76:24:0.076, v/v/v) at a flow rate of 1 mL/min.",A rapid and simple high-performance liquid chromatography method for the determination of human plasma levofloxacin concentration and its application to bioequivalence studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17549677/),[ml] / [min],1,241319,DB01137,Levofloxacin
,17549677,retention times,"The retention times of levofloxacin and terazosin were 2.5 and 3.1 min, respectively.",A rapid and simple high-performance liquid chromatography method for the determination of human plasma levofloxacin concentration and its application to bioequivalence studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17549677/),min,2.5,241320,DB01137,Levofloxacin
,17549677,retention times,"The retention times of levofloxacin and terazosin were 2.5 and 3.1 min, respectively.",A rapid and simple high-performance liquid chromatography method for the determination of human plasma levofloxacin concentration and its application to bioequivalence studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17549677/),min,3.1,241321,DB01137,Levofloxacin
,17549677,recovery,"The recovery ranged from 86 to 89% at the concentrations of 0.0521, 0.5213 and 5.213 microg/mL.",A rapid and simple high-performance liquid chromatography method for the determination of human plasma levofloxacin concentration and its application to bioequivalence studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17549677/),%,86 to 89,241322,DB01137,Levofloxacin
,30302775,T½dist,"After intravenous administration, distribution was rapid (T½dist 0.127 ± 0.055 hr) and wide as reflected by the volume of distribution of 1.20 ± 0.13 L/kg.","Pharmacokinetics of levofloxacin after single intravenous, oral and subcutaneous administration to dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30302775/),h,0.127,241427,DB01137,Levofloxacin
,30302775,volume of distribution,"After intravenous administration, distribution was rapid (T½dist 0.127 ± 0.055 hr) and wide as reflected by the volume of distribution of 1.20 ± 0.13 L/kg.","Pharmacokinetics of levofloxacin after single intravenous, oral and subcutaneous administration to dogs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30302775/),[l] / [kg],1.20,241428,DB01137,Levofloxacin
,30302775,total body clearance,Drug elimination was relatively slow with a total body clearance of 0.11 ± 0.03 L kg-1 hr-1 and a T½ for this process of 7.85 ± 2.30 hr.,"Pharmacokinetics of levofloxacin after single intravenous, oral and subcutaneous administration to dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30302775/),[l] / [h·kg],0.11,241429,DB01137,Levofloxacin
,30302775,T½ for this process,Drug elimination was relatively slow with a total body clearance of 0.11 ± 0.03 L kg-1 hr-1 and a T½ for this process of 7.85 ± 2.30 hr.,"Pharmacokinetics of levofloxacin after single intravenous, oral and subcutaneous administration to dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30302775/),h,7.85,241430,DB01137,Levofloxacin
,30302775,absorption half-life,"After oral and subcutaneous administration, absorption half-life and Tmax were 0.35 and 0.80 hr and 1.82 and 2.82 hr, respectively.","Pharmacokinetics of levofloxacin after single intravenous, oral and subcutaneous administration to dogs. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30302775/),h,0.35,241431,DB01137,Levofloxacin
,30302775,Tmax,"After oral and subcutaneous administration, absorption half-life and Tmax were 0.35 and 0.80 hr and 1.82 and 2.82 hr, respectively.","Pharmacokinetics of levofloxacin after single intravenous, oral and subcutaneous administration to dogs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30302775/),h,0.80,241432,DB01137,Levofloxacin
,30302775,Tmax,"After oral and subcutaneous administration, absorption half-life and Tmax were 0.35 and 0.80 hr and 1.82 and 2.82 hr, respectively.","Pharmacokinetics of levofloxacin after single intravenous, oral and subcutaneous administration to dogs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30302775/),h,1.82,241433,DB01137,Levofloxacin
,30302775,Tmax,"After oral and subcutaneous administration, absorption half-life and Tmax were 0.35 and 0.80 hr and 1.82 and 2.82 hr, respectively.","Pharmacokinetics of levofloxacin after single intravenous, oral and subcutaneous administration to dogs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30302775/),h,2.82,241434,DB01137,Levofloxacin
,30302775,bioavailability,The bioavailability was significantly higher (p ˂ 0.05) after subcutaneous than oral administration (79.90 vs. 60.94%).,"Pharmacokinetics of levofloxacin after single intravenous, oral and subcutaneous administration to dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30302775/),%,79.90,241435,DB01137,Levofloxacin
,30302775,bioavailability,The bioavailability was significantly higher (p ˂ 0.05) after subcutaneous than oral administration (79.90 vs. 60.94%).,"Pharmacokinetics of levofloxacin after single intravenous, oral and subcutaneous administration to dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30302775/),%,60.94,241436,DB01137,Levofloxacin
,30302775,MIC,"Considering the AUC24 hr /MIC and Cmax /MIC ratios obtained, it can be concluded that LFX administered intravenously (2.5 mg/kg), subcutaneously (5 mg/kg) or orally (5 mg/kg) is efficacious against Gram-negative bacteria with MIC values of 0.1 μg/ml.","Pharmacokinetics of levofloxacin after single intravenous, oral and subcutaneous administration to dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30302775/),[μg] / [ml],0.1,241437,DB01137,Levofloxacin
,30302775,MIC,"For Gram-positive bacteria with MIC values of 0.5 μg/kg, only SC and PO administration at a dosage of 5 mg/kg showed to be efficacious.","Pharmacokinetics of levofloxacin after single intravenous, oral and subcutaneous administration to dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30302775/),[μg] / [kg],0.5,241438,DB01137,Levofloxacin
≤,30302775,MIC,"MIC-based PK/PD analysis by Monte Carlo simulation indicates that the proposed dose regimens of LFX, 5 and 7.5 mg/kg/24 hr by SC route and 10 mg/kg/24 hr by oral route, in dogs may be adequate to recommend as an empirical therapy against S. aureus strains with MIC ≤ 0.5 μg/ml and E. coli strains with MIC values ≤0.125 μg/ml.","Pharmacokinetics of levofloxacin after single intravenous, oral and subcutaneous administration to dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30302775/),[μg] / [ml],0.5,241439,DB01137,Levofloxacin
≤,30302775,MIC,"MIC-based PK/PD analysis by Monte Carlo simulation indicates that the proposed dose regimens of LFX, 5 and 7.5 mg/kg/24 hr by SC route and 10 mg/kg/24 hr by oral route, in dogs may be adequate to recommend as an empirical therapy against S. aureus strains with MIC ≤ 0.5 μg/ml and E. coli strains with MIC values ≤0.125 μg/ml.","Pharmacokinetics of levofloxacin after single intravenous, oral and subcutaneous administration to dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30302775/),[μg] / [ml],0.125,241440,DB01137,Levofloxacin
,8647752,peak plasma,"For the pharmacokinetic study, levofloxacin was given (10 mg/kg) by the intraperitoneal route to infected guinea pigs; mean peak plasma and lung concentrations were 3.4 mg/L and 1.4 micrograms/g, respectively, at 0.5 h and 2.6 mg/L and 0.6 micrograms/g at 1 h.","In-vitro activity of levofloxacin against clinical isolates of Legionella spp, its pharmacokinetics in guinea pigs, and use in experimental Legionella pneumophila pneumonia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8647752/),[mg] / [l],3.4,242420,DB01137,Levofloxacin
,8647752,peak plasma,"For the pharmacokinetic study, levofloxacin was given (10 mg/kg) by the intraperitoneal route to infected guinea pigs; mean peak plasma and lung concentrations were 3.4 mg/L and 1.4 micrograms/g, respectively, at 0.5 h and 2.6 mg/L and 0.6 micrograms/g at 1 h.","In-vitro activity of levofloxacin against clinical isolates of Legionella spp, its pharmacokinetics in guinea pigs, and use in experimental Legionella pneumophila pneumonia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8647752/),[mg] / [l],2.6,242421,DB01137,Levofloxacin
,8647752,lung concentrations,"For the pharmacokinetic study, levofloxacin was given (10 mg/kg) by the intraperitoneal route to infected guinea pigs; mean peak plasma and lung concentrations were 3.4 mg/L and 1.4 micrograms/g, respectively, at 0.5 h and 2.6 mg/L and 0.6 micrograms/g at 1 h.","In-vitro activity of levofloxacin against clinical isolates of Legionella spp, its pharmacokinetics in guinea pigs, and use in experimental Legionella pneumophila pneumonia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8647752/),[μg] / [g],1.4,242422,DB01137,Levofloxacin
,8647752,lung concentrations,"For the pharmacokinetic study, levofloxacin was given (10 mg/kg) by the intraperitoneal route to infected guinea pigs; mean peak plasma and lung concentrations were 3.4 mg/L and 1.4 micrograms/g, respectively, at 0.5 h and 2.6 mg/L and 0.6 micrograms/g at 1 h.","In-vitro activity of levofloxacin against clinical isolates of Legionella spp, its pharmacokinetics in guinea pigs, and use in experimental Legionella pneumophila pneumonia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8647752/),[mg] / [l],2.6,242423,DB01137,Levofloxacin
,8647752,lung concentrations,"For the pharmacokinetic study, levofloxacin was given (10 mg/kg) by the intraperitoneal route to infected guinea pigs; mean peak plasma and lung concentrations were 3.4 mg/L and 1.4 micrograms/g, respectively, at 0.5 h and 2.6 mg/L and 0.6 micrograms/g at 1 h.","In-vitro activity of levofloxacin against clinical isolates of Legionella spp, its pharmacokinetics in guinea pigs, and use in experimental Legionella pneumophila pneumonia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8647752/),[μg] / [g],0.6,242424,DB01137,Levofloxacin
,8647752,terminal half-life phase of elimination,The terminal half-life phase of elimination from plasma and lung was c. 1 h.,"In-vitro activity of levofloxacin against clinical isolates of Legionella spp, its pharmacokinetics in guinea pigs, and use in experimental Legionella pneumophila pneumonia. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8647752/),h,c.,242425,DB01137,Levofloxacin
,8647752,terminal half-life phase of elimination,The terminal half-life phase of elimination from plasma and lung was c. 1 h.,"In-vitro activity of levofloxacin against clinical isolates of Legionella spp, its pharmacokinetics in guinea pigs, and use in experimental Legionella pneumophila pneumonia. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8647752/),h,1,242426,DB01137,Levofloxacin
,18313879,MIC,"For the pathogens, levofloxacin MIC values ranged from 0.03 to 2 mg/L.",Use of pharmacodynamic endpoints for the evaluation of levofloxacin for the treatment of acute maxillary sinusitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18313879/),[mg] / [l],0.03 to 2,247256,DB01137,Levofloxacin
,18313879,time to sinus sterilization,"The median and mean time to sinus sterilization (pathogens only) was 1 and 1.4 days, respectively.",Use of pharmacodynamic endpoints for the evaluation of levofloxacin for the treatment of acute maxillary sinusitis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18313879/),d,1,247257,DB01137,Levofloxacin
,18313879,time to sinus sterilization,"The median and mean time to sinus sterilization (pathogens only) was 1 and 1.4 days, respectively.",Use of pharmacodynamic endpoints for the evaluation of levofloxacin for the treatment of acute maxillary sinusitis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18313879/),d,1.4,247258,DB01137,Levofloxacin
,18313879,time to resolution,"The median time to resolution of each sign and symptom ranged from 1.5 to 12-19 days, with the 83% of total signs and symptoms resolved by the end of therapy (day 5).",Use of pharmacodynamic endpoints for the evaluation of levofloxacin for the treatment of acute maxillary sinusitis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18313879/),d,1.5 to 12-19,247259,DB01137,Levofloxacin
,18313879,plasma area under the concentration-time curve (AUC),"The mean plasma area under the concentration-time curve (AUC) (mg x h/L) was 100.1 (n = 14, %CV = 27).",Use of pharmacodynamic endpoints for the evaluation of levofloxacin for the treatment of acute maxillary sinusitis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18313879/),[h·mg] / [l],100.1,247260,DB01137,Levofloxacin
,18313879,Plasma AUC/MIC ratios,Plasma AUC/MIC ratios ranged from 33.9 to 1696 for isolated pathogens.,Use of pharmacodynamic endpoints for the evaluation of levofloxacin for the treatment of acute maxillary sinusitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18313879/),,33.9 to 1696,247261,DB01137,Levofloxacin
,9559801,Cmax,"The mean values of Cmax and area under the concentration-time curve from 0 to 24 h (AUC0-24) following a single 750-mg dose were 7.1 microg/ml and 71.3 microg x h/ml, respectively, compared to 8.6 microg/ml and 90.7 microg x h/ml, respectively, at steady state.",Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559801/),[μg] / [ml],7.1,248177,DB01137,Levofloxacin
,9559801,Cmax,"The mean values of Cmax and area under the concentration-time curve from 0 to 24 h (AUC0-24) following a single 750-mg dose were 7.1 microg/ml and 71.3 microg x h/ml, respectively, compared to 8.6 microg/ml and 90.7 microg x h/ml, respectively, at steady state.",Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559801/),[μg] / [ml],8.6,248178,DB01137,Levofloxacin
,9559801,area under the concentration-time curve from 0 to 24 h (AUC0-24),"The mean values of Cmax and area under the concentration-time curve from 0 to 24 h (AUC0-24) following a single 750-mg dose were 7.1 microg/ml and 71.3 microg x h/ml, respectively, compared to 8.6 microg/ml and 90.7 microg x h/ml, respectively, at steady state.",Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559801/),[h·μg] / [ml],71.3,248179,DB01137,Levofloxacin
,9559801,area under the concentration-time curve from 0 to 24 h (AUC0-24),"The mean values of Cmax and area under the concentration-time curve from 0 to 24 h (AUC0-24) following a single 750-mg dose were 7.1 microg/ml and 71.3 microg x h/ml, respectively, compared to 8.6 microg/ml and 90.7 microg x h/ml, respectively, at steady state.",Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559801/),[h·μg] / [ml],90.7,248180,DB01137,Levofloxacin
,9559801,Cmax,"Following the single 1-g dose, mean Cmax and AUC0-24 values were 8.9 microg/ml and 95.4 microg x h/ml, respectively; corresponding values at steady state were 11.8 microg/ml and 118 microg x h/ml.",Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559801/),[μg] / [ml],8.9,248181,DB01137,Levofloxacin
,9559801,Cmax,"Following the single 1-g dose, mean Cmax and AUC0-24 values were 8.9 microg/ml and 95.4 microg x h/ml, respectively; corresponding values at steady state were 11.8 microg/ml and 118 microg x h/ml.",Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559801/),[μg] / [ml],11.8,248182,DB01137,Levofloxacin
,9559801,AUC0-24,"Following the single 1-g dose, mean Cmax and AUC0-24 values were 8.9 microg/ml and 95.4 microg x h/ml, respectively; corresponding values at steady state were 11.8 microg/ml and 118 microg x h/ml.",Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559801/),[h·μg] / [ml],95.4,248183,DB01137,Levofloxacin
,9559801,AUC0-24,"Following the single 1-g dose, mean Cmax and AUC0-24 values were 8.9 microg/ml and 95.4 microg x h/ml, respectively; corresponding values at steady state were 11.8 microg/ml and 118 microg x h/ml.",Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559801/),[μg] / [ml],11.8,248184,DB01137,Levofloxacin
,9559801,AUC0-24,"Following the single 1-g dose, mean Cmax and AUC0-24 values were 8.9 microg/ml and 95.4 microg x h/ml, respectively; corresponding values at steady state were 11.8 microg/ml and 118 microg x h/ml.",Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559801/),[h·μg] / [ml],118,248185,DB01137,Levofloxacin
,9559801,steady state,"Following the single 1-g dose, mean Cmax and AUC0-24 values were 8.9 microg/ml and 95.4 microg x h/ml, respectively; corresponding values at steady state were 11.8 microg/ml and 118 microg x h/ml.",Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559801/),[h·μg] / [ml],118,248186,DB01137,Levofloxacin
,9559801,CL/F,"Mean steady-state values for CL/F, Vss/F, t1/2, and CL(R) following 750 mg of levofloxacin were 143 ml/min, 100 liters, 8.8 h, and 116 ml/min, respectively; corresponding values for the 1-g dose were 146 ml/min, 105 liters, 8.9 h, and 105 ml/min.",Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559801/),[ml] / [min],143,248187,DB01137,Levofloxacin
,9559801,Vss/F,"Mean steady-state values for CL/F, Vss/F, t1/2, and CL(R) following 750 mg of levofloxacin were 143 ml/min, 100 liters, 8.8 h, and 116 ml/min, respectively; corresponding values for the 1-g dose were 146 ml/min, 105 liters, 8.9 h, and 105 ml/min.",Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559801/),l,100,248188,DB01137,Levofloxacin
,9559801,Vss/F,"Mean steady-state values for CL/F, Vss/F, t1/2, and CL(R) following 750 mg of levofloxacin were 143 ml/min, 100 liters, 8.8 h, and 116 ml/min, respectively; corresponding values for the 1-g dose were 146 ml/min, 105 liters, 8.9 h, and 105 ml/min.",Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559801/),h,8.8,248189,DB01137,Levofloxacin
,9559801,t1/2,"Mean steady-state values for CL/F, Vss/F, t1/2, and CL(R) following 750 mg of levofloxacin were 143 ml/min, 100 liters, 8.8 h, and 116 ml/min, respectively; corresponding values for the 1-g dose were 146 ml/min, 105 liters, 8.9 h, and 105 ml/min.",Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559801/),l,100,248190,DB01137,Levofloxacin
,9559801,t1/2,"Mean steady-state values for CL/F, Vss/F, t1/2, and CL(R) following 750 mg of levofloxacin were 143 ml/min, 100 liters, 8.8 h, and 116 ml/min, respectively; corresponding values for the 1-g dose were 146 ml/min, 105 liters, 8.9 h, and 105 ml/min.",Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559801/),h,8.8,248191,DB01137,Levofloxacin
,9559801,t1/2,"Mean steady-state values for CL/F, Vss/F, t1/2, and CL(R) following 750 mg of levofloxacin were 143 ml/min, 100 liters, 8.8 h, and 116 ml/min, respectively; corresponding values for the 1-g dose were 146 ml/min, 105 liters, 8.9 h, and 105 ml/min.",Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559801/),h,8.9,248192,DB01137,Levofloxacin
,9559801,CL(R),"Mean steady-state values for CL/F, Vss/F, t1/2, and CL(R) following 750 mg of levofloxacin were 143 ml/min, 100 liters, 8.8 h, and 116 ml/min, respectively; corresponding values for the 1-g dose were 146 ml/min, 105 liters, 8.9 h, and 105 ml/min.",Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559801/),[ml] / [min],116,248193,DB01137,Levofloxacin
,9559801,CL(R),"Mean steady-state values for CL/F, Vss/F, t1/2, and CL(R) following 750 mg of levofloxacin were 143 ml/min, 100 liters, 8.8 h, and 116 ml/min, respectively; corresponding values for the 1-g dose were 146 ml/min, 105 liters, 8.9 h, and 105 ml/min.",Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559801/),h,8.9,248194,DB01137,Levofloxacin
,9559801,CL(R),"Mean steady-state values for CL/F, Vss/F, t1/2, and CL(R) following 750 mg of levofloxacin were 143 ml/min, 100 liters, 8.8 h, and 116 ml/min, respectively; corresponding values for the 1-g dose were 146 ml/min, 105 liters, 8.9 h, and 105 ml/min.",Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9559801/),[ml] / [min],105,248195,DB01137,Levofloxacin
,10404342,terminal half-life (t1/2),"Nine S. pneumoniae strains (one penicillin G-resistant, one penicillin G-intermediate resistant, and two penicillin G- and cefotaxime-resistant) were exposed to a levofloxacin concentration of 6 mg/L diluted at a terminal half-life (t1/2) of 8 h.",Bactericidal activity of levofloxacin against Streptococcus pneumoniae in an in-vitro model simulating serum pharmacokinetic parameters. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10404342/),h,8,248489,DB01137,Levofloxacin
<,10404342,MIC,"All strains except one (strain 17134) had an MIC < 1.0 mg/L, and the minimum bactericidal concentrations (MBCs) were, at the most, one dilution higher than the respective MICs.",Bactericidal activity of levofloxacin against Streptococcus pneumoniae in an in-vitro model simulating serum pharmacokinetic parameters. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10404342/),[mg] / [l],1.0,248490,DB01137,Levofloxacin
,10404342,time required to,"The time required to achieve 99% death ranged from 0.9 to 3.1 h, and was longest for strain 17134 which had an MIC of 1.0 mg/L and an MBC of 2.0 mg/L. A 99.9% reduction in inoculum was achieved within 1.5-4.15 h.",Bactericidal activity of levofloxacin against Streptococcus pneumoniae in an in-vitro model simulating serum pharmacokinetic parameters. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10404342/),h,0.9 to 3.1,248491,DB01137,Levofloxacin
,10404342,MIC,"The time required to achieve 99% death ranged from 0.9 to 3.1 h, and was longest for strain 17134 which had an MIC of 1.0 mg/L and an MBC of 2.0 mg/L. A 99.9% reduction in inoculum was achieved within 1.5-4.15 h.",Bactericidal activity of levofloxacin against Streptococcus pneumoniae in an in-vitro model simulating serum pharmacokinetic parameters. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10404342/),[mg] / [l],1.0,248492,DB01137,Levofloxacin
,10404342,MBC,"The time required to achieve 99% death ranged from 0.9 to 3.1 h, and was longest for strain 17134 which had an MIC of 1.0 mg/L and an MBC of 2.0 mg/L. A 99.9% reduction in inoculum was achieved within 1.5-4.15 h.",Bactericidal activity of levofloxacin against Streptococcus pneumoniae in an in-vitro model simulating serum pharmacokinetic parameters. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10404342/),[mg] / [l],2.0,248493,DB01137,Levofloxacin
,12604547,MICs,"Gemifloxacin MICs were in the range of 0.016 to 0.25 mg/liter, and levofloxacin MICs ranged from 1 to 16 mg/liter.",Mechanism of fluoroquinolone resistance is an important factor in determining the antimicrobial effect of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12604547/),[mg] / [l],0.016 to 0.25,249229,DB01137,Levofloxacin
,12604547,MICs,"Gemifloxacin MICs were in the range of 0.016 to 0.25 mg/liter, and levofloxacin MICs ranged from 1 to 16 mg/liter.",Mechanism of fluoroquinolone resistance is an important factor in determining the antimicrobial effect of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12604547/),[mg] / [l],1 to 16,249230,DB01137,Levofloxacin
,12604547,area under the curve (AUC)/MIC ratios,"The area under the curve (AUC)/MIC ratios for gemifloxacin and levofloxacin were 35 to 544 and 3 to 48, respectively.",Mechanism of fluoroquinolone resistance is an important factor in determining the antimicrobial effect of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12604547/),,35 to 544,249231,DB01137,Levofloxacin
,12604547,area under the curve (AUC)/MIC ratios,"The area under the curve (AUC)/MIC ratios for gemifloxacin and levofloxacin were 35 to 544 and 3 to 48, respectively.",Mechanism of fluoroquinolone resistance is an important factor in determining the antimicrobial effect of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12604547/),,3 to 48,249232,DB01137,Levofloxacin
,29310119,Eradication rates,"Eradication rates of group B (reduced amoxicillin-regimen) were 84.2% in intention-to-treat analysis and 88.9% in per-protocol analysis, which were similar with group A (77.8 and 77.8%) and group C (74.6 and 81.0%).",Efficacy of Reduced Dosage of Amoxicillin in an Eradication Therapy for Helicobacter pylori Infection in Patients on Hemodialysis: A Randomized Controlled Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29310119/),%,84.2,249470,DB01137,Levofloxacin
,29310119,Eradication rates,"Eradication rates of group B (reduced amoxicillin-regimen) were 84.2% in intention-to-treat analysis and 88.9% in per-protocol analysis, which were similar with group A (77.8 and 77.8%) and group C (74.6 and 81.0%).",Efficacy of Reduced Dosage of Amoxicillin in an Eradication Therapy for Helicobacter pylori Infection in Patients on Hemodialysis: A Randomized Controlled Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29310119/),%,88.9,249471,DB01137,Levofloxacin
,29310119,Eradication rates,"Eradication rates of group B (reduced amoxicillin-regimen) were 84.2% in intention-to-treat analysis and 88.9% in per-protocol analysis, which were similar with group A (77.8 and 77.8%) and group C (74.6 and 81.0%).",Efficacy of Reduced Dosage of Amoxicillin in an Eradication Therapy for Helicobacter pylori Infection in Patients on Hemodialysis: A Randomized Controlled Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29310119/),%,77.8,249472,DB01137,Levofloxacin
,29310119,Eradication rates,"Eradication rates of group B (reduced amoxicillin-regimen) were 84.2% in intention-to-treat analysis and 88.9% in per-protocol analysis, which were similar with group A (77.8 and 77.8%) and group C (74.6 and 81.0%).",Efficacy of Reduced Dosage of Amoxicillin in an Eradication Therapy for Helicobacter pylori Infection in Patients on Hemodialysis: A Randomized Controlled Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29310119/),%,74.6,249473,DB01137,Levofloxacin
,29310119,Eradication rates,"Eradication rates of group B (reduced amoxicillin-regimen) were 84.2% in intention-to-treat analysis and 88.9% in per-protocol analysis, which were similar with group A (77.8 and 77.8%) and group C (74.6 and 81.0%).",Efficacy of Reduced Dosage of Amoxicillin in an Eradication Therapy for Helicobacter pylori Infection in Patients on Hemodialysis: A Randomized Controlled Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29310119/),%,81.0,249474,DB01137,Levofloxacin
,17993749,"distribution coefficient, alpha","Levofloxacin was rapidly distributed from blood to the tissue compartment as evidenced by the high values of the distribution coefficient, alpha (17.3 +/- 1.65 /h) and the ratio of K(12)/K(21) (1.83 +/- 0.12).",Disposition kinetics and dosage regimen of levofloxacin on concomitant administration with paracetamol in crossbred calves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17993749/),1/[h],17.3,250061,DB01137,Levofloxacin
,17993749,ratio of K(12)/K(21),"Levofloxacin was rapidly distributed from blood to the tissue compartment as evidenced by the high values of the distribution coefficient, alpha (17.3 +/- 1.65 /h) and the ratio of K(12)/K(21) (1.83 +/- 0.12).",Disposition kinetics and dosage regimen of levofloxacin on concomitant administration with paracetamol in crossbred calves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17993749/),,1.83,250062,DB01137,Levofloxacin
,17993749,AUC,The values of AUC and Vd(area) were 12.7 +/- 0.12 microg.h/ml and 0.63 +/- 0.01 l/kg.,Disposition kinetics and dosage regimen of levofloxacin on concomitant administration with paracetamol in crossbred calves. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17993749/),[h·μg] / [ml],12.7,250063,DB01137,Levofloxacin
,17993749,Vd(area),The values of AUC and Vd(area) were 12.7 +/- 0.12 microg.h/ml and 0.63 +/- 0.01 l/kg.,Disposition kinetics and dosage regimen of levofloxacin on concomitant administration with paracetamol in crossbred calves. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17993749/),[l] / [kg],0.63,250064,DB01137,Levofloxacin
,17993749,ratio of the AUC/ MIC,The high ratio of the AUC/ MIC (126.9 +/- 1.18) obtained in this study indicated the excellent antibacterial activity of levofloxacin in calves.,Disposition kinetics and dosage regimen of levofloxacin on concomitant administration with paracetamol in crossbred calves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17993749/),,126.9,250065,DB01137,Levofloxacin
,17993749,elimination half-life,"The elimination half-life, MRT and total body clearance were 1.38 +/- 0.01 h, 1.88 +/- 0.01 h and 0.32 +/- 0.003 l/kg/h, respectively.",Disposition kinetics and dosage regimen of levofloxacin on concomitant administration with paracetamol in crossbred calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17993749/),h,1.38,250066,DB01137,Levofloxacin
,17993749,MRT,"The elimination half-life, MRT and total body clearance were 1.38 +/- 0.01 h, 1.88 +/- 0.01 h and 0.32 +/- 0.003 l/kg/h, respectively.",Disposition kinetics and dosage regimen of levofloxacin on concomitant administration with paracetamol in crossbred calves. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17993749/),h,1.88,250067,DB01137,Levofloxacin
,17993749,total body clearance,"The elimination half-life, MRT and total body clearance were 1.38 +/- 0.01 h, 1.88 +/- 0.01 h and 0.32 +/- 0.003 l/kg/h, respectively.",Disposition kinetics and dosage regimen of levofloxacin on concomitant administration with paracetamol in crossbred calves. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17993749/),[l] / [h·kg],0.32,250068,DB01137,Levofloxacin
,32265612,serum levels,"Levofloxacin serum levels were obtained at 0.5, 3.5, and 11.5 hours after infusion, which were 8.61, 5.76, and 2.7 mg/L, respectively.",Therapeutic Drug Monitoring of Levoffoxacin in an Obese Adolescent: A Case Report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32265612/),,8,250619,DB01137,Levofloxacin
,32265612,serum levels,"Levofloxacin serum levels were obtained at 0.5, 3.5, and 11.5 hours after infusion, which were 8.61, 5.76, and 2.7 mg/L, respectively.",Therapeutic Drug Monitoring of Levoffoxacin in an Obese Adolescent: A Case Report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32265612/),,5.76,250620,DB01137,Levofloxacin
,32265612,serum levels,"Levofloxacin serum levels were obtained at 0.5, 3.5, and 11.5 hours after infusion, which were 8.61, 5.76, and 2.7 mg/L, respectively.",Therapeutic Drug Monitoring of Levoffoxacin in an Obese Adolescent: A Case Report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32265612/),,2.7,250621,DB01137,Levofloxacin
,32265612,peak level,"These concentrations translated into a peak level of 8.79 mg/L, a half-life of 6.4 hours, and an AUC of 80 mg·hr/L, which are discordant from the expected peak of 16 mg/L, a half-life of 8 hours, and an AUC of 120 mg·hr/L.",Therapeutic Drug Monitoring of Levoffoxacin in an Obese Adolescent: A Case Report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32265612/),[mg] / [l],8.79,250622,DB01137,Levofloxacin
,32265612,half-life,"These concentrations translated into a peak level of 8.79 mg/L, a half-life of 6.4 hours, and an AUC of 80 mg·hr/L, which are discordant from the expected peak of 16 mg/L, a half-life of 8 hours, and an AUC of 120 mg·hr/L.",Therapeutic Drug Monitoring of Levoffoxacin in an Obese Adolescent: A Case Report. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32265612/),h,6.4,250623,DB01137,Levofloxacin
,32265612,AUC,"These concentrations translated into a peak level of 8.79 mg/L, a half-life of 6.4 hours, and an AUC of 80 mg·hr/L, which are discordant from the expected peak of 16 mg/L, a half-life of 8 hours, and an AUC of 120 mg·hr/L.",Therapeutic Drug Monitoring of Levoffoxacin in an Obese Adolescent: A Case Report. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32265612/),[h·mg] / [l],80,250624,DB01137,Levofloxacin
,32265612,half-life,"These concentrations translated into a peak level of 8.79 mg/L, a half-life of 6.4 hours, and an AUC of 80 mg·hr/L, which are discordant from the expected peak of 16 mg/L, a half-life of 8 hours, and an AUC of 120 mg·hr/L.",Therapeutic Drug Monitoring of Levoffoxacin in an Obese Adolescent: A Case Report. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32265612/),h,8,250625,DB01137,Levofloxacin
,32265612,AUC,"These concentrations translated into a peak level of 8.79 mg/L, a half-life of 6.4 hours, and an AUC of 80 mg·hr/L, which are discordant from the expected peak of 16 mg/L, a half-life of 8 hours, and an AUC of 120 mg·hr/L.",Therapeutic Drug Monitoring of Levoffoxacin in an Obese Adolescent: A Case Report. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32265612/),[h·mg] / [l],120,250626,DB01137,Levofloxacin
,32265612,peak,"Based on these values, the levofloxacin regimen was adjusted to 1000 mg IV every 12 hours, and repeat levels 0.5, 3.5, and 11.5 hours after infusion were 9.91, 6.56, and 3.27 mg/L, respectively, corresponding to a peak of 10.5 mg/L, a half-life of 5.18 hours, and an AUC of 200 mg·hr/L.",Therapeutic Drug Monitoring of Levoffoxacin in an Obese Adolescent: A Case Report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32265612/),[mg] / [l],10.5,250627,DB01137,Levofloxacin
,32265612,half-life,"Based on these values, the levofloxacin regimen was adjusted to 1000 mg IV every 12 hours, and repeat levels 0.5, 3.5, and 11.5 hours after infusion were 9.91, 6.56, and 3.27 mg/L, respectively, corresponding to a peak of 10.5 mg/L, a half-life of 5.18 hours, and an AUC of 200 mg·hr/L.",Therapeutic Drug Monitoring of Levoffoxacin in an Obese Adolescent: A Case Report. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32265612/),h,5.18,250628,DB01137,Levofloxacin
,32265612,AUC,"Based on these values, the levofloxacin regimen was adjusted to 1000 mg IV every 12 hours, and repeat levels 0.5, 3.5, and 11.5 hours after infusion were 9.91, 6.56, and 3.27 mg/L, respectively, corresponding to a peak of 10.5 mg/L, a half-life of 5.18 hours, and an AUC of 200 mg·hr/L.",Therapeutic Drug Monitoring of Levoffoxacin in an Obese Adolescent: A Case Report. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32265612/),[h·mg] / [l],200,250629,DB01137,Levofloxacin
,11249827,times to 99.9% kill,"Moxifloxacin was bactericidal against all 6 staphylococci (times to 99.9% kill, 1-3 h).",Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11249827/),h,1-3,250858,DB01137,Levofloxacin
,11249827,total kills,"Against most strains, bacterial killing continued through 36 h, with total kills exceeding 5.5 logs.",Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11249827/),logs,5,250859,DB01137,Levofloxacin
<,12385678,MICs,"The efficacy of a new pharmacokinetically enhanced formulation of amoxycillin/clavulanate (AMX/CA) 2000/125 mg, twice daily, designed to provide adequate levels of amoxycillin over the 12-h dosing interval to eradicate penicillin-resistant Streptococcus pneumoniae (PRSP) with amoxycillin (+/-clavulanic acid) MICs of </=4 mg/l, was evaluated in patients with respiratory infections caused by S. pneumoniae, including PRSP (penicillin MICs 2-16 mg/l).","Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycillin/clavulanate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12385678/),[mg] / [l],4,259467,DB01137,Levofloxacin
,12385678,MICs,"The efficacy of a new pharmacokinetically enhanced formulation of amoxycillin/clavulanate (AMX/CA) 2000/125 mg, twice daily, designed to provide adequate levels of amoxycillin over the 12-h dosing interval to eradicate penicillin-resistant Streptococcus pneumoniae (PRSP) with amoxycillin (+/-clavulanic acid) MICs of </=4 mg/l, was evaluated in patients with respiratory infections caused by S. pneumoniae, including PRSP (penicillin MICs 2-16 mg/l).","Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycillin/clavulanate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12385678/),[mg] / [l],2-16,259468,DB01137,Levofloxacin
>,12385678,MICs,"In the AMX/CA 2000/125 mg bid-treated patients evaluable at follow-up (Day 14-39), outcome was successful in 60/64 (93.7%) patients with S. pneumoniae infections in the comparative studies and 348/363 (95.9%) in the non-comparative studies, including 95.6% of all patients and 95.2% of patients whose isolates had AMX/CA MICs of >/=4 mg/l.","Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycillin/clavulanate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12385678/),[mg] / [l],4,259469,DB01137,Levofloxacin
,12385678,MICs,"For PRSP (AMX/CA MICs of 0.5-8 mg/l), the overall success rate was 98.2% (55/56) at follow-up for AMX/CA 2000/125 mg and 50.0% (2/4) for comparators.","Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycillin/clavulanate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12385678/),[mg] / [l],0.5-8,259470,DB01137,Levofloxacin
,12385678,overall success rate,"For PRSP (AMX/CA MICs of 0.5-8 mg/l), the overall success rate was 98.2% (55/56) at follow-up for AMX/CA 2000/125 mg and 50.0% (2/4) for comparators.","Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycillin/clavulanate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12385678/),%,98,259471,DB01137,Levofloxacin
>,12385678,MICs,"Due to its favorable pharmacokinetic/pharmacodynamic profile and promising clinical success, the new AMX/CA 2000/125 mg formulation should be considered for the empirical treatment of respiratory tract infections in regions with a high prevalence of antimicrobial-resistant S. pneumoniae and in patients at high risk of antimicrobial-resistant S. pneumoniae infection as this formulation covers many PRSP that are non-susceptible to amoxycillin (+/-clavulanic acid) (MICs of >/=4 mg/l) as well as common beta-lactamase-producing respiratory pathogens.","Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycillin/clavulanate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12385678/),[mg] / [l],4,259472,DB01137,Levofloxacin
,32628058,AUC0-24,"After iv of levofloxacin, the mean (±SD) of AUC0-24, Vz, t½λz and MRT, was 19.05 ± 6.4 µg-h/ml, 2.43 ± 0.5 L/kg, 7.93 ± 1.41 hours and 8.7 ± 1.5 hours, respectively.","Pharmacokinetics of levofloxacin after single intravenous and oral administration, and its interaction with sucralfate in mixed-breed dogs. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32628058/),[µg-h] / [ml],19.05,260448,DB01137,Levofloxacin
,32628058,Vz,"After iv of levofloxacin, the mean (±SD) of AUC0-24, Vz, t½λz and MRT, was 19.05 ± 6.4 µg-h/ml, 2.43 ± 0.5 L/kg, 7.93 ± 1.41 hours and 8.7 ± 1.5 hours, respectively.","Pharmacokinetics of levofloxacin after single intravenous and oral administration, and its interaction with sucralfate in mixed-breed dogs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32628058/),[l] / [kg],2.43,260449,DB01137,Levofloxacin
,32628058,t½λz,"After iv of levofloxacin, the mean (±SD) of AUC0-24, Vz, t½λz and MRT, was 19.05 ± 6.4 µg-h/ml, 2.43 ± 0.5 L/kg, 7.93 ± 1.41 hours and 8.7 ± 1.5 hours, respectively.","Pharmacokinetics of levofloxacin after single intravenous and oral administration, and its interaction with sucralfate in mixed-breed dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32628058/),[l] / [kg],2.43,260450,DB01137,Levofloxacin
,32628058,MRT,"After iv of levofloxacin, the mean (±SD) of AUC0-24, Vz, t½λz and MRT, was 19.05 ± 6.4 µg-h/ml, 2.43 ± 0.5 L/kg, 7.93 ± 1.41 hours and 8.7 ± 1.5 hours, respectively.","Pharmacokinetics of levofloxacin after single intravenous and oral administration, and its interaction with sucralfate in mixed-breed dogs. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32628058/),h,8.7,260451,DB01137,Levofloxacin
,32628058,C max,"After oral administration, the C max, t½λz and bioavailability were 1.95 ± 0.7 µg/ml, 7.65 ± 1.38 hours and 71.93 ± 9.75%, respectively.","Pharmacokinetics of levofloxacin after single intravenous and oral administration, and its interaction with sucralfate in mixed-breed dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32628058/),[μg] / [ml],1.95,260452,DB01137,Levofloxacin
,32628058,t½λz,"After oral administration, the C max, t½λz and bioavailability were 1.95 ± 0.7 µg/ml, 7.65 ± 1.38 hours and 71.93 ± 9.75%, respectively.","Pharmacokinetics of levofloxacin after single intravenous and oral administration, and its interaction with sucralfate in mixed-breed dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32628058/),h,7.65,260453,DB01137,Levofloxacin
,32628058,bioavailability,"After oral administration, the C max, t½λz and bioavailability were 1.95 ± 0.7 µg/ml, 7.65 ± 1.38 hours and 71.93 ± 9.75%, respectively.","Pharmacokinetics of levofloxacin after single intravenous and oral administration, and its interaction with sucralfate in mixed-breed dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32628058/),%,71.93,260454,DB01137,Levofloxacin
,32628058,C max,"In animals given an oral dose of levofloxacin with sucralfate pre-treatment, there was a significant decrease (p < 0.05) in C max (0.57 ± 0.23 µg/ml), AUC (5.73 ± 2.26 µg-h/ml) and bioavailability (31.92 ± 14.19%).","Pharmacokinetics of levofloxacin after single intravenous and oral administration, and its interaction with sucralfate in mixed-breed dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32628058/),[μg] / [ml],0.57,260455,DB01137,Levofloxacin
,32628058,AUC,"In animals given an oral dose of levofloxacin with sucralfate pre-treatment, there was a significant decrease (p < 0.05) in C max (0.57 ± 0.23 µg/ml), AUC (5.73 ± 2.26 µg-h/ml) and bioavailability (31.92 ± 14.19%).","Pharmacokinetics of levofloxacin after single intravenous and oral administration, and its interaction with sucralfate in mixed-breed dogs. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32628058/),[µg-h] / [ml],5.73,260456,DB01137,Levofloxacin
,32628058,bioavailability,"In animals given an oral dose of levofloxacin with sucralfate pre-treatment, there was a significant decrease (p < 0.05) in C max (0.57 ± 0.23 µg/ml), AUC (5.73 ± 2.26 µg-h/ml) and bioavailability (31.92 ± 14.19%).","Pharmacokinetics of levofloxacin after single intravenous and oral administration, and its interaction with sucralfate in mixed-breed dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32628058/),%,31.92,260457,DB01137,Levofloxacin
,29438726,release rate,"The release profiles showed an obvious zero-order release of LVF from MWCNT@LC-MIP, which exhibited 3.8 μg/h of the release rate with duration of about 20 h.",Floating liquid crystalline molecularly imprinted polymer coated carbon nanotubes for levofloxacin delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29438726/),[μg] / [h],3.8,260629,DB01137,Levofloxacin
,29438726,relative bioavailability,"In vivo pharmacokinetic study displayed the relative bioavailability of the gastro-floating MWCNT@LC-MIP was 578.9%, whereas only 58.0% of MWCNT@MIP and 11.7% of the bared MWCNT.",Floating liquid crystalline molecularly imprinted polymer coated carbon nanotubes for levofloxacin delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29438726/),%,578.9,260630,DB01137,Levofloxacin
,29438726,relative bioavailability,"In vivo pharmacokinetic study displayed the relative bioavailability of the gastro-floating MWCNT@LC-MIP was 578.9%, whereas only 58.0% of MWCNT@MIP and 11.7% of the bared MWCNT.",Floating liquid crystalline molecularly imprinted polymer coated carbon nanotubes for levofloxacin delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29438726/),%,58.0,260631,DB01137,Levofloxacin
,29438726,relative bioavailability,"In vivo pharmacokinetic study displayed the relative bioavailability of the gastro-floating MWCNT@LC-MIP was 578.9%, whereas only 58.0% of MWCNT@MIP and 11.7% of the bared MWCNT.",Floating liquid crystalline molecularly imprinted polymer coated carbon nanotubes for levofloxacin delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29438726/),%,11.7,260632,DB01137,Levofloxacin
,17356095,area under the curve for 24 h (AUC(24)),"When compared to published data on non-CF patients, CF patients had similar area under the curve for 24 h (AUC(24)), total clearance, volume of distribution, maximum serum concentration (Cpmax), and elimination half-life: mean, 7.33 microg x h/mL/kg (SD, 1.70); 2.43 mL/min/kg (SD, 0.74); 1.33 L/kg (SD, 0.37); 7.06 microg/mL (SD, 2.35); and 6.44 h (SD, 1.1), respectively.",Levofloxacin pharmacokinetics in adult cystic fibrosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17356095/),[h·μg] / [kg·ml],7.33,261320,DB01137,Levofloxacin
,17356095,elimination half-life,"When compared to published data on non-CF patients, CF patients had similar area under the curve for 24 h (AUC(24)), total clearance, volume of distribution, maximum serum concentration (Cpmax), and elimination half-life: mean, 7.33 microg x h/mL/kg (SD, 1.70); 2.43 mL/min/kg (SD, 0.74); 1.33 L/kg (SD, 0.37); 7.06 microg/mL (SD, 2.35); and 6.44 h (SD, 1.1), respectively.",Levofloxacin pharmacokinetics in adult cystic fibrosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17356095/),h,6.44,261321,DB01137,Levofloxacin
,17356095,Time to reach maximum serum concentration (Tmax),"Time to reach maximum serum concentration (Tmax) in CF was longer: mean, 2.20 h (SD, 0.99) vs 1.1 h (SD, 0.4) [p < 0.01].",Levofloxacin pharmacokinetics in adult cystic fibrosis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17356095/),h,2.20,261322,DB01137,Levofloxacin
,17356095,Time to reach maximum serum concentration (Tmax),"Time to reach maximum serum concentration (Tmax) in CF was longer: mean, 2.20 h (SD, 0.99) vs 1.1 h (SD, 0.4) [p < 0.01].",Levofloxacin pharmacokinetics in adult cystic fibrosis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17356095/),h,1.1,261323,DB01137,Levofloxacin
,23830621,Peak,"Peak and trough concentrations were, respectively, 4.81 ± 1.03 and 0.59 ± 1.13 mg/L for moxifloxacin and 6.42 ± 1.08 and 0.79 ± 0.39 mg/L for levofloxacin.",Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23830621/),[mg] / [l],4.81,261422,DB01137,Levofloxacin
,23830621,Peak,"Peak and trough concentrations were, respectively, 4.81 ± 1.03 and 0.59 ± 1.13 mg/L for moxifloxacin and 6.42 ± 1.08 and 0.79 ± 0.39 mg/L for levofloxacin.",Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23830621/),[mg] / [l],6.42,261423,DB01137,Levofloxacin
,23830621,trough concentrations,"Peak and trough concentrations were, respectively, 4.81 ± 1.03 and 0.59 ± 1.13 mg/L for moxifloxacin and 6.42 ± 1.08 and 0.79 ± 0.39 mg/L for levofloxacin.",Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23830621/),[mg] / [l],0.59,261424,DB01137,Levofloxacin
,23830621,trough concentrations,"Peak and trough concentrations were, respectively, 4.81 ± 1.03 and 0.59 ± 1.13 mg/L for moxifloxacin and 6.42 ± 1.08 and 0.79 ± 0.39 mg/L for levofloxacin.",Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23830621/),[mg] / [l],0.79,261425,DB01137,Levofloxacin
,23830621,CL,"Pharmacokinetic data for moxifloxacin and levofloxacin, respectively, were: CL, 10.27 ± 1.24 and 22.66 ± 6.62 L/h; t1/2, 13.43 ± 5.12 and 6.75 ± 1.34 h; Vss, 163.03 ± 53.88 and 170.73 ± 39.59 L; and AUC(0-24), 39.38 ±5.28 and 47.06 ± 14.09 mg·h/L.",Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23830621/),[l] / [h],10.27,261426,DB01137,Levofloxacin
,23830621,CL,"Pharmacokinetic data for moxifloxacin and levofloxacin, respectively, were: CL, 10.27 ± 1.24 and 22.66 ± 6.62 L/h; t1/2, 13.43 ± 5.12 and 6.75 ± 1.34 h; Vss, 163.03 ± 53.88 and 170.73 ± 39.59 L; and AUC(0-24), 39.38 ±5.28 and 47.06 ± 14.09 mg·h/L.",Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23830621/),[l] / [h],22.66,261427,DB01137,Levofloxacin
,23830621,t1/2,"Pharmacokinetic data for moxifloxacin and levofloxacin, respectively, were: CL, 10.27 ± 1.24 and 22.66 ± 6.62 L/h; t1/2, 13.43 ± 5.12 and 6.75 ± 1.34 h; Vss, 163.03 ± 53.88 and 170.73 ± 39.59 L; and AUC(0-24), 39.38 ±5.28 and 47.06 ± 14.09 mg·h/L.",Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23830621/),h,13.43,261428,DB01137,Levofloxacin
,23830621,t1/2,"Pharmacokinetic data for moxifloxacin and levofloxacin, respectively, were: CL, 10.27 ± 1.24 and 22.66 ± 6.62 L/h; t1/2, 13.43 ± 5.12 and 6.75 ± 1.34 h; Vss, 163.03 ± 53.88 and 170.73 ± 39.59 L; and AUC(0-24), 39.38 ±5.28 and 47.06 ± 14.09 mg·h/L.",Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23830621/),h,6.75,261429,DB01137,Levofloxacin
,23830621,Vss,"Pharmacokinetic data for moxifloxacin and levofloxacin, respectively, were: CL, 10.27 ± 1.24 and 22.66 ± 6.62 L/h; t1/2, 13.43 ± 5.12 and 6.75 ± 1.34 h; Vss, 163.03 ± 53.88 and 170.73 ± 39.59 L; and AUC(0-24), 39.38 ±5.28 and 47.06 ± 14.09 mg·h/L.",Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23830621/),l,163.03,261430,DB01137,Levofloxacin
,23830621,Vss,"Pharmacokinetic data for moxifloxacin and levofloxacin, respectively, were: CL, 10.27 ± 1.24 and 22.66 ± 6.62 L/h; t1/2, 13.43 ± 5.12 and 6.75 ± 1.34 h; Vss, 163.03 ± 53.88 and 170.73 ± 39.59 L; and AUC(0-24), 39.38 ±5.28 and 47.06 ± 14.09 mg·h/L.",Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23830621/),l,170.73,261431,DB01137,Levofloxacin
,23830621,AUC(0-24),"Pharmacokinetic data for moxifloxacin and levofloxacin, respectively, were: CL, 10.27 ± 1.24 and 22.66 ± 6.62 L/h; t1/2, 13.43 ± 5.12 and 6.75 ± 1.34 h; Vss, 163.03 ± 53.88 and 170.73 ± 39.59 L; and AUC(0-24), 39.38 ±5.28 and 47.06 ± 14.09 mg·h/L.",Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23830621/),[h·mg] / [l],39.38,261432,DB01137,Levofloxacin
,23830621,AUC(0-24),"Pharmacokinetic data for moxifloxacin and levofloxacin, respectively, were: CL, 10.27 ± 1.24 and 22.66 ± 6.62 L/h; t1/2, 13.43 ± 5.12 and 6.75 ± 1.34 h; Vss, 163.03 ± 53.88 and 170.73 ± 39.59 L; and AUC(0-24), 39.38 ±5.28 and 47.06 ± 14.09 mg·h/L.",Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23830621/),[h·mg] / [l],47.06,261433,DB01137,Levofloxacin
≤,23830621,MICs,Moxifloxacin proved to be pharmacodynamically efficacious against Gram-positive bacteria with MICs ≤ 0.79 mg/L and Gram-negative bacteria with MICs ≤ 0.32 mg/L.,Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23830621/),[mg] / [l],0.79,261434,DB01137,Levofloxacin
≤,23830621,MICs,Moxifloxacin proved to be pharmacodynamically efficacious against Gram-positive bacteria with MICs ≤ 0.79 mg/L and Gram-negative bacteria with MICs ≤ 0.32 mg/L.,Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23830621/),[mg] / [l],0.32,261435,DB01137,Levofloxacin
,23830621,MIC threshold,"These MIC thresholds for levofloxacin were 1.1 mg/L and 0.38 mg/L, respectively.",Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23830621/),[mg] / [l],1.1,261436,DB01137,Levofloxacin
,23830621,MIC threshold,"These MIC thresholds for levofloxacin were 1.1 mg/L and 0.38 mg/L, respectively.",Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23830621/),[mg] / [l],0.38,261437,DB01137,Levofloxacin
≥,23830621,MICs,"However, the predicted efficacy against Gram-negative bacteria with MICs ≥ 0.5 mg/L appears to be low.",Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23830621/),[mg] / [l],0.5,261438,DB01137,Levofloxacin
,17159308,binding constants,The yield binding constants were between 3.19 x 10(4) and 1.21 x 10(5) M(-1).,Interaction between fluoroquinolones and bovine serum albumin studied by affinity capillary electrophoresis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17159308/),1/[M],3.19 x 10(4),263673,DB01137,Levofloxacin
,17159308,binding constants,The yield binding constants were between 3.19 x 10(4) and 1.21 x 10(5) M(-1).,Interaction between fluoroquinolones and bovine serum albumin studied by affinity capillary electrophoresis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17159308/),1/[M],1.21 x 10(5),263674,DB01137,Levofloxacin
,32408259,brain,"The results of pharmacokinetic study of the optimized SLN-HPMC gel in plasma and brain revealed significant increase in the brain peak concentration (420, 315 ng/g), the AUC 0-360 min (57130 and 48693.13 ng.",Brain uptake and accumulation of new levofloxacin-doxycycline combination through the use of solid lipid nanoparticles: Formulation; Optimization and in-vivo evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32408259/),[ng] / [g],"420, 315",265912,DB01137,Levofloxacin
,32408259,peak concentration,"The results of pharmacokinetic study of the optimized SLN-HPMC gel in plasma and brain revealed significant increase in the brain peak concentration (420, 315 ng/g), the AUC 0-360 min (57130 and 48693.13 ng.",Brain uptake and accumulation of new levofloxacin-doxycycline combination through the use of solid lipid nanoparticles: Formulation; Optimization and in-vivo evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32408259/),[ng] / [g],"420, 315",265913,DB01137,Levofloxacin
,32408259,AUC 0-360 min,"The results of pharmacokinetic study of the optimized SLN-HPMC gel in plasma and brain revealed significant increase in the brain peak concentration (420, 315 ng/g), the AUC 0-360 min (57130 and 48693.13 ng.",Brain uptake and accumulation of new levofloxacin-doxycycline combination through the use of solid lipid nanoparticles: Formulation; Optimization and in-vivo evaluation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32408259/),ng,57130,265914,DB01137,Levofloxacin
,32408259,AUC 0-360 min,"The results of pharmacokinetic study of the optimized SLN-HPMC gel in plasma and brain revealed significant increase in the brain peak concentration (420, 315 ng/g), the AUC 0-360 min (57130 and 48693.13 ng.",Brain uptake and accumulation of new levofloxacin-doxycycline combination through the use of solid lipid nanoparticles: Formulation; Optimization and in-vivo evaluation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32408259/),ng,48693.13,265915,DB01137,Levofloxacin
,32408259,drug-targeting efficiency (DTE %),"The optimized LD-SLN-HPMC gel gave a drug-targeting efficiency (DTE %) of 149.815 and 161.969 for LEVO and DOX, respectively, in comparison to the intravenous route.",Brain uptake and accumulation of new levofloxacin-doxycycline combination through the use of solid lipid nanoparticles: Formulation; Optimization and in-vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32408259/),,149.815,265916,DB01137,Levofloxacin
,32408259,drug-targeting efficiency (DTE %),"The optimized LD-SLN-HPMC gel gave a drug-targeting efficiency (DTE %) of 149.815 and 161.969 for LEVO and DOX, respectively, in comparison to the intravenous route.",Brain uptake and accumulation of new levofloxacin-doxycycline combination through the use of solid lipid nanoparticles: Formulation; Optimization and in-vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32408259/),,161.969,265917,DB01137,Levofloxacin
,32408259,direct transport percentage (DTP %),"Moreover, the optimized formulation had a direct transport percentage (DTP %) of 33.285 and 40.236 for LEVO and DOX, respectively, which indicates a significant contribution of direct nose-to-brain pathway in brain drug delivery.",Brain uptake and accumulation of new levofloxacin-doxycycline combination through the use of solid lipid nanoparticles: Formulation; Optimization and in-vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32408259/),,33.285,265918,DB01137,Levofloxacin
,32408259,direct transport percentage (DTP %),"Moreover, the optimized formulation had a direct transport percentage (DTP %) of 33.285 and 40.236 for LEVO and DOX, respectively, which indicates a significant contribution of direct nose-to-brain pathway in brain drug delivery.",Brain uptake and accumulation of new levofloxacin-doxycycline combination through the use of solid lipid nanoparticles: Formulation; Optimization and in-vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32408259/),,40.236,265919,DB01137,Levofloxacin
<,27458224,Cmax,"The primary node for failure had two competing variables, Cmax of <67 mg/liter and AUC0-24 of <568.30 mg · h/L; weight of >41 kg was a secondary node with a score of 35% relative to the primary node.",Artificial Intelligence and Amikacin Exposures Predictive of Outcomes in Multidrug-Resistant Tuberculosis Patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27458224/),[mg] / [l],67,266177,DB01137,Levofloxacin
<,27458224,AUC0-24,"The primary node for failure had two competing variables, Cmax of <67 mg/liter and AUC0-24 of <568.30 mg · h/L; weight of >41 kg was a secondary node with a score of 35% relative to the primary node.",Artificial Intelligence and Amikacin Exposures Predictive of Outcomes in Multidrug-Resistant Tuberculosis Patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27458224/),[h·mg] / [l],568.30,266178,DB01137,Levofloxacin
≥,27458224,Cmax,"In patients weighing >41 kg, sputum conversion was 3/3 (100%) in those with an amikacin Cmax of ≥67 mg/liter versus 3/15 (20%) in those with a Cmax of <67 mg/liter (relative risk [RR] = 5.00; 95% confidence interval [CI], 1.82 to 13.76).",Artificial Intelligence and Amikacin Exposures Predictive of Outcomes in Multidrug-Resistant Tuberculosis Patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27458224/),[mg] / [l],67,266179,DB01137,Levofloxacin
<,27458224,Cmax,"In patients weighing >41 kg, sputum conversion was 3/3 (100%) in those with an amikacin Cmax of ≥67 mg/liter versus 3/15 (20%) in those with a Cmax of <67 mg/liter (relative risk [RR] = 5.00; 95% confidence interval [CI], 1.82 to 13.76).",Artificial Intelligence and Amikacin Exposures Predictive of Outcomes in Multidrug-Resistant Tuberculosis Patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27458224/),[mg] / [l],67,266180,DB01137,Levofloxacin
,24707439,Total clearance (Cltot),Total clearance (Cltot) in renal damaged ducks (0.20 L kg(-1) h(-1)) was significantly lower as compared to that in healthy ones (0.41 L kg(-1) h(-1)).,Comparative Pharmacokinetics of Levofloxacin in Healthy and Renal Damaged Muscovy Ducks following Intravenous and Oral Administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24707439/),[l] / [h·kg],0.20,267983,DB01137,Levofloxacin
,24707439,Total clearance (Cltot),Total clearance (Cltot) in renal damaged ducks (0.20 L kg(-1) h(-1)) was significantly lower as compared to that in healthy ones (0.41 L kg(-1) h(-1)).,Comparative Pharmacokinetics of Levofloxacin in Healthy and Renal Damaged Muscovy Ducks following Intravenous and Oral Administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24707439/),[l] / [h·kg],0.41,267984,DB01137,Levofloxacin
,24707439,maximum time (t max),"Following PO administration, the peak serum concentration (C max) was higher in renal damaged than in healthy ducks and was achieved at maximum time (t max) of 2.47 and 2.05 h, respectively.",Comparative Pharmacokinetics of Levofloxacin in Healthy and Renal Damaged Muscovy Ducks following Intravenous and Oral Administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24707439/),h,2.47,267985,DB01137,Levofloxacin
,24707439,maximum time (t max),"Following PO administration, the peak serum concentration (C max) was higher in renal damaged than in healthy ducks and was achieved at maximum time (t max) of 2.47 and 2.05 h, respectively.",Comparative Pharmacokinetics of Levofloxacin in Healthy and Renal Damaged Muscovy Ducks following Intravenous and Oral Administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24707439/),h,2.05,267986,DB01137,Levofloxacin
,24707439,t 1/2(el),The drug was eliminated (t 1/2(el)) at a significant slower rate (3.94 h) in renal damaged than in healthy ducks (2.89 h).,Comparative Pharmacokinetics of Levofloxacin in Healthy and Renal Damaged Muscovy Ducks following Intravenous and Oral Administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24707439/),h,3.94,267987,DB01137,Levofloxacin
,24707439,t 1/2(el),The drug was eliminated (t 1/2(el)) at a significant slower rate (3.94 h) in renal damaged than in healthy ducks (2.89 h).,Comparative Pharmacokinetics of Levofloxacin in Healthy and Renal Damaged Muscovy Ducks following Intravenous and Oral Administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24707439/),h,2.89,267988,DB01137,Levofloxacin
,25573219,C(max),"The C(max) and T1/2 of each antibiotic were as the followings: piperacillin (7 950 ± 3 023) mg/L and (1.97 ± 1.23) h, ceftriaxone (1 104 ± 248) mg/L and (3.14 ± 0.57) h, cefoperazone (5 215 ± 2 225) mg/L and (0.89 ± 0.13) h, meropenem (31.97 ± 12.44) mg/L and (0.36 ± 0.11) h, levofloxacin (66.3 ± 36.9) mg/L and (3.32 ± 2.57) h, metronidazole (28.2 ± 10.2) mg/L and (0.81 ± 0.33) h, respectively.",[Experimental study on concentrations and pharmacokinetics of antibiotics in bile and evaluation of their microbicidal potential]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25573219/),[mg] / [l],7 950,268150,DB01137,Levofloxacin
,25573219,C(max),"The C(max) and T1/2 of each antibiotic were as the followings: piperacillin (7 950 ± 3 023) mg/L and (1.97 ± 1.23) h, ceftriaxone (1 104 ± 248) mg/L and (3.14 ± 0.57) h, cefoperazone (5 215 ± 2 225) mg/L and (0.89 ± 0.13) h, meropenem (31.97 ± 12.44) mg/L and (0.36 ± 0.11) h, levofloxacin (66.3 ± 36.9) mg/L and (3.32 ± 2.57) h, metronidazole (28.2 ± 10.2) mg/L and (0.81 ± 0.33) h, respectively.",[Experimental study on concentrations and pharmacokinetics of antibiotics in bile and evaluation of their microbicidal potential]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25573219/),[mg] / [l],1 104,268151,DB01137,Levofloxacin
,25573219,C(max),"The C(max) and T1/2 of each antibiotic were as the followings: piperacillin (7 950 ± 3 023) mg/L and (1.97 ± 1.23) h, ceftriaxone (1 104 ± 248) mg/L and (3.14 ± 0.57) h, cefoperazone (5 215 ± 2 225) mg/L and (0.89 ± 0.13) h, meropenem (31.97 ± 12.44) mg/L and (0.36 ± 0.11) h, levofloxacin (66.3 ± 36.9) mg/L and (3.32 ± 2.57) h, metronidazole (28.2 ± 10.2) mg/L and (0.81 ± 0.33) h, respectively.",[Experimental study on concentrations and pharmacokinetics of antibiotics in bile and evaluation of their microbicidal potential]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25573219/),[mg] / [l],5 215,268152,DB01137,Levofloxacin
,25573219,C(max),"The C(max) and T1/2 of each antibiotic were as the followings: piperacillin (7 950 ± 3 023) mg/L and (1.97 ± 1.23) h, ceftriaxone (1 104 ± 248) mg/L and (3.14 ± 0.57) h, cefoperazone (5 215 ± 2 225) mg/L and (0.89 ± 0.13) h, meropenem (31.97 ± 12.44) mg/L and (0.36 ± 0.11) h, levofloxacin (66.3 ± 36.9) mg/L and (3.32 ± 2.57) h, metronidazole (28.2 ± 10.2) mg/L and (0.81 ± 0.33) h, respectively.",[Experimental study on concentrations and pharmacokinetics of antibiotics in bile and evaluation of their microbicidal potential]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25573219/),[mg] / [l],31.97,268153,DB01137,Levofloxacin
,25573219,T1/2,"The C(max) and T1/2 of each antibiotic were as the followings: piperacillin (7 950 ± 3 023) mg/L and (1.97 ± 1.23) h, ceftriaxone (1 104 ± 248) mg/L and (3.14 ± 0.57) h, cefoperazone (5 215 ± 2 225) mg/L and (0.89 ± 0.13) h, meropenem (31.97 ± 12.44) mg/L and (0.36 ± 0.11) h, levofloxacin (66.3 ± 36.9) mg/L and (3.32 ± 2.57) h, metronidazole (28.2 ± 10.2) mg/L and (0.81 ± 0.33) h, respectively.",[Experimental study on concentrations and pharmacokinetics of antibiotics in bile and evaluation of their microbicidal potential]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25573219/),h,1.97,268154,DB01137,Levofloxacin
,25573219,T1/2,"The C(max) and T1/2 of each antibiotic were as the followings: piperacillin (7 950 ± 3 023) mg/L and (1.97 ± 1.23) h, ceftriaxone (1 104 ± 248) mg/L and (3.14 ± 0.57) h, cefoperazone (5 215 ± 2 225) mg/L and (0.89 ± 0.13) h, meropenem (31.97 ± 12.44) mg/L and (0.36 ± 0.11) h, levofloxacin (66.3 ± 36.9) mg/L and (3.32 ± 2.57) h, metronidazole (28.2 ± 10.2) mg/L and (0.81 ± 0.33) h, respectively.",[Experimental study on concentrations and pharmacokinetics of antibiotics in bile and evaluation of their microbicidal potential]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25573219/),h,0.89,268155,DB01137,Levofloxacin
,25573219,T1/2,"The C(max) and T1/2 of each antibiotic were as the followings: piperacillin (7 950 ± 3 023) mg/L and (1.97 ± 1.23) h, ceftriaxone (1 104 ± 248) mg/L and (3.14 ± 0.57) h, cefoperazone (5 215 ± 2 225) mg/L and (0.89 ± 0.13) h, meropenem (31.97 ± 12.44) mg/L and (0.36 ± 0.11) h, levofloxacin (66.3 ± 36.9) mg/L and (3.32 ± 2.57) h, metronidazole (28.2 ± 10.2) mg/L and (0.81 ± 0.33) h, respectively.",[Experimental study on concentrations and pharmacokinetics of antibiotics in bile and evaluation of their microbicidal potential]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25573219/),[mg] / [l],31.97,268156,DB01137,Levofloxacin
,25573219,T1/2,"The C(max) and T1/2 of each antibiotic were as the followings: piperacillin (7 950 ± 3 023) mg/L and (1.97 ± 1.23) h, ceftriaxone (1 104 ± 248) mg/L and (3.14 ± 0.57) h, cefoperazone (5 215 ± 2 225) mg/L and (0.89 ± 0.13) h, meropenem (31.97 ± 12.44) mg/L and (0.36 ± 0.11) h, levofloxacin (66.3 ± 36.9) mg/L and (3.32 ± 2.57) h, metronidazole (28.2 ± 10.2) mg/L and (0.81 ± 0.33) h, respectively.",[Experimental study on concentrations and pharmacokinetics of antibiotics in bile and evaluation of their microbicidal potential]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25573219/),h,0.36,268157,DB01137,Levofloxacin
,25573219,T1/2,"The C(max) and T1/2 of each antibiotic were as the followings: piperacillin (7 950 ± 3 023) mg/L and (1.97 ± 1.23) h, ceftriaxone (1 104 ± 248) mg/L and (3.14 ± 0.57) h, cefoperazone (5 215 ± 2 225) mg/L and (0.89 ± 0.13) h, meropenem (31.97 ± 12.44) mg/L and (0.36 ± 0.11) h, levofloxacin (66.3 ± 36.9) mg/L and (3.32 ± 2.57) h, metronidazole (28.2 ± 10.2) mg/L and (0.81 ± 0.33) h, respectively.",[Experimental study on concentrations and pharmacokinetics of antibiotics in bile and evaluation of their microbicidal potential]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25573219/),[mg] / [l],66.3,268158,DB01137,Levofloxacin
,25573219,T1/2,"The C(max) and T1/2 of each antibiotic were as the followings: piperacillin (7 950 ± 3 023) mg/L and (1.97 ± 1.23) h, ceftriaxone (1 104 ± 248) mg/L and (3.14 ± 0.57) h, cefoperazone (5 215 ± 2 225) mg/L and (0.89 ± 0.13) h, meropenem (31.97 ± 12.44) mg/L and (0.36 ± 0.11) h, levofloxacin (66.3 ± 36.9) mg/L and (3.32 ± 2.57) h, metronidazole (28.2 ± 10.2) mg/L and (0.81 ± 0.33) h, respectively.",[Experimental study on concentrations and pharmacokinetics of antibiotics in bile and evaluation of their microbicidal potential]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25573219/),h,3.32,268159,DB01137,Levofloxacin
,25573219,T1/2,"The C(max) and T1/2 of each antibiotic were as the followings: piperacillin (7 950 ± 3 023) mg/L and (1.97 ± 1.23) h, ceftriaxone (1 104 ± 248) mg/L and (3.14 ± 0.57) h, cefoperazone (5 215 ± 2 225) mg/L and (0.89 ± 0.13) h, meropenem (31.97 ± 12.44) mg/L and (0.36 ± 0.11) h, levofloxacin (66.3 ± 36.9) mg/L and (3.32 ± 2.57) h, metronidazole (28.2 ± 10.2) mg/L and (0.81 ± 0.33) h, respectively.",[Experimental study on concentrations and pharmacokinetics of antibiotics in bile and evaluation of their microbicidal potential]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25573219/),[mg] / [l],28.2,268160,DB01137,Levofloxacin
,25573219,T1/2,"The C(max) and T1/2 of each antibiotic were as the followings: piperacillin (7 950 ± 3 023) mg/L and (1.97 ± 1.23) h, ceftriaxone (1 104 ± 248) mg/L and (3.14 ± 0.57) h, cefoperazone (5 215 ± 2 225) mg/L and (0.89 ± 0.13) h, meropenem (31.97 ± 12.44) mg/L and (0.36 ± 0.11) h, levofloxacin (66.3 ± 36.9) mg/L and (3.32 ± 2.57) h, metronidazole (28.2 ± 10.2) mg/L and (0.81 ± 0.33) h, respectively.",[Experimental study on concentrations and pharmacokinetics of antibiotics in bile and evaluation of their microbicidal potential]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25573219/),h,0.81,268161,DB01137,Levofloxacin
,25573219,T(>MIC),"Piperacillin/tazobactam and cefoperazone/sulbactam had the largest bactericidal index and the longest T(>MIC), and their bactericidal indexes were (62.1 ± 23.6) - (993.8 ± 377.9) and (164.8 ± 69.0) - (659.3 ± 275.9), their T(>MIC) were (6.00 ± 2.53) - (8.00 ± 0.00) h and (6.33 ± 1.97) - (8.00 ± 0.00) h.",[Experimental study on concentrations and pharmacokinetics of antibiotics in bile and evaluation of their microbicidal potential]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25573219/),h,6.00,268162,DB01137,Levofloxacin
,25573219,T(>MIC),"Piperacillin/tazobactam and cefoperazone/sulbactam had the largest bactericidal index and the longest T(>MIC), and their bactericidal indexes were (62.1 ± 23.6) - (993.8 ± 377.9) and (164.8 ± 69.0) - (659.3 ± 275.9), their T(>MIC) were (6.00 ± 2.53) - (8.00 ± 0.00) h and (6.33 ± 1.97) - (8.00 ± 0.00) h.",[Experimental study on concentrations and pharmacokinetics of antibiotics in bile and evaluation of their microbicidal potential]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25573219/),h,8.00,268163,DB01137,Levofloxacin
,25573219,T(>MIC),"Piperacillin/tazobactam and cefoperazone/sulbactam had the largest bactericidal index and the longest T(>MIC), and their bactericidal indexes were (62.1 ± 23.6) - (993.8 ± 377.9) and (164.8 ± 69.0) - (659.3 ± 275.9), their T(>MIC) were (6.00 ± 2.53) - (8.00 ± 0.00) h and (6.33 ± 1.97) - (8.00 ± 0.00) h.",[Experimental study on concentrations and pharmacokinetics of antibiotics in bile and evaluation of their microbicidal potential]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25573219/),h,6.33,268164,DB01137,Levofloxacin
,25573219,bactericidal index,"The bactericidal index and T(>MIC) of levofloxacin were the smallest, which were (2.1 ± 1.2) - (8.3 ± 4.6) and (0.54 ± 0.25) - (2.67 ± 1.03) h .",[Experimental study on concentrations and pharmacokinetics of antibiotics in bile and evaluation of their microbicidal potential]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25573219/),h,2.1,268165,DB01137,Levofloxacin
,25573219,T(>MIC),"The bactericidal index and T(>MIC) of levofloxacin were the smallest, which were (2.1 ± 1.2) - (8.3 ± 4.6) and (0.54 ± 0.25) - (2.67 ± 1.03) h .",[Experimental study on concentrations and pharmacokinetics of antibiotics in bile and evaluation of their microbicidal potential]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25573219/),h,8.3,268166,DB01137,Levofloxacin
,25573219,T(>MIC),"The bactericidal index and T(>MIC) of levofloxacin were the smallest, which were (2.1 ± 1.2) - (8.3 ± 4.6) and (0.54 ± 0.25) - (2.67 ± 1.03) h .",[Experimental study on concentrations and pharmacokinetics of antibiotics in bile and evaluation of their microbicidal potential]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25573219/),h,0.54,268167,DB01137,Levofloxacin
,25573219,T(>MIC),"The bactericidal index and T(>MIC) of levofloxacin were the smallest, which were (2.1 ± 1.2) - (8.3 ± 4.6) and (0.54 ± 0.25) - (2.67 ± 1.03) h .",[Experimental study on concentrations and pharmacokinetics of antibiotics in bile and evaluation of their microbicidal potential]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25573219/),h,2.67,268168,DB01137,Levofloxacin
,25573219,bactericidal indexes,"Ceftriaxone and meropenem were as the medium, and their bactericidal indexes and T(>MIC) were (4.3 ± 1.0) - (69.2 ± 15.5) , (1.42 ± 0.65) - (8.00 ± 0.00) h and (2.0 ± 0.8) - (1 031.3 ± 401.4) , (0.29 ± 0.10) - (1.83 ± 0.26) h.",[Experimental study on concentrations and pharmacokinetics of antibiotics in bile and evaluation of their microbicidal potential]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25573219/),h,4.3,268169,DB01137,Levofloxacin
,25573219,bactericidal indexes,"Ceftriaxone and meropenem were as the medium, and their bactericidal indexes and T(>MIC) were (4.3 ± 1.0) - (69.2 ± 15.5) , (1.42 ± 0.65) - (8.00 ± 0.00) h and (2.0 ± 0.8) - (1 031.3 ± 401.4) , (0.29 ± 0.10) - (1.83 ± 0.26) h.",[Experimental study on concentrations and pharmacokinetics of antibiotics in bile and evaluation of their microbicidal potential]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25573219/),h,69.2,268170,DB01137,Levofloxacin
,25573219,bactericidal indexes,"Ceftriaxone and meropenem were as the medium, and their bactericidal indexes and T(>MIC) were (4.3 ± 1.0) - (69.2 ± 15.5) , (1.42 ± 0.65) - (8.00 ± 0.00) h and (2.0 ± 0.8) - (1 031.3 ± 401.4) , (0.29 ± 0.10) - (1.83 ± 0.26) h.",[Experimental study on concentrations and pharmacokinetics of antibiotics in bile and evaluation of their microbicidal potential]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25573219/),h,1.42,268171,DB01137,Levofloxacin
,25573219,bactericidal indexes,"Ceftriaxone and meropenem were as the medium, and their bactericidal indexes and T(>MIC) were (4.3 ± 1.0) - (69.2 ± 15.5) , (1.42 ± 0.65) - (8.00 ± 0.00) h and (2.0 ± 0.8) - (1 031.3 ± 401.4) , (0.29 ± 0.10) - (1.83 ± 0.26) h.",[Experimental study on concentrations and pharmacokinetics of antibiotics in bile and evaluation of their microbicidal potential]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25573219/),h,8.00,268172,DB01137,Levofloxacin
,25573219,T(>MIC),"Ceftriaxone and meropenem were as the medium, and their bactericidal indexes and T(>MIC) were (4.3 ± 1.0) - (69.2 ± 15.5) , (1.42 ± 0.65) - (8.00 ± 0.00) h and (2.0 ± 0.8) - (1 031.3 ± 401.4) , (0.29 ± 0.10) - (1.83 ± 0.26) h.",[Experimental study on concentrations and pharmacokinetics of antibiotics in bile and evaluation of their microbicidal potential]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25573219/),h,69.2,268173,DB01137,Levofloxacin
,25573219,T(>MIC),"Ceftriaxone and meropenem were as the medium, and their bactericidal indexes and T(>MIC) were (4.3 ± 1.0) - (69.2 ± 15.5) , (1.42 ± 0.65) - (8.00 ± 0.00) h and (2.0 ± 0.8) - (1 031.3 ± 401.4) , (0.29 ± 0.10) - (1.83 ± 0.26) h.",[Experimental study on concentrations and pharmacokinetics of antibiotics in bile and evaluation of their microbicidal potential]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25573219/),h,1.42,268174,DB01137,Levofloxacin
,25573219,T(>MIC),"Ceftriaxone and meropenem were as the medium, and their bactericidal indexes and T(>MIC) were (4.3 ± 1.0) - (69.2 ± 15.5) , (1.42 ± 0.65) - (8.00 ± 0.00) h and (2.0 ± 0.8) - (1 031.3 ± 401.4) , (0.29 ± 0.10) - (1.83 ± 0.26) h.",[Experimental study on concentrations and pharmacokinetics of antibiotics in bile and evaluation of their microbicidal potential]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25573219/),h,8.00,268175,DB01137,Levofloxacin
,25573219,T(>MIC),"Ceftriaxone and meropenem were as the medium, and their bactericidal indexes and T(>MIC) were (4.3 ± 1.0) - (69.2 ± 15.5) , (1.42 ± 0.65) - (8.00 ± 0.00) h and (2.0 ± 0.8) - (1 031.3 ± 401.4) , (0.29 ± 0.10) - (1.83 ± 0.26) h.",[Experimental study on concentrations and pharmacokinetics of antibiotics in bile and evaluation of their microbicidal potential]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25573219/),h,2.0,268176,DB01137,Levofloxacin
,25573219,T(>MIC),"Ceftriaxone and meropenem were as the medium, and their bactericidal indexes and T(>MIC) were (4.3 ± 1.0) - (69.2 ± 15.5) , (1.42 ± 0.65) - (8.00 ± 0.00) h and (2.0 ± 0.8) - (1 031.3 ± 401.4) , (0.29 ± 0.10) - (1.83 ± 0.26) h.",[Experimental study on concentrations and pharmacokinetics of antibiotics in bile and evaluation of their microbicidal potential]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25573219/),h,1 031.3,268177,DB01137,Levofloxacin
,25573219,T(>MIC),"Ceftriaxone and meropenem were as the medium, and their bactericidal indexes and T(>MIC) were (4.3 ± 1.0) - (69.2 ± 15.5) , (1.42 ± 0.65) - (8.00 ± 0.00) h and (2.0 ± 0.8) - (1 031.3 ± 401.4) , (0.29 ± 0.10) - (1.83 ± 0.26) h.",[Experimental study on concentrations and pharmacokinetics of antibiotics in bile and evaluation of their microbicidal potential]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25573219/),h,0.29,268178,DB01137,Levofloxacin
,25573219,T(>MIC),"Ceftriaxone and meropenem were as the medium, and their bactericidal indexes and T(>MIC) were (4.3 ± 1.0) - (69.2 ± 15.5) , (1.42 ± 0.65) - (8.00 ± 0.00) h and (2.0 ± 0.8) - (1 031.3 ± 401.4) , (0.29 ± 0.10) - (1.83 ± 0.26) h.",[Experimental study on concentrations and pharmacokinetics of antibiotics in bile and evaluation of their microbicidal potential]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25573219/),h,1.83,268179,DB01137,Levofloxacin
,25573219,b,"The bactericidal index of metronidazole to anaerobic ranged from 7.4 to 294.9, and the T(>MIC) ranged from 1.88 to 5.00 h.",[Experimental study on concentrations and pharmacokinetics of antibiotics in bile and evaluation of their microbicidal potential]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25573219/),,7.4 to 294.9,268180,DB01137,Levofloxacin
,25573219,T(>MIC),"The bactericidal index of metronidazole to anaerobic ranged from 7.4 to 294.9, and the T(>MIC) ranged from 1.88 to 5.00 h.",[Experimental study on concentrations and pharmacokinetics of antibiotics in bile and evaluation of their microbicidal potential]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25573219/),h,1.88 to 5.00,268181,DB01137,Levofloxacin
,9333047,Tmax,"The only consistent effect of the coadministration of levofloxacin with a high-fat meal for most subjects was that levofloxacin absorption was delayed and Cmax was slightly reduced (Tmax, 1.0 and 2.0 h for fasting and fed conditions, respectively [P = 0.002]; Cmax, 5.9 +/- 1.3 and 5.1 +/- 0.9 microg/ml [90% confidence interval = 0.79 to 0.94] for fasting and fed conditions, respectively).",Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333047/),h,1.0,268569,DB01137,Levofloxacin
,9333047,Tmax,"The only consistent effect of the coadministration of levofloxacin with a high-fat meal for most subjects was that levofloxacin absorption was delayed and Cmax was slightly reduced (Tmax, 1.0 and 2.0 h for fasting and fed conditions, respectively [P = 0.002]; Cmax, 5.9 +/- 1.3 and 5.1 +/- 0.9 microg/ml [90% confidence interval = 0.79 to 0.94] for fasting and fed conditions, respectively).",Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333047/),h,2.0,268570,DB01137,Levofloxacin
,9333047,Cmax,"The only consistent effect of the coadministration of levofloxacin with a high-fat meal for most subjects was that levofloxacin absorption was delayed and Cmax was slightly reduced (Tmax, 1.0 and 2.0 h for fasting and fed conditions, respectively [P = 0.002]; Cmax, 5.9 +/- 1.3 and 5.1 +/- 0.9 microg/ml [90% confidence interval = 0.79 to 0.94] for fasting and fed conditions, respectively).",Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333047/),[μg] / [ml],5.9,268571,DB01137,Levofloxacin
,9333047,Cmax,"The only consistent effect of the coadministration of levofloxacin with a high-fat meal for most subjects was that levofloxacin absorption was delayed and Cmax was slightly reduced (Tmax, 1.0 and 2.0 h for fasting and fed conditions, respectively [P = 0.002]; Cmax, 5.9 +/- 1.3 and 5.1 +/- 0.9 microg/ml [90% confidence interval = 0.79 to 0.94] for fasting and fed conditions, respectively).",Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333047/),[μg] / [ml],5.1,268572,DB01137,Levofloxacin
,9333047,Cmax,"Mean values of Cmax and AUC from time zero to infinity were 6.7 +/- 3.2 microg/ml and 47.9 +/- 8.4 microg x h/ml, respectively, following the administration of sucralfate compared to values of 5.9 +/- 1.3 microg/ml and 50.5 +/- 8.1 microg x h/ml, respectively, under fasting conditions.",Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333047/),[μg] / [ml],6.7,268573,DB01137,Levofloxacin
,9333047,Cmax,"Mean values of Cmax and AUC from time zero to infinity were 6.7 +/- 3.2 microg/ml and 47.9 +/- 8.4 microg x h/ml, respectively, following the administration of sucralfate compared to values of 5.9 +/- 1.3 microg/ml and 50.5 +/- 8.1 microg x h/ml, respectively, under fasting conditions.",Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333047/),[μg] / [ml],5.9,268574,DB01137,Levofloxacin
,9333047,AUC from time zero to infinity,"Mean values of Cmax and AUC from time zero to infinity were 6.7 +/- 3.2 microg/ml and 47.9 +/- 8.4 microg x h/ml, respectively, following the administration of sucralfate compared to values of 5.9 +/- 1.3 microg/ml and 50.5 +/- 8.1 microg x h/ml, respectively, under fasting conditions.",Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333047/),[h·μg] / [ml],47.9,268575,DB01137,Levofloxacin
,9333047,AUC from time zero to infinity,"Mean values of Cmax and AUC from time zero to infinity were 6.7 +/- 3.2 microg/ml and 47.9 +/- 8.4 microg x h/ml, respectively, following the administration of sucralfate compared to values of 5.9 +/- 1.3 microg/ml and 50.5 +/- 8.1 microg x h/ml, respectively, under fasting conditions.",Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333047/),[h·μg] / [ml],50.5,268576,DB01137,Levofloxacin
,11451675,peak levels,"When gemifloxacin (10 mg/kg) was given by the intraperitoneal (i.p.) route to infected guinea pigs, mean peak levels in plasma were 1.3 microg/ml at 0.5 h and 1.2 microg/ml at 1 h postinjection.","In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11451675/),[μg] / [ml],1.3,269388,DB01137,Levofloxacin
,11451675,peak levels,"When gemifloxacin (10 mg/kg) was given by the intraperitoneal (i.p.) route to infected guinea pigs, mean peak levels in plasma were 1.3 microg/ml at 0.5 h and 1.2 microg/ml at 1 h postinjection.","In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11451675/),[μg] / [ml],1.2,269389,DB01137,Levofloxacin
,11451675,terminal half-life phase of elimination,"The terminal half-life phase of elimination from plasma was 1.3 h, and the area under the concentration-time curve from 0 to 24 h (AUC(0--24)) was 2.1 microg.","In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11451675/),h,1.3,269390,DB01137,Levofloxacin
,11451675,area under the concentration-time curve from 0 to 24 h (AUC(0--24)),"The terminal half-life phase of elimination from plasma was 1.3 h, and the area under the concentration-time curve from 0 to 24 h (AUC(0--24)) was 2.1 microg.","In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11451675/),μg,2.1,269391,DB01137,Levofloxacin
,11451675,half-life,"For the same drug dose, mean levels in lungs were 3.4 microg/g at both 0.5 and 1 h, with a half-life of 1.5 h and an AUC(0--24) of 6.0 microg.","In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11451675/),h,1.5,269392,DB01137,Levofloxacin
,11451675,AUC(0--24),"For the same drug dose, mean levels in lungs were 3.4 microg/g at both 0.5 and 1 h, with a half-life of 1.5 h and an AUC(0--24) of 6.0 microg.","In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11451675/),μg,6.0,269393,DB01137,Levofloxacin
,9068926,peak drug plasma concentration (Cmax),"Plasma concentrations in healthy volunteers reach a mean peak drug plasma concentration (Cmax) of approximately 2.8 and 5.2 mg/L within 1 to 2 hours after oral administration of levofloxacin 250 and 500mg tablets, respectively.",The clinical pharmacokinetics of levofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[mg] / [l],2.8,273446,DB01137,Levofloxacin
,9068926,peak drug plasma concentration (Cmax),"Plasma concentrations in healthy volunteers reach a mean peak drug plasma concentration (Cmax) of approximately 2.8 and 5.2 mg/L within 1 to 2 hours after oral administration of levofloxacin 250 and 500mg tablets, respectively.",The clinical pharmacokinetics of levofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[mg] / [l],5.2,273447,DB01137,Levofloxacin
,9068926,bioavailability,The bioavailability of oral levofloxacin approaches 100% and is little affected by the administration with food.,The clinical pharmacokinetics of levofloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),%,100,273448,DB01137,Levofloxacin
,9068926,Cmax,"Single oral doses of levofloxacin 50 to 1000mg produce a mean Cmax and area under the concentration-time curve (AUC) ranging from approximately 0.6 to 9.4 mg/L and 4.7 to 108 mg.h/L, respectively, both increasing linearly in a dose-proportional fashion.",The clinical pharmacokinetics of levofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[mg] / [l],0.6 to 9.4,273449,DB01137,Levofloxacin
,9068926,area under the concentration-time curve (AUC),"Single oral doses of levofloxacin 50 to 1000mg produce a mean Cmax and area under the concentration-time curve (AUC) ranging from approximately 0.6 to 9.4 mg/L and 4.7 to 108 mg.h/L, respectively, both increasing linearly in a dose-proportional fashion.",The clinical pharmacokinetics of levofloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[h·mg] / [l],4.7 to 108,273450,DB01137,Levofloxacin
,9068926,volume of distribution,"Levofloxacin is widely distributed throughout the body, with a mean volume of distribution of 1.1 L/kg, and penetrates well into most body tissues and fluids.",The clinical pharmacokinetics of levofloxacin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[l] / [kg],1.1,273451,DB01137,Levofloxacin
,9068926,plasma elimination half-life (t1/2 beta),The plasma elimination half-life (t1/2 beta) ranges from 6 to 8 hours in individuals with normal renal function.,The clinical pharmacokinetics of levofloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),h,6 to 8,273452,DB01137,Levofloxacin
,10991830,peak concentration (C(max),"Levofloxacin had the highest peak concentration (C(max), in micrograms per milliliter) (6.21+/-1.34), followed by moxifloxacin (4.34+/-1.61) and gatifloxacin (3.42+/-0.74).","Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μg] / [milliliter],6.21,273557,DB01137,Levofloxacin
,10991830,peak concentration (C(max),"Levofloxacin had the highest peak concentration (C(max), in micrograms per milliliter) (6.21+/-1.34), followed by moxifloxacin (4.34+/-1.61) and gatifloxacin (3.42+/-0.74).","Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μg] / [milliliter],4.34,273558,DB01137,Levofloxacin
,10991830,peak concentration (C(max),"Levofloxacin had the highest peak concentration (C(max), in micrograms per milliliter) (6.21+/-1.34), followed by moxifloxacin (4.34+/-1.61) and gatifloxacin (3.42+/-0.74).","Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μg] / [milliliter],3.42,273559,DB01137,Levofloxacin
,10991830,Elimination half-lives,Elimination half-lives ranged from 12.12+/-3.93 h (grepafloxacin) to 5.37+/-0.82 h (ciprofloxacin).,"Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),h,12.12,273560,DB01137,Levofloxacin
,10991830,Elimination half-lives,Elimination half-lives ranged from 12.12+/-3.93 h (grepafloxacin) to 5.37+/-0.82 h (ciprofloxacin).,"Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),h,5.37,273561,DB01137,Levofloxacin
,10991830,total areas under the curve (AUC(tot),"The total areas under the curve (AUC(tot), in microgram-hours per milliliter) for levofloxacin (44.8+/-4.4), moxifloxacin (39.3+/-5.35), and gatifloxacin (30+/-3.8) were significantly higher than that for ciprofloxacin (5.75+/-1.25).","Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μgram-hours] / [milliliter],44.8,273562,DB01137,Levofloxacin
,10991830,total areas under the curve (AUC(tot),"The total areas under the curve (AUC(tot), in microgram-hours per milliliter) for levofloxacin (44.8+/-4.4), moxifloxacin (39.3+/-5.35), and gatifloxacin (30+/-3.8) were significantly higher than that for ciprofloxacin (5.75+/-1.25).","Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μgram-hours] / [milliliter],39.3,273563,DB01137,Levofloxacin
,10991830,total areas under the curve (AUC(tot),"The total areas under the curve (AUC(tot), in microgram-hours per milliliter) for levofloxacin (44.8+/-4.4), moxifloxacin (39.3+/-5.35), and gatifloxacin (30+/-3.8) were significantly higher than that for ciprofloxacin (5.75+/-1.25).","Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μgram-hours] / [milliliter],30,273564,DB01137,Levofloxacin
,10991830,total areas under the curve (AUC(tot),"The total areas under the curve (AUC(tot), in microgram-hours per milliliter) for levofloxacin (44.8+/-4.4), moxifloxacin (39.3+/-5.35), and gatifloxacin (30+/-3.8) were significantly higher than that for ciprofloxacin (5.75+/-1.25).","Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μgram-hours] / [milliliter],5.75,273565,DB01137,Levofloxacin
,10991830,C(max)s,"Calculated from a normalized dose of 200 mg, the highest C(max)s (in micrograms per milliliter) were observed for levofloxacin (2.48 +/-0.53), followed by moxifloxacin (2.17+/-0.81) and trovafloxacin (2.09+/-0.58).","Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μg] / [milliliter],2.48,273566,DB01137,Levofloxacin
,10991830,C(max)s,"Calculated from a normalized dose of 200 mg, the highest C(max)s (in micrograms per milliliter) were observed for levofloxacin (2.48 +/-0.53), followed by moxifloxacin (2.17+/-0.81) and trovafloxacin (2.09+/-0.58).","Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μg] / [milliliter],2.17,273567,DB01137,Levofloxacin
,10991830,C(max)s,"Calculated from a normalized dose of 200 mg, the highest C(max)s (in micrograms per milliliter) were observed for levofloxacin (2.48 +/-0.53), followed by moxifloxacin (2.17+/-0.81) and trovafloxacin (2.09+/-0.58).","Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μg] / [milliliter],2.09,273568,DB01137,Levofloxacin
,10991830,AUC(tot),The highest AUC(tot) (in microgram-hours per milliliter) for a 200-mg dose were observed for moxifloxacin (19.7+/-2.67) and trovafloxacin (19.5+/-3.1); the lowest was observed for ciprofloxacin (4.6+/-1.0).,"Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μgram-hours] / [milliliter],19.7,273569,DB01137,Levofloxacin
,10991830,AUC(tot),The highest AUC(tot) (in microgram-hours per milliliter) for a 200-mg dose were observed for moxifloxacin (19.7+/-2.67) and trovafloxacin (19.5+/-3.1); the lowest was observed for ciprofloxacin (4.6+/-1.0).,"Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μgram-hours] / [milliliter],19.5,273570,DB01137,Levofloxacin
,10991830,AUC(tot),The highest AUC(tot) (in microgram-hours per milliliter) for a 200-mg dose were observed for moxifloxacin (19.7+/-2.67) and trovafloxacin (19.5+/-3.1); the lowest was observed for ciprofloxacin (4.6+/-1.0).,"Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991830/),[μgram-hours] / [milliliter],4.6,273571,DB01137,Levofloxacin
,24989061,dose,"The median (5th, 95th percentile) daily dose and AUC24 was 1,000 (250, 1,500) mg and 90.7 (44.4, 228) mg·h/L, respectively.",Levofloxacin dosing regimen in severely morbidly obese patients (BMI ≥40 kg/m(2)) should be guided by creatinine clearance estimates based on ideal body weight and optimized by therapeutic drug monitoring. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24989061/),mg,"1,000",273650,DB01137,Levofloxacin
,24989061,AUC24,"The median (5th, 95th percentile) daily dose and AUC24 was 1,000 (250, 1,500) mg and 90.7 (44.4, 228) mg·h/L, respectively.",Levofloxacin dosing regimen in severely morbidly obese patients (BMI ≥40 kg/m(2)) should be guided by creatinine clearance estimates based on ideal body weight and optimized by therapeutic drug monitoring. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24989061/),mg,1,273651,DB01137,Levofloxacin
,24989061,AUC24,"The median (5th, 95th percentile) daily dose and AUC24 was 1,000 (250, 1,500) mg and 90.7 (44.4, 228) mg·h/L, respectively.",Levofloxacin dosing regimen in severely morbidly obese patients (BMI ≥40 kg/m(2)) should be guided by creatinine clearance estimates based on ideal body weight and optimized by therapeutic drug monitoring. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24989061/),[h·mg] / [l],90.7,273652,DB01137,Levofloxacin
,24989061,AUC24,"An empiric four-category daily-dose regimen (500, 750, 1,000, 1,250 mg) stratified by CLcr (CG-IBW) is expected to have >90 % probability of achieving an AUC24 of 50-150 mg·h/L in morbidly obese patients.",Levofloxacin dosing regimen in severely morbidly obese patients (BMI ≥40 kg/m(2)) should be guided by creatinine clearance estimates based on ideal body weight and optimized by therapeutic drug monitoring. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24989061/),[h·mg] / [l],50-150,273653,DB01137,Levofloxacin
